TrialID,Last Refreshed on,Public title,Scientific title,Acronym,Primary sponsor,Date registration,Date registration3,Export date,Source Register,web address,Recruitment Status,other records,Inclusion agemin,Inclusion agemax,Inclusion gender,Date enrollement,Target size,Study type,Study design,Phase,Countries,Contact Firstname,Contact Lastname,Contact Address,Contact Email,Contact Tel,Contact Affiliation,Inclusion Criteria,Exclusion Criteria,Condition,Intervention,Primary outcome,Secondary outcome,Secondary ID,Source Name,Secondary Sponsor,Ethics Status,Ethics Approval Date,Ethics Contact Name,Ethics Contact Address,Ethics Contact Phone,Ethics Contact Email,results yes no,results date posted,results url link,results url protocol,results date completed,results date first publication,results summary,results baseline char,results adverse events,results outcome measures,results ipd plan,results ipd description,Prospective registration,Bridging flag truefalse,Bridged type,Year,Min_Age,Includes_Children,Includes_Pregnant
NCT05515770,14 October 2024,The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir,"An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)",ImPrepCab,Evandro Chagas National Institute of Infectious Disease,2022-08-23,20220823,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05515770,Recruiting,No,18 Years,30 Years,Male,20/09/2022,1200.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 3,Brazil, ; ; ; ,"Beatriz Grinsztejn, MD, PhD;Valdilea Veloso, MD, PhD;Thiago Torres, Pharm D, PhD;Thiago Torres, Pharm D, PhD",,;;thiago.torres@ini.fiocruz.br;,;;+55213865-9573;+55213865-9573,Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ;Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ;,"Inclusion Criteria:<br><br> 1. Cisgender men, non-binary (assigned as male at birth) or transgender women and men<br><br> 2. Report having anal sex with a person assigned male at birth in the last six months<br>   (Persons born female having sex only with other persons born female are excluded)<br><br> 3. Age 18-30 years<br><br> 4. Seek a study clinic looking for PrEP<br><br> 5. CAB LA and TDF/FTC PrEP naïve<br><br> 6. Willing and able to provide written informed consent and adhere to the study<br>   requirements<br><br> 7. Non-reactive / negative HIV test results, including both HIV rapid tests and an<br>   undetectable HIV RNA at enrollment for individuals choosing injectable CAB-LA.<br><br> 8. No report of hepatic dysfunction. Candidates reporting liver disease will have their<br>   enrollment visit postponed until laboratory results of liver function are available.<br>   Individuals with ALT >=5x ULN, OR ALT>=3xULN and bilirubin >=1.5xULN will be<br>   excluded. See section 7 (Study Procedures - Enrollment visit).<br><br> 9. Willing to undergo all required study procedures.<br><br>Exclusion Criteria:<br><br> 1. One or more reactive or positive HIV test result at enrollment visit, even if HIV<br>   infection is not confirmed.<br><br> 2. Currently participating in interventional trial of PrEP agents, HIV vaccine trial or<br>   experimental medication.<br><br> 3. Positive pregnancy test, breastfeeding, or intention to become pregnant at enrolment<br>   (for transgender men).<br><br> 4. Prior participation in studies with Cabotegravir.<br><br> 5. A history or presence of allergy to the study drug components.<br><br> 6. Past participation in HIV vaccine trial. An exception will be made for participants<br>   that can provide documentation of receipt of placebo (not active arm).<br><br> 7. Plan to relocate out of the area during the study period.<br><br> 8. Surgically placed or injected buttock implants or fillers, per self-report.<br><br> 9. Has a dermatological/inflammatory skin condition overlying the buttock region which<br>   in the opinion of the study investigator, in consultation with the Clinical Study<br>   Coordination (CSC), may interfere with interpretation of injection site reactions.<br><br> 10. Active or planned use of contraindicated co-administered for which significant<br>   decreases in Cabotegravir plasma concentrations may occur due uridine diphosphate<br>   glucuronosyltransferase (UGT1A1):<br><br>    - Anticonvulsants: Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin<br><br>    - Antimycobacterials: Rifampin, Rifapentine *Any prohibited medications that<br>     decrease CAB concentrations should be discontinued for a minimum of four weeks<br>     or a minimum of three half-lives (whichever is longer) prior to the first dose.<br><br> 11. Current or anticipated need for chronic systemic anticoagulation or a history of<br>   known or suspected bleeding disorder, including a history of prolonged bleeding.<br><br> 12. History of severe hepatic impairment (including but not limited to a history of<br>   liver failure or hospitalization for liver disease, a history of hepatocellular<br>   carcinoma or near liver transplant).<br><br> 13. Individuals with advanced Hepatitis C.<br><br> 14. Other medical conditions that, in the opinion of the study investigator, would<br>   interfere with the conduct of the study (e.g., provided by self-report, or found<br>   upon medical).",,HIV Infections,Drug: Cabotegravir Injection,Incident HIV infection,,59166522.7.1001.5262,Please refer to primary and secondary sponsors,Beatriz Grinsztejn;Thiago Torres;Valdilea Gonçalves;Brenda Hoagland,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2022,18.0,No,Yes
NCT05519046,14 April 2025,Cardiac Contractility Modulation in Chagas Heart Disease,Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas,FIX-Chagas,InCor Heart Institute,2022-08-10,20220810,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05519046,Recruiting,No,18 Years,75 Years,All,25/05/2022,60.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). ,Unknown,Brazil, ; ,"Martino Martinelli Filho, PhD;Martino MM Martinelli Filho, PHD",,martino@incor.usp.br;martino.filho@incor.usp.br,+551126615515;55 11 2661 5517,,"Inclusion Criteria:<br><br> - Signing of an informed consent form (ICF) before randomization and any study<br>   procedure,<br><br> - Both genders, age >18 years and <75 years,<br><br> - Recent positive (last two years) and documented serology for Chagas disease, in at<br>   least two different tests (indirect hemagglutination, indirect immunofluorescence,<br>   or ELISA),<br><br> - NYHA II-III heart failure functional class,<br><br> - LVEF< 35%,<br><br> - Non left bundle branch block<br><br> - Intraventricular desynchrony (Yu index)<br><br> - Global longitudinal strain >11 %.<br><br>Exclusion Criteria:<br><br> - Participation in another study, presently or terminated <1 year ago, except for a<br>   totally unrelated observational study,<br><br> - Other concomitant cardiovascular diseases, including uncontrolled diabetes mellitus<br>   (systemic arterial hypertension without permitted target organ compromise),<br><br> - Kidney dysfunction (serum creatinine >1.5mg/dL or eGFR <30mL/min/1.73m2) or liver<br>   dysfunction, with diagnosis of cirrhosis or portal hypertension or elevated serum<br>   enzymes (AST or ALT) > 3x the upper limit of normality,<br><br> - Moderate or severe chronic obstructive pulmonary disease,<br><br> - Peripheral polyneuropathy,<br><br> - Hyperthyroidism,<br><br> - Current alcoholism or not abandoned for >2 years,<br><br> - Diagnosed with psychopathy or psychosis or addiction to illicit drugs,<br><br> - Life expectancy <1 year, due to the disease itself or comorbidities (including NYHA<br>   class IV),<br><br> - Pregnancy or breastfeeding,<br><br> - Potential to become pregnant during the study (non-menopausal patients who have not<br>   undergone a radical and safe contraceptive process),<br><br> - Previously withdrawn from this study.",,Chagas Cardiomyopathy;Heart Failure;Systolic Dysfunction;Right Bundle Branch Block and Left Anterior Fascicular Block;Right Bundle Branch Block and Left Posterior Fascicular Block,Device: Cardiac Contractility Modulation (CCM);Device: CRT,QoL Score;QoL Score;GLS;GLS,6MWT;6MWT;NYHAFC;NYHAFC;LVEF;LVEF;Heart Failure Hospitalization (HFH) checklist,57563722.3.0000.0068,Please refer to primary and secondary sponsors,Impulse Dynamics;I2medi Comercial Medica LTDA,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2022,18.0,No,Yes
NCT05477953,15 September 2025,An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health,"Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant",,Bayer,2022-05-19,20220519,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05477953,Not recruiting,No,,,Female,31/12/2025,50.0,Observational,,Unknown,United States;Argentina;Bolivia;Chile;El Salvador;Germany;Guatemala;Honduras;Spain;Uruguay;Argentina;Bolivia;Chile;El Salvador;Germany;Guatemala;Honduras;Spain;United States;Uruguay, ,Bayer Clinical Trials Contact,,clinical-trials-contact@bayer.com,(+)1-888-84 22937,,"Inclusion Criteria:<br><br> - Females exposed to at least 1 dose of nifurtimox at any time during pregnancy (i.e.,<br>   from the first day of the last menstrual period / time of conception to pregnancy<br>   outcome).<br><br> - Written informed consent (for adolescents under the age of majority, written<br>   informed assent by the pregnant minor (where applicable) and written informed<br>   consent by the parent/legal guardian).<br><br>Exclusion Criteria:<br><br> - None",,Chagas Disease,Drug: Nifurtimox (BAYA2502),Major Congenital Malformations (birth defects),Events of Interest in Neonates and Infants through 12 Months of Age: Hospitalizations for serious illness;Events of Interest in Neonates and Infants through 12 Months of Age: Medications;Events of Interest in Neonates and Infants through 12 Months of Age: Growth and development milestones;Events of Interest in Neonates and Infants through 12 Months of Age: Neonatal or infant mortality;Maternal Complications: Premature rupture of membranes (PROM);Maternal Complications: Preeclampsia;Maternal Complications: Severe pregnancy-induced hypertension (PIH);Maternal Complications: Proteinuria;Maternal Complications: Gestational diabetes;Maternal Complications: Measures of fetal growth deficiency (small for gestational age);Spontaneous abortion;Elective/Induced abortion;Fetal death/Still birth;Preterm delivery;Live Birth;Ectopic or Molar Pregnancy,21944,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2022,,Unknown,Yes
NCT04984265,29 July 2024,SBRT in Chagas Disease Ventricular Tachycardia,Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia in Chagas Disease Patients,,University of Sao Paulo General Hospital,2021-07-21,20210721,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04984265,Not recruiting,No,18 Years,,All,14/07/2021,10.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 1/Phase 2,Brazil, ,"Mauricio I Scanavacca, MD, PhD",,,,University of São Paulo General Hospital,"Inclusion Criteria:<br><br> 1. Diagnosis of Chagas heart disease including positive serology<br><br> 2. Recurrent sustained ventricular tachycardia requiring therapy due to symptoms, ICD<br>   shocks, or requiring hospitalization.<br><br> 3. Age>18 years.<br><br> 4. Able to give written, informed consent. If the patient requires continuous<br>   sedation/anesthesia for arrhythmia control consent can be provided by the next of<br>   kin.<br><br> 5. Medically fit to undergo radiation planning and treatment sessions.<br><br> 6. Failed antiarrhythmic medications due to VT recurrence, drug intolerance, or<br>   contraindication.<br><br> 7. Failed prior catheter ablation due to arrhythmia recurrence or ineligible for<br>   endocardial or epicardial catheter ablation (LV thrombus, epicardial adhesion,<br>   megacolon, prior open chest surgery)<br><br>Exclusion Criteria:<br><br> 1. Cardiogenic shock not due to VT with no possibility of heart transplant or<br>   ventricular assist device.<br><br> 2. Inability for patient to be adequately immobilized for radiation planning and<br>   treatment.<br><br> 3. Repeat catheter ablation is felt to be a reasonable option.<br><br> 4. Previous radiation to the chest.<br><br> 5. Pregnancy or refusal to use contraception.",,Ventricular Tachycardia;Chagas Disease;Cardiac Arrhythmia,Radiation: Stereotactic Body Radiation Therapy,Safety of SBRT for the treatment of Ventricular Tachycardia;Efficacy of SBRT for the treatment of Ventricular Tachycardia,Time to VT Recurrence;VT Burden;Mortality;Cardiac Mortality,4920/19/139,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2021,18.0,No,Yes
NCT04984616,23 September 2024,Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease,Effect of Statins (Atorvastatin) on Inflammation and Cardiac Function in Patients with Chronic Chagas Disease: Pathophysiological Studies in a Multicenter Proof-of-concept,ATOCHA,Juan D. Maya,2021-06-29,20210629,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04984616,Not recruiting,No,18 Years,50 Years,All,12/10/2021,300.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 2,Chile, ,"Juan D. Maya, Ph.D.",,,,Full Professor,"Inclusion Criteria:<br><br> - Adults older than 18 and younger than 50 years,<br><br> - with a weight higher than 40 kg<br><br> - Positive conventional confirmatory serology for T. cruzi infection from the NAtional<br>   Public Health institute (ISPCH), and<br><br> - A positive qPCR<br><br> - Have normal laboratory test values for the following parameters: total white blood<br>   cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT),<br>   aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl<br>   transferase (GGT) > 2 times the upper limit of normal (X ULN);<br><br> - Women of reproductive age must have a negative serum pregnancy test, must not be<br>   breastfeeding, and must consistently use a highly effective contraceptive method<br>   throughout the treatment phase<br><br> - Ability to comply with all protocol-specified follow-up tests and visits and have a<br>   permanent address;<br><br> - Signed written informed consent form<br><br>Exclusion Criteria:<br><br> - Signs and symptoms of the digestive form of Chagas Disease;<br><br> - Chronic cardiac Chagas Disease stage II or higher;<br><br> - Acute or chronic health conditions such as acute infections, history of HIV<br>   infection, diabetes, liver and kidney disease;<br><br> - Hypothyroidism<br><br> - Family history of muscle disorders<br><br> - Pre-existing heart disease unrelated to Chagas disease;<br><br> - Formal contraindication to receive nifurtimox or benznidazole,<br><br> - Known history of hypersensitivity, allergy or severe adverse reactions to<br>   atorvastatin, benznidazole or nifurtimox;<br><br> - History of previous treatment for Chagas Disease;<br><br> - History of prior treatment with atorvastatin, lovastatin, rosuvastatin, simvastatin<br>   or any other statin;<br><br> - Any concomitant use of antimicrobial agents;<br><br> - History of alcohol or drug abuse;<br><br> - Any condition that precludes oral medication;<br><br> - Concomitant or intended use of CYP3A4 modifiers;<br><br> - Medical history of familial short QT syndrome or concomitant therapy with<br>   medications that may shorten the QT interval.<br><br> - Abnormal laboratory test values for the following parameters: total white blood cell<br>   count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT),<br>   aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl<br>   transferase (GGT) > 2 times the upper limit of normal (X ULN);<br><br> - Being pregnant or breastfeeding<br><br> - Refusing to use a highly effective contraceptive method during the treatment phase.",,Chronic Chagas Disease,Drug: 40 mg Atorvastatin/day for 120 days P.O.;Drug: Atorvastatin 80;Drug: Placebo,Number of patients that present a change in the phase of the chronic cardiomyopathy,plasma levels of cytokines (pg/mL);Plasma levels of endothelial adhesion molecules (pg/mL);Proportion of patients with change in heart rate measured by electrocardiographic examination;Proportion of patients with changes in the QT interval duration (milliseconds);Proportion of patients with abnormalities in ventricular electrical conduction determined by the duration of the QRS interval (milliseconds);Proportion of patients with alterations in ventricular function as measured by changes in the ejection fraction percentage estimated by echocardiography;Plasma levels of Cardiac function biomarkers (pg/mL);Parasite load in a blood sample (number of parasites/mL);Incidence of severe adverse events,U1111-1267-3513,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2021,18.0,No,Yes
NCT04897516,11 December 2023,Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease,"Phase III Randomized,Multicenter Non-inferiority Study to Evaluate the Efficacy and Safety of Shorter Benznidazole Regimens Compared to the Standard Regimen to Treat Adult Patients With Chronic Chagas Disease",NuestroBen,Laboratorio Elea Phoenix S.A.,2021-05-18,20210518,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04897516,Recruiting,No,18 Years,60 Years,All,28/07/2021,300.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 3,Argentina, ; ,"María Jesús Pinazo, MD;Carola Lombas, MD",,;carola.lombas@elea.com,;(54) 11 44898300,Drugs for Neglected Diseases;,"<br>    Inclusion criteria (Subjects must meet ALL the inclusion requirements listed below to enter<br>    the study):<br><br>     - Signed informed consent form;<br><br>     - Between =18 and =60 years of age;<br><br>     - Weight = 50 kg to = 95 kg;<br><br>     - Confirmation of the diagnosis of T. cruzi infection by conventional serology (a<br>       minimum of two tests must be reactive);<br><br>     - Serial qualitative PCR (one blood sample divided in three DNA extractions, at least<br>       one of which must be positive);<br><br>     - Women of childbearing potential must have a negative pregnancy result at the time of<br>       inclusion, must not be breast-feeding, and must use a highly effective method of<br>       contraception during study treatment and until 30 days after the last dose of study<br>       treatment or demonstrate permanent sterilization;<br><br>     - Ability to comply with all exams and specific protocol visits;<br><br>     - Having a permanent address;<br><br>     - ECG criteria: (Heart rate: 50 -100 bpm or isolate sinus bradycardia from 41 to 59<br>       beats/min; QRS =120 msec, and QTc = 350 msec and = 450 msec) at screening) or<br>       following findings belonging to non-severe chagasic cardiomyopathy: uncomplete right<br>       bundle branch block, Left anterior fascicular block, First-degree atrioventricular<br>       block, Low voltage. The abnormalities included are not exclusionary;<br><br>     - Normal or minimal structural changes in echocardiogram (left ventricular diastolic<br>       diameter (LVDD) <= 55 mm, diastolic dysfunction, absence of Microaneurysm or tip<br>       aneurysm, absence of hypo or generalized akinesia, absence of Systolic dysfunction<br>       (low fractional shortening and ejection fraction), and/or absence of mural thrombus);<br><br>     - Not presenting signs or symptoms of moderate- severe chronic cardiac and/or digestive<br>       forms of Chagas disease (criteria detailed in Study Manual and specific SOP);<br><br>     - No prior history of mental disorders or suicidal tendencies;<br><br>     - Not suffering from known acute or chronic illnesses at the moment of selection for the<br>       study that, in the Investigator's discretion, may interfere with the evaluation of the<br>       efficacy or safety of the investigational product (such as acute infections,<br>       immunosuppressive conditions, or liver or kidney diseases that have required<br>       treatment);<br><br>     - Not having received a formal indication not to take BZN (contraindication, according<br>       to the Summary of Product Characteristics - SmPC);<br><br>     - No prior history of hypersensitivity, allergy, or serious adverse reactions to any of<br>       the nitroimidazole compounds (including BNZ) and/or its components/excipients;<br><br>     - Have not previously undergone antiparasitic treatment for T. cruzi infection;<br><br>     - No prior history of drug abuse or alcoholism;<br><br>     - Not suffering from any disease or condition that prevents subjects from consuming oral<br>       medication.<br><br>    Exclusion criteria (The presence of any of the items below will exclude subjects from<br>    inclusion in the study):<br><br>     - Subject pregnant or intending to become pregnant during treatment and within 30 days<br>       of the last dose of study treatment;<br><br>     - Signs or symptoms of the established (moderate- severe) chronic cardiac and/or<br>       digestive form of Chagas disease, or any ECG/ echocardiographic findings not included<br>       at Inclusion criteria;<br><br>     - History of cardiomyopathy, heart failure, or severe ventricular arrhythmia;<br><br>     - History of digestive surgery potentially related to Chagas Disease or megacolon /<br>       mega-esophagus;<br><br>     - Acute or chronic disease that, in the Investigator's discretion, may interfere with<br>       the evaluation of the efficacy or safety of the investigational product (such as acute<br>       infection, history of immunosuppressive conditions, or liver or kidney disease that<br>       has required treatment);<br><br>     - Laboratory test values that are considered clinically significant or outside the<br>       allowable values, per Common Terminology Criteria for Adverse Events (CTCAE) version<br>       5.0 grade 1;<br><br>     - Disease or clinical condition that prevents subjects from consuming oral medication;<br><br>     - Subjects with a contraindication (known hypersensitivity) to any of the nitroimidazole<br>       compounds, e.g. metronidazole;<br><br>     - Subjects with a history of allergy (serious or not), allergic rash, asthma,<br>       intolerance, sensitivity or photosensitivity;<br><br>     - Concomitant use and/or consumption of allopurinol, antimicrobial and antiparasitic<br>       agents, herbal medicines, dietary supplements and energy drinks;<br><br>     - Scheduled surgery that may interfere with the conduct of the trial and/or with the<br>       treatment evaluation;<br><br>     - Inability to attend study visits, comply with treatment, and cooperate with study<br>       procedures;<br><br>     - Previous participation in a trial for the evaluation of the treatment of T. cruzi<br>       infection;<br><br>     - Simultaneous participation in another trial or within 3 months prior to screening for<br>       this trial (in accordance with national regulations).<br><br>     - Subjects suffering from a serious medical or psychiatric illness that increases the<br>       risk associated with study participation or that interferes with the interpretation of<br>       study results should not be included.<br>   ",,Chagas Disease,Drug: Short regimen of benznidazole;Drug: Short treatment with benznidazole;Drug: Standard treatment with benznidazole,Proportion of patients with sustained negativation of parasitemia according to the results of qualitative PCR tests,"Proportion of patients with negative parasitemia at 1, 4, 6 and 8 months follow-up form the end of treatment;Incidence and severity of adverse events;Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption;Descriptions of patients adherence to treatment in each study arm.",NuestroBen,Please refer to primary and secondary sponsors,Drugs for Neglected Diseases,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2021,18.0,No,Yes
NCT04023227,8 September 2025,"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC","A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy. The Study is Also Know as Prevention And Reduction of Adverse Outcomes in Chagasic Heart failUre Trial Evaluation (PARACHUTE-HF).",PARACHUTE-HF,Novartis Pharmaceuticals,2019-07-10,20190710,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04023227,Not recruiting,No,18 Years,100 Years,All,10/12/2019,918.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 4,Argentina;Brazil;Colombia;Mexico;Argentina;Brazil;Colombia;Mexico, ,Novartis Pharmaceuticals,,,,Novartis Pharmaceuticals,"Key Inclusion Criteria:<br><br> - Male or female = 18 years of age<br><br> - Diagnosis of NYHA Class II-IV HFrEF established by:<br><br>    1. LVEF = 40% within 12 months prior to Visit 1 made by any local measurement<br>     using echocardiography, multiple gated acquisition scan (MUGA), computerized<br>     tomography (CT) scanning, magnetic resonance imaging (MRI), or ventricular<br>     angiography, provided no subsequent measurement above 40% AND<br><br>    2. NT-proBNP = 600 pg/mL (or BNP = 150 pg/mL) at Visit 1 OR<br><br>    3. NT-proBNP = 400 pg/mL (or BNP = 100 pg/mL) at Visit 1 and a hospitalization for<br>     HF within the last 12 months<br><br> - Chagas' disease diagnosis confirmed by at least two different serological tests for<br>   anti-Trypanosoma cruzi based on different principles or with different antigenic<br>   preparations, such as: enzyme-linked immunosorbent assay [ELISA], indirect<br>   immunofluorescence [IFI], indirect hemagglutination [IHA], western blot (WB),<br>   chemiluminescent immunoassay (CLIA). If documented history is not available, the<br>   tests may be performed during the screening<br><br>Key Exclusion Criteria:<br><br> - Patients with history of suspected or proven angioedema or unable to tolerate ACEIs,<br>   ARBs or ARNI (e.g., due to cough, hypotension, renal dysfunction, hyperkalemia)<br><br> - Use of sacubitril/valsartan in the past 3 months<br><br> - Patients requiring continuous intravenous inotropic therapy or with indication of<br>   advanced support intervention for HF:<br><br>    1. already on list for a heart transplantation<br><br>    2. with current indication of left ventricular assist device, or cardiac<br>     resynchronization therapy (CRT)<br><br> - Systemic systolic blood pressure lower than 95 mmHg or symptomatic hypotension<br><br> - Serum potassium > 5.2 mmol/L<br><br> - Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 of body surface area<br><br> - Severe gastrointestinal form of chronic Chagas' disease (demonstrated megaesophagus<br>   and/or important megacolon, e.g.: with compromised oral intake or surgical<br>   indication).<br><br> - Clinical conditions or systemic diseases limiting proper patient participation<br><br> - Pregnant or nursing women or women of child-bearing potential unless they are using<br>   highly effective methods of contraception<br><br> - Presence of other cardiac conditions:<br><br>    1. Previous cardiac surgery<br><br>    2. Heart failure where, in the Investigator's judgement, there is a possible<br>     alternative primary etiology e.g., due to coronary artery disease, valve<br>     disease, congenital heart disease or other causes.<br><br>    3. Untreated arrhythmia or serious conduction disease e.g., bradyarrhythmias,<br>     atrial fibrillation with rapid ventricular response, second or third degree<br>     atrioventricular block, etc.<br><br>    4. Primary uncorrected valvar pathology like moderate to severe aortic stenosis,<br>     mitral stenosis and primary mitral regurgitation<br><br>    5. Planned organ transplantation (or in listing for transplantation), planned<br>     cardiac or other major surgery (including ventricular assist device<br>     implantation)<br><br> - History of malignancy of any organ system within the past 5 years.<br><br> - Current confirmed COVID19 infection<br><br> - Past COVID19 infection with persistent symptom burden suspected due to COVID19<br>   (persistent symptoms may include, but are not limited to, continued cough, breathing<br>   difficulty, muscle/joint aches, and gastrointestinal symptoms from the time of<br>   COVID19 infection onward)",,Chagas Disease;Heart Failure,Drug: Sacubitril/valsartan;Drug: Enalapril,"Hierarchical composite endpoint composed of time to CV death, time to first HF hospitalization, relative change in NT-proBNP from baseline to Week 12",Time to the first occurrence of a composite of CV events;Time to all-cause mortality;Time to sudden death or resuscitated sudden cardiac arrest;Number of visits to an ER due to HF (where intravenous therapy is required);Number of days alive out of the hospital;Number of ventricular fibrillation or sustained ventricular tachycardia;Number of anti-tachycardia pacing or shock therapies,CLCZ696B3302,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2019,18.0,No,Yes
NCT03981523,29 July 2024,New Therapies and Biomarkers for Chagas Infection,New Chemotherapy Regimens and Biomarkers for Chagas Disease,TESEO,"University of Texas, El Paso",2019-04-08,20190408,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03981523,Not recruiting,No,18 Years,50 Years,All,18/12/2019,450.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Bolivia, ; ; ,"Igor C Almeida, D.Sc.;Faustino Torrico, M.D., Ph.D;Joaquim Gascon, M.D., Ph.D",,;;,;;,The University of Texas at El Paso (UTEP);Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES);Barcelona Institute for Global Health,"Inclusion Criteria:<br><br> 1. Adults, 18-50 years.<br><br> 2. Weight: 88-198 pounds (40-90 Kg).<br><br> 3. Individuals diagnosed as being infected with T. cruzi by conventional serology (two<br>   positive tests with different antigens) with at least one positive qualitative<br>   RT-PCR assay out of three during the screening.<br><br> 4. Patient classified as being in the indeterminate form (without clinical<br>   manifestations) or early cardiac form (Kushnir 1) of chronic Chagas disease.<br><br> 5. Signed informed consent form (ICF).<br><br>Exclusion Criteria:<br><br> 1. Clinical signs of dilated cardiomyopathy (dyspnea, legs' edema, syncope, pulmonary<br>   crackles). Patients with an EKG showing the following characteristics: sinus<br>   tachycardia or atrial fibrillation, ventricular arrhythmias, left atrial<br>   enlargement, left bundle-branch block (LBBB) accompanied by right axis deviation<br>   (RAD), and/or patients with Calculation of Fridericia's corrected QT interval (QTcF)<br>   > 450ms, a formula for calculating the QT interval on an electrocardiogram (ECG).<br><br> 2. History of Chagas disease treatment with BZN or NFX or any triazole drug(s) in the<br>   last five years.<br><br> 3. Clinical signs and/or symptoms of digestive form of Chagas disease, which is<br>   characterized by the presence of two or more of the following criteria *:<br><br>    1. Excessive exertion in at least 25% of bowel movements<br><br>    2. Hard stools in at least 25% of stools (type 1-2 of Bristol)<br><br>    3. Feeling of incomplete evacuation in at least 25% of bowel movements<br><br>    4. Feeling of obstruction or anorectal block in at least 25% of bowel movements<br><br>    5. Manual maneuvers to facilitate defecation in at least 25% of bowel movements<br><br>    6. Less than 3 complete spontaneous stools per week<br><br>      - Criteria must be met for at least the last three months and symptoms must<br>        have been started for at least six months before diagnosis.<br><br> 4. Hypersensitivity to the active substances (BZN or NFX) or to the excipient.<br><br> 5. Previous diagnosis of porphyria.<br><br> 6. Any other acute or chronic health conditions that in the opinion of the PI, may<br>   interfere with the efficacy and/or safety evaluation of the study drug.<br><br> 7. Formal contraindication to BZN or NFX.<br><br> 8. Any concomitant or anticipated use of drugs that are contraindicated with the use of<br>   BZN or NFX.<br><br> 9. Individuals currently known to abuse alcohol and/or drugs. Furthermore, if<br>   throughout the course of the study the team becomes aware that a participant is<br>   using drugs/alcohol that participant will be excluded from the treatment but will<br>   continue with the follow-up visits. The study manual outlines how abuse and<br>   dependence will be measured for this study.<br><br> 10. Pregnancy. Females of childbearing potential will be required to complete a<br>   pregnancy test prior to enrollment and throughout the course of treatment.<br><br> 11. Women in reproductive age must have a negative serum pregnancy test at screening,<br>   must not be breastfeeding, and consistently use and/or have partner consistently use<br>   a highly effective contraceptive method during the entire treatment phase of the<br>   trial.<br><br> 12. Transaminases (alanine aminotransferase-ALT and aspartate aminotransferase- AST).<br>   AST must be within the normal range, within an acceptable margin of 25% above the<br>   upper limit of normality for both, according to the insert of the biochemical kit<br>   being used in this study.<br><br> 13. Creatinine must be within an acceptable range, within an acceptable margin of 10%<br>   above the upper limit of normality, according to the insert of the biochemical kit<br>   being used. The normal ranges of transaminases (ALT and AST) and creatinine are<br>   defined by the inserts of the commercial biochemical kits selected to be used in the<br>   present study. All treatment centers (Chagas Platforms in Cochabamba, Sucre, and<br>   Tarija) are going to use the same biochemical kits. The participating clinical<br>   laboratories at the Platforms (in Cochabamba, Sucre, and Tarija) will use the Common<br>   Terminology Criteria for Adverse Events (CTCAE, v.5.0;<br>   ttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_qui<br>   ck_reference_5x7.pdf).<br><br> 14. Total bilirubin must be within the normal range, within an acceptable margin of 15%<br>   above the upper limit of normality for both sexes, according to the insert of the<br>   biochemical kit being used in this study.<br><br> 15. For other standard exclusion criteria, a detailed explanation for each criterion is<br>   provided in the Manual of Operations and Procedures (MOP).",,Trypanosoma Cruzi Infection;Chagas Disease,Drug: Benznidazole;Drug: Nifurtimox,Sustained Parasitological Clearance by qPCR at End of Follow-Up (36 months),"Changes Over Time in the blood parasitic load by qPCR;Changes Over Time in the Conventional Serology using parasite antigenic mixture;Changes Over Time in the Conventional Serology using recombinant parasite antigens;Changes Over Time in the Non-Conventional Serology Biomarker """"Lytic Anti-a-Gal Antibodies"""";Changes Over Time in the Non-Conventional Serology Biomarker """"Anti-KMP11 Antibodies"""";Changes in the Non-Conventional Serology Biomarker """"Anti-HSP70 Antibodies"""";Changes Over Time in the Non-Conventional Serology Biomarker """"Anti-PFR2 Antibodies"""";Changes Over Time in the Non-Conventional Serology Biomarker """"Anti-Peptide 3973 Antibodies"""";Changes Over Time in the Non-Conventional Serology Biomarker """"Trypomastigote Excreted/Secreted Antigens (TESA)""""",U01AI129783;743474,Please refer to primary and secondary sponsors,Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES);Barcelona Institute for Global Health;Institute of Parasitology and Biomedicine Lopez Neyra;U.S. Food and Drug Administration (FDA);Drugs for Neglected Diseases;Mundo Sano Foundation;National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2019,18.0,No,Yes
NCT04239144,15 May 2023,Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease,Role of Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease - Pilot Study Randomized Controlled Trial,,University of Sao Paulo General Hospital,2019-01-23,20190123,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04239144,Recruiting,No,18 Years,,All,09/11/2018,45.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Unknown,Brazil, ; ; ; ; ,"Paulo M Pego Fernandes, MD, PhD;Rodrigo M Kulchetscki, MD;Maurício I Scanavacca, MD, PhD;Paulo M Pego Fernandes, PhD;Rodrigo M Kulchetscki, MD",,;;;paulo.fernandes@incor.usp.br;r.kulchetscki@gmail.com,;;;+551126615921;+5511982468680,Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP);Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP);Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP);,"<br>    Inclusion Criteria:<br><br>     - Patients with Chagas Disease Cardiomyopathy having an ICD<br><br>     - At least four appropriate ICD therapies in the past six months, documented by device<br>       interrogation or medical records;<br><br>     - Use of amiodarone and beta blockers in an optimized fashion;<br><br>     - Life expectancy of more than one year<br><br>     - Conditions for following the plan of clinical follow-up of the study.<br><br>    Exclusion criteria:<br><br>     - Presence of an absolute contraindication to receive any of the possible treatments of<br>       the study;<br><br>     - Pregnant Woman;<br><br>     - Less than 18 years-old;<br><br>     - Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);<br><br>     - Mobile thrombus in the left ventricle;<br><br>     - Left Ventricle Ejection fraction < 10%;<br><br>     - Unstable angina;<br><br>     - Severe aortic stenosis<br><br>     - Primary severe mitral insufficiency;<br><br>     - New York Heart Association (NYHA) functional class IV;<br><br>     - Previous cardiac surgery or scheduled.<br>   ",,Chagas Cardiomyopathy;Ventricular Arrythmia,Procedure: Bilateral sympathectomy;Procedure: Catheter ablation,Time to Ventricular Tachycardia Recurrence;Burden of Ventricular Tachycardia Recurrence,Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.;Mortality and Transplant Rate;Ventricular Ectopic Beats Density;Length of Hospital Stay;Rate of Complications Following Intervention;Impact on Left Ventricular Ejection Fraction;Autonomic Measures,49701215.2.0000.0068,Please refer to primary and secondary sponsors,"Biosense Webster, Inc.",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2019,18.0,No,Yes
NCT03708133,12 December 2020,Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation,"Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chronic Chagas' Disease",,Bayer,2018-10-12,20181012,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03708133,Not recruiting,No,18 Years,45 Years,All,05/12/2018,24.0,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label). ,Phase 1,Argentina,,,,,,,"<br>    Inclusion Criteria:<br><br>    - Male/female patient diagnosed with chronic Chagas' disease: Previous diagnosis of acute<br>    or chronic Chagas' disease by a health clinic prior to screening for the study. The<br>    diagnosis of chronic Chagas' disease may be made by clinical findings, supported by<br>    antibody titers if available. If there is a known history of acute disease, it is<br>    preferable to have documentation of parasites on the blood smear, if available.<br><br>     - Women and men of reproductive potential must agree to use adequate contraception when<br>       sexually active. This applies for the time period between signing of the informed<br>       consent form and 12 weeks after the last administration of study drug. The definition<br>       of adequate contraception will be based on the judgment of the investigator and on<br>       local requirements. Acceptable methods of contraception include, but are not limited<br>       to: (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm<br>       or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based<br>       contraception. Subjects must agree to utilize two reliable and acceptable methods of<br>       contraception simultaneously.<br><br>     - Women of childbearing potential with confirmed last menstrual period by anamnesis and<br>       negative serum pregnancy test (beta-human chorionic gonadotropin [ßhCG]) at screening<br>       and negative urine pregnancy test (ßhCG) at pre-dose of each treatment.<br><br>     - Women of non-childbearing potential, such as surgically sterile women with either<br>       written documentation of surgical sterility or negative serum pregnancy test (ßhCG) at<br>       screening and negative urine pregnancy test (ßhCG) at pre-dose of each treatment.<br><br>     - Male subjects who agree not to act as sperm donors for 12 weeks after last<br>       administration of study drug.<br><br>     - Age: 18 to 45 years (inclusive) at screening.<br><br>     - Body mass index (BMI): =18 and <29.9 kg/m².<br><br>     - At least 3 months since delivery or abortion, or 3 months since cessation of lactation<br>       before screening.<br><br>     - Ability to understand and follow study-related instructions.<br><br>    Exclusion Criteria<br><br>     - Acute Chagas' disease. (During the acute phase, the parasite on a blood smear may be<br>       seen under a microscope. Different antibodies are present, depending on the course of<br>       the disease).<br><br>     - Known hypersensitivity to the study drug (active substance or excipients of the<br>       preparations)<br><br>     - Suspected or known porphyria.<br><br>     - Clinically significant allergies (e.g. allergies affecting the lower respiratory tract<br>       such as allergic asthma or allergies requiring therapy with systemic corticosteroids)<br>       within 1 year.<br><br>     - Clinically significant non-allergic drug reactions, or multiple severe drug allergies<br>       (e.g. adverse reactions in the form of bronchospasm, asthma, rhinitis or urticaria<br>       after taking non-steroidal anti-inflammatory drugs).<br><br>     - Unstable or uncontrolled medical condition such as hypertension or diabetes,<br>       decompensated heart failure, GI conditions that would interfere with the absorption of<br>       the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal<br>       reflux, or other GI disease affecting gastroesophageal junction), conditions that<br>       could potentially have an impact on drug metabolism or elimination (renal, hepatic<br>       such as known hepatic or biliary abnormalities), or any clinically relevant active<br>       infections in the opinion of the investigator within 4 weeks before the screening<br>       visit, e.g. clinically relevant history or presence of significant respiratory (e.g.<br>       interstitial lung disease), hematological, lymphatic, neurological, cardiovascular,<br>       psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes),<br>       and dermatological or connective tissue disease.<br><br>     - Incompletely cured pre-existing diseases (except chronic Chagas' disease without<br>       active GI condition) for which it can be assumed that the absorption, distribution,<br>       metabolism, elimination, and effects of the study drugs will not be normal.<br><br>     - Febrile illness within 1 week before the first study drug administration.<br><br>     - Systolic blood pressure <100 or >140 mmHg (after resting in supine position for a<br>       minimum of 15 minutes).<br><br>     - Diastolic blood pressure <50 or >90 mmHg (after resting in supine position for a<br>       minimum of 15 minutes).<br><br>     - Heart rate <45<br><br>     - Positive pregnancy test.<br><br>     - Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus<br>       antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV 1+2).<br><br>     - Positive urine drug screening.<br>   ",,Bioequivalence,"Drug: Nifurtimox (Lampit, BAYA2502)_Test;Drug: Nifurtimox (Lampit, BAYA2502)_Reference",AUC of nifurtimox in plasma;AUC(0-tlast) of nifurtimox in plasma;Cmax of nifurtimox in plasma,"tmax of nifurtimox in plasma;t1/2 of nifurtimox in plasma;AUCnorm of nifurtimox in plasma;Cmax,norm of nifurtimox in plasma;Number of participants with treatment emergent adverse events",19500,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2018,18.0,No,Yes
NCT03587766,12 December 2020,Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease,"Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease",FEXI12,Drugs for Neglected Diseases,2018-04-27,20180427,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03587766,Not recruiting,No,18 Years,60 Years,All,13/11/2017,45.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 2,Spain, ,"Joaquim Gascón, MD",,,,"Centro de Salud Internacional, Hospital Clínico de Barcelona ISGlobal - Barcelona Institute for Global Health","<br>    Screening Criteria:<br><br>     - Signed, written informed consent form<br><br>     - Age >18 to < 60 years<br><br>     - Weight > 50 kg to < 90 kg<br><br>     - Diagnosis of T. cruzi infection by:<br><br>     - Conventional serology (a minimum of two positive tests [Conventional ELISA,<br>       Recombinant Elisa, Chemiluminescence Immunoassays and/or Indirect Immunofluorescence<br>       (IIF)]<br><br>     - Ability to comply with all protocol specified tests and visits and have a permanent<br>       address<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of Chagas<br>       Disease (CD) (as per study operating procedures)<br><br>     - No personal history of mental disability or suicidal tendencies<br><br>     - No acute or chronic health conditions, that in the opinion of the PI, may interfere<br>       with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, liver, and renal disease requiring treatment)<br><br>     - No formal contraindication to FEXI (according to the latest available Investigator's<br>       Brochure)<br><br>     - No history of hypersensitivity, allergic, or serious adverse reactions to any of the<br>       """"nitro-imidazoles"""" compound, and/or its components<br><br>     - No history of CD treatment with BZN, FEXI or Nifurtimox (NFX) at any time in the past<br><br>     - No history of alcohol abuse or any other drug addiction (as per Study Manual of<br>       Operations)<br><br>     - No condition that prevents patient from taking oral medication<br><br>     - No concomitant medication with drug known risk of Torsade de Pointe, according AZCERT<br>       Scientific Publications and Sudden Arrhythmia Death Syndromes Foundation (SADS<br>       Foundation) (https://www.crediblemeds.org/index.php/new-drug-list)<br><br>     - No family history of sudden death<br><br>     - No family history of sudden infant death syndrome<br><br>    Inclusion Criteria:<br><br>    Following the screening period, patients must also meet all of the following inclusion<br>    criteria to be eligible for randomization:<br><br>     - Confirmed diagnosis of T. cruzi infection by:<br><br>     - Serial qualitative PCR (three samples collected over a single day, at least one of<br>       which must be positive),<br><br>    and<br><br>     - Conventional serology (a minimum of two positive tests must be positive, Conventional<br>       ELISA, Recombinant Elisa, Chemiluminescence immunoassays and/or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening, must<br>       not be breastfeeding, must consistently use a highly effective contraceptive method<br>       until end of treatment and estimated FEXI, M1 and M2 clearance (total of 21 days).<br>       After this, contraception is no longer required.<br><br>     - Normal ECG (Heart rate: 50-100bpm; PR interval =200 msec, QRS complex =120 msec, and<br>       QT interval corrected for heart rate (QTc) =350msec and =450 msec interval durations)<br>       at screening<br><br>     - 24 hour Holter-monitoring with no clinically relevant arrythmias (defined as<br>       Ventricular Tachycardia (defined as >3 ventricular beats with >100bpm); Sustained<br>       Accelerated Idio-Ventricular rhythm (defined as >30 seconds duration and Heart Rate<br>       (HR): 50bpm<HR<100bpm); frequent Ventricular Premature Beats (10/hour); Atrial<br>       Fibrillation/flutter; Mobitz type 2 second degree AV block; High degree and complete<br>       AV block; Bradycardia episodes <40bpm)<br><br>    Exclusion Criteria:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study<br>       Manual of Operations).<br><br>     - History of cardiomyopathy, heart failure, or ventricular arrhythmia.<br><br>     - History of digestive surgery or mega syndromes.<br><br>     - Personal history of mental disability or suicidal tendencies<br><br>     - Hospital Anxiety and Depression Scale (HADS - Appendix 1) self-assessment score >11 in<br>       each of the sub-scales. (Note: If HADS score >11, retesting would be allowed before<br>       after a minimum period of 15 days and referral to counseling/evaluation.)<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood<br>       pressure, liver, and renal diseases requiring medical treatment).<br><br>     - Laboratory test values considered clinically significant or out of the allowable range<br>       at selection period as follows:<br><br>        - Total White Blood Count (WBC) must be within the normal range, with an acceptable<br>         margin of +/- 5% (3,800 - 10,500 / mm3).<br><br>        - Platelets must be within the normal range up to 550,000/mm3<br><br>        - Total bilirubin must be within the normal range<br><br>        - Transaminases (ALT and AST) must be within the normal range, with an acceptable<br>         margin of 25% above the upper limit of normality (ULN), < 1.25 x ULN.<br><br>        - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.<br><br>        - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (<,2.5 x<br>         ULN)<br><br>        - Gamma-glutamyl Transpeptidase (GGT) must be within the normal range up to 2x ULN.<br><br>        - Fasting glucose (minimum of 8 hours from latest meal) must be within the normal<br>         range<br><br>        - Electrolytes (Ca, Mg, K) must be within the normal range<br><br>        - Hepatitis screen must be negative for acute and/or chronic infection (Hepatitis A<br>         antibody, Imunoglobulina M (IgM); Hepatitis B surface Ag, Hepatitis B<br><br>    If the results of the blood tests (hematology and biochemistry) are out of the ranges<br>    defined above, but within the limits of CTCAE (version 4.03) Grade 1, and this laboratory<br>    finding is considered as non-clinically significant, a new sample can be collected for a<br>    retest. Only one retest will be allowed within the screening period.<br><br>    If the result of the retest is within the margins defined above, the Investigator will<br>    review the parameter(s) together with all other medical information available (medical<br>    history, clinical examinations, vital signs, etc.) and upon his/her medical judgement will<br>    decide if the patient is eligible or not for trial randomization.<br><br>    Any condition that prevents the patient from taking oral medication.<br><br>     - Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles,<br>       e.g. metronidazole<br><br>     - Patients with history of allergy (serious or not), allergic skin rash, asthma,<br>       intolerance, sensitivity or photosensitivity to any drug<br><br>     - Any concomitant use of allopurinol, antimicrobial, anti-parasitic agents, and/or of<br>       herbal medicines, food supplements and energetic drinks<br><br>     - Any concomitant medication with drug known r",,Chagas' Disease (Chronic) Nos,Drug: Fexinidazole;Drug: Placebo Oral Tablet,Incidence and severity of adverse events.,"Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine AUC0-t values, for all dose levels.;Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine Cmax values, for all dose levels.",2016-004905-15;DNDi-FEX-12-CH,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,Yes,"Not yet decided how Individual Participant Data (IPD) will be shared, This action is under internal review within DNDi.",No,False,          ,2018,18.0,No,Yes
NCT03378661,8 January 2018,BENDITA BEnznidazole New Doses Improved Treatment and Associations,"Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease",BENDITA,Drugs for Neglected Diseases,2017-11-23,20171123,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03378661,Not recruiting,No,18 Years,50 Years,All,30/11/2016,210.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 2,Bolivia;Bolivia;Bolivia;Bolivia, ; ; ; ; ; ; ; ,"Faustino Torrico, PhD;Joaquim Gascón, PhD;Faustino Torrico, PhD;Joaquim Gascón, PhD;Faustino Torrico, PhD;Joaquim Gascón, PhD;Faustino Torrico, PhD;Joaquim Gascón, PhD",,;;;;;;;,;;;;;;;,"Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas. Cochabamba, Bolivia.;Centro de Salud Internacional, Hospital Clínico de Barcelona CRESIB - Centre de Recerca en Salut Internacional de Barcelona Barcelona, España.;Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas. Cochabamba, Bolivia.;Centro de Salud Internacional, Hospital Clínico de Barcelona CRESIB - Centre de Recerca en Salut Internacional de Barcelona Barcelona, España.;Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas. Cochabamba, Bolivia.;Centro de Salud Internacional, Hospital Clínico de Barcelona CRESIB - Centre de Recerca en Salut Internacional de Barcelona Barcelona, España.;Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas. Cochabamba, Bolivia.;Centro de Salud Internacional, Hospital Clínico de Barcelona CRESIB - Centre de Recerca en Salut Internacional de Barcelona Barcelona, España.","<br>    Screening criteria<br><br>     - Signed, written informed consent form<br><br>     - Age >18 to <50 years<br><br>     - Weight >50 kg to <80 kg<br><br>     - Diagnosis of T. cruzi infection by: Conventional serology (a minimum of two positive<br>       tests [Conventional ELISA, Recombinant Elisa and/or Indirect Immunofluorescence<br>       (IIF)])<br><br>     - Ability to comply with all protocol specified tests and visits and have a permanent<br>       address<br><br>     - Patients must be residents of areas free of vectorial transmission (Triatoma<br>       infestans). For this protocol, it will be accepted the status of Vectorial<br>       Transmission Interruption or Consolidation as per the definition of PAHO/WHO, or the<br>       Local Health Program.<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of CD<br><br>     - No acute or chronic health conditions, that in the opinion of the PI, may interfere<br>       with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, liver and renal disease requiring treatment)<br><br>     - No formal contraindication to BZN (according to the Summary of Product<br>       Characteristics) and E1224 (according to the Investigator's Brochure) Note: The<br>       contraindications described for Benznidazole and E1224 are essentially<br>       hypersensitivity to the active ingredient or any excipient. In the case of hepatic or<br>       renal impairment or blood dyscrasia, the medication should only be administered under<br>       strict medical supervision. During all the treatment period, the blood count will be<br>       monitored, with special attention to leucocytes. Subjects will be indicated about the<br>       need of no alcohol intake.<br><br>     - No history of hypersensitivity, allergic, or serious adverse reactions to any of the<br>       """"azoles"""" compound, and/or its components<br><br>     - No history of CD treatment with BZN or NFX at any time in the past<br><br>     - No history of systemic treatment with itraconazole, ketoconazole, posaconazole,<br>       isavuconazole, or allopurinol in the past<br><br>     - No history of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations)<br><br>     - No condition that prevents patient from taking oral medication<br><br>     - No concomitant or anticipated use of drugs that are either sensitive CYP3A4 substrates<br>       and/or extensively metabolized by CYP3A4 with a narrow therapeutic range (as per<br>       Appendix 2)<br><br>     - No medical history of Familial Short QT syndrome or concomitant therapy with<br>       medications that can shorten the QT interval (as per Appendix 2)<br><br>     - No family history of sudden death<br><br>     - No family history of sudden infant death syndrome<br><br>    Inclusion criteria<br><br>    Following the screening period, patients must meet ALL of the following inclusion criteria<br>    to be eligible for randomization:<br><br>     - Confirmed diagnosis of T. cruzi infection by: Serial qualitative PCR (three samples<br>       collected over a single day, at least one of which must be positive) AND Conventional<br>       serology (a minimum of two positive tests must be positive [Conventional ELISA,<br>       Recombinant Elisa and/or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening, must<br>       not be breastfeeding, and must use a double barrier method of contraception to avoid<br>       pregnancy throughout a clinical trial and for 3 months after completion of the trial,<br>       in such a manner that the risk of pregnancy is minimized especially during exposure to<br>       treatment. Women who are using oral, implanted, or injectable contraceptive hormones<br>       or mechanical products such as an intrauterine device with a hormonal component are<br>       required to use an additional barrier method of contraception for the time period<br>       specified.<br><br>     - Normal EKG (PR =200 msec, QRS <120 msec, and QTc =350 msec and =450 msec interval<br>       durations in males and QTc =470 msec in women) at screening.<br><br>    Exclusion criteria<br><br>    The presence of any of the following will exclude a patient from trial randomization:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD<br><br>     - History of cardiomyopathy, heart failure, or ventricular arrhythmia.<br><br>     - History of digestive surgery or mega syndromes.<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood<br>       pressure, liver, and renal disease requiring medical treatment).<br><br>     - Laboratory test values considered clinically significant or out of the allowable range<br>       at selection period as follows:<br><br>     - Total WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800<br>       - 10,500/mm3).<br><br>     - Platelets must be within the normal range up to 550,000/mm3<br><br>     - Total bilirubin must be within the normal range<br><br>     - Transaminases (ALT and AST) must be within the normal range, with an acceptable margin<br>       of 25% above the upper limit of normality (ULN), <1.25 x ULN.<br><br>     - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.<br><br>     - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (< 2.5 x ULN)<br><br>     - GGT must be within the normal range up to 2x ULN.<br><br>     - Fasting glucose must be within the normal range<br><br>     - Electrolytes (Ca, Mg, K) must be within the normal range<br><br>     - If the results of the blood tests (hematology and biochemistry) are out of the ranges<br>       defined above, but within the limits of CTCAE (version 4.03) Grade 1, and the<br>       laboratory finding is considered as non-clinically significant, a new sample can be<br>       collected for a retest. Only one retest will be allowed within the screening period.<br><br>     - If the result of retest is within the margins defined above, the Investigator will<br>       review the parameter(s) together with all other medical information available (medical<br>       history, clinical examinations, vital signs, etc.) and upon his/her medical judgment<br>       will decide if the patient is eligible or not for trial randomization.<br><br>     - Any condition that prevents the patient from taking oral medication<br><br>     - Patients with history of allergy (serious or not), allergic skin rash, asthma,<br>       intolerance, sensitivity or photosensitivity to any drug<br><br>     - Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles,<br>       e.g. metronidazole.<br><br>     - Any concomitant use of allopurinol, antimicrobial, or anti-parasitic agents.<br><br>     - Any planned surgery likely to interfere with the trial conduction and/or treatment<br>       evaluation<br><br>     - Unlikely to c;<br>    Screening criteria<br><br>     - Signed, written informed consent form<br><br>     - Age >18 to <50 years<br><br>     - Weight >50 kg to <80 kg<br><br>     - Diagnosis of T. cruzi infection by: Conventional serology (a minimum of two positive<br>       tests [Conventional ELISA, Recombinant Elisa and/or Indirect Immunofluorescence<br>       (IIF)])<br><br>     - Ability to comply with all protocol specified tests and visits and have a permanent<br>       address<br><br>     - Patients must be residents of areas free of vectorial transmission (Triatoma<br>       infestans). For this protocol, it will be accepted the status of Vectorial<br>       Transmission Interruption or Consolidation as per the definition of PAHO/WHO, or the<br>       Local Health Program.<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of CD<br><br>     - No acute or chronic health conditions, that in the opinion of the PI, may interfere<br>       with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, liver and renal disease requiring treatment)<br><br>     - No formal contraindication to BZN (according to the Summary of Product<br>       Characteristics) and E1224 (according to the Investigator's Brochure) Note: The<br>       contraindications described for Benznidazole and E1224 are essentially<br>       hypersensitivity to the active ingredient or any excipient. In the case of hepatic or<br>       renal impairment or blood dyscrasia, the medication should only be administered under<br>       strict medical supervision. During all the treatment period, the blood count will be<br>       monitored, with special attention to leucocytes. Subjects will be indicated about the<br>       need of no alcohol intake.<br><br>     - No history of hypersensitivity, allergic, or serious adverse reactions to any of the<br>       """"azoles"""" compound, and/or its components<br><br>     - No history of CD treatment with BZN or NFX at any time in the past<br><br>     - No history of systemic treatment with itraconazole, ketoconazole, posaconazole,<br>       isavuconazole, or allopurinol in the past<br><br>     - No history of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations)<br><br>     - No condition that prevents patient from taking oral medication<br><br>     - No concomitant or anticipated use of drugs that are either sensitive CYP3A4 substrates<br>       and/or extensively metabolized by CYP3A4 with a narrow therapeutic range (as per<br>       Appendix 2)<br><br>     - No medical history of Familial Short QT syndrome or concomitant therapy with<br>       medications that can shorten the QT interval (as per Appendix 2)<br><br>     - No family history of sudden death<br><br>     - No family history of sudden infant death syndrome<br><br>    Inclusion criteria<br><br>    Following the screening period, patients must meet ALL of the following inclusion criteria<br>    to be eligible for randomization:<br><br>     - Confirmed diagnosis of T. cruzi infection by: Serial qualitative PCR (three samples<br>       collected over a single day, at least one of which must be positive) AND Conventional<br>       serology (a minimum of two positive tests must be positive [Conventional ELISA,<br>       Recombinant Elisa and/or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening, must<br>       not be breastfeeding, and must use a double barrier method of contraception to avoid<br>       pregnancy throughout a clinical trial and for 3 months after completion of the trial,<br>       in such a manner that the risk of pregnancy is minimized especially during exposure to<br>       treatment. Women who are using oral, implanted, or injectable contraceptive hormones<br>       or mechanical products such as an intrauterine device with a hormonal component are<br>       required to use an additional barrier method of contraception for the time period<br>       specified.<br><br>     - Normal EKG (PR =200 msec, QRS <120 msec, and QTc =350 msec and =450 msec interval<br>       durations in males and QTc =470 msec in women) at screening.<br><br>    Exclusion criteria<br><br>    The presence of any of the following will exclude a patient from trial randomization:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD<br><br>     - History of cardiomyopathy, heart failure, or ventricular arrhythmia.<br><br>     - History of digestive surgery or mega syndromes.<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood<br>       pressure, liver, and renal disease requiring medical treatment).<br><br>     - Laboratory test values considered clinically significant or out of the allowable range<br>       at selection period as follows:<br><br>     - Total WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800<br>       - 10,500/mm3).<br><br>     - Platelets must be within the normal range up to 550,000/mm3<br><br>     - Total bilirubin must be within the normal range<br><br>     - Transaminases (ALT and AST) must be within the normal range, with an acceptable margin<br>       of 25% above the upper limit of normality (ULN), <1.25 x ULN.<br><br>     - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.<br><br>     - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (< 2.5 x ULN)<br><br>     - GGT must be within the normal range up to 2x ULN.<br><br>     - Fasting glucose must be within the normal range<br><br>     - Electrolytes (Ca, Mg, K) must be within the normal range<br><br>     - If the results of the blood tests (hematology and biochemistry) are out of the ranges<br>       defined above, but within the limits of CTCAE (version 4.03) Grade 1, and the<br>       laboratory finding is considered as non-clinically significant, a new sample can be<br>       collected for a retest. Only one retest will be allowed within the screening period.<br><br>     - If the result of retest is within the margins defined above, the Investigator will<br>       review the parameter(s) together with all other medical information available (medical<br>       history, clinical examinations, vital signs, etc.) and upon his/her medical judgment<br>       will decide if the patient is eligible or not for trial randomization.<br><br>     - Any condition that prevents the patient from taking oral medication<br><br>     - Patients with history of allergy (serious or not), allergic skin rash, asthma,<br>       intolerance, sensitivity or photosensitivity to any drug<br><br>     - Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles,<br>       e.g. metronidazole.<br><br>     - Any concomitant use of allopurinol, antimicrobial, or anti-parasitic agents.<br><br>     - Any planned surgery likely to interfere with the trial conduction and/or treatment<br>       evaluation<br><br>     - Unlikely to c;<br>    Screening criteria<br><br>     - Signed, written informed consent form<br><br>     - Age >18 to <50 years<br><br>     - Weight >50 kg to <80 kg<br><br>     - Diagnosis of T. cruzi infection by: Conventional serology (a minimum of two positive<br>       tests [Conventional ELISA, Recombinant Elisa and/or Indirect Immunofluorescence<br>       (IIF)])<br><br>     - Ability to comply with all protocol specified tests and visits and have a permanent<br>       address<br><br>     - Patients must be residents of areas free of vectorial transmission (Triatoma<br>       infestans). For this protocol, it will be accepted the status of Vectorial<br>       Transmission Interruption or Consolidation as per the definition of PAHO/WHO, or the<br>       Local Health Program.<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of CD<br><br>     - No acute or chronic health conditions, that in the opinion of the PI, may interfere<br>       with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, liver and renal disease requiring treatment)<br><br>     - No formal contraindication to BZN (according to the Summary of Product<br>       Characteristics) and E1224 (according to the Investigator's Brochure) Note: The<br>       contraindications described for Benznidazole and E1224 are essentially<br>       hypersensitivity to the active ingredient or any excipient. In the case of hepatic or<br>       renal impairment or blood dyscrasia, the medication should only be administered under<br>       strict medical supervision. During all the treatment period, the blood count will be<br>       monitored, with special attention to leucocytes. Subjects will be indicated about the<br>       need of no alcohol intake.<br><br>     - No history of hypersensitivity, allergic, or serious adverse reactions to any of the<br>       """"azoles"""" compound, and/or its components<br><br>     - No history of CD treatment with BZN or NFX at any time in the past<br><br>     - No history of systemic treatment with itraconazole, ketoconazole, posaconazole,<br>       isavuconazole, or allopurinol in the past<br><br>     - No history of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations)<br><br>     - No condition that prevents patient from taking oral medication<br><br>     - No concomitant or anticipated use of drugs that are either sensitive CYP3A4 substrates<br>       and/or extensively metabolized by CYP3A4 with a narrow therapeutic range (as per<br>       Appendix 2)<br><br>     - No medical history of Familial Short QT syndrome or concomitant therapy with<br>       medications that can shorten the QT interval (as per Appendix 2)<br><br>     - No family history of sudden death<br><br>     - No family history of sudden infant death syndrome<br><br>    Inclusion criteria<br><br>    Following the screening period, patients must meet ALL of the following inclusion criteria<br>    to be eligible for randomization:<br><br>     - Confirmed diagnosis of T. cruzi infection by: Serial qualitative PCR (three samples<br>       collected over a single day, at least one of which must be positive) AND Conventional<br>       serology (a minimum of two positive tests must be positive [Conventional ELISA,<br>       Recombinant Elisa and/or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening, must<br>       not be breastfeeding, and must use a double barrier method of contraception to avoid<br>       pregnancy throughout a clinical trial and for 3 months after completion of the trial,<br>       in such a manner that the risk of pregnancy is minimized especially during exposure to<br>       treatment. Women who are using oral, implanted, or injectable contraceptive hormones<br>       or mechanical products such as an intrauterine device with a hormonal component are<br>       required to use an additional barrier method of contraception for the time period<br>       specified.<br><br>     - Normal EKG (PR =200 msec, QRS <120 msec, and QTc =350 msec and =450 msec interval<br>       durations in males and QTc =470 msec in women) at screening.<br><br>    Exclusion criteria<br><br>    The presence of any of the following will exclude a patient from trial randomization:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD<br><br>     - History of cardiomyopathy, heart failure, or ventricular arrhythmia.<br><br>     - History of digestive surgery or mega syndromes.<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood<br>       pressure, liver, and renal disease requiring medical treatment).<br><br>     - Laboratory test values considered clinically significant or out of the allowable range<br>       at selection period as follows:<br><br>     - Total WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800<br>       - 10,500/mm3).<br><br>     - Platelets must be within the normal range up to 550,000/mm3<br><br>     - Total bilirubin must be within the normal range<br><br>     - Transaminases (ALT and AST) must be within the normal range, with an acceptable margin<br>       of 25% above the upper limit of normality (ULN), <1.25 x ULN.<br><br>     - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.<br><br>     - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (< 2.5 x ULN)<br><br>     - GGT must be within the normal range up to 2x ULN.<br><br>     - Fasting glucose must be within the normal range<br><br>     - Electrolytes (Ca, Mg, K) must be within the normal range<br><br>     - If the results of the blood tests (hematology and biochemistry) are out of the ranges<br>       defined above, but within the limits of CTCAE (version 4.03) Grade 1, and the<br>       laboratory finding is considered as non-clinically significant, a new sample can be<br>       collected for a retest. Only one retest will be allowed within the screening period.<br><br>     - If the result of retest is within the margins defined above, the Investigator will<br>       review the parameter(s) together with all other medical information available (medical<br>       history, clinical examinations, vital signs, etc.) and upon his/her medical judgment<br>       will decide if the patient is eligible or not for trial randomization.<br><br>     - Any condition that prevents the patient from taking oral medication<br><br>     - Patients with history of allergy (serious or not), allergic skin rash, asthma,<br>       intolerance, sensitivity or photosensitivity to any drug<br><br>     - Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles,<br>       e.g. metronidazole.<br><br>     - Any concomitant use of allopurinol, antimicrobial, or anti-parasitic agents.<br><br>     - Any planned surgery likely to interfere with the trial conduction and/or treatment<br>       evaluation<br><br>     - Unlikely to c;<br>    Screening criteria<br><br>     - Signed, written informed consent form<br><br>     - Age >18 to <50 years<br><br>     - Weight >50 kg to <80 kg<br><br>     - Diagnosis of T. cruzi infection by: Conventional serology (a minimum of two positive<br>       tests [Conventional ELISA, Recombinant Elisa and/or Indirect Immunofluorescence<br>       (IIF)])<br><br>     - Ability to comply with all protocol specified tests and visits and have a permanent<br>       address<br><br>     - Patients must be residents of areas free of vectorial transmission (Triatoma<br>       infestans). For this protocol, it will be accepted the status of Vectorial<br>       Transmission Interruption or Consolidation as per the definition of PAHO/WHO, or the<br>       Local Health Program.<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of CD<br><br>     - No acute or chronic health conditions, that in the opinion of the PI, may interfere<br>       with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, liver and renal disease requiring treatment)<br><br>     - No formal contraindication to BZN (according to the Summary of Product<br>       Characteristics) and E1224 (according to the Investigator's Brochure) Note: The<br>       contraindications described for Benznidazole and E1224 are essentially<br>       hypersensitivity to the active ingredient or any excipient. In the case of hepatic or<br>       renal impairment or blood dyscrasia, the medication should only be administered under<br>       strict medical supervision. During all the treatment period, the blood count will be<br>       monitored, with special attention to leucocytes. Subjects will be indicated about the<br>       need of no alcohol intake.<br><br>     - No history of hypersensitivity, allergic, or serious adverse reactions to any of the<br>       """"azoles"""" compound, and/or its components<br><br>     - No history of CD treatment with BZN or NFX at any time in the past<br><br>     - No history of systemic treatment with itraconazole, ketoconazole, posaconazole,<br>       isavuconazole, or allopurinol in the past<br><br>     - No history of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations)<br><br>     - No condition that prevents patient from taking oral medication<br><br>     - No concomitant or anticipated use of drugs that are either sensitive CYP3A4 substrates<br>       and/or extensively metabolized by CYP3A4 with a narrow therapeutic range (as per<br>       Appendix 2)<br><br>     - No medical history of Familial Short QT syndrome or concomitant therapy with<br>       medications that can shorten the QT interval (as per Appendix 2)<br><br>     - No family history of sudden death<br><br>     - No family history of sudden infant death syndrome<br><br>    Inclusion criteria<br><br>    Following the screening period, patients must meet ALL of the following inclusion criteria<br>    to be eligible for randomization:<br><br>     - Confirmed diagnosis of T. cruzi infection by: Serial qualitative PCR (three samples<br>       collected over a single day, at least one of which must be positive) AND Conventional<br>       serology (a minimum of two positive tests must be positive [Conventional ELISA,<br>       Recombinant Elisa and/or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening, must<br>       not be breastfeeding, and must use a double barrier method of contraception to avoid<br>       pregnancy throughout a clinical trial and for 3 months after completion of the trial,<br>       in such a manner that the risk of pregnancy is minimized especially during exposure to<br>       treatment. Women who are using oral, implanted, or injectable contraceptive hormones<br>       or mechanical products such as an intrauterine device with a hormonal component are<br>       required to use an additional barrier method of contraception for the time period<br>       specified.<br><br>     - Normal EKG (PR =200 msec, QRS <120 msec, and QTc =350 msec and =450 msec interval<br>       durations in males and QTc =470 msec in women) at screening.<br><br>    Exclusion criteria<br><br>    The presence of any of the following will exclude a patient from trial randomization:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD<br><br>     - History of cardiomyopathy, heart failure, or ventricular arrhythmia.<br><br>     - History of digestive surgery or mega syndromes.<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the trial drug (such as acute<br>       infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood<br>       pressure, liver, and renal disease requiring medical treatment).<br><br>     - Laboratory test values considered clinically significant or out of the allowable range<br>       at selection period as follows:<br><br>     - Total WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800<br>       - 10,500/mm3).<br><br>     - Platelets must be within the normal range up to 550,000/mm3<br><br>     - Total bilirubin must be within the normal range<br><br>     - Transaminases (ALT and AST) must be within the normal range, with an acceptable margin<br>       of 25% above the upper limit of normality (ULN), <1.25 x ULN.<br><br>     - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.<br><br>     - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (< 2.5 x ULN)<br><br>     - GGT must be within the normal range up to 2x ULN.<br><br>     - Fasting glucose must be within the normal range<br><br>     - Electrolytes (Ca, Mg, K) must be within the normal range<br><br>     - If the results of the blood tests (hematology and biochemistry) are out of the ranges<br>       defined above, but within the limits of CTCAE (version 4.03) Grade 1, and the<br>       laboratory finding is considered as non-clinically significant, a new sample can be<br>       collected for a retest. Only one retest will be allowed within the screening period.<br><br>     - If the result of retest is within the margins defined above, the Investigator will<br>       review the parameter(s) together with all other medical information available (medical<br>       history, clinical examinations, vital signs, etc.) and upon his/her medical judgment<br>       will decide if the patient is eligible or not for trial randomization.<br><br>     - Any condition that prevents the patient from taking oral medication<br><br>     - Patients with history of allergy (serious or not), allergic skin rash, asthma,<br>       intolerance, sensitivity or photosensitivity to any drug<br><br>     - Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles,<br>       e.g. metronidazole.<br><br>     - Any concomitant use of allopurinol, antimicrobial, or anti-parasitic agents.<br><br>     - Any planned surgery likely to interfere with the trial conduction and/or treatment<br>       evaluation<br><br>     - Unlikely to c",,Chagas Disease;Chagas Disease;Chagas Disease;Chagas Disease,Drug: Benznidazole;Drug: E1224;Drug: E1224 Placebo;Drug: Benznidazole Placebo;Drug: Benznidazole;Drug: E1224;Drug: E1224 Placebo;Drug: Benznidazole Placebo;Drug: Benznidazole;Drug: E1224;Drug: E1224 Placebo;Drug: Benznidazole Placebo;Drug: Benznidazole;Drug: E1224;Drug: E1224 Placebo;Drug: Benznidazole Placebo,"Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.;Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.;Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.;Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.","Incidence of Adverse Events (AEs);Severity of Adverse Events (AEs);Incidence of Serious Adverse Events (SAEs) and/or adverse events leading to treatment discontinuation;Sustained parasitological clearance at 12 weeks and 12 months of follow-up;Parasite clearance as measured by qualitative PCR;Change in parasite load over time assessed as measured by quantitative PCR;Serological response by conventional serology assessed at 12 months of follow up and non-conventional serology assessed at W12, 4, 6, and 12 months of follow up. (changes in titters over time)",DNDi-CH-E1224-003,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2017,18.0,No,Yes
NCT03350295,12 December 2020,"Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg","Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Disease",,Bayer,2017-11-09,20171109,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03350295,Not recruiting,No,18 Years,45 Years,All,14/06/2018,48.0,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 1,Argentina, ,Bayer Study Director,,,,Bayer,"<br>    Inclusion Criteria<br><br>     - Women and men of reproductive potential must agree to use adequate contraception when<br>       sexually active. This applies for the time period between signing of the informed<br>       consent form and 12 weeks after the last administration of study drug. The definition<br>       of adequate contraception will be based on the judgment of the investigator and on<br>       local requirements. Acceptable methods of contraception include, but are not limited<br>       to: (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm<br>       or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based<br>       contraception. Subjects must agree to utilize two reliable and acceptable methods of<br>       contraception simultaneously.<br><br>     - Women of childbearing potential with confirmed last menstrual period by anamnesis and<br>       negative serum pregnancy test (beta-human chorionic gonadotropin [ßhCG]) at screening<br>       and negative urine pregnancy test (ßhCG) at pre-dose of each treatment.<br><br>     - Women of non-childbearing potential, such as surgically sterile women with either<br>       written documentation of surgical sterility or negative serum pregnancy test (ßhCG) at<br>       screening and negative urine pregnancy test (ßhCG) at pre-dose of each treatment.<br><br>     - Male subjects who agree not to act as sperm donors for 12 weeks after last<br>       administration of study drug.<br><br>     - Age: 18 to 45 years (inclusive) at screening.<br><br>     - Body mass index (BMI): =18 and <29.9 kg/m².<br><br>     - Written informed consent must be provided before any study-specific tests or<br>       procedures are performed.<br><br>     - Male/female patient diagnosed with chronic Chagas' disease:<br><br>     - Previous diagnosis of acute or chronic Chagas' disease by a health clinic prior to<br>       screening for the study. The diagnosis of chronic Chagas' disease may be made by<br>       clinical findings, supported by antibody titers if available. If there is a known<br>       history of acute disease, it is preferable to have documentation of parasites on the<br>       blood smear, if available.<br><br>    Exclusion Criteria<br><br>     - Incompletely cured pre-existing diseases (except chronic Chagas' disease without<br>       active GI condition) for which it can be assumed that the absorption, distribution,<br>       metabolism, elimination, and effects of the study drugs will not be normal.<br><br>     - Acute Chagas' disease. (During the acute phase, the parasite on a blood smear may be<br>       seen under a microscope. Different antibodies are present, depending on the course of<br>       the disease).<br><br>     - Known hypersensitivity to the study drug (active substance or excipients of the<br>       preparations)<br><br>     - Unstable or uncontrolled medical condition such as hypertension or diabetes,<br>       decompensated heart failure, GI conditions that would interfere with the absorption of<br>       the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal<br>       reflux, or other GI disease affecting gastroesophageal junction), conditions that<br>       could potentially have an impact on drug metabolism or elimination (renal, hepatic<br>       such as known hepatic or biliary abnormalities), or any clinically relevant active<br>       infections in the opinion of the investigator within 4 weeks before the screening<br>       visit, e.g. clinically relevant history or presence of significant respiratory (e.g.<br>       interstitial lung disease), hematological, lymphatic, neurological, cardiovascular,<br>       psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes),<br>       and dermatological or connective tissue disease.<br><br>     - Use of systemic or topical medicines or substances which oppose the study objectives<br>       (including clinical treatment with nifurtimox and benznidazole) or which might<br>       influence them within 4 weeks before the first study drug administration, e.g. an<br>       investigational drug, any drug altering GI motility and/or gastric pH (e.g. antacids,<br>       anticholinergic, para-sympatholytics), any drug known to induce liver enzymes (e.g.<br>       dexamethasone, barbiturates, St. John's Wort [hypericum perforatum]), any drug known<br>       to inhibit liver enzymes (e.g. ketoconazole, macrolides).<br><br>     - Clinically relevant findings in the ECG such as a second- or third-degree<br>       atrioventricular block, prolongation of the QRS complex over 120 msec or of the QT<br>       interval over 450 msec using Bazett's formula (QTcB). (Clinically stable subjects with<br>       Chagas'-related heart disease and pacemaker in place for >1 year and evaluated by a<br>       cardiologist =6 months before the first dose of study drug will not be excluded.)<br><br>     - Systolic blood pressure <100 or >140 mmHg (after resting in supine position for a<br>       minimum of 3 minutes).<br><br>     - Diastolic blood pressure <50 or >90 mmHg (after resting in supine position for a<br>       minimum of 3 minutes).<br><br>     - Findings that would exclude the subject in the investigator's judgment, e.g. enlarged<br>       liver, irregular heartbeat, undiagnosed acute illness, and melanoma.<br><br>     - Positive pregnancy test.<br><br>     - Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus<br>       antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV 1+2).<br><br>     - Positive urine drug screening..<br>   ",,Chagas Disease,"Drug: Nifurtimox (Lampit, BAYA2502)",AUC(0-tlast) of nifurtimox;Cmax of nifurtimox;AUC of nifurtimox,Number of participants with adverse events;AUC divided by dose: AUC/D;AUC(0-tlast) divided by dose: AUC(0-tlast)/D;Cmax divided by dose: Cmax/D,16007,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2017,18.0,No,Yes
NCT03334838,12 December 2020,Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study,"Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease",,Bayer,2017-11-03,20171103,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03334838,Not recruiting,No,18 Years,45 Years,All,10/06/2019,36.0,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 1,Argentina,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Written informed consent must be provided before any study-specific tests or<br>       procedures are performed.<br><br>     - Male/female patient diagnosed with chronic Chagas' disease:<br><br>    Previous diagnosis of acute or chronic Chagas' disease by a health clinic prior to<br>    screening for the study. The diagnosis of chronic Chagas' disease may be made by clinical<br>    findings, supported by antibody titers if available. If there is a known history of acute<br>    disease, it is preferable to have documentation of parasites on the blood smear, if<br>    available.<br><br>     - Women and men of reproductive potential must agree to use adequate contraception when<br>       sexually active. This applies for the time period between signing of the informed<br>       consent form and 12 weeks after the last administration of study drug. The definition<br>       of adequate contraception will be based on the judgment of the investigator and on<br>       local requirements. Acceptable methods of contraception include, but are not limited<br>       to: (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm<br>       or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based<br>       contraception. Subjects must agree to utilize two reliable and acceptable methods of<br>       contraception simultaneously.<br><br>     - Women of childbearing potential with confirmed last menstrual period by anamnesis and<br>       negative serum pregnancy test (beta-human chorionic gonadotropin [ßhCG]) at screening<br>       and negative urine pregnancy test (ßhCG) at pre-dose of each treatment.<br><br>     - Women of non-childbearing potential, such as surgically sterile women with either<br>       written documentation of surgical sterility or negative serum pregnancy test (ßhCG) at<br>       screening and negative urine pregnancy test (ßhCG) at pre-dose of each treatment.<br><br>     - Male subjects who agree not to act as sperm donors for 12 weeks after last<br>       administration of study drug.<br><br>     - Age: 18 to 45 years (inclusive) at screening.<br><br>     - Body mass index (BMI): =18 and <29.9 kg/m².<br><br>    Exclusion Criteria:<br><br>     - Incompletely cured pre-existing diseases (except chronic Chagas' disease without<br>       active GI condition) for which it can be assumed that the absorption, distribution,<br>       metabolism, elimination, and effects of the study drugs will not be normal.<br><br>     - Acute Chagas' disease. (During the acute phase, the parasite on a blood smear may be<br>       seen under a microscope. Different antibodies are present, depending on the course of<br>       the disease).<br><br>     - Known hypersensitivity to the study drug (active substance or excipients of the<br>       preparations)<br><br>     - Unstable or uncontrolled medical condition such as hypertension or diabetes,<br>       decompensated heart failure, GI conditions that would interfere with the absorption of<br>       the study drug (e.g. GI ulceration, peptic ulceration, GI bleeding, gastroesophageal<br>       reflux, or other GI disease affecting gastroesophageal junction), conditions that<br>       could potentially have an impact on drug metabolism or elimination (renal, hepatic<br>       such as known hepatic or biliary abnormalities), or any clinically relevant active<br>       infections in the opinion of the investigator within 4 weeks before the screening<br>       visit, e.g. clinically relevant history or presence of significant respiratory (e.g.<br>       interstitial lung disease), hematological, lymphatic, neurological, cardiovascular,<br>       psychiatric, musculoskeletal, genitourinary, immunological, metabolic (e.g. diabetes),<br>       and dermatological or connective tissue disease.<br><br>     - Use of systemic or topical medicines or substances which oppose the study objectives<br>       (including clinical treatment with nifurtimox and benznidazole) or which might<br>       influence them within 4 weeks before the first study drug administration, e.g. an<br>       investigational drug, any drug altering GI motility and/or gastric pH (e.g. antacids,<br>       anticholinergic, para-sympatholytics), any drug known to induce liver enzymes (e.g.<br>       dexamethasone, barbiturates, St. John's Wort [hypericum perforatum]), any drug known<br>       to inhibit liver enzymes (e.g. ketoconazole, macrolides).<br><br>     - Clinically relevant findings in the ECG such as a second- or third-degree<br>       atrioventricular block, prolongation of the QRS complex over 120 msec or of the QT<br>       interval over 450 msec using Bazett's formula (QTcB). (Clinically stable subjects with<br>       Chagas'-related heart disease and pacemaker in place for >1 year and evaluated by a<br>       cardiologist =6 months before the first dose of study drug will not be excluded.)<br><br>     - Systolic blood pressure <100 or >140 mmHg (after resting in supine position for a<br>       minimum of 3 minutes).<br><br>     - Diastolic blood pressure <50 or >90 mmHg (after resting in supine position for a<br>       minimum of 3 minutes).<br>   ",,Chagas' Disease,"Drug: Nifurtimox (Lampit, BAYA2502)",AUC(0-tlast) of nifurtimox;Cmax of nifurtimox,Number of participants with adverse events as a measure of safety and tolerability;AUC(0-tlast) divided by dose: AUC(0-tlast)/D;Cmax divided by dose: Cmax/D,16006,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2017,18.0,No,Yes
EUCTR2016-004905-15-ES,1 February 2020,Oral fexinidazole dosing regimens for the treatment of adults with chronic indeterminate Chagas disease,"Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",,Drugs for Neglected Diseases initiative (DNDi),2017-05-29,20170529,10/13/2025 15:56:09,EU Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004905-15,Not Recruiting,No,,,<br> Female: yes<br> Male: yes<br>,13/09/2017,45.0,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 3<br>","
                Human pharmacology (Phase I): no
                Therapeutic exploratory (Phase II): yes
                Therapeutic confirmatory - (Phase III): no
                Therapeutic use (Phase IV): no
",Spain,Irene Mínguez Ardura,,"Avd. Ordoño II, 37-2º dcha.",iminguez@leonresearch.es,0034987261 064,Leon Research S.L.,"Inclusion criteria: <br>        1. Confirmed diagnosis of T. cruzi infection by:<br>        •Serial qualitative PCR (three samples collected over a single day, at least one of which must be positive),<br>        AND<br>        •Conventional serology (a minimum of two positive tests must be positive [Conventional ELISA, Recombinant Elisa and/or IIF)<br>        2. Women in reproductive age must have a negative serum pregnancy test at screening, must not be breastfeeding, must consistently use a highly effective contraceptive method until end of treatment and estimated FEXI, M1 and M2 clearance (total of 21 days). After this, contraception is no longer required.<br>        3. Normal ECG (Heart rate: 50-100bpm; PR =200 msec, QRS <120 msec, and QTc =350msec and =450 msec interval durations) at screening<br>        4. 24 hour Holter-monitoring with no clinically relevant arrythmias (defined as Ventricular Tachycardia (defined as >3 ventricular beats with >100bpm); Sustained Accelerated Idio-Ventricular rhythm (defined as >30 seconds duration and HR: 50bpm<HR<100bpm); frequent Ventricular Premature Beats (10/hour); Atrial Fibrillation/flutter; Mobitz type 2 second degree AV block; High degree and complete AV block; Bradycardia episodes <40bpm)<br>        Are the trial subjects under 18? no<br>        Number of subjects for this age range:<br>        F.1.2 Adults (18-64 years) yes<br>        F.1.2.1 Number of subjects for this age range 45<br>        F.1.3 Elderly (>=65 years) no<br>        F.1.3.1 Number of subjects for this age range<br>      ","Exclusion criteria: <br>        •Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study Manual of Operations).<br>        •History of cardiomyopathy, heart failure, or ventricular arrhythmia.<br>        •History of digestive surgery or mega syndromes.<br>        •Personal or family history of mental disability, suicidal tendencies or any other neuropsychiatric disorders, including previous treatment for anxiety or depression.<br>        •Hospital Anxiety and Depression Scale (HADS – Appendix 1) self-assessment score >11 in each of the sub-scales. (Note: If HADS score >11, retesting would be allowed before after a minimum period of 15 days and referral to counseling/evaluation.)<br>        •Any other acute or chronic health conditions that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial drug (such as acute infections, history of HIV infection, diabetes, uncontrolled systolic/diastolic blood pressure, liver, and renal diseases requiring medical treatment).<br>        •Laboratory test values considered clinically significant or out of the allowable range at selection period as follows:<br>        oTotal WBC must be within the normal range, with an acceptable margin of +/- 5% (3,800 – 10,500 / mm3).<br>        oPlatelets must be within the normal range up to 550,000/mm3<br>        oTotal bilirubin must be within the normal range<br>        oTransaminases (ALT and AST) must be within the normal range, with an acceptable margin of 25% above the upper limit of normality (ULN), < 1.25 x ULN.<br>        oCreatinine must be within an acceptable margin of 10% above the ULN, <1.10 x ULN.<br>        oAlkaline phosphatase must be within the normal range up to Grade 1 CTCAE (<,2.5 x ULN)<br>        oGGT must be within the normal range up to 2x ULN.<br>        oFasting glucose (minimum of 8 hours from latest meal) must be within the normal range<br>        oElectrolytes (Ca, Mg, K) must be within the normal range<br>        oHepatitis screen must be negative for acute and/or chronic infection (Hepatitis A antibody, IgM; Hepatitis B surface Ag, Hepatitis B core antibody, IgM/IgG, anti-HBs; Hepatitis C antibody)<br><br>        If the results of the blood tests (hematology and biochemistry) are out of the ranges defined above, but within the limits of CTCAE (version 4.03) Grade 1, and this laboratory finding is considered as non-clinically significant, a new sample can be collected for a retest. Only one retest will be allowed within the screening period.<br>        If the result of the retest is within the margins defined above, the Investigator will review the parameter(s) together with all other medical information available (medical history, clinical examinations, vital signs, etc.) and upon his/her medical judgement will decide if the patient is eligible or not for trial randomization.<br>        •Any condition that prevents the patient from taking oral medication.<br>        •Patients with any contra-indication (known hypersensitivity) to any nitroimidazoles, e.g. metronidazole<br>        •Patients with history of allergy (serious or not), allergic skin rash, asthma, intolerance, sensitivity or photosensitivity to any drug<br>        •Any concomitant use of allopurinol, antimicrobial, or anti-parasitic agents and/or of herbal medicines, food supplements and ene","Chagas disease (CD) is a disease caused by Trypanosoma cruzi, ranking among the world’s most neglected diseases. There is significant associated morbidity and mortality, particularly in chronic phase with target organ involvement. In Latin America, 21 countries are endemic for CD with an estimated 70 million people at risk. Spain has an estimated 46,000 people infected. The current treatment for CD has significant limitations and new therapeutic options are urgently needed.;Therapeutic area: Diseases [C] - Parasitic Diseases [C03]",<br>        Product Name: Fexinidazole<br>        Pharmaceutical Form: Tablet<br>        INN or Proposed INN: FEXINIDAZOLE<br>        CAS Number: 59729-37-2<br>        Concentration unit: mg milligram(s)<br>        Concentration type: equal<br>        Concentration number: 600-<br>        Pharmaceutical form of the placebo: Tablet<br>        Route of administration of the placebo: Oral use<br><br>,"Main Objective: To determine the efficacy of alternative dosing regimens of orally administered FEXI in individuals with chronic indeterminate CD, by determining the proportion of patients who convert from positive to negative in serial, qualitative PCR test results (3 negative PCR results) at end of treatment (EOT) and sustain parasitological clearance at 4 months of follow-up, in comparison to historical placebo control.;<br>        Secondary Objective: •To measure the reduction in parasite load at weeks 1 (D1, D2, D3), 2, 3, 4, 6, 10, 12 and at 4, 6 and 12-months follow-up, as measured by quantitative PCR.<br>        •To assess the time to parasite DNA clearance (below the quantitative PCR Limit of Detection [LOD]) for each of the regimens<br>        •To explore the sustained parasitological response at week 12, and 4, 6 and 12 months for each of the regimens, in comparison with BZN historical control.<br>        •To assess the time to sustained clearance of parasitemia for each of the treatment regimens.<br>        •To determine the efficacy of the different dosing regimens in individuals with chronic indeterminate CD, by determining the proportion of patients who convert from positive to negative in serial, qualitative PCR test results (3 negative PCR results) at EOT, in comparison with historical placebo control. [...]<br>      ;Timepoint(s) of evaluation of this end point: Sustained parasitological response will be determined from EOT until 4-months follow-up (with evaluations at weeks 1 (D1, D2, D3), 2, 3, 4, 6, 10, 12, and at 4 months).;<br>        Primary end point(s): •Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 4-months follow-up.<br><br>        For efficacy assessments, the EOT of each treatment arm will be defined in accordance to the duration of the allocated treatment regimen. Sustained response will be assessed in all treatment arms using the same number of PCR samples (i.e., EOT; 12 weeks; and 4 months).<br>        Key safety criteria:<br>        •Incidence and severity of adverse events (clinical, laboratory measurements, and ECG)<br>        •Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events leading to treatment discontinuation<br><br>        Safety will be assessed through routine monitoring of adverse events, evaluation of hematological and blood chemistry values, regular measurement of vital signs, physical examination, and conduct of ECGs at selected trial visits (according to the trial schedule).<br><br>        Key pharmacokinetics (PK) endpoints:<br><br>        •Blood level concentrations will be determined at D0 (pre-dose), after first day of treatment administration (day 1, up to two samples post-dose), at day 2 and day 3, at steady-state and elimination phase (week 2-10);<br><br>        •Population pharmacokinetic parameters will include: AUC, Cmax, Cmin, CL, Vd, and t1/2.<br><br>        On day 1 to 3, patients will undergo sampling at a randomly selected time-point to allow population PK analysis. An additional PK sample will be obtained on Day 1 in patients who accept and as trial logistics allow. Actual time of sampling will be recorded in all cases, as well as time of treatment administration.<br><br>        Covariates to be evaluated: age, body mass index, and parasite load at baseline, gender.<br>      ","<br>        Timepoint(s) of evaluation of this end point: •Parasitological endpoints will be assessed on weeks 1 (D1, D2, D3), 2, 3, 4, 6, 10, 12, and at 4, 6 and 12-months follow-up.<br><br>        •Serological endpoints will be assessed baseline and at 12 months, in the case of conventional serology; and at week 12, and 4, 6 and 12-months of follow up (changes in titters over time) in the case of non-conventional serology.<br>      ;<br>        Secondary end point(s): •Parasite reduction ratio at D, D2 and -D3.<br>        •Parasite clearance at weeks 1 (D1, D2, D3), 2, 3, 4, 6, 10, 12, and at 4, 6 and 12-months follow-up as measured by qualitative PCR.<br>        •Change in parasite load over time assessed at weeks 1 (D1, D2, D3), 2, 3, 4, 6, 10, 12, and at 4, 6 and 12-months follow-up as measured by quantitative PCR.<br>        •Serological response by conventional serology assessed at 12 months of follow up and non-conventional serology assessed at week 12, and 4, 6 and 12-months of follow up (changes in titters over time)<br>      ",DNDi-FEX-12-CH,Drugs for Neglected Diseases initiative,,Approved,28/07/2017,,,,,Unknown,,,,,,,No results available,No results available,No results available,,,Yes,False,          ,2017,,Unknown,Yes
EUCTR2016-003789-21-ES,31 January 2017,Phase II trial for assessing different benznidazol regimens in the treatment of Chagas disease in adult patients on chronic phase . BERINECE project,Phase II trial for assessing different benznidazol regimens in the treatment of Chagas disease in adult patients on chronic phase . BERINECE project - MULTBENZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ,,Fundación Hospital Universitari Vall d'Hebron - Institut de Recerca,2016-11-17,20161117,10/13/2025 15:56:09,EU Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003789-21,Authorised,Yes,,,<br>Female: yes<br>Male: yes<br>,11/01/2017,240.0,Interventional clinical trial of medicinal product,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Different doses of IMP
Number of treatment arms in the trial: 3
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Argentina;Brazil;Spain;Colombia,PROSICS,,"Passeig de la Vall d'Hebron, 119-129",,34932746080,Fundación Hospital Universitari Vall d'Hebron - Institut de Recerca,"Inclusion criteria: <br>-Patients = 18 years old<br>-Patients diagnosed of Chagas disease through 2 positive serologic tests, using different antigens.<br>-Detectable DNA of T.Cruzi in peripheral blood through PCR.<br>-Written Informed Consent<br>-Weight = 50 kg to =80 kg<br>-Patients capable to fulfill with the protocol visits and procedures and have a permanent address<br>-Patients must be residents of Free Areas transmission vector (Triatoma infestans). (Defined by local health programs or under the definition of PAHO / WHO<br>-Childbearing Woman with a negative pregnancy test in serum or urine at baseline. During the treatment phase, breastfeeding is not allow and a barrier contraceptive method has to be used.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 200<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 40<br>","Exclusion criteria: <br>-Patients treated previously with benznidazol o nifurtimox (complete or incomplete)<br>-Inability to do the Follow Up at the stipulated dates<br>-Acute or chronic health problems, that according to PI opinion can interfere in the efficacy and/or safety drug evaluation (exemple: acute infections, HIV infection, hepatic disease with liver function affected and renal disease that needs supportive treatment)<br>-Precedent of alcohol abuse<br>-Patients with Known hypersensibility to nitroimidazols, for example metronidazol<br>-Any concomitant use or a history of use of allopurinol, antimicrobial or anti-parasitic agents or antifungal<br>-Laboratory parameters out of range o clinically relevant according to investigator criteria:<br>oLeukocytes must be within the normal range, with an acceptable margin of +/- 5%<br>oPlatelets must be within the normal range up to 550,000 / mm3 or 550x109 / L<br>oTotal bilirubin must be within the normal range<br><br>oTransaminases (ALT and AST) should be within the normal range, with an acceptable margin of 25% above the upper limit of normal (ULN) <1.25 x ULN.<br>oCreatinine should be within the normal range, with an acceptable margin of 10% above the ULN, <1.10 x ULN.<br>oAlkaline phosphatase must be within the normal range until CTCAE Grade 1 (<2.5 x ULN)<br>oGGT should be within the normal range up to 2x ULN.<br>oFasting glucose should be within the normal range<br>",Chagas Disease on chronic phase <br>MedDRA version: 19.0Level: LLTClassification code 10008384Term: Chagas' diseaseSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Parasitic Diseases [C03],<br>Product Name: Benznidazol<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: BENZNIDAZOLE<br>CAS Number: 22994-85-0<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 150-400<br><br>,"Main Objective: Evaluate the effectiveness of different regimens of benznidazole by the proportion of patients with sustained suppression of the parasitic load measured by PCR in peripheral blood during the first 12 months of follow up after the start of treatment in patients older than 18 years with Chagas disease in chronic phase in both its indeterminate or organic form (digestive or heart ) .;Secondary Objective: - Assess for different regimes, the parasitic kinetic at week 1,2,4 and 8 of treatment and 4,6,8 and 12 months after starting treatment in patients over 18 with chronic phase Chagas both its indeterminate form and organic ( gastrointestinal or cardiac )<br>-Evaluate for different regimes, the serologic response in chronic phase indeterminate form both in symptomatic and by trend curves OD by ELISA methods<br>-Assess tolerability and safety of different regimens of benznidazole for Chagas disease in chronic phase, in form with or without apparent pathology ( digestive or heart )<br>- Correlate Benznidazol blood levels in the equilibrium phase with the therapeutic response and adverse effects.<br>- Correlate the presence of HLA B3505 with serious side effects<br>- Correlate different DTUs parasites and geographical origins with therapeutic response;Primary end point(s): Efficacy:<br>Parasitological response determined by the presence of parasite DNA in peripheral blood measured by PCR and interpreted qualitatively during the treatment and follow-up. Treatment times and are defined by monitoring the different treatment arms.<br>Safety: <br>- Incidence and severity of the side effects<br>- Treatment interruption;Timepoint(s) of evaluation of this end point: 15 or 60 days depending on the treatment arm",Secondary end point(s): Negativization maintained during the treatment phase and the first 12 months of follow up. <br>• Proportion of patients with positive PCR in each of the points of analysis. <br>• Changes in the parasite load in the different points of analysis measured by detecting parasite DNA in peripheral blood by quantitative PCR <br>• Evolution of the serological response comparing baseline results with the end of follow-up results. <br>• Range of biomarker levels decreased at 6 and 12 months follow-up on the screening visit <br>• Proportion of patients achieving marker levels decrease below the threshold of positivity (previously defined).;Timepoint(s) of evaluation of this end point: - During treatment phase and 12 months after treatment<br>- Different time point.<br>- Different time point<br>- At the end of follow up<br>- 6 and 12 months follow-up period<br>- Different time point,MULTBENZ,European Comission,,,,,,,,Unknown,,,,,,,,,,,,Yes,True ,parent    ,2016,,Unknown,Yes
NCT02646943,18 January 2016,Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project),Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project),SaMi-Trop,University of Sao Paulo,2015-12-27,20151227,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02646943,Not recruiting,No,18 Years,,Both,01/07/2013,1959.0,Observational,"Observational Model: Cohort, Time Perspective: Prospective",Unknown,Unknown, ,"Ester C Sabino, PhD",,,,University of São Paulo,"<br>    Eligibility Criteria: to be a client of the TMS TeleHealth System, have a positive history<br>    for T cruzi infection or Chagas disease, have an abnormal ECG and to consent to<br>    participating in the research program.<br><br>    Exclusion Criteria: The exclusion criteria include pregnancy or breast feeding, and any<br>    severe condition with ominous prognosis that indicates a life expectancy of less than two<br>    years.<br>   ",,Chagas Disease,,Death,Changes in the ECG pattern;Hospitalization due to cardiovascular,P50AI098461-02;2111129,Please refer to primary and secondary sponsors,National Institute of Allergy and Infectious Diseases (NIAID);Federal University of Minas Gerais;Federal University of São João del-Rei,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2015,18.0,No,Yes
NCT02517632,16 December 2017,Physical Exercise Program in Chronic Chagas Heart Disease,Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial),PEACH,Evandro Chagas National Institute of Infectious Disease,2015-08-05,20150805,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02517632,Not recruiting,No,18 Years,,All,01/03/2015,30.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 3,Brazil;Brazil;Brazil;Brazil;Brazil, ; ; ; ; ,"Fernanda Mendes, M.D.;Fernanda Mendes, M.D.;Fernanda Mendes, M.D.;Fernanda Mendes, M.D.;Fernanda Mendes, M.D.",,;;;;,;;;;,Evandro Chagas National Institute of Infectious Disease;Evandro Chagas National Institute of Infectious Disease;Evandro Chagas National Institute of Infectious Disease;Evandro Chagas National Institute of Infectious Disease;Evandro Chagas National Institute of Infectious Disease,"<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ;<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ;<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ;<br>    Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic<br>    cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure<br>    (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical<br>    treatment and (5) age above 18 years.<br><br>    Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4)<br>    evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise<br>    practice or hemodynamic stress tests (6) unavailability to attend three times a week for a<br>    minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.<br>   ",,Chagas Disease;Chagas Cardiomyopathy;Chagas Disease;Chagas Cardiomyopathy;Chagas Disease;Chagas Cardiomyopathy;Chagas Disease;Chagas Cardiomyopathy,"Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling;Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling;Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling;Behavioral: Exercise, nutritional and pharmaceutical counceling;Behavioral: Nutritional and pharmaceutical counceling",Functional capacity measured by peak exercise oxygen consumption;Functional capacity measured by peak exercise oxygen consumption;Functional capacity measured by peak exercise oxygen consumption,Muscle respiratory strength;Body composition (body fat percentage);Cardiac function (maily ejection fraction);Laboratorial biomarkers composite;Quality of life;24 hours Holter;Nutritional assessment;Pharmaceutical assessment;Microvascular reactivity;Body mass index,CAAE:38038914.6.0000.5262,Please refer to primary and secondary sponsors,"National Institute of Cardiology, Laranjeiras, Brazil",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2015,18.0,No,Yes
NCT02369978,16 December 2017,CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY),Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis),CHICAMOCHA-3,Universidad Autónoma de Bucaramanga,2015-02-17,20150217,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02369978,Recruiting,No,20 Years,55 Years,All,01/08/2015,500.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 2/Phase 3,Colombia;Colombia;Colombia;Colombia;Colombia, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ,"Juan C Villar, MD, PhD;Juan C Villar, MD, PhD;Gustavo A Parra, MD;Juan C Villar, MD, PhD;Juan C Villar, MD, PhD;Gustavo A Parra, MD;Juan C Villar, MD, PhD;Juan C Villar, MD, PhD;Gustavo A Parra, MD;Juan C Villar, MD, PhD;Juan C Villar, MD, PhD;Gustavo A Parra, MD;Juan C Villar, MD, PhD;Juan C Villar, MD, PhD;Gustavo A Parra, MD",,;jvillar@unab.edu.co;guparra@unab.edu.co;;jvillar@unab.edu.co;guparra@unab.edu.co;;jvillar@unab.edu.co;guparra@unab.edu.co;;jvillar@unab.edu.co;guparra@unab.edu.co;;jvillar@unab.edu.co;guparra@unab.edu.co,;+5776436111;;;+5776436111;;;+5776436111;;;+5776436111;;;+5776436111;,Universidad Autónoma de Bucaramanga;;Universidad Autónoma de Bucaramanga;;Universidad Autónoma de Bucaramanga;;Universidad Autónoma de Bucaramanga;;Universidad Autónoma de Bucaramanga;,"<br>    Inclusion Criteria:<br><br>     - Positive serology status to Trypanosoma cruzi<br><br>     - No clinical signs of dilated cardiomyopathy<br><br>    Exclusion Criteria:<br><br>     - Unacceptable risk of re-infection, based on the investigators judgment<br><br>     - Previous treatment with NFX or BZN<br><br>     - History of peripheral neuropathy<br><br>     - Health condition limiting the mobility, cognitive function or life expectancy within<br>       two years of the enrollment visit<br><br>     - Pregnancy / Unwilling to use reliable contraceptive methods during childbearing age<br>   ;<br>    Inclusion Criteria:<br><br>     - Positive serology status to Trypanosoma cruzi<br><br>     - No clinical signs of dilated cardiomyopathy<br><br>    Exclusion Criteria:<br><br>     - Unacceptable risk of re-infection, based on the investigators judgment<br><br>     - Previous treatment with NFX or BZN<br><br>     - History of peripheral neuropathy<br><br>     - Health condition limiting the mobility, cognitive function or life expectancy within<br>       two years of the enrollment visit<br><br>     - Pregnancy / Unwilling to use reliable contraceptive methods during childbearing age<br>   ;<br>    Inclusion Criteria:<br><br>     - Positive serology status to Trypanosoma cruzi<br><br>     - No clinical signs of dilated cardiomyopathy<br><br>    Exclusion Criteria:<br><br>     - Unacceptable risk of re-infection, based on the investigators judgment<br><br>     - Previous treatment with NFX or BZN<br><br>     - History of peripheral neuropathy<br><br>     - Health condition limiting the mobility, cognitive function or life expectancy within<br>       two years of the enrollment visit<br><br>     - Pregnancy / Unwilling to use reliable contraceptive methods during childbearing age<br>   ;<br>    Inclusion Criteria:<br><br>     - Positive serology status to Trypanosoma cruzi<br><br>     - No clinical signs of dilated cardiomyopathy<br><br>    Exclusion Criteria:<br><br>     - Unacceptable risk of re-infection, based on the investigators judgment<br><br>     - Previous treatment with NFX or BZN<br><br>     - History of peripheral neuropathy<br><br>     - Health condition limiting the mobility, cognitive function or life expectancy within<br>       two years of the enrollment visit<br><br>     - Pregnancy / Unwilling to use reliable contraceptive methods during childbearing age<br>   ",,Chagas Disease;Chagas Disease;Chagas Disease;Chagas Disease,Drug: Nifurtimox;Drug: Benznidazole;Drug: Placebo;Drug: Nifurtimox;Drug: Benznidazole;Drug: Placebo;Drug: Nifurtimox;Drug: Benznidazole;Drug: Placebo;Drug: Nifurtimox;Drug: Benznidazole;Drug: Placebo,Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruzi;Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruzi;Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruzi,T. cruzi positive serology status;Mean change in T. cruzi antibody titers,124156935014,Please refer to primary and secondary sponsors,Fundación Cardioinfantil Instituto de Cardiología;Instituto Nacional de Salud (Colombia);Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2015,20.0,No,Yes
NCT02386358,16 March 2015,Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial,Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial,TRAENA,Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben,2015-01-19,20150119,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT02386358,Not recruiting,No,20 Years,55 Years,Both,01/03/1999,910.0,Interventional,"Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment",Phase 3,Argentina, ,"Adellina R Riarte, MD",,,,"Chief of Clinical, Pathology and Treatment Department","<br>    Inclusion Criteria:<br><br>     - Patients living in urban areas<br><br>     - Reactive to at least 2 for serological test performed in Fatala Chaben Institute<br>       (ELISA and IFI) ,<br><br>     - Patients who agreed to be part of this protocol through informed consent form signed<br><br>    Exclusion Criteria:<br><br>     - Patients with chronic Chagas disease who have received prior treatment with<br>       benznidazole<br><br>     - Other cardiomyopathies : idiopathic , alcoholic , peripartum myocarditis, secondary<br>       to coronary artery disease, valve disease, hypertension, restrictive, hypertrophic<br>       or congenital<br><br>     - Chronic renal disease<br><br>     - Bleeding disorders<br><br>     - History of liver disease or current liver disease ,<br><br>     - Any other severe clinical disease that decreases their life expectancy<br><br>     - History of severe allergies<br><br>     - Pregnant patients<br><br>     - Patients who have not signed the informed consent.<br>   ",,Chagas Disease,Drug: Benznidazole;Drug: Placebo,Cardiovascular Mortality;Development of heart failure;Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillator,Electrocardiographic endpoints. New development of permanent changes in the electrocardiographic;Changes in clinical stage in chronic Chagas disease;Enlargement of the left ventricle (LV) detected by echocardiography.;New Heart Failure;Stroke;Serological negativization;Development and validation of RT-PCR;Changes of the secondary objectives during RCT development. New single endpoints;Combined clinical endpoints:,TRAENA,Please refer to primary and secondary sponsors,"National Council of Scientific and Technical Research, Argentina;Pan American Health Organization;Becas Carrillo Oñativia, Ministerio de Salud, Argentina;Drugs for Neglected Diseases Initiative (DNDi)",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2015,20.0,No,Yes
NCT02498782,3 August 2015,Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease,"Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease.",,Drugs for Neglected Diseases,2014-08-20,20140820,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02498782,Recruiting,No,18 Years,50 Years,Both,01/07/2014,140.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2,Bolivia, ; ; ; ,"Faustino Torrico, MD;Joaquim Gascón, MD;Lourdes O Daza, MD;Isabela Ribeiro, MD",,;;;iribeiro@dndi.org,;;;+552125290400,"Plataforma de Antención Integral de Pacientes con Enfermedad de Chagas, Cochabamba, Bolivia;Centro de Salud Internacional, Hospital Clínico de Barcelona;Plataforma de Antención Integral de Pacientes con Enfermedad de Chagas, Tarija, Bolivia;","<br>    Inclusion Criteria:<br><br>     - Confirmed diagnosis of T. cruzi infection by Serial qualitative PCR (three samples<br>       collected over a single day, at least one of which must be positive) AND<br>       Conventional serology (a minimum of two out of three positive tests must be positive<br>       [Conventional ELISA, Recombinant Elisa or IIF)<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening,<br>       must not be breastfeeding, and consistently use a highly effective contraceptive<br>       method during the entire trial.<br><br>     - Normal EKG  (PR =200 msec, QRS =120 msec, and QTc =400msec and =450 msec interval<br>       durations) at screening<br><br>    Exclusion Criteria:<br><br>     - Signs and/or symptoms of chronic cardiac and/or digestive form of CD (as per Study<br>       Manual of Operations)<br><br>     - History of cardiomyopathy, heart failure or ventricular arrhythmia<br><br>     - Any other acute or chronic health conditions that, in the opinion of the PI, may<br>       interfere with the efficacy and/or safety evaluation of the study drug (such as acute<br>       infections, history of HIV infection, diabetes, liver and renal disease requiring<br>       medical treatment)<br><br>     - Laboratory test values considered clinically significant or out of the allowable<br>       range at screening as follows:<br><br>        - Total WBC must be within the normal range, with an acceptable margin of +/- 5%<br>         (3,800 - 10,500 / mm3).<br><br>        - Platelets must be within the normal range up to 550,000 / mm3<br><br>        - Total bilirubin must be within the normal range Transaminases (ALT and AST) must<br>         be within the normal range, with an acceptable margin of 25% above the upper<br>         limit of normality (ULN), < 1.25 x ULN.<br><br>        - Creatinine must be within an acceptable margin of 10% above the ULN, <1.10 x<br>         ULN.<br><br>        - Alkaline phosphatase must be within the normal range up to Grade 1 CTCAE (< 2.5<br>         x ULN)<br><br>        - GGT must be within the normal range up to 2x ULN.<br><br>        - Potassium, Magnesium, Calcium must be within the normal range<br><br>     - History of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations).<br><br>     - Any condition that prevents the patient from taking oral medication.<br><br>     - Patients  with  contra-indication  (known  hypersensitivity)  to  other<br>       nitroimidazoles, e.g. metronidazole.<br><br>     - Any concomitant use of antimicrobial or anti-parasitic agents.<br>   ",,"Chagas Disease;Trypanosomiasis, South American;South American Trypanosomiasis;Disease, Chagas",Drug: Fexinidazole;Drug: Placebo,Parasitological cure rate (PCR);Adverse events;Serious Adverse events,Parasite Clearance (qualitative PCR);Parasite load;Serological response;Blood culture for parasite genotyping,DNDi-CH-FEXI-001,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2014,18.0,No,Yes
NCT01755377,29 August 2016,"New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease",Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases,BIOMARCHA,Barcelona Centre for International Health Research,2012-12-19,20121219,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01755377,Not recruiting,No,18 Years,50 Years,Both,01/12/2012,63.0,Observational,"Observational Model: Cohort, Time Perspective: Prospective",Unknown,Spain, ,"Joaquim Gascón, PhD",,,,Barcelona Centre for International Health Research (CRESIB),"<br>    Inclusion Criteria:<br><br>     - Patients from endemic areas (Latin America)<br><br>     - Older than 18 years old and younger than 50<br><br>     - With serological confirmation of Chagas Disease infection with two different<br>       techniques<br><br>     - Indeterminate or initial cardiac form<br><br>     - No previously treated for Chagas Disease<br><br>    Exclusion Criteria:<br><br>     - Co-morbidity: previous cardiac disease from other aetiology (ischemic, alcoholic or<br>       hypertensive), active inflammatory or immunology diseases for another agent. Hepatic<br>       disfunction<br><br>     - Pregnancy or lactation<br>   ",,Chagas Disease,Drug: Benznidazole,"Biomarkers for prognosis, early diagnosis and effectiveness of treatment.",Cardiac function after antiparasitic treatment,BIOMARCHA,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,18.0,No,Yes
NCT01755403,8 June 2015,Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease,Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.,CINEBENZ,Barcelona Centre for International Health Research,2012-12-19,20121219,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01755403,Not recruiting,No,18 Years,60 Years,Both,01/12/2012,52.0,Interventional,"Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 4,Spain, ,"Joaquim Gascón, PhD",,,,Barcelona Centre for International Health Research (CRESIB),"<br>    Inclusion Criteria:<br><br>     - Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive<br>       serological tests.<br><br>     - Patients with Chronic Chagas Disease who are going to start treatment with<br>       Benznidazole.<br><br>     - Any gender.<br><br>     - All the participants must agree to participate in the study and must sign the<br>       informed consent.<br><br>    Exclusion Criteria:<br><br>     - Patients younger than 18.<br><br>     - Patients with previous hypersensitivity to Benznidazole.<br><br>     - Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need,<br>       primary immunodeficiency, or any other.<br><br>     - Hepatic dysfunction<br><br>     - Renal dysfunction: serum creatinin higher than 3 mg/dl.<br><br>     - Pregnancy or lactation.<br><br>     - Low adhesion to treatment or check-up.<br><br>     - Impossibility of follow-up.<br><br>     - Severe adverse reaction to Benznidazole.<br><br>     - Any other situation that could be risky for the patient.<br>   ",,Chagas Disease,Drug: Benznidazole,Population pharmacokinetic parameters of Benznidazole,Adverse reactions,CINEBENZ,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,18.0,No,Yes
NCT01744405,30 March 2015,Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease,Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease,LACTNFX,Hospital de Niños R. Gutierrez de Buenos Aires,2012-12-05,20121205,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01744405,Not recruiting,No,18 Years,40 Years,Female,01/12/2012,12.0,Observational,"Observational Model: Cohort, Time Perspective: Prospective",Unknown,Argentina, ,"Facundo Garcia Bournissen, MD PhD",,,,Buenos Aires Children´s Hospital Ricardo Gutierrez ; CONICET,"<br>    Inclusion Criteria:<br><br>     - Lactating women with Chagas disease, not treated before<br><br>     - Use of contraception<br><br>    Exclusion Criteria:<br><br>     - History of allergy to nifurtimox or its excipients<br><br>     - Pregnancy<br><br>     - Significant heart involvement (due to Chagas disease)<br><br>     - Significant systemic diseases that could affect the interpretation of the results in<br>       the opinion of the principal investigator<br>   ",,Chagas Disease;Lactation,,Nifurtimox concentration in breastmilk and in plasma,Incidence of adverse drug reactions in women treated with nifurtimox during lactation,LACT-NIFURTIMOX,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,18.0,No,Yes
NCT01566617,1 February 2016,Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease,Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial,ChagasCare,Evandro Chagas Institute of Clinical Research,2012-03-23,20120323,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01566617,Recruiting,No,18 Years,76 Years,Both,01/10/2012,88.0,Interventional,"Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)",Unknown,Brazil, ; ; ,"Gilberto M Silva, pharmaceutical;Mayara C Chambela, pharmaceutics;Gilberto M Sperandio da Silva, pharmaceutist",,;Mayarachambela@gmail.com;gilbertomarcelo@gmail.com,;552138659648;552138659648,Evandro Chagas Clinical Research Institute;,"<br>    Inclusion Criteria:<br><br>     - The proposed clinical trial will be conducted in volunteers with Chagas disease<br>       complicated by heart failure.<br><br>     - Subjects will include adults, men and women, racial or ethnic minorities.<br><br>     - Diagnosed by two distinct Chagas serology tests (indirect immunofluorescence and<br>       enzyme linked immunosorbent assay<br><br>    Exclusion Criteria:<br><br>     - Patients with any of comorbidities that significantly affect the cardiac performance,<br>       such as coronary artery disease, moderate or severe heart valvular disease, left<br>       ventricular (LV) hypertrophy, congenital heart disease, or that limit their survival,<br>       such as malignant tumors and HIV, will be excluded from the study.<br><br>     - Patients will be also be excluded in case of failure to give informed consent,<br>       inability to perform 6 minute- walk test, significant cognitive impairment, or<br>       pregnancy.<br><br>     - Individuals who are participating in others intervention trials will also be<br>       excluded.<br>   ",,Chagas Heart Disease,Other: Standard care and Pharmaceutical care;Other: Standard care,Quality of life.,Incidence and types of drug-related problems;Physical functional capacity.,0034.0.009.000-11;Chagas2303,Please refer to primary and secondary sponsors,"Alejandro Marcel Hasslocher Moreno, MD MSc PhD student;Andrea Costa, MD PhD;Andrea Silvestre de Sousa, MD PhD;Luiz Henrique C. Sangenis, MD MSc PhD student;Marcelo Teixeira de Holanda, MD MSc PhD student;Mayara da Costa Chambela - MSc student;Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD;Roberto Magalhães Saraiva, MD PhD;Sergio Salles Xavier, MD PhD",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2012,18.0,No,Yes
NCT01549236,12 December 2020,Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease,Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease,Pop PK Chagas,Drugs for Neglected Diseases,2012-03-01,20120301,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01549236,Not recruiting,No,,12 Years,All,01/05/2011,80.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 4,Argentina, ,"Jaime Altcheh, MD",,,,Argentina: FIPEC Foundation (Fundación para el Estudio de las Infecciones Parasitarias y Enfermedad de Chagas,"<br>    Inclusion Criteria:<br><br>     - Age between newborn (1day) - 12 years<br><br>     - Diagnosis of T. cruzi infection by:<br><br>        - Direct microscopic examination or<br><br>        - Conventional serology, at least two positive tests (ELISA, IIF or HAI)<br><br>     - Written informed consent form by parent/ legal representative<br><br>     - Children assent if > 7 years<br><br>    Exclusion Criteria:<br><br>     - Pre-term (< 37 weeks gestational age) or weight < 2500 g<br><br>     - Female subject who has reached menarche<br><br>     - Subjects presenting any other acute or chronic health conditions, that in the opinion<br>       of the PI, may interfere with the PK, efficacy and/or safety evaluation of the study<br>       drug<br><br>     - Known history of hypersensitivity or serious adverse reactions to nitro- imidazoles<br><br>     - History of CD treatment with benznidazole or nifurtimox in the past<br><br>     - Immunocompromised patients (clinical history compatible with HIV infection, primary<br>       immunodeficiency or prolonged treatment with corticosteroids or other<br>       immunosuppressive drugs)<br><br>     - Abnormal laboratory test values at screening for the following parameters: total WBC<br>       count, platelet count, ALT, AST, total bilirubin and creatinine.<br><br>    Exception for this criterion is considered for newborns with congenital Chagas Disease, for<br>    whom ALT/AST and bilirubin will not be considered exclusion criteria unless considered<br>    clinically significant by the investigator.<br><br>     - Inability to comply with follow-up and/or not having a permanent address<br><br>     - Any condition that prevents the subject from taking oral medication<br>   ",,Chagas' Disease,"Drug: Benznidazole 12,5mg or 100mg",Pharmacokinetics Endpoints,Efficacy Endpoints;Safety endpoints;Safety Endpoints,DNDi-CD-PEDBZ-001,Please refer to primary and secondary sponsors,LAT Research,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,,Unknown,Yes
NCT01678599,12 December 2020,Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease,"Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia",PCR,Drugs for Neglected Diseases,2012-03-01,20120301,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01678599,Not recruiting,No,18 Years,60 Years,All,01/04/2011,220.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ,Phase 4,Bolivia, ,"Lourdes Loza, Biochemist",,,,Medicin Sans Frontièrs,"<br>    Inclusion Criteria:<br><br>     - Age between > 18 - 60 years<br><br>     - Diagnosis of T. cruzi infection by Chagas serology. Two out of three serological tests<br>       must be positive [conventional ELISA, recombinant ELISA, or HAI)<br><br>     - Written informed consent form<br><br>    Exclusion Criteria:<br><br>     - Women in reproductive age who have a positive pregnancy test at screening, or who are<br>       breastfeeding Note: Women in reproductive age must accept to use a contraceptive<br>       method during the entire treatment phase of the trial<br><br>     - Current presentation of serious health condition such as: active pulmonary<br>       tuberculosis and clinical signs of liver or renal failure.<br><br>     - Chagasic cardiomyopathy stage II, III and IV (according to the NYHA classification)<br><br>     - Subjects requiring pacemaker implantation or other serious cardiac conduction defects<br><br>     - History of CD treatment with benznidazole or nifurtimox at any time in the past<br><br>     - Inability to comply with follow-up and/or not having a permanent address<br><br>     - History of alcohol abuse or any other drug addiction<br>   ",,Chagas Disease,Drug: Benznidazole,The primary endpoints are: - A positive or negative PCR at baseline (BL) among serology positive patients.;- Identification of the optimal relationship between sensitivity and feasibility at baseline.,"- Identification of the optimal relationship between sensitivity and Identification of the optimal relationship between sensitivity and feasibility at End Of Treatment (EOT);- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at EOT - to be estimated using 1) the current sampling schedule (CS), the most sensitive one and the optimal one.;- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at 6 and 12 months follow-up - to be estimated using 1) the current sampling schedule (CS) and the optimal one (based on EOT data).;- Relative reduction [(parasite count at baseline - parasite count at EOT, 6 and 12 months)/parasite count at baseline] of parasitemia - to be evaluated through parasite load at EOT, 6 and 12 months through quantitative PCR.",MSF/DNDi-CD-PCR-01,Please refer to primary and secondary sponsors,"Medecins Sans Frontieres, Netherlands",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,18.0,No,Yes
NCT01547533,30 March 2015,Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease,Study of Benznidazole Transfer Into Breastmilk in Lactating Women Treated for Chagas Disease,LACTBENZ,Hospital de Niños R. Gutierrez de Buenos Aires,2012-03-01,20120301,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01547533,Not recruiting,No,18 Years,40 Years,Female,01/08/2011,10.0,Observational,"Observational Model: Cohort, Time Perspective: Prospective",Unknown,Argentina, ,"Facundo Garcia Bournissen, MD PhD",,,,Buenos Aires Children´s Hospital Ricardo Gutierrez ; CONICET,"<br>    Inclusion Criteria:<br><br>     - Lactating women with Chagas disease, not treated before<br><br>     - Use of contraception<br><br>    Exclusion Criteria:<br><br>     - History of allergy to benznidazole or its excipients<br><br>     - Pregnancy<br><br>     - Significant heart involvement (due to Chagas disease)<br><br>     - Significant systemic diseases that could affect the interpretation of the results in<br>       the opinion of the principal investigator<br>   ",,Chagas Disease;Lactation,,Benznidazole concentration in breastmilk and in plasma,incidence of adverse drug reactions in women treated with benznidazole during lactation,LACT-BENZNIDAZOLE,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,18.0,No,Yes
NCT01557140,24 August 2015,A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy,A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy,,Federal University of Minas Gerais,2012-02-21,20120221,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01557140,Not recruiting,No,18 Years,,Both,01/05/2003,42.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Phase 4,Brazil, ,"Fernando A Botoni, MD, PhD",,,,Federal University of Minas Gerais,"<br>    Inclusion Criteria:<br><br>     - Criteria for inclusion were positivity for T cruzi as confirmed by 2 or more<br>       serological tests (indirect immunofluorescence, ELISA, and/or indirect<br>       hemagglutination) and having cardiomyopathy.<br><br>     - Cardiomyopathy was present when at least 3 of the following criteria were fulfilled:<br><br>        - LV enddiastolic diameter (LVDD) N55 mm<br><br>        - LVDD/body surface area > 2.7cm/m2<br><br>        - LV ejection fraction (LVEF) < 55%<br><br>        - QRS interval > 120 ms<br><br>        - echocardiographic evidence of diffuse or segmental systolic wall motion<br>         abnormalities.<br><br>    Exclusion Criteria:<br><br>     - Exclusion criteria were being pregnant<br><br>     - Using any h-blocker<br><br>     - Having additional comorbidities (eg, hypertension, diabetes mellitus, thyroid<br>       dysfunction, chronic obstructive pulmonary disease, asthma, and renal or hepatic<br>       failure).<br>   ",,Chagas Cardiomyopathy;Heart Failure;Dilated Cardiomyopathy,Drug: RASi plus carvedilol,Changes in left ventricular ejection fraction,Changes in Framingham score;Changes in quality of life (36-item Short-Form Health Survey);Changes in New York Heart Association functional class;Changes in cardiothoracic ratio;Changes in echocardiographic diastolic function indices;Changes in brain natriuretic peptide levels;Changes in chemokines;Changes in autoantibodies levels,Carvedilol in Chagas disease,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2012,18.0,No,Yes
NCT01489228,19 February 2015,Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease,"Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease",,Drugs for Neglected Diseases,2011-11-24,20111124,10/13/2025 15:56:09,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01489228,Recruiting,No,18 Years,50 Years,Both,01/06/2011,230.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Phase 2,Bolivia, ; ; ; ,"Isabela Ribeiro, MD;Faustino Torrico, PhD;Joaquim Gascón, PhD;Fabiana P Alves, PhD",,;;;falves@dndi.org,;;;+552122152941,"Drugs for Neglected Diseases initiative;Universidad Mayor San Simón. Cochabamba, Bolivia.;CRESIB - Centre de Recerca en Salut Internacional de Barcelona, Spain.;","<br>    Screening Criteria:<br><br>     - Age >18 to < 50 years<br><br>     - Weight > 40 kg<br><br>     - Diagnosis of T. cruzi infection by conventional serology (a minimum of two out of<br>       three positive tests [enzyme linked immunosorbent assay (ELISA), indirect<br>       immunofluorescence (IIF), or hemagglutination inhibition (HAI)])<br><br>     - Signed, written informed consent form<br><br>     - No signs and/or symptoms of the chronic cardiac and/or digestive form of CD<br><br>     - No acute or chronic health conditions that may interfere with the efficacy and/or<br>       safety evaluation of the study drug<br><br>     - No formal contraindication to BZN and E1224<br><br>     - No known history of hypersensitivity, allergic, or serious adverse reactions to the<br>       study drugs<br><br>     - No history of CD treatment with BZN or NFX at any time in the past<br><br>     - No history of systemic treatment with itraconazole, ketoconazole, posaconazole,<br>       isavuconazole, or allopurinol in the past<br><br>    Inclusion Criteria:<br><br>     - Confirmed diagnosis of T. cruzi infection by serial qualitative PCR AND Conventional<br>       serology<br><br>     - Women in reproductive age must have a negative serum pregnancy test at screening,<br>       must not be breastfeeding, and consistently use and/or have partner consistently use<br>       an adequate contraceptive method<br><br>     - Normal ECG at screening<br><br>    Exclusion Criteria:<br><br>     - Abnormal laboratory test values at screening for the following parameters: total<br>       White Blood Cells (WBC) count, platelet count, alanine transaminase (ALT), aspartate<br>       transaminase (AST), total bilirubin, or creatinine; or gamma-glutamyl transferase<br>       (GGT)<br><br>     - History of alcohol abuse or any other drug addiction (as specified in the Study<br>       Manual of Operations)<br><br>     - Any condition that prevents the patient from taking oral medication<br><br>     - Any concomitant use of antimicrobial or antiparasitic agents<br>   ",,"Chronic Chagas Disease, Indeterminate",Drug: E1224;Drug: Benznidazole;Drug: Placebo,Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment,"Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication;Qualitative PCR as a measure of parasite eradication;Quantitative PCR as a measure of change in parasite load over time;Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies;Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay;Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole;Incidence and severity of adverse events (clinical and laboratory);Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation;Early and late predictors of sustainable response to treatments;Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes",DNDi-CH-E1224-001,Please refer to primary and secondary sponsors,"Eisai Co., Ltd.",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2011,18.0,No,Yes
NCT01377480,12 December 2020,A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267),"Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)",STOP CHAGAS,Merck Sharp & Dohme Corp.,2011-05-13,20110513,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01377480,Not recruiting,No,18 Years,50 Years,All,06/07/2011,120.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 2,Argentina;Chile;Colombia;Germany;Guatemala;Mexico;Spain, ,Medical Director,,,,Merck Sharp & Dohme Corp.,"<br>    Inclusion Criteria:<br><br>    - Must have a positive serology result for Trypanosoma cruzi on any 2 of 3 of the following<br>    tests: indirect immunofluorescence, indirect hemagglutination, or enzyme-linked<br>    immunoabsorbent assay (ELISA)<br><br>     - Must have a positive qualitative polymerase chain reaction (PCR) for Trypanosoma cruzi<br><br>     - Must have a normal 12-lead electrocardiogram (ECG)<br><br>     - Must have a normal 2-D echocardiogram<br><br>     - Must have no evidence of ventricular tachycardia on 24-hour Holter monitoring<br><br>     - Female participants of childbearing age must be using a medically accepted method of<br>       birth control before beginning study drug treatment and must agree to continue its use<br>       during the study, or must have been surgically sterilized<br><br>     - Female participants of childbearing potential must have a negative serum beta-human<br>       chorionic gonadotropin (hCG) pregnancy test at Screening and a negative urine<br>       pregnancy test at Baseline or within 72 hours before the start of study drug<br><br>    Exclusion Criteria:<br><br>     - Are breastfeeding, pregnant, or planning to become pregnant<br><br>     - Body weight <60 kg<br><br>     - Have an immunodeficiency or are immunosuppressed<br><br>     - History of megacolon with obstipation or megaesophagus with severe swallowing<br>       impairment.<br><br>     - Have previously received treatment with benznidazole or nifurtimox<br><br>     - Known allergy/sensitivity to azoles<br><br>     - Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater<br>       than 2.5 times the upper limit of normal at Screening<br><br>     - Has serum creatinine >2.5 mg/dL or 200 micromoles at Screening<br><br>     - Has a history of severe alcohol abuse within two years from Screening<br><br>     - Is taking any of the prohibited medication<br>   ",,Chagas Disease,Drug: Posaconazole;Drug: Placebo for posaconazole;Drug: Benznidazole,Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction,,MK-5592-055;P05267,Please refer to primary and secondary sponsors,,,,,,,,Yes,10/08/2015,https://clinicaltrials.gov/ct2/show/results/NCT01377480,,,,,,,,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,Yes,False,          ,2011,18.0,No,Yes
NCT00875173,23 November 2015,Selenium Treatment and Chagasic Cardiopathy (STCC),Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease,STCC,Oswaldo Cruz Foundation,2008-10-20,20081020,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00875173,Recruiting,No,18 Years,65 Years,Both,01/10/2008,130.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment",Phase 3,Brazil, ; ; ,"Tania C Araujo-Jorge, MD/PhD;Alejandro MH Moreno, MD;Pedro EA Brasil, MD, PhD",,;alejandro.hasslocher@ipec.fiocruz.br;pedro.brasil@ini.fiocruz.br,;55 21 3865 9579;213865-9648,Instituto Oswaldo Cruz;,"<br>    Inclusion Criteria:<br><br>     - altered ECHO (LVEF between 0,35 % and 45 %)<br><br>     - age between 20 and 65 years<br><br>    Exclusion Criteria:<br><br>     - patients > 65 years of age<br><br>     - smoke habit, patients with non-chagasic cardiopathy, live close to mineral deposit,<br>       metals industries and place with radioactive exposition, vegetarian<br><br>     - depressive psychological profile<br><br>     - pregnant or in lactating period<br><br>     - present or presented cancer or diabetes.<br><br>     - patients will be excluded if they take anti-convulsive medicines (Clozapine, Valproic<br>       Acid)<br>   ",,Chagas Disease,Drug: Selenium;Drug: Placebo (for Selenium),Ejection fraction by echocardiography,Electrocardiography,Oswaldo Cruz,Please refer to primary and secondary sponsors,"Conselho Nacional de Desenvolvimento Científico e Tecnológico;Ministry of Health, Brazil",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2008,18.0,No,Yes
NCT00123916,12 December 2020,BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease,Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial,BENEFIT,Population Health Research Institute,2005-07-21,20050721,10/13/2025 15:56:09,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00123916,Not recruiting,No,18 Years,75 Years,All,01/11/2004,2854.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). ",Phase 3,Argentina;Bolivia;Brazil;Colombia;El Salvador;Argentina;Bolivia;Brazil;Colombia;El Salvador;Canada, ; ; ; ; ,"Carlos Morillo, MD;Jose Antonio Marin-Neto, MD, PhD;Salim Yusuf, MD, DPh;Sergio Sosa-Estani, MD, PhD;Fernando Rosas, M.D.",,;;;;,;;;;,"Population Health Research Institute - McMaster University;University of Sao Paulo;Population Health Research Institute - McMaster University;Argentina National Coordinator - CenDIE, Argentina;Fundacion Clinica Shaio, Bogota, Colombia","<br>    Inclusion Criteria:<br><br>     - Consenting patients (between 18 and 75 years of age) with serological evidence of<br>       Chagas infection (any combination of 2 positive tests) and that have one or more of<br>       the following:<br><br>     - Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left<br>       anterior or posterior fascicular block; ventricular premature beat; first degree<br>       atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T<br>       changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);<br><br>     - Abnormal ECG (Mobitz type II, advanced or third degree AV block);<br><br>     - Increased cardiothoracic ratio (> 0.50);<br><br>     - Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;<br><br>     - Evidence of regional wall motion abnormality or reduced global left ventricular<br>       systolic function or increased left ventricular and diastolic diameter on 2D-Echo.<br><br>    Exclusion Criteria:<br><br>    Patients will be excluded if having:<br><br>     - NYHA heart failure class IV or decompensated heart failure<br><br>     - Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated<br>       cardiomyopathy<br><br>     - Previous treatment with antitrypanosomal agents or an accepted indication for<br>       antiparasitic therapy<br><br>     - Inability to comply with follow-up visits<br><br>     - History of severe alcohol abuse within 2 years<br><br>     - Known chronic renal or hepatic insufficiency or hepatic insufficiency<br><br>     - Pregnancy or breast feeding<br><br>     - Megaesophagus with swallowing impairment<br><br>     - Other severe disease significantly curtailing life expectancy<br>   ",,Chagas Disease;Trypanosomiasis;Heart Disease,Drug: Benznidazole;Drug: Placebo,"Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.","New development of any of the following echo changes, segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction >5%, increase in LVDD> 5 mm compared to baseline.;New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc).;Progression of NYHA functional class by at least one category;New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.);Progression of New York Heart Association (NYHA) functional class by at least one category;Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment;Determination of the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.;Safety and tolerability of benznidazole",CONEP-11394;BEN01,Please refer to primary and secondary sponsors,Canadian Institutes of Health Research (CIHR);World Health Organization;Instituto Dante Pazzanese de Cardiologia;University of Sao Paulo,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2005,18.0,No,Yes
NCT02947581,21 November 2022,Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO),A Randomized Trial of Combined Albendazole Plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns,SANTO,Universidad Peruana Cayetano Heredia,2016-10-24,20161024,10/13/2025 16:04:25,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02947581,Not recruiting,No,18 Years,65 Years,All,14/11/2016,107.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 3,Peru, ,"Hector H. Garcia Lescano, Ph.D",,,,Universidad Peruana Cayetano Heredia,"<br>    Inclusion Criteria:<br><br>     - - Male or female adult individuals (18 to 65 y.o.) with a diagnosis of basal<br>       subarachnoid cysticercosis (including locations in the Sylvian fissure or lower<br>       interhemispheric spaces) by neuroimaging and confirmed by serology.<br><br>     - Baseline laboratory results along acceptable ranges (specifically defined in the study<br>       protocol).<br><br>     - Willingness to accomplish the two-week minimum hospitalization required.<br><br>    Exclusion Criteria:<br><br>     - Previous therapy with ABZ or PZQ in the preceding 3 years (except for patients who<br>       received single-dose ABZ for intestinal parasites, or patients who received<br>       antiparasitic treatment between one and three years before enrollment but demonstrated<br>       lesion persistence or progression during the past 12 months).<br><br>     - A type of NCC which can expose the patient to increased risk during the study,<br>       specifically: a) intraventricular cysts; b) cysts in brainstem; c) concomitant<br>       intraparenchymal lesions greater than 3 cm of diameter in addition to their SANCC<br>       lesions; d) more than 20 intraparenchymal cysts in addition to their SANCC lesions; or<br>       d) untreated ocular cysticercosis. Patients with a lateral ventricle cyst, less than 2<br>       cm in diameter, without hydrocephalus or intracranial hypertension, can be included.<br>       The presence of concomitant intraparenchymal cysts of less than 3 cm in diameter will<br>       not exclude the patient unless there are more than 20 of them.<br><br>     - Active pulmonary tuberculosis evidenced by positive chest X-ray and positive sputum<br>       smears, or symptoms compatible with tuberculosis (fever+sweats or fever+cough) not<br>       otherwise explained.<br><br>     - Individuals with positive markers for active hepatitis.<br><br>     - Systemic disease that may affect therapy or short-term prognosis, including but not<br>       limited to chronic renal failure, hepatic insufficiency, cardiac failure, and<br>       steroid-dependent immune diseases.<br><br>     - Patients in unstable condition or with symptomatic intracranial hypertension (ICH).<br>       Definition of symptomatic ICH for this study is the presence of headaches, nausea, and<br>       vomiting, with papilledema at fundoscopic examination. Patients in this category can<br>       be considered for entrance into the study only after resolution of ICH by<br>       ventricular-peritoneal shunting or neuroendoscopic procedures involving CSF flow<br>       derivation. These procedures would be done as part of their standard medical care and<br>       are not part of the trial intervention.<br><br>     - Pregnancy during anti-parasitic treatment. If a patient becomes pregnant after<br>       treatment, she will continue in the study but will have radiological exams delayed<br>       until after delivery.<br><br>     - History of hypersensitivity to ABZ or PZQ<br><br>     - Chronic or drug abuse as defined in the study protocol.<br><br>     - Unwilling or unable to undergo MRI exams (like patients with ferromagnetic implants)<br><br>     - Inability or unwillingness of subject or legal representative to give written informed<br>       consent.<br>   ",,Neurocysticercosis,Drug: Albendazole and praziquantel;Drug: Albendazole and praziquantel placebo,Radiological efficacy at three months (3-month improvement).,"Radiological efficacy at six months (marked improvement or """"radiological cure"""") (evaluated only in patients with improvement at month 3).;Effect persistence at 12 months (no relapse) (evaluated only in patients with marked improvement at month 6) Effect persistence at 12 months (no relapse) (evaluated only in patients with marked improvement at month 6);Clinically asymptomatic patient;Decrease in serum levels",61449,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2016,18.0,No,Yes
NCT00133458,12 December 2020,RCT ALB for SA Cysticercosis,"Randomized, Double Blind Comparison of Two Lenghts of Albendazole Therapy for Subarachnoid Cysticercosis",,National Institute of Allergy and Infectious Diseases (NIAID),2005-08-19,20050819,10/13/2025 16:04:25,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00133458,Not recruiting,No,18 Years,65 Years,All,01/09/2005,0.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double. ,Phase 3,Brazil;Colombia;Ecuador;Peru;Brazil;Colombia;Ecuador;Peru,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Male or female individuals between 18-65 year of age with a diagnosis of basal<br>       subarachnoid cysticercosis, based on MRI and confirmed by serological test.<br><br>     - Willingness to accomplish the two weeks minimal hospitalization required.<br><br>     - Female of child-bearing potential willing to use an adequate method of contraception<br>       including implants, injectables, combined oral contraceptives, effective intrauterine<br>       devices, sexual abstinence, or vasectomized partner while participating in the study.<br><br>     - Patients with normal laboratory values for hemoglobin, platelet counts, total white<br>       blood cells, glucose, creatinine, bilirubin, ALT, AST, and electrolytes.<br><br>     - Negative fecal exam for Taenia eggs.<br><br>    Exclusion Criteria:<br><br>     - Previous therapy with albendazole (does not include patients who received single-dose<br>       400 mg ABZ for intestinal parasites), or praziquantel.<br><br>     - Pulmonary tuberculosis evidenced by a positive chest X-ray and positive sputum smears.<br><br>     - Pre-existing diagnosis of diabetes<br><br>     - Systemic disease other than NCC that may affect therapy or short-term prognosis,<br>       including but not limited to chronic renal failure, hepatic insufficiency, cardiac<br>       failure, and steroid-dependent immune diseases. Identification of systemic diseases<br>       will be left to the discretion of each Site PI.<br><br>     - Patients in unstable condition or with severe intracranial hypertension (ICH).<br>       Definition of severe ICH for this study would be the presence of headaches, nausea,<br>       and vomiting and papilledema at fundoscopic examination (all of them). Patients in<br>       this category can be considered for entrance into the study only after treatment of<br>       ICH by ventricle-peritoneal shunting. Patients with CT findings compatible with<br>       intracranial hypertension will have neurosurgical evaluation (by non study personal)<br>       before study entry.<br><br>     - Pregnancy<br><br>     - History of hypersensitivity to albendazole<br><br>     - Concurrent treatment with praziquantel, cimetidine or teophylline.<br><br>     - Chronic alcohol or drug abuse<br>   ",,Subarachnoid Cysticercosis,Drug: Albendazole,,,04-003,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2005,18.0,No,Yes
NCT00001912,16 December 2017,Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis,Analysis of the Occurrence of Perilesional Edema and Seizures in Patients With Inactive Cysticercosis,,National Institute of Allergy and Infectious Diseases (NIAID),1999-11-03,19991103,10/13/2025 16:04:25,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00001912,Not recruiting,No,18 Years,,All,10/08/1999,6.0,Observational,,Unknown,United States;Peru;United States;United States;Peru;United States;United States;Peru;United States;United States;Peru;United States;United States;Peru;United States, ; ; ; ; ,"Henry Masur, M.D.;Henry Masur, M.D.;Henry Masur, M.D.;Henry Masur, M.D.;Henry Masur, M.D.",,;;;;,;;;;,National Institutes of Health Clinical Center (CC);National Institutes of Health Clinical Center (CC);National Institutes of Health Clinical Center (CC);National Institutes of Health Clinical Center (CC);National Institutes of Health Clinical Center (CC),"<br>    - INCLUSION CRITERIA:<br><br>       18 years of age or older. If children are evaluated they can be seen under the general<br>       protocol and they may be entered into the present protocol under an exception.<br><br>    Likely diagnosis of inactive cysticercosis and present or past seizure activity. Requires<br>    """"a"""" and """"b"""" plus any one of the remaining criteria:<br><br>     1. History of seizures or present seizure activity;<br><br>     2. Previously treated or has inactive disease and declines treatment;<br><br>     3. Single calcified lesions and positive serology;<br><br>     4. Multiple calcified lesions;<br><br>     5. Multiple small enhancing nodular lesions;<br><br>     6. History of cystic lesions responding to specific chemotherapy.<br><br>    If female, not pregnant and using effective birth control methods.<br><br>    EXCLUSION CRITERIA:<br><br>    Less than 18 years of age.<br><br>    Pregnant or unwilling to use effective birth control measures.<br><br>    Refuse blood tests.<br><br>    Unwilling or unable to undergo testing according to the schedule.<br><br>    Unable to undergo MRI or CT examinations.<br><br>    Patients who require anesthesia to undergo imaging studies.<br>   ;<br>    - INCLUSION CRITERIA:<br><br>       18 years of age or older. If children are evaluated they can be seen under the general<br>       protocol and they may be entered into the present protocol under an exception.<br><br>    Likely diagnosis of inactive cysticercosis and present or past seizure activity. Requires<br>    """"a"""" and """"b"""" plus any one of the remaining criteria:<br><br>     1. History of seizures or present seizure activity;<br><br>     2. Previously treated or has inactive disease and declines treatment;<br><br>     3. Single calcified lesions and positive serology;<br><br>     4. Multiple calcified lesions;<br><br>     5. Multiple small enhancing nodular lesions;<br><br>     6. History of cystic lesions responding to specific chemotherapy.<br><br>    If female, not pregnant and using effective birth control methods.<br><br>    EXCLUSION CRITERIA:<br><br>    Less than 18 years of age.<br><br>    Pregnant or unwilling to use effective birth control measures.<br><br>    Refuse blood tests.<br><br>    Unwilling or unable to undergo testing according to the schedule.<br><br>    Unable to undergo MRI or CT examinations.<br><br>    Patients who require anesthesia to undergo imaging studies.<br>   ;<br>    - INCLUSION CRITERIA:<br><br>       18 years of age or older. If children are evaluated they can be seen under the general<br>       protocol and they may be entered into the present protocol under an exception.<br><br>    Likely diagnosis of inactive cysticercosis and present or past seizure activity. Requires<br>    """"a"""" and """"b"""" plus any one of the remaining criteria:<br><br>     1. History of seizures or present seizure activity;<br><br>     2. Previously treated or has inactive disease and declines treatment;<br><br>     3. Single calcified lesions and positive serology;<br><br>     4. Multiple calcified lesions;<br><br>     5. Multiple small enhancing nodular lesions;<br><br>     6. History of cystic lesions responding to specific chemotherapy.<br><br>    If female, not pregnant and using effective birth control methods.<br><br>    EXCLUSION CRITERIA:<br><br>    Less than 18 years of age.<br><br>    Pregnant or unwilling to use effective birth control measures.<br><br>    Refuse blood tests.<br><br>    Unwilling or unable to undergo testing according to the schedule.<br><br>    Unable to undergo MRI or CT examinations.<br><br>    Patients who require anesthesia to undergo imaging studies.<br>   ;<br>    - INCLUSION CRITERIA:<br><br>       18 years of age or older. If children are evaluated they can be seen under the general<br>       protocol and they may be entered into the present protocol under an exception.<br><br>    Likely diagnosis of inactive cysticercosis and present or past seizure activity. Requires<br>    """"a"""" and """"b"""" plus any one of the remaining criteria:<br><br>     1. History of seizures or present seizure activity;<br><br>     2. Previously treated or has inactive disease and declines treatment;<br><br>     3. Single calcified lesions and positive serology;<br><br>     4. Multiple calcified lesions;<br><br>     5. Multiple small enhancing nodular lesions;<br><br>     6. History of cystic lesions responding to specific chemotherapy.<br><br>    If female, not pregnant and using effective birth control methods.<br><br>    EXCLUSION CRITERIA:<br><br>    Less than 18 years of age.<br><br>    Pregnant or unwilling to use effective birth control measures.<br><br>    Refuse blood tests.<br><br>    Unwilling or unable to undergo testing according to the schedule.<br><br>    Unable to undergo MRI or CT examinations.<br><br>    Patients who require anesthesia to undergo imaging studies.<br>   ",,Cysticercosis;Cysts;Seizures;Cysticercosis;Cysts;Seizures;Cysticercosis;Cysts;Seizures;Cysticercosis;Cysts;Seizures,,,,99-I-0149;990149,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,1999,18.0,No,Yes
NCT00906880,19 February 2015,"Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase","Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage",NECT-FIELD,Drugs for Neglected Diseases,2009-05-19,20090519,10/13/2025 15:57:23,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00906880,Not recruiting,No,,,Both,01/04/2009,630.0,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 4,Congo, ; ,"Johannes Blum, MD;Victor Kande, MD",,;,;,Swiss Tropical & Public Health Institute;PNLTHA-DRC;,"<br>    Inclusion Criteria:<br><br>    All patients diagnosed as stage 2 HAT according to the diagnostic protocols in use at the<br>    treatment center (generally, if presence of parasites in blood, lymph node fluid or CSF<br>    and an elevated white blood cell count in the CSF, but this can vary from center to<br>    center) will be included if a written Informed Consent is given by the patient or a<br>    legally acceptable representative if the patient is a minor or unable to communicate.<br><br>     - Pregnancy and breastfeeding women: On a case by case basis according to the<br>       guidelines of the National HAT Control Programme or the NGO, the Investigator will<br>       decide to treat the patient or to defer the treatment. In case of inclusion, the<br>       mother-child pairs or the children of lactating mothers will be closely monitored<br>       during treatment and follow up.<br><br>     - Children under 2 years of age: On a case by case basis, the Investigator will decide<br>       to treat an infant with NECT or an alternative treatment (preferably eflornithine).<br>       In case of inclusion, these infants will be closely monitored during treatment and<br>       follow up like all children less than 12 years of age.<br><br>    Exclusion Criteria:<br><br>     - Unable to take oral medication, and impossibility to use a nasogastric tube.<br><br>     - Treatment failure after nifurtimox-eflornithine treatment.<br><br>     - Any other condition or reason for which the Investigator (or the responsible treating<br>       staff member) judges that another or no HAT treatment is warranted.<br>   ",,Human African Trypanosomiasis,Drug: Nifurtimox-Eflronithine Combination Treatment (NECT),Proportion of patients discharged alive from the hospital or the treatment center,"Incidence of serious AE (SAE) and severe AE (CTC score 3 and 4) related to treatment, and overall frequency and nature of AE and need for additional medications to manage these.;Effectiveness: The clinical cure rate (Survival without clinical and/or parasitological signs of HAT);Number of temporary treatment interruptions, number of premature treatment cessations, length of hospitalization stay (including observation period), treatment compliance (deviation in dosing), and other feasibility indicators.",HAT0208,Please refer to primary and secondary sponsors,"Ministry of Public Health, Democratic Republic of the Congo;Swiss Tropical & Public Health Institute",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2009,,Unknown,Yes
NCT00489658,19 February 2015,"Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda","Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda",NECS,Epicentre,2007-06-20,20070620,10/13/2025 15:57:23,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00489658,Not recruiting,No,,,Both,01/10/2002,31.0,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label",Phase 2/Phase 3,Uganda, ; ,"Patrice Piola, MD MSc;Gerardo Priotto, MD MPH",,;,;,Epicentre;Epicentre,"<br>    Inclusion Criteria:<br><br>     - Stage 2 infection with Trypanosoma brucei gambiense diagnosed within the previous 14<br>       days, as defined by either of the following: (i) Presence of trypanosomes in blood or<br>       lymph node fluid and WBC count in CSF > 5 / mm3, or (ii) Presence of trypanosomes in<br>       the CSF with any CSF WBC count<br><br>     - Residence in the study area<br><br>     - Written informed consent (to be obtained from parent/guardian for children under 18<br>       years and patients with impaired cognition)<br><br>    Exclusion Criteria:<br><br>     - Pregnancy or clinical history suggestive thereof<br><br>     - Weight < 10 Kg<br><br>     - History of any HAT treatment within the previous 24 months<br><br>     - Inability to undergo hospitalisation or attend follow-up visits during the 24 months<br>       following discharge<br><br>     - Severe anemia (Hb< 5g/dl)<br><br>     - Active tuberculosis (sputum positive)<br><br>     - HIV positive (if patient has been tested and results are known)<br><br>     - Severe renal or hepatic failure<br><br>     - Bacterial or cryptococcal meningitis<br><br>     - Other severe underlying diseases upon admission<br><br>     - Refugee status<br>   ",,"Trypanosomiasis, African",Drug: Eflornithine plus Nifurtimox combination therapy,"Treatment failure (death within 30 days of inclusion, or later if judged as related to Human African trypanosomiasis; termination of treatment due to adverse events; evidence of infection relapse at or after discharge, up to 24 months post discharge)","Occurrence and severity of serious clinically apparent adverse events;Occurrence and severity of biochemical (ALAT, creatinine, bilirubin) and haematological (abnormal total and differential leukocyte count, haemoglobin) adverse events",NECS,Please refer to primary and secondary sponsors,Medecins Sans Frontieres,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2007,,Unknown,Yes
NCT00330148,19 February 2015,Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis,"Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase",,Epicentre,2006-05-24,20060524,10/13/2025 15:57:23,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00330148,Not recruiting,No,,,Both,01/03/2001,435.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 3,Uganda, ,"Gerardo Priotto, MD, MPH",,,,Epicentre,<br>    Inclusion Criteria:<br><br>     - confirmed second-stage T.b. gambiense infection :<br><br>        - Infection diagnosed parasitologically (blood or lymph node fluid) and white<br>         blood cells > 5/mm3 in cerebrospinal fluid (CSF)<br><br>        - or Trypanosomes detected in the CSF with any CSF cell count<br><br>     - and resident in the district<br><br>     - and written consent of the patient or of one of the parents/guardians for children<br>       under 15 years of age.<br><br>    Exclusion Criteria:<br><br>     - Trypanosome absent from blood (or lymph node fluid) and from CSF<br><br>     - Or women pregnant on inclusion<br><br>     - Or previous history of HAT confirmed treated during the last 24 months<br><br>     - Or impossibility of regular access to the treatment centre during the 2 years<br>       following the end of the treatment<br><br>     - Or less than 10 kg of body weight<br><br>     - Or refugee patient<br>   ,,"Trypanosomiasis, African","Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;Drug: melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;Drug: nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d",Cure rate,Adverse events temporally associated with the treatment;Major adverse events temporally associated with the treatment,EPICENTRE-BTT,Please refer to primary and secondary sponsors,"Medecins Sans Frontieres;Embassy of France in Uganda;National Sleeping Sickness Control Program, Uganda",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2006,,Unknown,Yes
NCT06627257,14 October 2024,Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy,"A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Participants in Areas Endemic for Leprosy",,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),2023-08-21,20230821,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06627257,Not recruiting,No,18 Years,55 Years,All,02/01/2025,54.0,Interventional,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 1,Brazil, ; ,"Cassio P Ferreira, PhD, Principal investigator;Cassio P Ferreira, PhD",,cassio.ferreira@ioc.fiocruz.br;,+ 55 (21) 2562-1527;,,"Inclusion Criteria:<br><br> - Men and women between 18 and 55 years old.<br><br> - They should be in good general health, confirmed by a medical history and physical<br>   examination, with negative clinical evaluation for leprosy.<br><br> - Female subjects of childbearing potential must have a negative serum pregnancy test<br>   at screening and a negative urine pregnancy test on study vaccination days (D0, D28,<br>   and D56). They must not be breastfeeding and must use at least one method of<br>   contraception from the time of study enrollment (Day 0) through 30 days after the<br>   last injection if they have sex with men.<br><br> - Screening laboratory tests with normal, within laboratory reference limits for:<br>   sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine,<br>   glucose, total WBC count, hemoglobin and platelet count. Abnormal results may be<br>   repeated at the discretion of the Principal Investigator and/or sub-investigators,<br>   who may share doubts with the sponsor's Scientific Leader and if necessary, with the<br>   DSMB.<br><br> - Negative serological tests for: HIV 1/2 antibody, hepatitis B surface antigen<br>   (HBsAg), and hepatitis C virus (HCV) antibody.<br><br> - Normal or not clinically significant urinalysis as determined by the study doctor or<br>   designee. Abnormal results may be repeated at the discretion of the Principal<br>   Investigator.<br><br> - Must be able to complete the study adverse events diary.<br><br> - Must consent to participate in the study, be able and willing to make all evaluation<br>   visits, be accessible by telephone or home visits, and live in the region until<br>   study follow-up completion.<br><br> - Having completed the primary vaccination course for Covid 19, at least 14 days<br>   before inclusion in the study. If 14 days have not been completed, the participant<br>   may be rescheduled for a new eligibility assessment<br><br>Exclusion Criteria:<br><br> - History of infection with Mycobacterium leprae.<br><br> - History of exposure to experimental products containing GLA-SE.<br><br> - History of active tuberculosis or documented recurrence.<br><br> - History of previous infection with other non-tuberculous mycobacteria.<br><br> - Participation in another trial protocol and/or receipt of any trial products in the<br>   last 3 months prior to screening.<br><br> - Treatment with immunosuppressive drugs (eg, oral or injectable steroids such as<br>   prednisone; high-dose inhaled steroids) or cytotoxic therapies (eg, chemotherapy or<br>   radiotherapy) within six months prior to screening.<br><br> - Have received blood transfusion within the last 3 months prior to screening.<br><br> - Donated blood products (platelets, whole blood, plasma, etc.) within the last month<br>   prior to screening.<br><br> - Received any vaccine 1 month prior to screening or planned immunizations during the<br>   follow-up from D0 to D63 and D154 to D168.<br><br> - History of autoimmune disease or other immunosuppressive causes.<br><br> - History of any other uncompensated acute or chronic disease (including<br>   cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological,<br>   metabolic or renal disease, uncontrolled hypertension) or use of medications that,<br>   in the opinion of the Principal Investigator, may interfere with safety or<br>   immunogenicity of the vaccine.<br><br> - Rash, tattoos, or any other dermatological condition that may adversely affect the<br>   injection site of the vaccine or interfere with its evaluation.<br><br> - Body mass index (BMI) = 32.<br><br> - Systemic arterial hypertension (systolic > 150 or diastolic > 95).<br><br> - History of psychiatric illness with current medication use.<br><br> - Alcohol or drug abuse in the last 6 months prior to screening.<br><br> - Chronic smoker (1 pack or more per day).<br><br> - History of previous anaphylaxis or severe allergic reaction to unknown vaccines or<br>   allergens.<br><br> - Individuals who do not wish to cooperate with all procedures recommended in the<br>   study protocol.",,Leprosy,Drug: LepVax (2 µg LEP-F1 + 5 µg GLA-S): Low dose;Drug: LepVax (10 µg LEP-F1 + 5 µg GLA-SE): High dose;Other: Placebo Comparator: Placebo,Phase 1b_The number of participants who receive the injection and experience local and systemic reactions within 7 days of each study injection.;Phase 1b_Number of participants experiencing unsolicited AEs;Phase 1b_The number of physician-attended adverse events,"Phase 1b_IgG antibody responses to LEP-F1 by ELISA on Days 0, 35, 63,and 168.;Phase 1b_ The T cell responses measured by LEP-F1-specific cytokine production in PBMC assay by ELISA or multiplex assay on Days 0, 35, 63,and 168.whole blood assay",ASCLIN 001/2023,Please refer to primary and secondary sponsors,Oswaldo Cruz Institute,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2023,18.0,No,Yes
NCT05243654,8 September 2025,Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy,"Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia",MetLep,Oxford University Clinical Research Unit Indonesia,2021-09-30,20210930,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05243654,Recruiting,No,18 Years,65 Years,All,01/10/2022,166.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 2,Indonesia, ; ,"Hardiyanto Soebono, Prof.Dr.dr;Marlous Grijsen, MD, PhD",,;mgrijsen@oucru.org,;62-21-23599099,"Center of Tropical Medicine, University of Gadjah Mada;","Inclusion Criteria:<br><br> - Participant is a male or female, aged =18 and =65 years.<br><br> - Participant is newly diagnosed with MB leprosy and has been receiving MDT = 28 days.<br><br> - Participant is willing and able to give informed consent for participation in the<br>   trial.<br><br> - Participant is willing to adhere to study follow-up schedule for 48 weeks.<br><br>Exclusion Criteria:<br><br> - Participant has received MDT >28 days for the current episode of MB leprosy, prior<br>   to study enrolment.<br><br> - Presence of leprosy reaction and/or nerve function impairment requiring systemic<br>   corticosteroids on screening/enrolment evaluation.<br><br> - Participants who have been treated for leprosy in the past.<br><br> - Chronic systemic corticosteroid use for any other medical condition on screening<br>   evaluation (chronic use defined as = 2 weeks).<br><br> - History of diabetes mellitus or diabetes mellitus diagnosed on screening evaluation<br>   (random blood glucose is elevated =200 mg/dL (or =11,1 mmol/L) or fasting blood<br>   glucose = 126 mg/dL (or =7.0 mmol/L)).<br><br> - History of hypoglycaemia (random blood glucose <55 mg/dL (or <3.0 mmol/L).<br><br> - History of cardiac failure, ischaemic heart disease, alcoholism, history of lactic<br>   acidosis or states associated with lactic acidosis such as shock or pulmonary<br>   insufficiency, and conditions associated with hypoxia.<br><br> - History of intolerance or hypersensitivity to metformin.<br><br> - Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73m2 calculated by the<br>   CKDEPI equation.<br><br> - AST or ALT =3 times the upper limit of normal (ULN) on screening evaluation.<br><br> - Any serious medical condition for which participation in the trial, as judged by the<br>   investigator or treating physician, could compromise the well-being of the subject<br>   or prevent, limit or confound protocol-specified assessments.<br><br> - HIV-positive on screening evaluation.<br><br> - Female participant of childbearing age who is pregnant (clinically confirmed or<br>   urine dipstick for human chorionic gonadotrophin hormone) or breastfeeding.<br><br> - Use of metformin within 12 weeks prior to study enrolment.<br><br> - Use of other regular hypoglycaemic agents, including insulin.<br><br> - Participation in another research trial involving an investigational product within<br>   12 weeks prior to study enrolment.",,"Leprosy;Leprosy, Multibacillary;Neglected Tropical Diseases",Drug: Metformin;Drug: Placebo,The proportion of participants experiencing a leprosy reaction;The proportion of participants with at least one adverse events,"The proportion of participants experiencing a Type 1 Reactions (T1R);The proportion of participants experiencing a Type 2 Reactions (T2R);The time to the first leprosy reaction;The time to the first Type 1 Reactions (T1R);The time to the first Tipe 2 Reaction (T2R);The difference in the number of T1R episodes;The difference in the number of T2R episodes;The severity of T1R, based on investigator-assessed validated Clinical Severity Scores;The severity of T2R, based on investigator-assessed validated Clinical Severity Scores;The proportion of participants with at least one serious adverse event;Total number of adverse events;The cumulative corticosteroid usage;The proportion of participants experiencing clinical nerve function impairment;The difference in Quality of Life between start and end of treatment intervention, and end of study by means of SF-36 questionnaires;The difference in Quality of Life between start and end of treatment intervention, and end of study by means of the Dermatology Life Quality Index (DLQI) questionnaires.",OXTREC 14-21;EOCRU.2021.002,Please refer to primary and secondary sponsors,"University of Gadjah Mada, Faculty of Medicine;University of Diponegoro;Papua Agency of Health Research and Development (NIHRD);London School of Hygiene and Tropical Medicine;Radboud University Medical Center;Oxford University Clinical Research Unit",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2021,18.0,No,Yes
RBR-88jm8yk,29 May 2023,"Study Aimed at Assessing whether the Vaccine is safe, how much the body tolerates and how much the immune system reacts to the LEP-F1 + GLA-SE Vaccine in adult participants in a region where there are many patients with leprosy","Clinical Trial for the Assessment of Safety, Tolerance and Immune Responses toVaccine, for the Prevention of Leprosy, LepVax in Adult Participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",,Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos / Fiocruz,2021-08-11,20210811,10/13/2025 15:59:22,REBEC,http://ensaiosclinicos.gov.br/rg/RBR-88jm8yk,Not Recruiting,No,18Y,55Y,-,04/01/2022,200.0,Intervention,,1-2,Brazil,Cristiane,Domingues,"Avenida Brasil, 4365, Manguinhos Rio de Janeiro 21040-360, Brasil",cris.c.dom@gmail.com,55 21 25621588,,"Inclusion criteria: Men and women between 18 years and 55 years of age;For phase 1b, they must be in good general health, confirmed by medical history and physical examination, with negative clinical assessment for leprosy. For phase 2a, the diagnosis of paucibacillary leprosy must be confirmed;Female participants of childbearing potential must test negative on a serum pregnancy test at screening and a urine pregnancy test on study vaccination days (D0, D28, and D56). They must not be breastfeeding and must use at least one method of contraception from the time of study enrollment (Day 0) until 30 days after the last injection if they have sex with men;Screening laboratory tests with normal or non-clinically significant values ??for: sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine, glucose, total white blood cell count, hemoglobin, and platelet count. Abnormal results may be repeated at the discretion of the Responsible Researcher and/or sub-researchers, and may share doubts with the sponsor's Scientific Leader and, if necessary, with the DSMB;Negative serological tests for: Anti-HIV 1/2 antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV);Normal or non-clinically significant urinalysis as determined by the study physician or designee. Abnormal results may be repeated at the discretion of the Lead Investigator;Must be able to complete the study adverse event diary; Must consent to participate in the study, be able and willing to attend all assessment visits, be accessible by telephone or home visits, and live in the region until the study follow-up is completed","Exclusion criteria: In phase 1b, history of Mycobacterium leprae infection.History of exposure to experimental products containing GLA-SE.History of active tuberculosis or with documented recurrence.History of previous infection with other non-tuberculous mycobacteria;Participation in another study protocol and/or administration of any study product in the last three months prior to screening.Treatment with immunosuppressive drugs (eg, oral or injectable steroids, such as prednisone; high-dose inhaled steroids) or cytotoxic therapies (eg, chemotherapy or radiotherapy) within six months of screening.Received blood transfusion in the last three months prior to screening.<br>8. Donated blood products (platelets, whole blood, plasma, etc.) in the last month before screening.Received any vaccine one month prior to screening or planned immunizations during follow-up from D0 to D63 and D154 to D168.History of autoimmune disease or other immunosuppressive causes.History of any other decompensated acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disease, uncontrolled hypertension) or use of medications that, in the opinion of the Responsible Investigator, may interfere with safety or immunogenicity of the vaccine.Skin rash, tattoos, or any other dermatological condition that may adversely affect the vaccine injection site or interfere with its evaluation.Body mass index (BMI) = 32.Systemic arterial hypertension (systolic > 150 or diastolic > 95).History of psychiatric illness with current medication use.<br>16. Alcohol or drug abuse in the last six months prior to screening.Chronic smoker (one pack or more per day).History of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.Individuals who do not wish to cooperate with all procedures recommended in the study protocol.",Leprosy;Tuberculoid leprosy; Borderline tuberculoid leprosy; Leprosy sequelae (leprosy),"The study will include 30 healthy participants in phase 1b and 24 participants diagnosed with paucibacillary leprosy undergoing multidrug therapy (MDT-PB) in phase 2a. Safety at the lowest vaccine dose will be demonstrated in healthy subjects prior to antigen dose escalation. In addition, the safety of all healthy participants will be demonstrated prior to the inclusion of leprosy patients.<br>Participants will be randomized in each group to receive three doses of vaccine or placebo administered IM on days 0, 28 and 56 of the study. Participants will be monitored for one year after the last injection in the study, including laboratory safety analyzes seven days after each injection. Blood samples will be collected for immunological analysis on days 0, 35, 63 and 168 of the study.<br>In phase 1b (healthy individuals) they will be divided into two groups: Group 1, 12 patients will receive 2 µg of LEP-F1 + 5 µg of GLA-SE and 3 will receive placebo. In Group 2, 12 patients will receive 10 µg of LEP-F1 + 5 µg of GLA-SE and 3 will receive placebo.<br>In phase 2a (individuals with leprosy) Group 3, 20 participants will receive the dose defined in the phase 1b study + *LEP-F1 + 5 µg of GLA-SE and 4 participants will receive placebo.;D20.215.894","Assess the safety and tolerability of 2 or 10 µg of LEP-F1 + GLA-SE after intramuscular administration on Days 0, 28 and 56. It will be verified by the number of participants who receive the injection and present local and systemic reactions within 7 days after each study injection by the number of participants spontaneously reporting adverse events from Day 0 to Day 84, by the number of adverse events seen by physicians considered related to any of the study injections reported at any time during the study period.","Evaluate the immunogenicity of 2 or 10 µg of LEP-F1 + GLA-SE after intramuscular administration on Days 0, 28 and 56 by quantifying cytokine production and IgG antibody responses to LEP-F1 at specific times through the response methods of the IgG antibodies to LEP-F1 evaluated by ELISA on Days 0, 35, 63 and 168 and through T cell responses measured by the production of selected cytokines to LEP-F1 in an assay with peripheral blood mononuclear cells (PBMCs) by ELISA or assay multiplex on Days 0, 35, 63 and 168.;Evaluate the immunogenicity of 2 or 10 µg of LEP-F1 + GLA-SE after intramuscular administration on Days 0, 28 and 56 by quantifying antigen-specific T cell responses at specific time points. The evaluation will be done through T cell responses measured by intracellular cytokine staining (ICS) in PBMCs on Days 0, 35, 63 and 168.<br>Evaluate candidate biomarkers indicative of disease status to allow future studies to assess the impact of LEP-F1 + GLA-SE vaccination on disease status. It will be evaluated through assays with candidate biomarkers measured on Day 0 and 63 including gene expression signatures and multiplex serum protein assay<br>Evaluate the impact of LEP-F1 + GLA-SE vaccination on neurological function (Phase 2a) through clinical and neurophysiological tests (Phase 2a).",,Instituto Oswaldo Cruz,Fundação Oswaldo Cruz,Approved,13/11/2019,Genilson ,"Avenida Brasil, 4.036 - 7º andar, sala 705 - Expansão - Manguinhos - Rio de Janeiro-RJ ",55 21 3882-9011,cepfiocruz@ioc.fiocruz.br,Yes,,,,04/09/2024,,,,,,No,,Yes,False,          ,2021,18.0,No,Yes
NCT03947437,26 June 2023,Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients,"A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy",,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),2019-05-09,20190509,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03947437,Not recruiting,No,18 Years,55 Years,All,01/02/2024,142.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). ",Phase 1/Phase 2,Brazil, ; ; ,"Veronica Schmitz Pereira, PHD;Cassio Porto Ferreira, PhD;Veronica S Pereira, PHD",,;cassio.ferreira@fiocruz.br;veronicaschmitz@ioc.fiocruz.br,;+552125621588;+55 (21) 2562-1579,Instituto Oswaldo Cruz;,"<br>    Phase 1b<br><br>    Inclusion Criteria:<br><br>     1. Men and women between 18 and 55 years old.<br><br>     2. They should be in good general health, confirmed by a medical history and physical<br>       examination, with negative clinical evaluation for leprosy.<br><br>     3. Female participants of childbearing age should have a negative serum pregnancy test at<br>       screening and a negative urine pregnancy test on study vaccination days (D0, D28 and<br>       D56). They must not be breast-feeding and are required to use at least one<br>       contraceptive method from the time of study inclusion (Day 0) until 30 days after the<br>       last injection if they have sex with men.<br><br>     4. Screening laboratory tests with normal, within laboratory reference limits for::<br>       sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine,<br>       glucose, total leukocyte count, hemoglobin and platelet count. Abnormal results may be<br>       repeated at the discretion of the Principal Investigator and/or sub-investigators, who<br>       may share doubts with the sponsor's Scientific Leader and if necessary with the DSMB.<br><br>     5. Negative serological tests for: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg),<br>       and hepatitis C virus (HCV) antibody.<br><br>     6. Normal or not clinically significant urinalysis as determined by the study doctor or<br>       designee. Abnormal results may be repeated at the discretion of the Principal<br>       Investigator.<br><br>     7. Must be able to complete the study adverse events diary.<br><br>     8. Must consent to participate in the study, be able and willing to make all evaluation<br>       visits, be accessible by telephone or home visits, and live in the region until study<br>       follow-up completion.<br><br>     9. Having completed the primary vaccination course for Covid 19, at least 14 days before<br>       inclusion in the study. If 14 days have not been completed, the participant may be<br>       rescheduled for a new eligibility assessment<br><br>    Exclusion Criteria (Phase 1b)<br><br>    Individuals who meet ANY of the following criteria will be considered ineligible:<br><br>     1. History of infection with Mycobacterium leprae.<br><br>     2. History of exposure to experimental products containing GLA-SE.<br><br>     3. History of active or documented latent tuberculosis.<br><br>     4. History of previous infection with other non-tuberculous mycobacteria.<br><br>     5. Participation in another trial protocol and/or receipt of any trial products in the<br>       last 3 months prior to screening.<br><br>     6. Treatment with immunosuppressive drugs (eg oral or injected steroids, such as<br>       prednisone; high doses of inhaled steroids) or cytotoxic therapies (eg chemotherapy or<br>       radiation) within 6 months prior to screening.<br><br>     7. Have received blood transfusion within the last 3 months prior to screening.<br><br>     8. Donated blood products (platelets, whole blood, plasma, etc.) within the last month<br>       prior to screening.<br><br>     9. Received any vaccine 1 month prior to screening or planned immunizations during the<br>       follow-up from D0 to D63 and D154 to D168.<br><br>     10. History of autoimmune disease or other immunosuppressive causes.<br><br>     11. History of any other acute or chronic decompensated disease (including cardiovascular,<br>       pulmonary, neurological, hepatic, rheumatic, haematological, metabolic or renal<br>       disease, uncontrolled hypertension) or use of medication that, in the opinion of the<br>       Principal Investigator, may interfere with safety or immunogenicity of the vaccine.<br><br>     12. Rash, tattoos or any other dermatological condition that may adversely affect the<br>       injection site of the vaccine or interfere with its evaluation.<br><br>     13. Body mass index (BMI) = 32.<br><br>     14. Systemic arterial hypertension (systolic > 150 or diastolic > 95).<br><br>     15. History of psychiatric illness with current medication use.<br><br>     16. Alcohol or drug abuse in the last 6 months prior to screening.<br><br>     17. Chronic smoker (1 pack or more per day).<br><br>     18. History of previous anaphylaxis or severe allergic reaction to unknown vaccines or<br>       allergens.<br><br>     19. Individuals who do not wish to cooperate with all procedures recommended in the study<br>       protocol.<br><br>    Inclusion Criteria (Phase 2a)<br><br>    Participants must meet ALL of the following criteria listed below to be included in the<br>    study:<br><br>     1. Men and women between 18 and 55 years old.<br><br>     2. Diagnosis of PB leprosy (BI=0) before MDT treatment<br><br>     3. Female participants of childbearing age should have a negative serum pregnancy test at<br>       screening and a negative urine pregnancy test on study vaccination days (D0, D28 and<br>       D56). They must not be breast-feeding and are required to use at least one<br>       contraceptive method from the time of study inclusion (Day 0) until 30 days after the<br>       last injection if they have sex with men.<br><br>     4. Screening laboratory tests with normal, within laboratory reference limits for:<br>       sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine,<br>       glucose, total leukocyte count, hemoglobin and platelet count. Abnormal results may be<br>       repeated at the discretion of the Principal Investigator and/or sub-investigators, who<br>       may share doubts with the sponsor's Scientific Leader and if necessary with the DSMB.<br><br>     5. Negative serological tests for: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg),<br>       and hepatitis C virus (HCV) antibody.<br><br>     6. Normal or not clinically significant urinalysis as determined by the study doctor or<br>       designee. Abnormal results may be repeated at the discretion of the Principal<br>       Investigator.<br><br>     7. Must be able to complete the study adverse events diary.<br><br>     8. Must consent to participate in the study, be able and willing to make all evaluation<br>       visits, be accessible by telephone or home visits, and live in the region until study<br>       follow-up completion.<br><br>     9. Having completed the primary vaccination course for Covid 19, at least 14 days before<br>       inclusion in the study. If 14 days have not been completed, the participant may be<br>       rescheduled for a new eligibility assessment<br><br>    Exclusion Criteria (Phase 2a)<br><br>    Individuals who meet ANY of the following criteria will be considered ineligible:<br><br>     1. Previous treatment for leprosy.<br><br>     2. History of exposure to experimental products containing GLA-SE.<br><br>     3. History of active or documented latent tuberculosis.<br><br>     4. History of previous infection with other non-tuberculous mycobacteria.<br><br>     5. Participation in another trial protocol and/or receipt of any trial products in the<br>       last 3 months prior to screening.<br><br>     6. Treatment with immunosuppressive drugs (eg oral or injected steroids, such as<br>       prednisone; high doses of inhaled steroids) or cytotoxic therapies (eg chemotherapy or<br>  ",,Leprosy,Biological: LEP-F1 + GLA-SE;Biological: Placebo,"Phase 1b_The number of participants who receive the injection and experience local and systemic reactions within 7 days of each study injection.;Phase 1b_Number of participants experiencing unsolicited AEs;Phase 1b_The number of adverse events attended by physicians considered related to any of the study injections reported at any time during the study period.;Phase 1b_The LEP-F1 specific T cell IFN--? production responses in assay with PBMCs evaluated by ELISA on Days 0, 35 and 63.;Phase 2a_The number of participants who receive the injection and experience local and systemic reactions within 7 days of each study injection.;Phase 2a_The number of participants spontaneously reporting adverse events from Day 0 to Day 84.;Phase 2a_The number of physician-assisted adverse events considered related to any of the study injections reported at any time during the study period;Phase 2a_The frequency and intensity of solicited adverse events within 7 days of each study injection.;Phase 2a_The frequency and intensity of unsolicited adverse events during study participation (D0 to D421).;Phase 2a_The frequency and causality of serious adverse events occurring during study participation (D0 to D421).","Phase 1b_IgG antibody responses to LEP-F1 by ELISA on Days 0, 35, 63, and 168.;Phase 1b_ The T cell responses measured by LEP-F1-specific cytokine production in PBMC assay by ELISA or multiplex assay on Days 0, 35, 63, and 168.whole blood assay;Phase 2a_IgG antibody responses to LEP-F1 by ELISA on Days 0, 35, 63, and 168.;Phase 2a_T cell responses measured by LEP-F1-specific cytokine production in PBMC assay by ELISA or multiplex assay on Days 0, 35, 63, and 168.;Phase 2a_The neurological nerve function as measured by clinical and neurophysiological tests;Phase 2a_The number of participants who received LepVax and had episodes of RR after the start of the study.;Phase 2a_The number of M. leprae genome copies (bacillus quantification).",ASCLIN 002/2020,Please refer to primary and secondary sponsors,Oswaldo Cruz Institute,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2019,18.0,No,Yes
NCT03807362,12 December 2020,CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum,"A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum",,The Leprosy Mission Nepal,2018-09-14,20180914,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03807362,Recruiting,No,18 Years,65 Years,All,07/01/2018,50.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Nepal, ; ,"Mahesh Shah, MD;Mahesh Shah, MD",,;drmahesh_shah@yahoo.com,;+9779841203417,The Leprosy Mission Nepal;,"<br>    Inclusion Criteria:<br><br>    Study participants must satisfy the following criteria to be enrolled in the study:<br><br>     1. Must be 18 -65 years old, weight > 35kg for women and >40kg for men at the time of<br>       signing the informed consent.<br><br>     2. Understand and voluntarily sign an informed consent document prior to any study<br>       related assessments/procedures are conducted.<br><br>     3. Have signs or symptoms of new or new episode ENL. In Step one, participants must be<br>       male. In Step 2, participants can be either male or female.<br><br>     4. Able to adhere to the study schedule and other protocol requirements.<br><br>    Exclusion Criteria:<br><br>    The presence of any of the following will exclude a participant from enrollment:<br><br>     1. Any significant medical condition, laboratory abnormality, or psychiatric illness that<br>       would prevent the participants from participating in the study.<br><br>     2. Patients on continuous rifampicin will be excluded, however, If rifampicin is given<br>       only once a month as part of a multi-drug regimen, a minimum of 2-week washout period<br>       is required prior to administration of CC-11050<br><br>     3. Any condition including the presence of laboratory abnormalities, which places the<br>       participant at unacceptable risk if he were to participate in the study.<br><br>     4. Any condition that confounds the ability to interpret data from the study (ie, HIV,<br>       chronic HepB, chronic HepC or TB patients under active treatment). Resolved TB<br>       patients will not be excluded from the study.<br><br>     5. Stable and well managed patients with Diabetes and hypertension will not be excluded<br>       from the study.<br><br>     6. Use of systemic corticosteroid or immunosuppressant therapy within 7 days of study<br>       medication initiation<br><br>     7. Pregnant or nursing females.<br>   ",,Erythema Nodosum Leprosum;Leprosy,Drug: CC-11050,Number of participants with moderate to severe ENL with severity changes as assessed by the ENL Severity Scale.,Number of participants with moderate to severe ENL with decreased duration of episode(s) as assessed by standard ENL episode definition.;Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed by slit skin smear microscopy.;Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed skin histopathology.;Number of patients with moderate to severe ENL with improved peripheral neuropathy as assessed by standardized monofilament and voluntary muscle tests.;Number of participants with moderate to severe ENL with improved quality of life as assessed by the World Health Organization Quality of Life tool.;Number of participants with moderate to severe ENL as assessed by standard blood panel and basic metabolic testing.;Number of participants with moderate to severe ENL as assessed by urinalysis.;Number of participants with moderate to severe ENL as assessed by serological indicators associated with ENL.,Nepal CC-11050,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,Undecided,,No,False,          ,2018,18.0,No,Yes
NCT03384641,12 February 2024,A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy,An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy,,"Janssen Research & Development, LLC",2017-12-20,20171220,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03384641,Not recruiting,No,18 Years,65 Years,All,26/09/2018,11.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Brazil, ,"Janssen Research & Development, LLC Clinical Trial",,,,"Janssen Research & Development, LLC","<br>    Inclusion Criteria:<br><br>     - Participant has: a) multibacillary (MB) leprosy, defined as 6 or more skin lesions or<br>       extensive confluent lesions or diffuse skin involvement, and is either borderline<br>       lepromatous or polar lepromatous, as determined using Ridley and Jopling<br>       classification system; and b) has a bacteriological index of >=4+ from the lesion<br>       biopsy obtained at screening, and a bacteriological index of >= 1+ from each of 4 slit<br>       skin smear assessments taken at screening<br><br>     - Otherwise healthy on the basis of physical examination, medical history, vital signs,<br>       and 12-lead electrocardiogram (ECG) performed at screening. If there are<br>       abnormalities, they must be consistent with the underlying illness in the study<br>       population. This determination must be recorded in the participant's source documents<br>       and initialed by the investigator<br><br>     - Otherwise healthy on the basis of clinical laboratory tests performed at screening. If<br>       the results of the serum chemistry panel, including liver enzymes, other specific<br>       tests, blood coagulation, hematology, or urinalysis are outside the normal reference<br>       ranges, the participant may be included only if the investigator judges the<br>       abnormalities or deviations from normal to be not clinically significant or to be<br>       appropriate and reasonable for the population under study. This determination must be<br>       recorded in the participant's source documents and initialed by the investigator<br><br>     - a man must agree not to donate sperm throughout treatment with TMC207 and for 3 months<br>       after treatment is stopped<br><br>     - Willing and able to adhere to the prohibitions, restrictions, and long-term follow up<br>       requirements specified in this protocol<br><br>     - If a woman is of childbearing potential, must be practising a highly effective method<br>       of birth control (failure rate of <1% per year when used consistently and correctly)<br>       before entry, and must also agree to use a barrier contraceptive method (that is, male<br>       or female condom, diaphragm or cervical cap) plus spermicide. participant must also<br>       agree to continue to use a highly effective method of contraception plus a barrier<br>       method throughout treatment with TMC207 and until 6 months after treatment is stopped<br><br>    Exclusion Criteria:<br><br>     - Has experienced or is experiencing a lepra reaction requiring treatment with a<br>       prohibited therapy<br><br>     - Has a contraindication limiting the implementation of a medically accepted MB leprosy<br>       regimen<br><br>     - a) Has ever received pharmacotherapy for leprosy; b) has ever been treated with a drug<br>       that is a component of the primary World Health Organization (WHO) regimen for the<br>       treatment of MB leprosy (example, dapsone, rifampicin, clofazimine). Short-term (<=2<br>       weeks) pharmacotherapy with any antibiotic that could be used as a second line<br>       treatment for leprosy (eg, of the macrolide, quinolone, or tetracycline class) is<br>       acceptable as long as the last administration occurred >=4 weeks before first dose of<br>       study drug (TMC207)<br><br>     - Has a concomitant infection that requires an additional systemic antimicrobial agent<br><br>     - Has tuberculosis (TB), as determined by medical history and chest x-ray<br><br>     - Is a woman who is pregnant, or breast-feeding, or planning to become pregnant while<br>       enrolled in this study or within 6 months after the last dose of study drug<br>   ",,"Leprosy, Multibacillary",Drug: Bedaquiline 200 mg,Change from Baseline in the Odds of Mycobacterium leprae (M. leprae) Growth in Mouse Footpads Following 8 Weeks of Treatment with Bedaquiline,Number of Participants with Adverse Events (AEs);Number of Participants with AEs by Severity,TMC207LEP2001;CR108416,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2017,18.0,No,Yes
NCT03302897,12 December 2020,Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers,"A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects",,IDRI,2017-10-02,20171002,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03302897,Not recruiting,No,18 Years,55 Years,All,02/10/2017,24.0,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 1,United States, ,"Corey Casper, MD, MPH",,,,IDRI,"<br>    Inclusion Criteria:<br><br>     1. Males and females 18 years to 55 years of age.<br><br>     2. Must be in good general health as confirmed by a medical history and physical exam.<br><br>     3. Female subjects of childbearing potential must have a negative serum pregnancy test at<br>       screening and a negative urine pregnancy test on the day of each study vaccination,<br>       must not be breast-feeding, and are required to use one of the following methods of<br>       contraception from enrollment (Day 0) in study until 30 days after last injection<br>       (only if in sexual relationships with men): hormonal (e.g. oral, transdermal,<br>       intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm, or<br>       cervical cap with spermicide); intrauterine device (IUD) or system (IUS); vasectomized<br>       partner (6 months minimum); or abstinence; bilateral tubal ligation (if no conception<br>       post-procedure); tubal occlusion; or bilateral salpingectomy. These precautions are<br>       necessary due to unknown effects that LEP-F1 + GLA-SE might cause in a fetus or<br>       newborn infant. Women are considered non-child-bearing potential if they are<br>       post-menopausal (defined as at least 12 months spontaneous amenorrhea and confirmed<br>       with FSH > 40 mIU/ml) or have had documented hysterectomy and/or oophorectomy.<br><br>     4. The following screening laboratory values must be within the normal ranges or not<br>       clinically significant as determined by the Investigator and approved by the Medical<br>       Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase,<br>       creatinine, fasting glucose, total WBC count, hemoglobin, and platelet count. Abnormal<br>       results may be repeated once for confirmation at Investigator discretion.<br><br>     5. The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface<br>       antigen (HBsAg), QuantiFERON®-TB Gold (QFT), and hepatitis C virus (HCV) antibody.<br><br>     6. Negative test for recreational drugs and alcohol per Clinical Research Unit standards.<br><br>     7. Normal or not clinically significant urinalysis as determined by the study clinician<br>       or designee. Abnormal results may be repeated at Investigator discretion.<br><br>     8. Must be capable of completing a study memory aid in English.<br><br>     9. Must give informed consent, be able and willing to make all evaluation visits, be<br>       reachable by telephone or personal contact by the study site personnel, and have a<br>       permanent address.<br><br>    Exclusion Criteria:<br><br>     1. History of infection with M. leprae or previous exposure to M. leprae vaccines or<br>       experimental products containing GLA-SE.<br><br>     2. History of BCG vaccination.<br><br>     3. History of active or documented latent TB.<br><br>     4. History of previous infection with other non-tuberculous mycobacteria.<br><br>     5. Travel to or residence in India, Brazil, or Indonesia for more than 6 months.<br><br>     6. Participation in another experimental protocol and/or receipt of any investigational<br>       products within the past 3 months prior to Screening.<br><br>     7. Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as<br>       prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy<br>       drugs or radiation) in the past 6 months prior to Screening.<br><br>     8. Received a blood transfusion within past 3 months prior to Screening.<br><br>     9. Donated blood products (platelets, whole blood, plasma, etc.) within past one month<br>       prior to Screening.<br><br>     10. Received any vaccine within past 1 month prior to Screening or have any planned<br>       immunizations while on study, with the exception of seasonal influenza vaccine which<br>       can be given after 1 month post the third study injection (Day 84).<br><br>     11. History of autoimmune disease or other causes of immunosuppressive states.<br><br>     12. History of any other acute or chronic illness (including cardiovascular, pulmonary,<br>       neurological, hepatic, rheumatic, hematological, metabolic or renal disorders,<br>       uncontrolled hypertension), or use of medication that, in the opinion of the Principal<br>       Investigator, may interfere with the evaluation of the safety or immunogenicity of the<br>       vaccine.<br><br>     13. Rash, tattoos, or any other dermatological condition that could adversely affect the<br>       vaccine injection site or interfere with its evaluation.<br><br>     14. BMI = 32.<br><br>     15. Hypertension (systolic > 150 or diastolic > 95) at screening and Day 0.<br><br>     16. History of significant psychiatric illness with current use of medication.<br><br>     17. Known or suspected alcohol or drug abuse within the past 6 months prior to Screening.<br><br>     18. Chronic tobacco user (> 20 pack years).<br><br>     19. Subjects with a history of previous anaphylaxis or severe allergic reaction to<br>       vaccines or unknown allergens.<br><br>     20. Subjects who are unlikely to cooperate with the requirements of the study protocol.<br>   ",,Leprosy,Biological: LEP-F1 + GLA-SE,Number of adverse events,Immunogenicity (IgG antibody and T cell responses to LEP-F1),IDRI-LEPVPX-118,Please refer to primary and secondary sponsors,American Leprosy Missions,,,,,,,Unknown,,,,,,,,,,No,,Yes,False,          ,2017,18.0,No,Yes
NCT03324035,16 December 2017,Treatment of Neuropathic Pain in Leprosy,Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study,AmyNeLe,University of Sao Paulo,2017-06-14,20170614,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03324035,Recruiting,No,18 Years,85 Years,All,01/03/2017,102.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 3,Brazil;Brazil;Brazil;Brazil;Brazil, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ,"Daniel Andrade, PhD;Renato Pazzini, MD;Renato Pazzini, MD;Daniel Andrade, PhD;Renato Pazzini, MD;Renato Pazzini, MD;Daniel Andrade, PhD;Renato Pazzini, MD;Renato Pazzini, MD;Daniel Andrade, PhD;Renato Pazzini, MD;Renato Pazzini, MD;Daniel Andrade, PhD;Renato Pazzini, MD;Renato Pazzini, MD",,;renatopazzini@me.com;renatopazzini@me.com;;renatopazzini@me.com;renatopazzini@me.com;;renatopazzini@me.com;renatopazzini@me.com;;renatopazzini@me.com;renatopazzini@me.com;;renatopazzini@me.com;renatopazzini@me.com,;5511974429181;5511974429181;;5511974429181;5511974429181;;5511974429181;5511974429181;;5511974429181;5511974429181;;5511974429181;5511974429181,University of Sao Paulo;;University of Sao Paulo;;University of Sao Paulo;;University of Sao Paulo;;University of Sao Paulo;,"<br>    Inclusion Criteria:<br><br>     - Presence of spontaneous pain of medium intensity in the last 24 hours with a minimum<br>       value of 4 in 10 on a numerical scale, with a maximum of 10 points (summed pain<br>       questionnaire)<br><br>     - Duration of pain of at least 6 months<br><br>     - Presence of neuropathic pain """"pure"""" or of clearly dominant character (no other pain,<br>       or pain associated unimportant)<br><br>     - Pain due to leprosy confirmed by clinical examination and / or appropriate<br>       electrophysiological examination<br><br>     - Ability to properly understand the Portuguese language, being able to understand the<br>       methodology of the study and questionnaires<br><br>     - Having provided their consent in writing of their participation in the study<br><br>    Exclusion Criteria:<br><br>     - Linked to the disease in study:<br><br>     - Neuropathic pain from other causes that not Hansen's disease (Diabetes, HIV, and after<br>       chemotherapy);<br><br>     - Linked to the treatment:<br><br>     - Hypersensitivity to amitriptyline and tramadol;<br><br>     - Ongoing treatment with monoamine oxidase inhibitors (MAOIs);<br><br>     - Cardiac and ophthalmologic disorders that contraindicate the use of amitryptiline;<br><br>     - Pregnant or nursing women, or even women of childbearing age without the use of<br>       contraceptives.<br><br>     - General<br><br>     - Other pain with intensity higher then the neuropathic one;<br><br>     - Ant other condition that may interfere with the evaluation of the study;<br><br>     - Patients who have not given or signed the informed consent form;<br><br>     - Incorrectly completion of the self-assessment of pain notebook in the period between<br>       inclusion and randomization (at least 4 scores in 7 days);<br><br>     - Patients who can't be followed on a regular basis or that miss the appointments (we<br>       will give a 7 day tolerance for each appointment);<br><br>     - Documented abuse of psychoactive drugs or alcohol;<br><br>     - History of past or actual psychosis;<br><br>     - Actual diagnosis of major depression following the DSM-IV criteria;<br><br>     - Language and cognitive deficits that are capable of interfering with the understanding<br>       of the study;<br><br>     - Patients not affiliated with a social security scheme (beneficiary or recipient);<br><br>     - Patients who refuses to sign or are unable to understand the informed consent, under<br>       guardianship;<br><br>     - Participation in other research protocol involving the use of any medication during<br>       the 30 days preceding the inclusion in the project.<br>   ;<br>    Inclusion Criteria:<br><br>     - Presence of spontaneous pain of medium intensity in the last 24 hours with a minimum<br>       value of 4 in 10 on a numerical scale, with a maximum of 10 points (summed pain<br>       questionnaire)<br><br>     - Duration of pain of at least 6 months<br><br>     - Presence of neuropathic pain """"pure"""" or of clearly dominant character (no other pain,<br>       or pain associated unimportant)<br><br>     - Pain due to leprosy confirmed by clinical examination and / or appropriate<br>       electrophysiological examination<br><br>     - Ability to properly understand the Portuguese language, being able to understand the<br>       methodology of the study and questionnaires<br><br>     - Having provided their consent in writing of their participation in the study<br><br>    Exclusion Criteria:<br><br>     - Linked to the disease in study:<br><br>     - Neuropathic pain from other causes that not Hansen's disease (Diabetes, HIV, and after<br>       chemotherapy);<br><br>     - Linked to the treatment:<br><br>     - Hypersensitivity to amitriptyline and tramadol;<br><br>     - Ongoing treatment with monoamine oxidase inhibitors (MAOIs);<br><br>     - Cardiac and ophthalmologic disorders that contraindicate the use of amitryptiline;<br><br>     - Pregnant or nursing women, or even women of childbearing age without the use of<br>       contraceptives.<br><br>     - General<br><br>     - Other pain with intensity higher then the neuropathic one;<br><br>     - Ant other condition that may interfere with the evaluation of the study;<br><br>     - Patients who have not given or signed the informed consent form;<br><br>     - Incorrectly completion of the self-assessment of pain notebook in the period between<br>       inclusion and randomization (at least 4 scores in 7 days);<br><br>     - Patients who can't be followed on a regular basis or that miss the appointments (we<br>       will give a 7 day tolerance for each appointment);<br><br>     - Documented abuse of psychoactive drugs or alcohol;<br><br>     - History of past or actual psychosis;<br><br>     - Actual diagnosis of major depression following the DSM-IV criteria;<br><br>     - Language and cognitive deficits that are capable of interfering with the understanding<br>       of the study;<br><br>     - Patients not affiliated with a social security scheme (beneficiary or recipient);<br><br>     - Patients who refuses to sign or are unable to understand the informed consent, under<br>       guardianship;<br><br>     - Participation in other research protocol involving the use of any medication during<br>       the 30 days preceding the inclusion in the project.<br>   ;<br>    Inclusion Criteria:<br><br>     - Presence of spontaneous pain of medium intensity in the last 24 hours with a minimum<br>       value of 4 in 10 on a numerical scale, with a maximum of 10 points (summed pain<br>       questionnaire)<br><br>     - Duration of pain of at least 6 months<br><br>     - Presence of neuropathic pain """"pure"""" or of clearly dominant character (no other pain,<br>       or pain associated unimportant)<br><br>     - Pain due to leprosy confirmed by clinical examination and / or appropriate<br>       electrophysiological examination<br><br>     - Ability to properly understand the Portuguese language, being able to understand the<br>       methodology of the study and questionnaires<br><br>     - Having provided their consent in writing of their participation in the study<br><br>    Exclusion Criteria:<br><br>     - Linked to the disease in study:<br><br>     - Neuropathic pain from other causes that not Hansen's disease (Diabetes, HIV, and after<br>       chemotherapy);<br><br>     - Linked to the treatment:<br><br>     - Hypersensitivity to amitriptyline and tramadol;<br><br>     - Ongoing treatment with monoamine oxidase inhibitors (MAOIs);<br><br>     - Cardiac and ophthalmologic disorders that contraindicate the use of amitryptiline;<br><br>     - Pregnant or nursing women, or even women of childbearing age without the use of<br>       contraceptives.<br><br>     - General<br><br>     - Other pain with intensity higher then the neuropathic one;<br><br>     - Ant other condition that may interfere with the evaluation of the study;<br><br>     - Patients who have not given or signed the informed consent form;<br><br>     - Incorrectly completion of the self-assessment of pain notebook in the period between<br>       inclusion and randomization (at least 4 scores in 7 days);<br><br>     - Patients who can't be followed on a regular basis or that miss the appointments (we<br>       will give a 7 day tolerance for each appointment);<br><br>     - Documented abuse of psychoactive drugs or alcohol;<br><br>     - History of past or actual psychosis;<br><br>     - Actual diagnosis of major depression following the DSM-IV criteria;<br><br>     - Language and cognitive deficits that are capable of interfering with the understanding<br>       of the study;<br><br>     - Patients not affiliated with a social security scheme (beneficiary or recipient);<br><br>     - Patients who refuses to sign or are unable to understand the informed consent, under<br>       guardianship;<br><br>     - Participation in other research protocol involving the use of any medication during<br>       the 30 days preceding the inclusion in the project.<br>   ;<br>    Inclusion Criteria:<br><br>     - Presence of spontaneous pain of medium intensity in the last 24 hours with a minimum<br>       value of 4 in 10 on a numerical scale, with a maximum of 10 points (summed pain<br>       questionnaire)<br><br>     - Duration of pain of at least 6 months<br><br>     - Presence of neuropathic pain """"pure"""" or of clearly dominant character (no other pain,<br>       or pain associated unimportant)<br><br>     - Pain due to leprosy confirmed by clinical examination and / or appropriate<br>       electrophysiological examination<br><br>     - Ability to properly understand the Portuguese language, being able to understand the<br>       methodology of the study and questionnaires<br><br>     - Having provided their consent in writing of their participation in the study<br><br>    Exclusion Criteria:<br><br>     - Linked to the disease in study:<br><br>     - Neuropathic pain from other causes that not Hansen's disease (Diabetes, HIV, and after<br>       chemotherapy);<br><br>     - Linked to the treatment:<br><br>     - Hypersensitivity to amitriptyline and tramadol;<br><br>     - Ongoing treatment with monoamine oxidase inhibitors (MAOIs);<br><br>     - Cardiac and ophthalmologic disorders that contraindicate the use of amitryptiline;<br><br>     - Pregnant or nursing women, or even women of childbearing age without the use of<br>       contraceptives.<br><br>     - General<br><br>     - Other pain with intensity higher then the neuropathic one;<br><br>     - Ant other condition that may interfere with the evaluation of the study;<br><br>     - Patients who have not given or signed the informed consent form;<br><br>     - Incorrectly completion of the self-assessment of pain notebook in the period between<br>       inclusion and randomization (at least 4 scores in 7 days);<br><br>     - Patients who can't be followed on a regular basis or that miss the appointments (we<br>       will give a 7 day tolerance for each appointment);<br><br>     - Documented abuse of psychoactive drugs or alcohol;<br><br>     - History of past or actual psychosis;<br><br>     - Actual diagnosis of major depression following the DSM-IV criteria;<br><br>     - Language and cognitive deficits that are capable of interfering with the understanding<br>       of the study;<br><br>     - Patients not affiliated with a social security scheme (beneficiary or recipient);<br><br>     - Patients who refuses to sign or are unable to understand the informed consent, under<br>       guardianship;<br><br>     - Participation in other research protocol involving the use of any medication during<br>       the 30 days preceding the inclusion in the project.<br>   ",,"Pain, Neuropathic;Leprosy;Leprosy Neuropathy;Amitriptyline;Pain, Neuropathic;Leprosy;Leprosy Neuropathy;Amitriptyline;Pain, Neuropathic;Leprosy;Leprosy Neuropathy;Amitriptyline;Pain, Neuropathic;Leprosy;Leprosy Neuropathy;Amitriptyline",Drug: Amitriptyline;Drug: Placebo oral capsule;Drug: Tramadol;Drug: Amitriptyline;Drug: Placebo oral capsule;Drug: Tramadol;Drug: Amitriptyline;Drug: Placebo oral capsule;Drug: Tramadol;Drug: Amitriptyline;Drug: Placebo oral capsule;Drug: Tramadol,Reduction in pain intensity of 30% from baseline measured by verbal analog scale (VAS);Reduction in pain intensity of 30% from baseline measured by verbal analog scale (VAS);Reduction in pain intensity of 30% from baseline measured by verbal analog scale (VAS),Neuropathic pain;Neuropathic Pain Symptoms;Quality of Life;Number of participants with treatment-related adverse events;Predictive factor of response;Use of backup pain medication,AmyNeLe,Please refer to primary and secondary sponsors,Cristália Produtos Químicos Farmacêuticos Ltda.,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2017,18.0,No,Yes
RBR-774vv2,29 May 2023,"A multicenter, randomized, double-blind study,to verify whether the treatment with dextrocetamina association with clonidine in the form of cream for application to the skin is superior to placebo (cream without any drug) in the treatment of neuropathic pain.","A multicenter randomized, double blind, placebo controlled study to determine the efficacy and safety of dextro-ketamine 1% in combination with clonidine 0.03% topical gel cream in the treatment of neuropathic pain syndromes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",,Faculdade de Medicina do ABC,2016-03-31,20160331,10/13/2025 15:59:22,REBEC,http://ensaiosclinicos.gov.br/rg/RBR-774vv2,Not Recruiting,No,18Y,,-,16/01/2017,200.0,Intervention,"A multicenter randomized, double blind, placebo controlled study,two treament arms, phase 3.",3,Brazil,Rosana,Athiê,"Rua Padre Eugênio Lopes, 361",luandre.rosana@cristalia.com.br,+55 11 3723-6479,Cristalia Produtos Químicos Farmacêuticos Ltda,"Inclusion criteria: Signed and dated informed consent form. Male or female patients of any ethnic origin aged 18 years or over. Outpatient status. Patients with diagnosis of neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), post traumatic or post operative peripheral neuropathy and leprosy; DPN defined as peripheral, somatic or autonomic nerve damage attributable solely to diabetes mellitus; PHN defined as pain lasting longer than three months beyond the crusting of the skin lesions after an acute attack of Herpes zoster.Patients with moderate to severe pain all or most of the time, that has persisted for three months or longer (for patients with post herpetic neuralgia pain present for more than three months after healing of Herpes zoster skin rash. Patients with DN4 score 4. Patients with pharmacological therapies for neuropathic pain [anticonvulsants, selective and non- selective serotonin reuptake inhibitors, antidepressants, gabapentoids, nonsteroidal anti-inflammatory drugs (NSAIDS), salicylates, or acetaminophen] should be dose stabilized for at least 14 days before randomization and be willing to maintain therapy constant, avoid changes, or initiate new therapies throughout the study. Patients with normal cognitive and communicative ability as judged by clinical assessment and ability to complete self-report questionnaires. Women of childbearing potential must have a negative urine pregnancy test before randomization and must be using and willing to continue using adequate contraception (hormonal, double barrier or intrauterine device, according to medical indication) or be sexually abstinent during the study, and must not be lactating. Post-menopausal women for less than two years are considered of childbearing potential.","Exclusion criteria: Patients with severe pain associated with conditions other than diabetic peripheral neuropathy, post herpetic neuralgia, leprosy and post traumatic or post operative peripheral neuropathy [e.g., significant vasculitis, collagen vascular disorder, familial neuropathy, alcoholism, pernicious anemia, hepatitis, malignancy, syphilis, chronic inflammatory demyelinating polyradiculopathy, human immunodeficiency virus (HIV), medication-induced neuropathy, vitamin B12 deficiency, and others]. Patients with other sustained pain with intensity at, or greater than neuropathic pain. Patients with major depression requiring treatment. Patients with known allergy to clonidine or ketamine. Patients with ongoing use of a monoamine oxidase inhibitor. Patients with current use of antiarrhythmic drugs of class one (sodium channel blockers). Patients with uncontrolled diabetes mellitus (fasting blood glucose ? 130 mg/dL) or uncontrolled hypertension (systolic blood pression ? 180mmHg or diastolic ? 110mmHg). Patients using implanted medical device (e.g., spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for pain treatment. Patients clinically hypotensive with a resting diastolic blood pressure <60 mm Hg or a systolic blood pressure <90 mm Hg.<br>Patients with diagnosis of any significant or unstable medical or psychiatric condition that would interfere with their ability to participate in the study. Patients with history of substance abuse disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) within the previous year. Patients with symptomatic or severe coronary insufficiency, clinically significant, cardiac conduction disturbances, myocardial infarction (within last 12 months), moderate to severe cerebrovascular disease, or severe chronic obstructive pulmonary disease (COPD) requiring oxygen therapy. Patients with serum creatinine value >2 times the upper limit of normal or values for alanine transaminase (ALT) or aspartate transaminase (AST) >2.5 times the upper limit of normal at screening. Patients treated with ketamine or clonidine oral, transdermal patch, or topical gel over the last four weeks prior to the screening visit.<br>Patients that used any topically applied pain medication within a period of 7 days before the screening. Patients with evidence of clinically significant peripheral vascular disease as evidenced by history of intermittent claudication or evidence of vascular ulcers, including venous stasis ulcers. Patients receiving any medications that could affect neuropathic pain not at stable dose for at least 14 days prior to the screening visit (other than medications containing NSAIDs and aspirin which must be stable for seven days prior to the screening visit). Patients receiving complementary therapies (acupuncture, TENS, central blockage)and/or """"alternative medicines"""" (naturopathy, homeopathy, etc.) for pain treatment of 7 days prior to the screening visit. Patients with history of malignancy within the previous five years. Patients that have been hospitalized within 30 days of the screening visit, or planning to have a surgery during the study period. Patients with any dermatologic condition that could affect study drug absorption. Patients carrying pacemaker, impantable cardiac defibrillator, or cardiac resynchronizer.","Neuropathic pain syndrome associated with diabetic peripheral neuropathy, post herpetic neuralgia, post traumatic or post operative peripheral neuropathy, and leprosy.;G63.2;G62.8","Investigational group (Cristália ketamine-clonidine combination): 76 patients suffering of neuropathic pain will receive dextro ketamine 1%in combination with clonidine 0.03% topical gel cream. The product should be topically applied every day,every 12 hours,to all previously defined painful areas and respecting the maximum limit of two grams for each application period, during 12 weeks.<br>Comparator group (placebo): 76 patients suffering of neuropathic pain will receive placebo. The product should be topically applied every day, every 12 hours,to all previously defined painful areas and respecting the maximum limit of two grams for each application period, during 12 weeks.;Drug;D02.455.426.392.368.367.652;D03.383.129.308.436.500;D26.660","Decrease of at least 2.3 points in pain intensity measured by a scale of 11 points, where 0 means no pain and 10 the most intense pain possible, by comparing the measurements of baseline and after 12 weeks of treatment.","Comparison of pain intensity from baseline periods and after 1, 4 and 8 weeks of treatment, using a numerical scale for Pain Intensity Rating of 11 points;Points of comparison of Catastrophizing scale of pain between the baseline period and after 1, 4, 8 and 12 weeks of treatment;Comparison of the need for rescue medication use between the arms;Comparison between the arms of the global evaluation of treatment by the patient (GPI) after 12 weeks of treatment;Comparison between the arms of the global evaluation of treatment by the patient (CGI) after 12 weeks of treatment;Change in quality of life at week 0, 1, 4, 8, and 12, as measured by Quality of Life Short Form survey (SF-12). ;Incidence of adverse events (AE).",,Cristalia Produtos Químicos Farmacêuticos Ltda,Cristalia Produtos Químicos Farmacêuticos Ltda,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2016,18.0,No,Yes
NCT02550080,16 December 2017,"Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome","A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome",,Shandong Provincial Institute of Dermatology and Venereology,2015-08-20,20150820,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02550080,Recruiting,No,18 Years,65 Years,All,01/07/2015,3130.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). ",Phase 4,China;China;China;China;China, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ,"Furen Zhang;Yonghu Sun, PhD;Furen Zhang;Furen Zhang;Yonghu Sun, PhD;Furen Zhang;Furen Zhang;Yonghu Sun, PhD;Furen Zhang;Furen Zhang;Yonghu Sun, PhD;Furen Zhang;Furen Zhang;Yonghu Sun, PhD;Furen Zhang",,;hongyue2519@hotmail.com;zhangfuren@hotmail.com;;hongyue2519@hotmail.com;zhangfuren@hotmail.com;;hongyue2519@hotmail.com;zhangfuren@hotmail.com;;hongyue2519@hotmail.com;zhangfuren@hotmail.com;;hongyue2519@hotmail.com;zhangfuren@hotmail.com,;+86-531-87298870;+86-531-87298808;;+86-531-87298870;+86-531-87298808;;+86-531-87298870;+86-531-87298808;;+86-531-87298870;+86-531-87298808;;+86-531-87298870;+86-531-87298808,Shandong Provincial Institute of Dermatology and Venereology;;Shandong Provincial Institute of Dermatology and Venereology;;Shandong Provincial Institute of Dermatology and Venereology;;Shandong Provincial Institute of Dermatology and Venereology;;Shandong Provincial Institute of Dermatology and Venereology;,"<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ;<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ;<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ;<br>    Inclusion Criteria:<br><br>     - Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin<br>       diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients<br>       who need dapsone administration.<br><br>     - Subjects are dapsone-naive.<br><br>     - All subjects must have a clinical need for treatment with dapsone that precedes the<br>       decision to participate in the study.<br><br>     - All subjects are willing to complete the 6-weeks period clinical trial.<br><br>     - All subjects are written informed consent.<br><br>    Exclusion Criteria:<br><br>     - Has previously received Dapsone therapy.<br><br>     - The subject or any of their healthcare providers is aware of the subjects HLA type.<br><br>     - Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin<br>       reductase deficiency<br><br>     - Satisfies any contraindications or restrictions to Dapsone therapy as listed in the<br>       product labels.<br><br>     - Current severe illness, including heart, liver and renal failure, major organ<br>       allograft, malignancy requiring parenteral chemotherapy that can not be discontinued<br>       for the duration of the trial, or any other conditions which, in the opinion of the<br>       Investigator, would make the patient unsuitable for the study.<br><br>     - Any laboratory abnormality at Screening which, in the opinion of the Investigator,<br>       should preclude the subject's participation in the study [alanine aminotransferase<br>       (ALT), glutamic oxaloacetic transaminase(ALT), et al).<br><br>     - Pregnant women or women who are breastfeeding.<br><br>     - Subject is, in the opinion of the Investigator, unable to complete the 6 week<br>       Observation period and the EPT assessments as required.<br><br>     - A positive result for HLA-B*1301 in those subjects randomised to the genetic screening<br>       arm.<br>   ",,Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia;Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia;Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia;Allergic Cutaneous Vasculitis;Urticaria;Psoriasis;Acne;Bullous Skin Diseases;Sterile Pustulosis;Leprosy;Pneumocystis Pneumonia,Drug: Dapsone;Genetic: HLA-B*1301;Drug: Dapsone;Genetic: HLA-B*1301;Drug: Dapsone;Genetic: HLA-B*1301;Drug: Dapsone;Genetic: HLA-B*1301,Incidence of clinically-suspected DHS during the 6-week observation period;Incidence of immunologically-confirmed DHS during the 6-week observation period;Incidence of clinically-suspected DHS during the 6-week observation period;Incidence of immunologically-confirmed DHS during the 6-week observation period;Incidence of clinically-suspected DHS during the 6-week observation period;Incidence of immunologically-confirmed DHS during the 6-week observation period,,SDPIDV-DDS-001,Please refer to primary and secondary sponsors,"Shandong Provincial Hospital;Jinan Central Hospital;Shandong Qianfo Hospital;Jinan Military General Hospital;Qingdao Center Medical Group;Liaocheng People's Hospital;Dongying People's Hospital,Shandong;Shandong Jining No. 1 People's Hospital;Dezhou People's Hospital,Shandong;Jinan City Dermatology Hospital Prevention and Treatment;Linyi City Dermatology Hospital Prevention and Treatment;Jining City Dermatology Hospital Prevention and Treatment;Weifang City Dermatology Hospital Prevention and Treatment;Laiwu City Dermatology Hospital Prevention and Treatment;Rizhao City Dermatology Hospital Prevention and Treatment",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2015,18.0,No,Yes
NCT01920750,19 February 2015,Leprosy Skin Test Antigens Phase 1,Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA,,National Institute of Allergy and Infectious Diseases (NIAID),2013-07-25,20130725,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01920750,Not recruiting,No,18 Years,40 Years,Both,01/01/1989,10.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic",Phase 1,Unknown,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Born in the United States (less chance of previous exposure to tuberculosis or<br>       leprosy)<br><br>     - Healthy individuals who are free of any evidence of leprosy or tuberculosis by<br>       established clinical examinations<br><br>     - Between the ages of 18 and 40 years old<br><br>     - Females of child-bearing age (defined from the period of menarche to menopause,<br>       usually between the ages of 15 to 45), certified as not pregnant (as determined by a<br>       pregnancy test performed within 7 days prior to admission into the study)<br><br>     - Agreement to participate in the study after verbal explanation by the physician and<br>       nurses and signing of an informed consent form.<br><br>     - Weight greater than 100 lbs. (female) and.140 lbs. (male)<br><br>     - No known hypersensitivities or allergies<br><br>     - Negative tuberculin skin test (as determined by skin tests performed 3 weeks prior to<br>       study entry)<br><br>    Exclusion Criteria:<br><br>     - Pregnant or lactating females<br><br>     - Oral corticosteroid treatment<br><br>     - Chronic illness<br><br>     - Immunosuppressive condition<br><br>     - Tuberculosis<br><br>     - Leprosy<br><br>     - Age <18 or >40<br><br>     - Weight <100 lbs. (female) or <140 lbs. (male)<br><br>     - Positive tuberculin skin test<br><br>     - Extensive travel (2-3 trips/year) in leprosy/tuberculosis endemic regions<br>   ",,Leprosy,Biological: MLCwA;Biological: MLSA-LAM;Other: Mock Antigen,"Range of concentration (1, 10, and 25 micrograms/ml) responses in the two leprosy skin test antigens in the control and mock antigens;Incidence of leprosy",,98-011,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2013,18.0,No,Yes
NCT01885611,16 December 2017,Virgin Coconut Oil Oral Supplementation for Leprosy Patients,The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study,,Philippine Dermatological Society,2013-06-14,20130614,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01885611,Not recruiting,No,18 Years,,All,01/06/2013,0.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Outcomes Assessor). ,Phase 1/Phase 2,Philippines;Philippines;Philippines;Philippines;Philippines,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ;<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ;<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ;<br>    Inclusion Criteria:<br><br>     - Patients aged 18 years and above, male or female<br><br>     - Patients with clinical evidence and histological confirmation of lepromatous leprosy<br>       (LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline<br>       tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and<br>       Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on<br>       the World Health Organization (WHO) classification<br><br>     - Patients should not have been on MDT in the past<br><br>     - Patients with normal blood test results for complete blood count (CBC), liver<br>       aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay,<br>       creatinine, lipid profile and chest x-ray<br><br>    Exclusion Criteria:<br><br>     - HD patients with reactions needing prednisone therapy at time of diagnosis<br><br>     - Patients who are already taking VCO or any other oral or intravenous antioxidant<br>       supplements<br><br>     - Patients taking long term medications unrelated to leprosy<br><br>     - Pregnant women<br><br>     - Patients with history of smoking, co-infections such as tuberculosis, diabetes<br>       mellitus, any other systemic diseases or health problems<br><br>     - Patients not willing to return for follow-up<br>   ",,Hansen's Disease;Hansen's Disease;Hansen's Disease;Hansen's Disease,Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil;Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil;Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil;Other: Multi-Drug Therapy (Novartis ?);Dietary Supplement: Virgin Coconut Oil,Change in Bacterial Indices;Change in Oxidative Stress Markers;Change in Bacterial Indices;Change in Oxidative Stress Markers;Change in Bacterial Indices;Change in Oxidative Stress Markers,Change in Clinical Response Score (CRS);Lepra reactions,UPMREB MED-2013-P3-053;PDS_PGH_2013_003,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2013,18.0,No,Yes
NCT01165840,19 October 2017,Effect of Weight and/or Obesity on Dapsone Drug Concentrations,"Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers",,Texas Tech University Health Sciences Center,2010-07-16,20100716,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01165840,Not recruiting,No,18 Years,,All,01/07/2010,37.0,Interventional,,Phase 4,United States;United States;United States;United States, ; ; ; ,"Ronald Hall, PharmD, MSCS;Ronald Hall, PharmD, MSCS;Ronald Hall, PharmD, MSCS;Ronald Hall, PharmD, MSCS",,;;;,;;;,Texas Tech UHSC;Texas Tech UHSC;Texas Tech UHSC;Texas Tech UHSC,"<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male and female subjects, age >18 years, of all racial and ethnic origins.<br><br>     - Non-English speaking Spanish speakers will be included in the study.<br><br>     - We are recruiting 12 normal or underweight (BMI <25 kg/m2), 12 overweight or obese<br>       (BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index<br>       is calculated using the volunteer's height and weight (Formula: weight (lb) / [height<br>       (in)]2 x 703). Half of each group will be male; the other half will be female.<br><br>    Exclusion Criteria:<br><br>     - Pregnant or nursing or unwilling to use a reliable contraception method during the<br>       study. The effects of dapsone on pregnancy are unknown. In addition, the metabolic<br>       changes that accompany pregnancy may alter the concentration-time profile of dapsone,<br>       so that the pregnancy and post-partum state would be a confounding variable.<br><br>     - Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline<br>       phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of<br>       normal.<br><br>     - History of allergies to dapsone, sulfones, or sulfonamides.<br><br>     - Dapsone, sulfones, or sulfonamides are contraindicated for any reason.<br><br>     - Volunteers unwilling to comply with study procedures.<br><br>     - Current suspected or documented infection of any kind.<br><br>     - Volunteers with colon resection, gastric bypass, lap band, or any other conditions<br>       inhibiting gastric absorption of drug.<br><br>     - Current or previous participation within 28 days of enrollment in another research<br>       study that involves the use of medication, contrast, or any other compound that may<br>       alter blood count and/or blood chemistry (liver function, kidney function or<br>       electrolyte balance), unless waved by PI.<br><br>     - Donation of 450 milliliters (ml) (one unit) of blood or more within 8 weeks (56 days)<br>       prior to study enrollment, unless waved by PI.<br><br>     - Current use of zidovudine, amprenavir, rifabutin, rifapentine, or saquinavir.<br><br>     - Creatinine clearance < 70 ml/minute (min) as estimated by the Cockcroft-gault<br>       equation.<br>   ",,Obesity;Leprosy;Tuberculosis;Obesity;Leprosy;Tuberculosis;Obesity;Leprosy;Tuberculosis;Obesity;Leprosy;Tuberculosis,Drug: Dapsone;Drug: Dapsone;Drug: Dapsone;Drug: Dapsone,Serum Clearance;Serum Clearance,,5UL1RR024982-02;AMAIRB97,Please refer to primary and secondary sponsors,National Center for Research Resources (NCRR),,,,,,,Yes,21/07/2016,https://clinicaltrials.gov/ct2/show/results/NCT01165840,,,,,,,,,,No,False,          ,2010,18.0,No,Yes
NCT00919542,30 March 2015,Ciclosporin in the Management of New Erythema Nodosum Leprosum,A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.,,London School of Hygiene and Tropical Medicine,2009-06-11,20090611,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919542,Not recruiting,No,18 Years,65 Years,Female,01/07/2010,12.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2,Ethiopia, ,"Diana NJ Lockwood, MBchB",,,,London SHTM,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of new ENL<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive patients<br>   ",,Leprosy,Drug: Ciclosporin;Drug: prednisolone,Number of ENL recurrence episodes per patient,Mean time to ENL recurrence after initial control;Amount of additional prednisolone required by patients;Frequency of adverse events for patients in each treatment arm;Difference in score in Quality of Life assessment between start and end for patients in each treatment arm,ITCRBY24-ENLA,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2009,18.0,No,Yes
NCT00919815,30 March 2015,Ciclosporin in the Management of New Type 1 Reactions in Leprosy,A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions,,London School of Hygiene and Tropical Medicine,2009-06-11,20090611,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919815,Not recruiting,No,18 Years,65 Years,Both,01/08/2010,73.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2/Phase 3,Ethiopia, ,"Diana Lockwood, MBChB",,,,London School of Hygiene and Tropical Medicine,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of T1R with new nerve function impairment (NFI).<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive patients<br>   ",,Leprosy,Drug: Ciclosporin;Drug: Prednisolone,improvement in nerve function and Clinical Severity Score,Incidence of adverse events;Number of T1R recurrence episodes per patient in each treatment arm;Severity of T1R recurrence for patients in each treatment arm;extra prednisolone needed to control reaction;6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm;Mean time to recurrence of T1R for patients in each treatment arm,ITCRBY24-T1RA,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2009,18.0,No,Yes
NCT00919776,7 April 2015,Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum,"A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only.",,London School of Hygiene and Tropical Medicine,2009-06-11,20090611,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919776,Not recruiting,No,18 Years,65 Years,Both,01/08/2010,20.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",Phase 2,Ethiopia, ,"Diana NJ Lockwood, MBChB",,,,London School of Hygiene and Tropical Medicine,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of recurrent or chronic ENL<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive patients<br>   ",,Leprosy,Drug: prednisolone;Drug: ciclosporin,number of ENL recurrence episodes per patient,Mean time to ENL recurrence after initial control;Severity of ENL at recurrence;Amount of additional prednisolone required by patients;Frequency of adverse events for patients in each treatment arm;Difference in score in Quality of Life assessment between start and end for patients in each treatment arm,ITCCRBY24-ENLB,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2009,18.0,No,Yes
NCT00919451,7 April 2015,Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy,A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.,,London School of Hygiene and Tropical Medicine,2009-06-11,20090611,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00919451,Not recruiting,No,18 Years,65 Years,Both,01/08/2010,16.0,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 2,Ethiopia, ,"Diana NJ Lockwood, MBChB",,,,London SHTM,"<br>    Inclusion Criteria:<br><br>     - Individuals with clinical evidence of Type 1 Reaction who have not responded to 3<br>       months Prednisolone Treatment<br><br>     - Aged 18-65<br><br>     - Weigh more than 30Kg<br><br>    Exclusion Criteria:<br><br>     - Unwillingness to give informed consent<br><br>     - Patients with severe active infections such as tuberculosis<br><br>     - Pregnant or breastfeeding women (see Appendix II)<br><br>     - Those with renal failure, abnormal renal function, hypertensive<br><br>     - Patients taking thalidomide currently or within the last 3 months<br><br>     - Patients not willing to return for follow-up<br><br>     - Women of reproductive age not willing to use contraception for the duration of the<br>       study ( see Appendix II)<br><br>     - HIV positive<br>   ",,Leprosy,Drug: ciclosporin,improvement in nerve function,incidence of adverse effects;Skin lesion inflammation improvement;rate of improvement of reaction;Time to next reactional episode;extra prednisolone needed to control reaction,ITCRBY24-T1RB,Please refer to primary and secondary sponsors,"Homes and Hospitals of St Giles;Alert Hospital, Ethiopia;Armauer Hansen Research Institute, Ethiopia",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2009,18.0,No,Yes
NCT00860717,19 February 2015,The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients,Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial,,Para Federal University,2009-03-11,20090311,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00860717,Not recruiting,No,,,Both,01/11/2006,25.0,Interventional,"Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Unknown,Brazil, ,"Claudio G Salgado, Dr",,,,Federal University of Pará,"<br>    Inclusion Criteria:<br><br>     - presented with neuropathic ulcer<br><br>     - attended at least 3 weekly appointments at the dressing service of UREMC<br><br>     - completed specific multi-drug therapy for M. leprae<br><br>     - gave written informed consent to participate in the study<br><br>    Exclusion Criteria:<br><br>     - clinically detectable infection in the ulcer<br><br>     - use of drugs, like corticosteroids that could interfere with the wound healing<br>       process<br><br>     - use of special dressings like hydrocolloid, calcium alginate, activated carbon or any<br>       kind of therapeutic procedure different from that used routinely for both groups of<br>       study<br><br>     - non-attendance to therapeutic program (six sequential times or nine intercalated)<br><br>     - pregnancy<br><br>     - discomfort during treatment procedure<br>   ",,Leprosy,Procedure: Routine treatment;Radiation: Low level laser therapy (LLLT),Wound healing,"Ulcer surface area, depth and PUSH tool score.",FINEP 1460/03,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2009,,Unknown,Yes
NCT00852345,13 April 2015,Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy,"Clofazamine in the Long Term Treatment of Leprosy, Phase III",,Kaiser Permanente,2009-02-26,20090226,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00852345,Not recruiting,No,18 Years,,Both,01/02/2009,200.0,Expanded Access,,Unknown,United States, ,"Arnold M Henson, MD",,,,Kaiser Permanente,"<br>    Inclusion Criteria:<br><br>     - Known or suspected leprosy confirmed by skin biopsy and/or slit skin smears.<br><br>     - Multibacillary leprosy (lepromatous leprosy or borderline-lepromatous).<br><br>     - Paucibacillary leprosy (borderline, borderline tuberculoid, or indeterminate) if<br>       there is involvement of the cranial nerves or active acute neuritis.<br><br>     - Known or suspected ENL(erythema nodosum leprosum) (a specific immune reaction with<br>       painful skin nodules and fever)<br><br>     - Known or suspected dapsone-resistant leprosy or relapsed leprosy.<br><br>     - Intolerance of other antileprosy antibiotic (where clofazamine is substituted as<br>       apart of multidrug regimen)<br><br>    Exclusion Criteria:<br><br>     - Uncomplicated paucibacillary leprosy which would otherwise be treated with dapsone<br>       and rifampin only.<br><br>     - Known prior intolerance of Clofazamine<br><br>     - Any minor (even with parental consent)<br><br>     - Any fertile woman who is pregnant a specific immune reaction with painful skin rash<br>       and fever)<br>   ",,Leprosy,Drug: clofazamine,,,KPSC IRB 5347;IRB 5347,Please refer to primary and secondary sponsors,Health Resources and Services Administration (HRSA),,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2009,18.0,No,Yes
NCT00138437,19 February 2015,"Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses",Molecular Epidemiology of Leprosy in Colombia,,Colorado State University,2005-08-26,20050826,10/13/2025 15:59:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00138437,Not recruiting,No,18 Years,70 Years,Both,01/04/2006,1554.0,Observational,"Observational Model: Cohort, Time Perspective: Cross-Sectional",Unknown,Colombia, ; ,"Varalakshmi Vissa, PhD;Nora Cardona-Castro, MD, MSc",,;,;,Colorado State University;Instituto Colombiano de Medicina Tropical - Universidad CES,"<br>    Inclusion Criteria:<br><br>     - All leprosy patients (Group1), their household contacts (Group 2) and healthy persons<br>       with no known contacts with leprosy patients (Group 3), between the ages of 18 and 70<br>       years willing to participate in this study.<br><br>    Exclusion Criteria:<br><br>     - Patients unwilling to participate or unable to give informed consent will be excluded<br>       from the study.<br><br>     - Pregnant women will be excluded.<br><br>    Exclusion criteria for objective A.5 are one or more of the following conditions:<br><br>     - Chronic illnesses such as cancer<br><br>     - Diabetes<br><br>     - Hepatitis<br><br>     - HIV<br><br>     - Tuberculosis<br><br>     - Undergoing corticosteroid therapy<br><br>     - Current or previous history of immunosuppressive therapy as assessed from medical<br>       records and interviews with a physician.<br>   ",,Leprosy,,Strain typing: identification of genotypes,,09-817H,Please refer to primary and secondary sponsors,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2005,18.0,No,Yes
NCT00128193,19 October 2017,Leprosy Skin Test Antigens Trial,Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region,,National Institute of Allergy and Infectious Diseases (NIAID),2005-08-05,20050805,10/13/2025 15:59:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00128193,Not recruiting,No,18 Years,60 Years,All,01/04/2002,260.0,Interventional,,Phase 2,United States;Nepal;United States;United States;Nepal;United States;United States;Nepal;United States;United States;Nepal;United States,,,,,,,"<br>    Inclusion Criteria:<br><br>    All Subjects<br><br>     - Between the ages of 18 and 60 years old<br><br>     - Male or female; not less than 30 percent for one gender<br><br>     - Agree to participate in the study after verbal explanation by the physician and<br>       nurses, as indicated by signing an informed consent form<br><br>     - Weight greater than 30 Kg (female) and 38 Kg (male)<br><br>     - Available for skin test readings<br><br>     - Nepali residents, including expatriates from India<br><br>    Healthy, Non-Contacts<br><br>     - Healthy (determined by history and physical examination)<br><br>     - No household or working contact with tuberculosis or leprosy patients<br><br>    Contacts of Leprosy Patients<br><br>     - Healthy (determined by history and physical examination)<br><br>     - Household contact of a person with leprosy for at least 6 months duration, and within<br>       6 months of this study, or a person professionally exposed to leprosy for at least 5<br>       years duration, and within 6 months of this study<br><br>    Persons with Leprosy<br><br>     - Having one or more of the following symptoms:<br><br>        1. Hypopigmented or erythematous skin lesion(s) with definite loss of sensation<br><br>        2. Damage to the peripheral nerves as demonstrated by palpable thickening with or<br>         without impairment of sensation and/or weakness of the muscles of hands, feet or<br>         face<br><br>        3. Presence of acid-fast bacilli in slit skin smears<br><br>        4. Histological changes diagnostic of leprosy in skin biopsy<br><br>     - Receiving standard multi drug treatment for leprosy or completed treatment for leprosy<br>       no more than 4 years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - Having active tuberculosis as defined by one of the following:<br><br>        1. Extra-pulmonary tuberculosis if confirmed by culture<br><br>        2. Pulmonary tuberculosis, defined as:<br><br>     - Having a history of a productive cough of more than 3 weeks duration that may be<br>       accompanied by night sweats, loss of appetite, haemoptysis, weight loss, chest pain,<br>       or shortness of breath, and<br><br>     - Having one or more of the following diagnostic criteria:<br><br>     - Sputum smear-positive, defined as one or more of the following: at least 2 of 3<br>       successive sputum samples positive for acid-fast bacilli by microscopy; or at least<br>       one sputum specimen positive and x-ray abnormalities consistent with pulmonary<br>       tuberculosis; or at least one positive sputum specimen that is culture positive for<br>       Mycobacterium tuberculosis<br><br>     - Sputum smear-negative, defined as three sputum specimens negative for acid-fast<br>       bacilli but with x-ray evidence consistent with pulmonary tuberculosis and that does<br>       not clear with non-tuberculosis antibiotics; or three sputum samples negative for<br>       acid-fast bacilli by microscopy but culture positive for Mycobacterium tuberculosis<br><br>     - Completed the intensive phase of chemotherapy for tuberculosis, but still undergoing<br>       the continuation phase of therapy<br><br>    Exclusion Criteria:<br><br>    All subjects<br><br>     - Pregnant (as determined by a urine pregnancy test performed on females of<br>       child-bearing age on Day 0, prior to admission into the study) or lactating females<br><br>     - Currently on oral corticosteroid or other immunosuppressive treatment<br><br>     - Cancer, diabetes, or other chronic illness<br><br>     - Extra-pulmonary tuberculosis not confirmed by culture<br><br>     - Known hypersensitivities or allergies<br><br>     - Expatriates other than those from India<br><br>     - Participation in an earlier stage of this study<br><br>     - Concurrent participation in another clinical trial<br><br>    Healthy, Non-Contacts<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>     - Known contact with persons with leprosy or tuberculosis<br><br>    Healthy Contacts of Leprosy Patients<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>    Persons with Leprosy<br><br>     - Leprosy patients in reversal reaction or erythema nodosum leprosum (ENL) reaction or<br>       those being treated with corticosteroids or thalidomide for these conditions<br><br>     - History of treated tuberculosis<br><br>     - Clinical signs of tuberculosis<br><br>     - Completed full course of standard multidrug treatment (MDT) for leprosy more than 4<br>       years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - History of treated leprosy<br><br>     - Clinical signs of leprosy<br><br>     - Completed full course of standard tuberculosis treatment<br><br>     - Known contact with leprosy patients<br>   ;<br>    Inclusion Criteria:<br><br>    All Subjects<br><br>     - Between the ages of 18 and 60 years old<br><br>     - Male or female; not less than 30 percent for one gender<br><br>     - Agree to participate in the study after verbal explanation by the physician and<br>       nurses, as indicated by signing an informed consent form<br><br>     - Weight greater than 30 Kg (female) and 38 Kg (male)<br><br>     - Available for skin test readings<br><br>     - Nepali residents, including expatriates from India<br><br>    Healthy, Non-Contacts<br><br>     - Healthy (determined by history and physical examination)<br><br>     - No household or working contact with tuberculosis or leprosy patients<br><br>    Contacts of Leprosy Patients<br><br>     - Healthy (determined by history and physical examination)<br><br>     - Household contact of a person with leprosy for at least 6 months duration, and within<br>       6 months of this study, or a person professionally exposed to leprosy for at least 5<br>       years duration, and within 6 months of this study<br><br>    Persons with Leprosy<br><br>     - Having one or more of the following symptoms:<br><br>        1. Hypopigmented or erythematous skin lesion(s) with definite loss of sensation<br><br>        2. Damage to the peripheral nerves as demonstrated by palpable thickening with or<br>         without impairment of sensation and/or weakness of the muscles of hands, feet or<br>         face<br><br>        3. Presence of acid-fast bacilli in slit skin smears<br><br>        4. Histological changes diagnostic of leprosy in skin biopsy<br><br>     - Receiving standard multi drug treatment for leprosy or completed treatment for leprosy<br>       no more than 4 years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - Having active tuberculosis as defined by one of the following:<br><br>        1. Extra-pulmonary tuberculosis if confirmed by culture<br><br>        2. Pulmonary tuberculosis, defined as:<br><br>     - Having a history of a productive cough of more than 3 weeks duration that may be<br>       accompanied by night sweats, loss of appetite, haemoptysis, weight loss, chest pain,<br>       or shortness of breath, and<br><br>     - Having one or more of the following diagnostic criteria:<br><br>     - Sputum smear-positive, defined as one or more of the following: at least 2 of 3<br>       successive sputum samples positive for acid-fast bacilli by microscopy; or at least<br>       one sputum specimen positive and x-ray abnormalities consistent with pulmonary<br>       tuberculosis; or at least one positive sputum specimen that is culture positive for<br>       Mycobacterium tuberculosis<br><br>     - Sputum smear-negative, defined as three sputum specimens negative for acid-fast<br>       bacilli but with x-ray evidence consistent with pulmonary tuberculosis and that does<br>       not clear with non-tuberculosis antibiotics; or three sputum samples negative for<br>       acid-fast bacilli by microscopy but culture positive for Mycobacterium tuberculosis<br><br>     - Completed the intensive phase of chemotherapy for tuberculosis, but still undergoing<br>       the continuation phase of therapy<br><br>    Exclusion Criteria:<br><br>    All subjects<br><br>     - Pregnant (as determined by a urine pregnancy test performed on females of<br>       child-bearing age on Day 0, prior to admission into the study) or lactating females<br><br>     - Currently on oral corticosteroid or other immunosuppressive treatment<br><br>     - Cancer, diabetes, or other chronic illness<br><br>     - Extra-pulmonary tuberculosis not confirmed by culture<br><br>     - Known hypersensitivities or allergies<br><br>     - Expatriates other than those from India<br><br>     - Participation in an earlier stage of this study<br><br>     - Concurrent participation in another clinical trial<br><br>    Healthy, Non-Contacts<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>     - Known contact with persons with leprosy or tuberculosis<br><br>    Healthy Contacts of Leprosy Patients<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>    Persons with Leprosy<br><br>     - Leprosy patients in reversal reaction or erythema nodosum leprosum (ENL) reaction or<br>       those being treated with corticosteroids or thalidomide for these conditions<br><br>     - History of treated tuberculosis<br><br>     - Clinical signs of tuberculosis<br><br>     - Completed full course of standard multidrug treatment (MDT) for leprosy more than 4<br>       years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - History of treated leprosy<br><br>     - Clinical signs of leprosy<br><br>     - Completed full course of standard tuberculosis treatment<br><br>     - Known contact with leprosy patients<br>   ;<br>    Inclusion Criteria:<br><br>    All Subjects<br><br>     - Between the ages of 18 and 60 years old<br><br>     - Male or female; not less than 30 percent for one gender<br><br>     - Agree to participate in the study after verbal explanation by the physician and<br>       nurses, as indicated by signing an informed consent form<br><br>     - Weight greater than 30 Kg (female) and 38 Kg (male)<br><br>     - Available for skin test readings<br><br>     - Nepali residents, including expatriates from India<br><br>    Healthy, Non-Contacts<br><br>     - Healthy (determined by history and physical examination)<br><br>     - No household or working contact with tuberculosis or leprosy patients<br><br>    Contacts of Leprosy Patients<br><br>     - Healthy (determined by history and physical examination)<br><br>     - Household contact of a person with leprosy for at least 6 months duration, and within<br>       6 months of this study, or a person professionally exposed to leprosy for at least 5<br>       years duration, and within 6 months of this study<br><br>    Persons with Leprosy<br><br>     - Having one or more of the following symptoms:<br><br>        1. Hypopigmented or erythematous skin lesion(s) with definite loss of sensation<br><br>        2. Damage to the peripheral nerves as demonstrated by palpable thickening with or<br>         without impairment of sensation and/or weakness of the muscles of hands, feet or<br>         face<br><br>        3. Presence of acid-fast bacilli in slit skin smears<br><br>        4. Histological changes diagnostic of leprosy in skin biopsy<br><br>     - Receiving standard multi drug treatment for leprosy or completed treatment for leprosy<br>       no more than 4 years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - Having active tuberculosis as defined by one of the following:<br><br>        1. Extra-pulmonary tuberculosis if confirmed by culture<br><br>        2. Pulmonary tuberculosis, defined as:<br><br>     - Having a history of a productive cough of more than 3 weeks duration that may be<br>       accompanied by night sweats, loss of appetite, haemoptysis, weight loss, chest pain,<br>       or shortness of breath, and<br><br>     - Having one or more of the following diagnostic criteria:<br><br>     - Sputum smear-positive, defined as one or more of the following: at least 2 of 3<br>       successive sputum samples positive for acid-fast bacilli by microscopy; or at least<br>       one sputum specimen positive and x-ray abnormalities consistent with pulmonary<br>       tuberculosis; or at least one positive sputum specimen that is culture positive for<br>       Mycobacterium tuberculosis<br><br>     - Sputum smear-negative, defined as three sputum specimens negative for acid-fast<br>       bacilli but with x-ray evidence consistent with pulmonary tuberculosis and that does<br>       not clear with non-tuberculosis antibiotics; or three sputum samples negative for<br>       acid-fast bacilli by microscopy but culture positive for Mycobacterium tuberculosis<br><br>     - Completed the intensive phase of chemotherapy for tuberculosis, but still undergoing<br>       the continuation phase of therapy<br><br>    Exclusion Criteria:<br><br>    All subjects<br><br>     - Pregnant (as determined by a urine pregnancy test performed on females of<br>       child-bearing age on Day 0, prior to admission into the study) or lactating females<br><br>     - Currently on oral corticosteroid or other immunosuppressive treatment<br><br>     - Cancer, diabetes, or other chronic illness<br><br>     - Extra-pulmonary tuberculosis not confirmed by culture<br><br>     - Known hypersensitivities or allergies<br><br>     - Expatriates other than those from India<br><br>     - Participation in an earlier stage of this study<br><br>     - Concurrent participation in another clinical trial<br><br>    Healthy, Non-Contacts<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>     - Known contact with persons with leprosy or tuberculosis<br><br>    Healthy Contacts of Leprosy Patients<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>    Persons with Leprosy<br><br>     - Leprosy patients in reversal reaction or erythema nodosum leprosum (ENL) reaction or<br>       those being treated with corticosteroids or thalidomide for these conditions<br><br>     - History of treated tuberculosis<br><br>     - Clinical signs of tuberculosis<br><br>     - Completed full course of standard multidrug treatment (MDT) for leprosy more than 4<br>       years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - History of treated leprosy<br><br>     - Clinical signs of leprosy<br><br>     - Completed full course of standard tuberculosis treatment<br><br>     - Known contact with leprosy patients<br>   ;<br>    Inclusion Criteria:<br><br>    All Subjects<br><br>     - Between the ages of 18 and 60 years old<br><br>     - Male or female; not less than 30 percent for one gender<br><br>     - Agree to participate in the study after verbal explanation by the physician and<br>       nurses, as indicated by signing an informed consent form<br><br>     - Weight greater than 30 Kg (female) and 38 Kg (male)<br><br>     - Available for skin test readings<br><br>     - Nepali residents, including expatriates from India<br><br>    Healthy, Non-Contacts<br><br>     - Healthy (determined by history and physical examination)<br><br>     - No household or working contact with tuberculosis or leprosy patients<br><br>    Contacts of Leprosy Patients<br><br>     - Healthy (determined by history and physical examination)<br><br>     - Household contact of a person with leprosy for at least 6 months duration, and within<br>       6 months of this study, or a person professionally exposed to leprosy for at least 5<br>       years duration, and within 6 months of this study<br><br>    Persons with Leprosy<br><br>     - Having one or more of the following symptoms:<br><br>        1. Hypopigmented or erythematous skin lesion(s) with definite loss of sensation<br><br>        2. Damage to the peripheral nerves as demonstrated by palpable thickening with or<br>         without impairment of sensation and/or weakness of the muscles of hands, feet or<br>         face<br><br>        3. Presence of acid-fast bacilli in slit skin smears<br><br>        4. Histological changes diagnostic of leprosy in skin biopsy<br><br>     - Receiving standard multi drug treatment for leprosy or completed treatment for leprosy<br>       no more than 4 years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - Having active tuberculosis as defined by one of the following:<br><br>        1. Extra-pulmonary tuberculosis if confirmed by culture<br><br>        2. Pulmonary tuberculosis, defined as:<br><br>     - Having a history of a productive cough of more than 3 weeks duration that may be<br>       accompanied by night sweats, loss of appetite, haemoptysis, weight loss, chest pain,<br>       or shortness of breath, and<br><br>     - Having one or more of the following diagnostic criteria:<br><br>     - Sputum smear-positive, defined as one or more of the following: at least 2 of 3<br>       successive sputum samples positive for acid-fast bacilli by microscopy; or at least<br>       one sputum specimen positive and x-ray abnormalities consistent with pulmonary<br>       tuberculosis; or at least one positive sputum specimen that is culture positive for<br>       Mycobacterium tuberculosis<br><br>     - Sputum smear-negative, defined as three sputum specimens negative for acid-fast<br>       bacilli but with x-ray evidence consistent with pulmonary tuberculosis and that does<br>       not clear with non-tuberculosis antibiotics; or three sputum samples negative for<br>       acid-fast bacilli by microscopy but culture positive for Mycobacterium tuberculosis<br><br>     - Completed the intensive phase of chemotherapy for tuberculosis, but still undergoing<br>       the continuation phase of therapy<br><br>    Exclusion Criteria:<br><br>    All subjects<br><br>     - Pregnant (as determined by a urine pregnancy test performed on females of<br>       child-bearing age on Day 0, prior to admission into the study) or lactating females<br><br>     - Currently on oral corticosteroid or other immunosuppressive treatment<br><br>     - Cancer, diabetes, or other chronic illness<br><br>     - Extra-pulmonary tuberculosis not confirmed by culture<br><br>     - Known hypersensitivities or allergies<br><br>     - Expatriates other than those from India<br><br>     - Participation in an earlier stage of this study<br><br>     - Concurrent participation in another clinical trial<br><br>    Healthy, Non-Contacts<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>     - Known contact with persons with leprosy or tuberculosis<br><br>    Healthy Contacts of Leprosy Patients<br><br>     - History of treated tuberculosis or leprosy<br><br>     - Clinical signs of leprosy or tuberculosis<br><br>    Persons with Leprosy<br><br>     - Leprosy patients in reversal reaction or erythema nodosum leprosum (ENL) reaction or<br>       those being treated with corticosteroids or thalidomide for these conditions<br><br>     - History of treated tuberculosis<br><br>     - Clinical signs of tuberculosis<br><br>     - Completed full course of standard multidrug treatment (MDT) for leprosy more than 4<br>       years prior to study enrollment<br><br>    Persons with Tuberculosis<br><br>     - History of treated leprosy<br><br>     - Clinical signs of leprosy<br><br>     - Completed full course of standard tuberculosis treatment<br><br>     - Known contact with leprosy patients<br>   ",,Leprosy;Leprosy;Leprosy;Leprosy,"Biological: Tuberculin, Purified Protein Derivative;Other: MLSA-LAM;Other: MLCwA;Biological: Tuberculin, Purified Protein Derivative;Other: Placebo;Biological: Tuberculin, Purified Protein Derivative;Other: MLSA-LAM;Other: MLCwA;Biological: Tuberculin, Purified Protein Derivative;Other: Placebo;Biological: Tuberculin, Purified Protein Derivative;Other: MLSA-LAM;Other: MLCwA;Biological: Tuberculin, Purified Protein Derivative;Other: Placebo;Biological: Tuberculin, Purified Protein Derivative;Other: MLSA-LAM;Other: MLCwA;Biological: Tuberculin, Purified Protein Derivative;Other: Placebo",Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram;Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram;Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram;Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram;Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram;Number of Participants With Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram;Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram;Number of Participants With the Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram;Number of Participants With Reactions to the Antigen Purified Protein Derivative (PPD);Number of Participants With the Reaction of Itching to the Antigen Purified Protein Derivative (PPD);Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen PPD.;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen PPD;Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram;Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram;Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram;Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram;Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram;Number of Participants With Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram;Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram;Number of Participants With the Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram;Number of Participants With Reactions to the Antigen Purified Protein Derivative (PPD);Number of Participants With the Reaction of Itching to the Antigen Purified Protein Derivative (PPD);Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms;Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD);Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram.;Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen PPD.;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram;Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen PPD,,00-002,Please refer to primary and secondary sponsors,,,,,,,,Yes,01/11/2010,https://clinicaltrials.gov/ct2/show/results/NCT00128193,,,,,,,,,,No,False,          ,2005,18.0,No,Yes
NCT04410406,6 November 2023,"Moxidectin for LF, Cote d'Ivoire (DOLF)",A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis,,Washington University School of Medicine,2020-05-27,20200527,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04410406,Not recruiting,No,18 Years,70 Years,All,20/08/2020,164.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 3,Côte D'Ivoire, ; ; ; ,"Philip Budge, MD, PhD;Catherine Bjerum, MD, MPH;Toki Pascal Gabo, MD;Benjamin Koudou, PhD",,;;;,;;;,"Washington University School of Medicine;Case Western Reserve University;Regional Hospital of Agboville, Southern Cote d'Ivoire;Regional Hospital of Agboville, Southern Cote d'Ivoire","<br>    Inclusion Criteria:<br><br>     - Provision of signed and dated informed consent form<br><br>     - Male or female, aged 18-70 years<br><br>     - In good general health as evidenced by medical history<br><br>     - Peripheral night blood W. bancrofti Mf levels =40 Mf/mL<br><br>     - No history of taking antifilarial medications in past 12 months<br><br>     - Resident of the study area with no plans to change residence in the next 36 months<br><br>     - For women of childbearing potential, willing to use appropriate method of<br>       contraception for one month following each treatment<br><br>    Exclusion Criteria:<br><br>     - Pregnancy or currently breastfeeding<br><br>     - Known allergic reactions to any of the study medications<br><br>     - Evidence of severe or systemic comorbidities (aside from features of filarial<br>       disease), as judged by the principal investigator<br><br>     - Baseline biochemical abnormalities, as indicated by AST, ALT, or creatinine > 2 times<br>       the upper limit of normal<br><br>     - Evidence of urinary tract infection as indicated by 3+ nitrites on dipstick<br>       (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic kidney<br>       disease as indicated by 3+ protein or 3+ blood on urine dipstick exam<br><br>     - Hgb < 7 gm/dL (any such individuals will be referred to the local health center for<br>       evaluation and treatment)<br><br>     - Positive skin snip for onchocerciasis<br>   ",,Lymphatic Filariasis,Drug: Ivermectin;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Moxidectin,Clearance of microfilaremia (IA vs. MoxA);Clearance of microfilaremia (IDA vs. MoxDA),Clearance of microfilaremia;Reduction in Mf counts;Reduction in circulating filarial antigen (CFA) counts;Inactivation of adult worm nests;Frequency and severity of AEs;Plasma levels of drugs/metabolites post treatment,202005076,Please refer to primary and secondary sponsors,"Case Western Reserve University;Regional Hospital of Agboville, Southern Cote d'Ivoire",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2020,18.0,No,Yes
NCT03664063,12 December 2020,PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ),"A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases",,Lihir Medical Centre,2018-09-03,20180903,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03664063,Not recruiting,No,18 Years,65 Years,All,01/09/2018,42.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Papua New Guinea,,,,,,,<br>    Inclusion Criteria:<br><br>     - Adult aged 18-65<br><br>     - Able to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Known chronic illness<br><br>     - Hb <7 at baseline<br><br>     - Liver function or Creatinine * 1.5 Upper Limit of Normal<br><br>     - Urinary tract infection at baseline<br><br>     - Pregnancy (female participants only)<br><br>     - Routine medications which interact with study drugs<br><br>     - Lactose/Gluten intolerance<br><br>     - Permanent disability impeding study participation<br>   ,,Lymphatic Filariasis;Yaws;Trauma,Drug: Azithromycin;Drug: Albendazole;Drug: Ivermectin;Drug: Diethylcarbamazine,"Drug levels of Azithromycin, Ivermectin, Diethylcarbamazine, Albendazole",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,ComboNTDs-PK,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2018,18.0,No,Yes
ISRCTN65756724,6 January 2025,Doxycycline to improve filarial lymphedema (LEDoxy Tanzania),"Doxycycline 200mg/d vs 100mg/d for 6 weeks to improve filarial lymphedema: a multi-national, double-blind, randomized, placebo-controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",,The National Institute of Medical Research (NIMR),2017-07-25,20170725,10/13/2025 15:59:53,ISRCTN,https://www.isrctn.com/ISRCTN65756724,Recruiting,No,,,Both,18/07/2018,420.0,Interventional,Multi-national interventional randomized double-blind placebo-controlled phase II trial (Treatment),Phase II,Tanzania,Akili,Kalinga,The National Institute of Medical Research (NIMR) Headquarters,akili.kalinga@nimr.or.tz,+255 719223937,,"Inclusion criteria: 1. Lymphedema of at least one leg grade 1-6 measured on a 7-point scale [3]<br>2. Age = 14 years and = 65 years<br>3. Men or non-pregnant women. If women of childbearing-potential, they must use an approved, effective method of contraception (including abstinence) before, during and for at least 2 weeks after the completion of the active intervention with doxycycline or placebo<br>4. Negative pregnancy test<br>5. Body weight = 40 kg<br>6. Resident in LF endemic area for = 2 years <br>7. Able and willing to give informed consent/ to provide assent to participate in the trial<br>8. Ability to use established standardized methods of hygiene and effectively applying it prior to the initiation of the drug treatment","Exclusion criteria: 1. No lymphedema or lymphedema stage 7<br>2. Age < 14 years or > 65 years<br>3. Body weight < 40 kg<br>4. Pregnant or breastfeeding women <br>5. Women of childbearing potential not using an agreed method of contraception (including abstinence; oral contraceptives are not allowed because of interaction with trial drugs) <br>6. Clinical or biologic evidence of hepatic or renal dysfunction or disease of the central nervous system (CNS)<br>7. Evidence of severe comorbidities except for features of filarial disease <br>8. Alcohol or drug abuse<br>9. History of adverse reactions to doxycycline or other tetracyclines <br>10. Any significant condition (including medical and psychological/ psychiatric disorder) which in the opinion of the study investigator might interfere with the conduct of the study<br>11. History of photosensitivity reactions after taking drugs.<br>12. Concomitant medication with antacids containing aluminium, magnesium or sucralfate and not able to discontinue<br>13. Concomitant medication with other antibiotics than doxycycline and not able to discontinue<br>14. Concomitant medication with diuretics or sulfonylurea<br>15. Concomitant medication with coumarin<br>16. Haemoglobin < 8 gm/dL<br>17. Neutrophil count <2000/mm3 - updated 03/08/2018: Neutrophil count <1100/mm3 <br>18. Platelet count <100,000/mm3 <br>19. Creatinine > 2 times upper limit of normal<br>20. AST (GOT) > 2 times upper limit of normal<br>21. ALT (GPT) > 2 times upper limit of normal<br>22. Gamma-GT > 2 times upper limit of normal<br>23. Positive urine pregnancy test",Lymphatic filariasis (LF) <br>Infections and Infestations <br>Lymphatic filariasis (LF),"Current interventions as of 03/08/2018 to 18/12/2024:<br>The study involves daily observed treatment with either doxycycline 200mg for 6 weeks, doxycycline 100mg for 6 weeks or placebo matching doxycycline for 6 weeks (42 days). Participants with lymphedema stage 1-3 are randomised using block randomisation to one of the three treatment regimens, participants with lymphedema stage 4-6 receive either doxycycline 200mg or placebo matching doxycycline.<br><br>1. DOX 200: Doxycycline 200mg/d for six weeks (2 100mg tablets/day orally) on top of standard MDA (ivermectin 200µg/kg plus albendazole 400mg once a year)<br><br>2. Placebo (control): Placebo matching Doxycycline for six weeks (2 tablets/day orally) on top of standard MDA (ivermectin 200µg/kg plus albendazole 400mg once a year)<br><br>3. DOX 100 (additional arm for group A [LE stage 1-3]): Doxycycline 100mg/d for six weeks (1 tablet 100mg doxycycline/day plus one tablet placebo matching doxycycline orally) on top of standard MDA (ivermectin 200µg/kg plus albendazole 400mg once a year)<br><br>Treatment is administered ad personam by the trial clinician directly in the villages in the form of daily observed treatment (DOT). All treatment regimens is administered on top of the standardized methods of hygiene (""""standard of care"""") and on top of standard mass drug administration (MDA; ivermectin 200µg/kg plus albendazole 400mg) in areas where MDA is still ongoing. Treatment is carried out in a blinded manner, meaning that neither the patients nor the caregiver know to which treatment arm the patients belong.<br><br>At baseline as well as six, 12, 18 and 24 months after treatment onset as well as minimum 2 years after the last contact with the participants, participants undergo lymphedema-specific measurements (circumference measurements of the leg, volume ","Lack of progression of lymphedema (LE) (stage reduction or same stage as pre-treatment using the 7-point scale staging according to Dreyer et al, 2002), examined 24 months after treatment onset","Current secondary outcome measures as of 18/12/2024:<br>1. Lack of progression of LE (stage reduction or same stage as pre-treatment using the 7-point scale staging according to Dreyer et al., 2002), examined 6, 12 or 18 months after treatment onset and at the Follow-Up Visit<br>2. Improvement of LE, i.e. stage reduction (at least one stage compared to pre-treatment), examined 6, 12, 18 and 24 months after treatment onset and at the Follow-Up Visit<br>3. Change of LE stages (reduction or increase) compared to baseline, assessed at 6, 12, 18 and 24 months after treatment onset and at the Follow-Up Visit<br>4. Changes (reduction or increase) of the circumference of the affected limbs compared to baseline circumferences, measured by tape measure at 6, 12 and 24 months after treatment onset and at the Follow-Up Visit<br>5. Changes in skin thickness of the affected limbs compared to baseline values, measured by ultrasound at 6, 12 and 24 months after treatment onset (outcome measure removed as of 03/08/2018)<br>6. Changes in the circumference of the affected limbs compared to baseline circumferences, measured with an infrared scanner (LymphaTech®) at 6, 12 and 24 months after treatment onset and at the Follow-Up Visit<br>7. Changes in the volume of the affected limbs compared to baseline volume, measured with an infrared scanner (LymphaTech®) at 6, 12 and 24 months after treatment onset and at the Follow-Up Visit<br>8. Changes in the duration of acute attacks compared to pre-treatment, as assessed with a questionnaire every two months after treatment onset and evaluated at 6, 12 and 24 months after treatment onset and at the Follow-Up Visit<br>9. Changes in the frequency of acute attacks compared to pre-treatment, as assessed with a questionnaire every two months after treatment onset and evaluated at 6, 12 and 24 months after treatment onset and at the Follow-Up Visit<br>10. Absence of acute attacks, as assessed with a questionnaire every two months after treatment onset and evaluated at 6, 12 and 24 months after treatment onset and at the Follow-Up Visit<br>11. Changes in the hygiene level compared to pre-treatment, assessed by using a hygiene survey especially developed for this study at 6, 12 and 24 months and at the Follow-Up Visit<br>12. Changes in the quality of life (QoL) compared to pre-treatment, assessed using the 12-item version of the WHODAS 2.0 at 12 and 24 months after treatment onset and at the Follow-Up Visit<br>13. Levels of angiogenic, lymphangiogenic, pro-fibrotic or pro-inflammatory biomarkers (such as VEGF, CECAM-a, MMPS) in blood and/or urine as a measure for prognostic effects, measured using ELISA and/or Luminex Multiplex Assay technique at baseline, 6, 12 and 24 months after treatment onset<br>14. T cell activation and differentiation markers in the blood such as HLADR, Ki67 and CD38 (activation), PD-1, CTLA-4, Eomes (exhaustion), CD45RA, CD27, CCR7 (differentiation) on CD4 and CD8 T cells, assessed using unstimulated whole blood which will be added to fluorochrome-conjugated antibodies that specifically detect the above-mentioned factors. The percentage of positive cells is measured using flow cytometry at baseline, 6, 12 and 24 months after treatment onset<br><br>Assessment of safety:<br>Adverse events (AE) assessed and described in the scope of the daily observed treatment (DOT). This involves: a) occurrence of AE, b) intensity of AE (Grade 0 [none], Grade 1 [mild], grade 2 [moderate] grade 3 [severe], c) SAE, d) relation to treatment (definite, probable, possible, remote, not related), e) outcome of AE (restored, improved, unchanged, deteriorated, death, unknown, overcome with sequelae, f) intervention<br><br><br><br><br><br>Previous secondary outcome measures:<br>1. Lack of progression of LE (stage reduction or same stage as pre-treatment using the 7-point scale staging according to Dreyer et al., 2002), examined 6, 12 or 18 months after treatment onset<br>2. Improvement of LE, i.e. stage reduction (at least one stage compared to pre-treatment), examined 6, 12, 18 and 24 months after treatment onset<br>3. Change of LE stages (reduction or increase) compared to baseline, assessed at 6, 12, 18 and 24 months after treatment onset<br>4. Changes (reduction or increase) of the circumference of the affected limbs compared to baseline circumferences, measured by tape measure at 6, 12 and 24 months after treatment onset<br>5. Changes of skin thickness of the affected limbs compared to baseline values, measured by ultrasound at 6, 12 and 24 months after treatment onset (outcome measure removed as of 03/08/2018)<br>6. Changes of the circumference of the affected limbs compared to baseline circumferences, measured with an infrared scanner (LymphaTech®) at 6, 12 and 24 months after treatment onset<br>7. Changes of the volume of the affected limbs compared to baseline volume, measured with an infrared scanner (LymphaTech®) at 6, 12 and 24 months after treatment onset<br>8. Changes in the duration of acute attacks compared to pre- treatment, as assessed with a questionnaire every two months after treatment onset and evaluated at 6, 12 and 24 months after treatment onset<br>9. Changes in the frequency of acute attacks compared to pre-treatment, as assessed with a questionnaire every two months after treatment onset and evaluated at 6, 12 and 24 months after treatment onset<br>10. Absence of acute attacks, as assessed with a questionnaire every two months after treatment onset and evaluated at 6, 12 and 24 months after treatment onset<br>11. Changes of the hygiene level compared to pre-treatment, assessed by using a hygiene survey especially developed for this study at 6, 12 and 24 months<br>12. Changes of the quality of life (QoL) compared to pre-treatment, assessed using the 12-item version of the WHODAS 2.0 at 12 and 24 months after treatment onset<br>13. Levels of angiogenic, lymphangiogenic, pro-fibrotic or pro-inflammatory biomarkers (such as VEGF, CECAM-a, MMPS) in blood and/or urine as a measure for prognostic effects, measured using ELISA and/or Luminex Multiplex Assay technique at baseline, 6, 12 and 24 months after treatment onset<br>14. T cell activation and differentiation markers in the blood such as HLADR, Ki67 and CD38 (activation), PD-1, CTLA-4, Eomes (exhaustion), CD45RA, CD27, CCR7 (differentiation) on CD4 and CD8 T cells, assessed using unstimulated whole blood which will be added to fluorochrome-conjugated antibodies that specifically detect the above mentioned factors. The percentage of positive cells is measured using flow cytometry at baseline, 6, 12 and 24 months after treatment onset<br><br>Assessment of safety:<br>Adverse events (AE) assessed and described in the scope of the daily observed treatment (DOT). This involves: a) occurrence of AE, b) intensity of AE (Grade 0 [none], Grade 1 [mild], grade 2 [moderate] grade 3 [severe], c) SAE, d) relation to treatment (definite, probable, possible, remote, not related), e) outcome of AE (restored, improved, unchanged, deteriorated, death, unknown, overcome with sequelae, f) intervention",TAKeOFF-4-0117-TZ,Research Networks for Health Innovations in Sub-Saharan Africa sponsored by the Federal Ministry of Education and Research (BMBF),,,01/01/1900,"Old ethics approval format; 1. Medical Research Coordinating Committee (MRCC, NIMR)/ Ministry of Health, Community Development, Gender, Elderly & Children, Dar es salaam, Tanzania: approval for first submission: 19/02/2018; approval for first amendment: 22/06/20182. Tanzania Food and Drug Authority, Dar es salaam,Tanzania: approval for first submission (incl. first amendment): 28/06/20183. Ethikkommission an der Medizinischen Fakultaet der Rheinischen Friedrich-Wilhelms-Universitaet Bonn, Bon",,,,Yes,,,,31/12/2025,,2020 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/32228663 protocol (added 02/04/2020)2024 Results article in https://doi.org/10.4269/ajtmh.24-0049 (added 03/12/2024),,,,No,Not expected to be made available. The datasets generated during and/or analysed during the current study are not expected to be made available as consent was not provided for this.,Yes,False,          ,2017,,Unknown,Yes
SLCTR/2017/021,15 September 2025,A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka,"A multi-center, double-blind, randomized, 24-month study, to compare the efficacy of doxycycline once daily for 6 weeks versus placebo in improving filarial lymphedema independent of active filarial infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",,Task Force for Global Health,2017-07-13,20170713,10/13/2025 15:59:53,SLCTR,https://slctr.lk/trials/slctr-2017-021,Recruiting,No,,,,16/02/2018,200.0,Interventional,Randomized controlled trial,Phase 3,"
            Sri Lanka
        ",T.C. Yahathugoda,,"Filariasis Research Unit, Department of Parasitology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka",tcyahath@yahoo.co.uk,Tel: +94(0)912234801,Head / Senior Lecturer,"Inclusion criteria: 1. Age <u>></u> 14 years and <65 years, male or non-pregnant women of childbearing-potential using an approved, effective method of contraception before, during and for at least 2 weeks after the completion of the active intervention with doxycycline or placebo<br>2. Able to give informed consent to participate in the trial <br>3. Resident in endemic area for five years or more<br>4. Body weight >40 kg <br>5. Lymphedema of a limb Grade 1-6 measured on a 7-point scale (Dreyer G et al. 2002). <br>6. Ability to use established standardized methods of hygiene and effectively applying it prior to the initiation of the drug treatment<br>7. No evidence of severe or systemic co-morbidities except for features of filarial disease <br>8. Normal laboratory profile <br>9. Consent to storage of blood samples for study","Exclusion criteria: 1. No lymphedema or lymphedema stage 7<br>2. Age < 14 years or > 65 years<br>3. Body weight < 40 kg<br>4. Pregnant or breastfeeding women <br>5. Women of childbearing potential not using an agreed method of contraception. (A pregnancy test will be conducted as part of the screening process to exclude pregnancy and repeated at 3 and 8 weeks. In addition, women of childbearing potential will be counseled against pregnancy during the treatment period)<br>6. Clinical or laboratory evidence of hepatic or renal dysfunction or CNS disease <br>7. Alcohol or drug abuse<br>8. History of adverse reactions to doxycycline or other tetracyclines <br>9. Patient has any situation or condition that may interfere with participation in the study as judged by the clinical investigator<br>10. Chronic headache and current headache<br>11. Persons who are currently taking doxycycline for other indications<br>12. Lymphedema due to post-radiation, post-surgical and primary (congenital) lymphedema",Chronic Lymphoedema due to Lymphatic Filariasis,"Study Settings (Sri Lanka): Galle and Matara Districts; Snowball sampling method will be used to complete recruitment.<br><br>Study design:<br><br>This (LEDOXY-SL) trial is designed as a randomized, controlled, observer-, provider- and patient-blinded multicenter superiority trial with two parallel groups and a primary endpoint of change in grade of lymphedema at 24 months. The population will be stratified according to the Grade (Early Grade 1-3; Late Grade 4-6). Randomization will be performed as block randomization within each center in blocks of (N=4-10) for each of the groups (early and late). <br><br>Intervention<br><br>Intervention arm will receive doxycycline hyclate tablets 200mg/daily for six weeks (100mg/day for ages 14-18 years and body weight 40-50kg) <br><br>Control arm will receive identical placebo tablets 100mg – 2 tablets/day for six weeks (1 tablet/day for ages 14-18 years and body weight 40-50kg) <br><br>Standard lymphedema management protocols based on the use of simple measures of hygiene (regular washing with soap and water, skin and nail care), use of topical antibiotics or antifungal agents, exercise and footwear will be continued in both arms.",Change in lymphedema grade at 24 months compared to baseline [At baseline and 24 months after commencement of the intervention]<br>,"Improvement or halt of progression (Lack of progression) of LE when examined 12 months after treatment onset [At baseline, 12 months and 24 months after commencement of the intervention]<br>Improvement of LE when examined 12 and 24 months after treatment onset [At baseline, 12 months and 24 months after commencement of the intervention]<br>Change of LE stages (reduction or increase) compared to baseline assessed at 12 and 24 months [At baseline, 12 months and 24 months after commencement of the intervention ]<br>Change in the circumference of the affected limb from baseline [At baseline, 12 months and 24 months after commencement of the intervention ]<br>Change in circumference through Lymphatech 3D-camera measurement compared to baseline [At baseline, 12 months and 24 months after commencement of the intervention ]<br>Change in volume through Lymphatech 3D-camera measurements compared to baseline [At baseline, 12 months and 24 months after commencement of the intervention ]<br>Reduction in the frequency of acute ADLA attacks evaluated from 0-12 months and from 12-24 months after treatment onset [At baseline, 12 months and 24 months after commencement of the intervention ]<br>Changes in skin thickness at 12 and 24 months compared to the baseline [At baseline, 12 months and 24 months after commencement of the intervention ]<br>Change in angiogenic, pro-fibrotic or pro-inflammatory biomarkers at 12 and 24 months following doxycycline administration (at sites where these tests are done) [At baseline, 12 months and 24 months after commencement of the intervention ]<br>",,United States Agency for International Development (USAID),,Approved,16/02/2017,ethicscommitteemfc@gmail.com ,ethicscommitteemfc@gmail.com ,+94-11-2695300 (Extension: 240),ethicscommitteemfc@gmail.com ,Unknown,,,,,,,,,,,Not Available,Yes,False,          ,2017,,Unknown,Yes
NCT02974049,2 May 2022,Lymphatic Filariasis (LF) in Ivory Coast,Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire],,University Hospitals Cleveland Medical Center,2016-11-22,20161122,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02974049,Not recruiting,No,18 Years,70 Years,All,01/01/2015,189.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Unknown,Côte D'Ivoire, ,"Christopher L King, MD PhD",,,,Case Western Reserve University,"<br>    Inclusion Criteria:<br><br>     - Women and men 18-70 years<br><br>     - =50 MF/mL based on Nuclepore filtration<br><br>     - Willing to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Prior treatment for LF within last 5 years<br><br>     - Pregnancy (perform pregnancy test)<br><br>     - Hemoglobin <7 g/dL<br><br>     - Permanent disability, serious medical illness that prevents or impedes study<br>       participation and/or comprehension<br><br>     - AST/ALT and creatinine >1.5 upper limit of normal<br><br>     - Proteinuria or hematuria >3+<br><br>     - Skin snip positivity for O. volvulus MF<br>   ",,Lymphatic Filariasis,Drug: Albendazole;Drug: Ivermectin;Drug: Diethylcarbamazine,Total clearance of Microfilariae,Total clearance of MF at 24 months;Percent MF reduction;Reduction in W. bancrofti antigen level;Alere Filariasis Test Strip negative;reduction in viable worm nests;Diversity of parasites;type and level of parasite-specific host immune response,08-14-13,Please refer to primary and secondary sponsors,Washington University School of Medicine,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2016,18.0,No,Yes
NCT02509481,12 December 2020,Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study,Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study,RIMDAMAL,Colorado State University,2015-07-23,20150723,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02509481,Not recruiting,No,,,All,01/06/2015,2712.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 2/Phase 3,United States;Burkina Faso;United States, ; ,"Brian D. Foy, PhD;Roch K Dabire, PhD",,;,;,Colorado State University;Institute de Recherche en Sciences de la Santé,"<br>    Inclusion Criteria:<br><br>     - Residence in the study site<br><br>     - Able to understand the information and willing to give consent and assent (parent or<br>       guardian consent if study participant age is < 18 years)<br><br>    Exclusion Criteria:<br><br>     - Residence outside of in the study site<br><br>     - Height = 90 cm<br><br>     - Permanent disability, serious medical illness that prevents or impedes study<br>       participation and/or comprehension<br><br>     - Pregnancy<br><br>     - Breast feeding if infant is within 1 week of birth<br><br>     - Known allergy to the study drugs<br>   ",,Malaria;Lymphatic Filariasis,Drug: Ivermectin;Drug: Albendazole,Incidence of Clinical Malaria Episodes,Adverse Events;Entomological Indicator of Parasite Transmission;Molecular Force of P. Falciparum Infection;Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH);Entomological Inoculation Rate,OPP1116536;5375011,Please refer to primary and secondary sponsors,"Institut de Recherche en Sciences de la Sante, Burkina Faso;Centre Muraz;Ministère de la Santé du Burkina Faso",,,,,,,Yes,04/01/2019,https://clinicaltrials.gov/ct2/show/results/NCT02509481,,,,,,,,,,No,False,          ,2015,,Unknown,Yes
NCT01975441,12 December 2020,"Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa","Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa",,University Hospitals Cleveland Medical Center,2013-10-28,20131028,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01975441,Not recruiting,No,18 Years,65 Years,All,01/05/2014,182.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 2,Papua New Guinea, ,"Peter Siba, PhD",,,,Papua New Guinea Institution for Medical Research,"<br>    Inclusion Criteria:<br><br>     - Men and women 18-65 years<br><br>     - >50 mf/ml in finger stick blood samples<br><br>     - Willing to give informed consent<br><br>    Exclusion Criteria:<br><br>     - Prior treatment for LF within last 5 years<br><br>     - Pregnant (do pregnancy test)<br><br>     - Hemoglobin < 7 g/dl<br><br>     - permanent disability, serious medical illness that prevents or impedes study<br>       participation and/or comprehension<br><br>     - AST/ALT and creatinine > 1.5 upper limit of normal.<br><br>     - Urine dipstick with glucose = 2+ and/or protein = 2+<br>   ",,Lymphatic Filariasis,Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Ivermectin,Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf),Percentage of subjects with total clearance of Mf at 24 months.;Percent reduction in W. bancrofti antigen levels compared to baseline measured at 24 and 36 months;Percent of subjects who become circulating antigen negative at 24 months and 36 months after the beginning of the study,CWRU 3 vs 2 LF ELIM PNG,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2013,18.0,No,Yes
NCT01213576,19 October 2017,Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi,"Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study",FED,London School of Hygiene and Tropical Medicine,2010-09-30,20100930,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01213576,Not recruiting,No,18 Years,55 Years,All,01/01/2009,70.0,Interventional,,Unknown,Malawi;Malawi;Malawi;Malawi, ; ; ; ,"Neil French, MB ChB PHD;Neil French, MB ChB PHD;Neil French, MB ChB PHD;Neil French, MB ChB PHD",,;;;,;;;,London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine,<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ;<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ;<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ;<br>    Inclusion Criteria:<br><br>     - understand and sign informed consent<br><br>     - willing to undergo night blood sampling every 6 months for 2 years<br><br>     - Age 18 to 55 years<br><br>     - Haemoglobin of equal or above 9g/dl<br><br>     - Microfilarial level of equal or above 80mg/dl<br><br>    Exclusion Criteria:<br><br>     - Non- consenting<br><br>     - Pregnancy or lactation<br><br>     - Treatment with albendazole or ivermectin within the previous 6 months<br><br>     - Known allergy to the study drugs<br>   ,,Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis,Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: Albendazole and ivermectin;Drug: Albendazole 400mg and ivermectin 200mcg/kg;Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually,Number of Participants Achieving Microfilarial Clearance;Number of Participants Achieving Microfilarial Clearance,Number of Participants With Microfilarial Clearance at 24 Months of Follow up,FED-311207,Please refer to primary and secondary sponsors,Emory University,,,,,,,Yes,27/02/2015,https://clinicaltrials.gov/ct2/show/results/NCT01213576,,,,,,,,,,No,False,          ,2010,18.0,No,Yes
NCT00511004,19 October 2017,Effect of Albendazole Dose on Treatment of Lymphatic Filariasis,"Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study",,National Institute of Allergy and Infectious Diseases (NIAID),2007-08-02,20070802,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00511004,Not recruiting,No,18 Years,55 Years,All,01/07/2007,40.0,Interventional,,Phase 2,India;United States;India;United States;India;United States;India;United States, ; ; ; ,"Thomas B Nutman, M.D.;Thomas B Nutman, M.D.;Thomas B Nutman, M.D.;Thomas B Nutman, M.D.",,;;;,;;;,National Institute of Allergy and Infectious Diseases (NIAID);National Institute of Allergy and Infectious Diseases (NIAID);National Institute of Allergy and Infectious Diseases (NIAID);National Institute of Allergy and Infectious Diseases (NIAID),"<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ;<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ;<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ;<br>    - INCLUSION CRITERIA:<br><br>    Inclusion Criteria for Screening:<br><br>     - Age 18 years to 55 years inclusive<br><br>     - Both genders<br><br>     - Not pregnant or breastfeeding by history<br><br>     - If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy<br>       Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India<br><br>     - If selected, subjects must be willing to undergo nighttime blood draws once every 6<br>       months and Doppler ultrasound twice yearly for 2 years<br><br>     - If selected, agree to have blood stored for future studies<br><br>     - Ability to understand and give informed consent<br><br>    Inclusion Criteria for Treatment:<br><br>     - Age 18 to 55 years inclusive<br><br>     - Men and non-pregnant or non-breast feeding women<br><br>     - Microfilarial levels greater than 50mf/mL<br><br>     - Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical<br>       College Hospital, Alleppey, Kerala, India every 6 months for 2 years<br><br>     - Willingness to undergo nighttime blood draws once every 6 months for 2 years<br><br>     - Ability to understand and give informed consent<br><br>     - Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL<br><br>     - Creatinine (Cr) less than or equal to 1.2 mg/dL<br><br>     - Alanine aminotransferase (ALT) less than 30 U/L<br><br>     - Willingness to have blood stored for future studies<br><br>    EXCLUSION CRITERIA:<br><br>    Exclusion Criteria for Screening:<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding by history<br><br>    Exclusion Criteria for Treatment:<br><br>     - Non-volunteers<br><br>     - Age less than 18 years or greater than 55 years<br><br>     - Pregnant or breast feeding<br><br>     - Hgb levels less than or equal to 9 g/dL<br><br>     - Cr greater than 1.3 mg/dL<br><br>     - ALT greater than 30 U/L<br><br>     - Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within<br>       a week of each drug administration<br><br>     - Temperature greater than 37.5 degrees Celsius<br><br>     - Serious medical illness<br><br>     - History of benzimidazole allergy<br><br>     - History of DEC allergy<br><br>     - Use of albendazole or DEC within past 6 months<br><br>     - Unwillingness to comply with required study visits<br>   ",,Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis;Lymphatic Filariasis,Drug: Albendazole;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Diethylcarbamazine;Drug: Albendazole;Drug: Diethylcarbamazine,Microfilarial Counts at 1 Year;Microfilarial Counts at 1 Year,Adult Worm Burdens at 2 Years;Microfilarial Levels at 2 Years;Brugia Specific Immunoglobulin G4 (IgG4) Antibodies,07-I-N197;999907197,Please refer to primary and secondary sponsors,,,,,,,,Yes,31/08/2015,https://clinicaltrials.gov/ct2/show/results/NCT00511004,,,,,,,,,,No,False,          ,2007,18.0,No,Yes
NCT00375583,16 December 2017,Effect of Albendazole Dose on Clearance of Filarial Worms,"Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study",,National Institute of Allergy and Infectious Diseases (NIAID),2006-09-12,20060912,10/13/2025 15:59:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00375583,Not recruiting,No,18 Years,55 Years,All,09/09/2006,1000.0,Interventional,Primary purpose: Treatment. ,Phase 2,India;United States;India;United States;India;United States;India;United States;India;United States,,,,,,,"<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ;<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ;<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ;<br>    - INCLUSION CRITERIA (SCREENING):<br><br>    Age 18 years to 55 years inclusive.<br><br>    Both genders.<br><br>    Not pregnant or breastfeeding by history.<br><br>    If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the<br>    Government General Hospital, Chennai India.<br><br>    If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2<br>    years.<br><br>    If selected, agree to have blood stored for future studies.<br><br>    Ability to understand and sign the informed consent.<br><br>    EXCLUSION CRITERIA (SCREENING):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnant or breastfeeding by history.<br><br>    INCLUSION (TREATMENT):<br><br>    Age 18 years to 55 years.<br><br>    Men and non-pregnant or non-breastfeeding women.<br><br>    Microfilarial levels greater than 50 mf/ml.<br><br>    Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,<br>    Chennai India.<br><br>    Willingness to undergo nighttime blood draws every 6 months for 2 years.<br><br>    Ability to understand and sign the informed consent.<br><br>    Hb levels for inclusion greater than 9 g/dL.<br><br>    Normal Cr, ALT.<br><br>    Willingness to have blood stored for future studies.<br><br>    EXCLUSION (TREATMENT):<br><br>    Non-volunteers.<br><br>    Age less than 18 years or greater than 55 years.<br><br>    Pregnancy or breast-feeding.<br><br>    Hgb less than or equal to 9 g/dL.<br><br>    Cr greater than 1.2/100 ml.<br><br>    ALT greater than 30 U.<br><br>    Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a<br>    week of each drug administration.<br><br>    Temperature greater than 37.5 degrees C.<br><br>    Serious medical illness.<br><br>    History of benzimidazole allergy.<br><br>    History of DEC allergy.<br><br>    Use of albendazole or DEC within past 6 months.<br><br>    Unwillingness to comply with required study visits.<br>   ",,Lymphatic Filariasis;Wuchereria Bancrofti Infection;Lymphatic Filariasis;Wuchereria Bancrofti Infection;Lymphatic Filariasis;Wuchereria Bancrofti Infection;Lymphatic Filariasis;Wuchereria Bancrofti Infection,Drug: DEC/Albendazole;Drug: DEC/Albendazole;Drug: DEC/Albendazole;Drug: DEC/Albendazole,Microfilarial levels.;Microfilarial levels.;Microfilarial levels.,Adult worm burden.,06-I-N244;999906244,Please refer to primary and secondary sponsors,"Tuberculosis Research Centre, India",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2006,18.0,No,Yes
NCT06070116,10 June 2024,Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis,Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis,,Washington University School of Medicine,2023-09-14,20230914,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06070116,Recruiting,No,18 Years,75 Years,All,05/04/2024,300.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Liberia, ; ; ,"Peter Fischer, PhD;Patrick Kpanyen, PhD;Gary Weil, MD",,;;,;;,Washington University School of Medicine;National Public Health Institute of Liberia;Washington University School of Medicine,"Inclusion Criteria:<br><br> - Adult men and women, 18 years to 75 years old<br><br> - Participants must have at least 1 palpable subcutaneous nodule (onchocercoma)<br><br> - Participants with mean skin Mf counts = 1 Mf/mg at the time of enrollment (prior to<br>   pretreatment)<br><br>Exclusion Criteria:<br><br> - History of treatment with IVM or Mox less than six months prior to pretreatment with<br>   IVM.<br><br> - Treatment with IVM or Mox outside of the study after the pre-treatment clearing dose<br>   before treatment with one of the four study treatments.<br><br> - Pregnant or breastfeeding mothers.<br><br> - Severe ocular disease at baseline (assessed just prior to the first study treatment,<br>   approximately 6-12 months after IVM pretreatment). Briefly, these conditions include<br>   severe uveitis, severe glaucoma, severe keratitis, and/or cataracts that interfere<br>   with visualization of the posterior segment of the eye. Details regarding ocular<br>   exclusion criteria are provided below. Individuals who are excluded with significant<br>   ocular disease will be referred for appropriate All ocular disease exclusion<br>   criteria apply to either eye. That is to say, participants will be excluded if any<br>   of the ocular exclusion criteria listed below are met for either eye. These<br>   exclusions are needed to reduce the risk of study treatments worsening severe<br>   pre-existing ocular disease. They also are needed to ensure that study staff will be<br>   able to adequately evaluate the posterior segment before and after treatment.<br><br>    1. Any cataract that prevents clear visualization of fundus or imaging by OCT.<br><br>    2. Severe retinal nerve fiber layer thinning of the optic nerve in the superior<br>     and inferior quadrant analysis by OCT with a corresponding visual field defect<br>     in the superior and inferior hemifield, and/or visual field loss within 5<br>     degrees of fixation in at least one hemifield. Note: If OCT is not available,<br>     the following exclusion criteria will apply: vertical cup/disc ratio by<br>     fundoscopy greater than or equal to 0.80 with a corresponding visual field<br>     defect in the superior and inferior hemifield, and/or visual field loss within<br>     5 degrees of fixation in at least one hemifield.<br><br>    3. Intraocular pressure (IOP) greater than or equal to 25 by Goldmann tonometry.<br><br>    4. Retinal detachment or retinal break.<br><br>    5. Acute ocular infection (i.e., viral conjunctivitis, corneal ulcer,<br>     endophthalmitis).<br><br>    6. Optic atrophy with a reproducible visual field defect detected by confrontation<br>     visual field testing.<br><br>    7. Exam consistent with Herpes simplex virus eye infection.<br><br>    8. Homonymous hemianopsia, quadrantopsia, bitemporal hemianopsia, or central<br>     scotoma related to cerebral vascular disease by Automated Visual field testing<br>     and confrontation visual field testing.<br><br>    9. Acute angle closure glaucoma.<br><br>   10. Gonioscopy grade 0 (slit) limiting ability to safely dilate participant.<br><br>   11. Severe tremor, blepharospasm, or other voluntary or involuntary motor condition<br>     that limits careful slit lamp examinations, OCT, gonioscopy, IOP measurement,<br>     fundus photography, and automated perimetry.<br><br>   12. Cognitive impairment that limits participant's ability to understand and<br>     perform a Visual Acuity Test with a Tumbling E chart, confrontation visual<br>     field, slit lamp exam, or any other ocular exam component.<br><br>   13. Optic nerve edema.<br><br>   14. Active retinopathy or retinitis not attributable to onchocercal disease.<br><br>   15. A history of uveitis not associated with onchocerciasis.<br><br>   16. Any pre-existing chorioretinal scar or retinal degeneration and other<br>     significant retinal pathologies (foveomacular schisis, dystrophies, arterial<br>     macroaneurysms etc) involving the macula.<br><br>   17. Severe ocular pain that the participant rates as 9 or 10 out of 10.<br><br>   18. Best corrected or pinhole visual acuity worse than 6/60 (20/200).<br><br>   19. Age-related macular degeneration (AMD).<br><br>   20. >5 motile Mf in the anterior chamber in either eye at the time of secondary<br>     screening (6 months after pre-treatment with IVM).*<br><br>   21. The presence of one or more Mf in the posterior segment of the eye (detected by<br>     any opthalmological test performed) at the time of treatment (at least six<br>     months after pre-treatment with IVM). *Note regarding exclusion criteria t and<br>     u: The cut-off of 5 Mf in either anterior chamber was suggested by external<br>     reviewers of our proposal to the Gates Foundation. These were experts in<br>     onchocerciasis selected by the Foundation. The reviews were anonymous, so we do<br>     not know their names. They also suggested that we exclude persons with any Mf<br>     in the posterior segment of the eye, and we have added that exclusion criterion<br>     to the protocol.<br><br> - Significant comorbidities such as renal insufficiency (creatinine > 2 times the<br>   upper limit of normal), liver disease (jaundice or either AST or ALT greater than<br>   2.5 times the upper limit of normal), or any other acute or chronic illness<br>   identified by study clinicians and investigators that interferes with the<br>   participant's ability to go to school or work or perform routine household chores.<br><br> - Prior allergic or hypersensitivity reactions or intolerance to IVM, Mox, ALB, or<br>   DEC.<br><br> - Evidence of severe or systemic comorbidities (aside from features of<br>   onchocerciasis), as judged by a study physician. Persons with baseline medical<br>   conditions that correspond to adverse event severity scores of grade 3 or higher<br>   will also be excluded.<br><br> - Evidence of urinary tract infection as indicated by 3+ nitrites by dipstick<br>   (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic<br>   kidney disease as indicated by 3+ protein or 3+ blood by dipstick. Persons with<br>   urinary tract infections can be enrolled after their infections are treated and<br>   cured.<br><br> - Hgb <7 gm/dL; any such individuals will be referred to a local health center for<br>   evaluation and treatment).",,"Onchocercal Subcutaneous Nodule;Onchocerciasis;Onchocerciasis, Ocular;Onchocerca Infection;Tropical Disease",Drug: Ivermectin w/ Albendazole;Drug: Ivermectin + Diethylcarbamazine + Albendazole;Drug: Moxidectin + Albendazole;Drug: Moxidectin + Diethylcarbamazine + Albendazole,Rates and types of severe or serious adverse events within 6 months following Ivermectin treatments;Rates and types of severe or serious adverse events within 6 months following Moxidectin treatments;Proportion of all adult female worms that are fertile 24 months after first treatment,"Rates of adverse events grade 3 or higher by Ivermectin treatment group, that occur within 7 days of treatment;Rates of adverse events grade 3 or higher by Moxidectin treatment group, that occur within 7 days of treatment;Rates of adverse events grade 3 or higher in participants with ocular MF in Ivermectin treatment groups.;Rates of adverse events grade 3 or higher in participants with ocular MF in Moxidectin treatment groups.;Rates of ocular adverse events (any grade) by Ivermectin treatment group;Rates of ocular adverse events (any grade) by Moxidectin treatment groups;Percentage of adult female worms in nodules that are alive;Percentage of nodules with microfilaria in tissue;Percentage of nodules that do not contain living adult worms;Percentage of participants without microfiladermia after the first study treatment.;Percentage of participants with recurrence of microfilariae in the skin across treatment groups;Microfilariae density in the skin across treatment groups;Percentage of nodules with fully or partially calcified worms",202307136,Please refer to primary and secondary sponsors,National Public Health Institute of Liberia,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2023,18.0,No,Yes
NCT04913610,3 October 2023,"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection","A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics",,AbbVie,2021-05-30,20210530,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04913610,Not recruiting,No,18 Years,65 Years,All,29/05/2021,153.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 2,"Congo, The Democratic Republic of the", ,ABBVIE INC.,,,,AbbVie,"<br>    Inclusion Criteria:<br><br>     - Diagnosis of Onchocerca volvulus infection at time of Screening:<br><br>        - Presence of at least one excisable subcutaneous nodule/ onchocercoma detected on<br>         palpation;<br><br>        - O. volvulus infection diagnosed by skin snip method: documented mfpositivity on<br>         skin assessment on at least 2 out of 4 skin snips.<br><br>     - Body weight > 40 kg at Screening.<br><br>     - For women of child-bearing potential, acceptance of the requirement to use a highly<br>       effective form of birth control from Day 0 until at least 1 month after the final<br>       intake of study drug (Part 1: day 43; Part 2: 1 month after the administration of<br>       ivermectin or matching placebo at the Month 6 visit). Choice of birth control method<br>       must be clearly documented.<br><br>    Exclusion Criteria:<br><br>     - Participation in any studies other than purely observational studies within 3 months<br>       prior to Screening, or during the trial, or within 5 times the half-life of the drug<br>       tested in the previous clinical trial or is currently in the follow-up period for any<br>       clinical trial.<br><br>     - Any vaccination within 4 weeks prior to investigational medicinal product (IMP)<br>       administration.<br><br>     - Acute infection and/or febrile illness requiring therapy within 14 days prior to IMP<br>       administration.<br><br>     - Administration of medication or herbal preparations as follows:<br><br>        - Administration of any medication (with the exception of diclofenac, paracetamol,<br>         ibuprofen and aspirin) or herbal preparation within 14 days prior to IMP<br>         administration;<br><br>        - Use of strong CYP3A inhibitors or inducers including but not limited to<br>         ritonavir, ketoconazole, rifampicin, phenytoin, phenobarbital, carbamazepine,<br>         cimetidine within 14 days or 10 half-lives, whichever is longer, prior to IMP<br>         administration;<br><br>        - Use of other drugs known to interact with albendazole i.e. praziquantel,<br>         theophylline or dexamethasone, within 14 days or 10 half-lives, whichever is<br>         longer, prior to IMP administration;<br><br>        - Antifilarial therapies, or medication that may have an antifilarial effect.<br><br>     - Requirement for and inability to avoid ivermectin during the first 6 months after IMP<br>       administration. Requirement for albendazole during the first 28 days after IMP<br>       administration or more than one dose per year thereafter given in MDA.<br><br>     - Presence of any of the following at Screening, that could interfere with the<br>       objectives of the trial or the safety of the participant, in the opinion of the<br>       Investigator:<br><br>        - Abnormal physical examination or laboratory findings;<br><br>        - Any clinically significant medical condition. Including, but not limited to<br>         significant acute or chronic liver or kidney condition or cardiovascular disease,<br>         active infection, current or previous epilepsy, known human immunodeficiency<br>         virus infection, disclosed by review of medical history or concomitant<br>         medication.<br><br>     - Ophthalmological history or conditions that could interfere with the objectives of the<br>       trial or compromise the safety of the subject in the opinion of the Investigator,<br>       assessed at Screening.<br><br>     - History of drug or alcohol abuse within 6 months prior to IMP administration.<br><br>     - Use of alcohol or drugs of abuse within 24 hours before IMP administration.<br><br>     - Clinically significant history of cardiac abnormality, and/or relevant pathological<br>       abnormalities in the ECG in the screening period.<br><br>     - Abnormal laboratory test results at Screening.<br><br>     - History of severe drug allergy, non-allergic drug reactions, severe adverse reaction<br>       to any drug, or multiple drug allergies.<br><br>     - Known hypersensitivity to any ingredient of the IMPs, including the active ingredient<br>       of ABBV-4083, macrolides, albendazole or to ivermectin or to any medication used<br>       during the study.<br><br>    Blood donation within 8 weeks prior to Screening or blood transfusion received within 1<br>    year prior to Screening.<br><br>     - Coincidental infection with high Loa loa load and/or Mansonella species or Wuchereria<br>       bancrofti, based on positive laboratory test at Screening.<br><br>     - Current hyperreactive onchodermatitis or severe manifestation due to onchocerciasis.<br><br>     - Any other past or current condition that the Investigator feels would exclude the<br>       participant from the study or place the subject at undue risk.<br><br>     - For women of child-bearing potential: pregnant, based on date of last menstrual<br>       period, and pregnancy test prior to first intake of IMP, or breastfeeding.<br><br>     - Unwilling or unable to comply with the requirements of the study protocol for the<br>       entire duration of the study, in the opinion of the Investigator.<br><br>     - Unable to participate in the study as per local law, if applicable.<br>   ",,Onchocerciasis,Drug: ABBV-4083;Drug: Placebo for ABBV-4083;Drug: Albendazole;Drug: Placebo for Albendazole;Drug: Placebo for Ivermectin;Drug: Ivermectin,Part 1: Status of Each Live Female Adult Worm as Without Wolbachia Endobacteria;Part 2: Status of Each Participant as Without Skin Microfilariae,Part 2: Percentage of Live Female Adult Worms per Participant;Part 2: Percentage of Live Female Adult Worms With Only Degenerated Embryos in Uterus per Participant;Part 1: Percentage of Live Female Adult Worms With Only Degenerated Embryos in the Uterus per Participant;Part 1: Percentage of Live Female Adult Worms out of all Female Adult Worms per Participant;Part 1: Absence of Microfilariae in Nodular Tissue per Participant;Part 1: Status of Each Participant as Without Skin Microfilariae or not;Part 1: Reduction in Skin Microfilarial Density Compared to Baseline (Week 0);Part 1: Status of Each Live Adult Worm as Without Wolbachia Endobacteria or not;Part 2: Status of Each Participant as Without Skin Microfilariae or not;Part 2: Reduction in Skin Microfilarial Density Compared to Baseline (Week 0);Part 2: Absence of Microfilariae in Nodular Tissue per Participant;Part 2: Status of Each Live Adult Female Worm as Without Wolbachia Endobacteria or not;Part 2: Status of Each Live Adult Worm as Without Wolbachia Endobacteria or not,DNDi-TYL-01;B18-894,Please refer to primary and secondary sponsors,Drugs for Neglected Diseases initiative,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2021,18.0,No,Yes
NCT04049630,27 September 2021,Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients,"Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients",EOLoa,"Programme National de Lutte contre l'Onchocercose, Republic of the Congo",2019-07-26,20190726,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04049630,Not recruiting,No,18 Years,65 Years,All,16/01/2021,255.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 2,Congo,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Written consent written, signed (or with thumbprint) and dated<br><br>     - Aged 18 to 65 inclusive<br><br>     - Individual microfilarial density = 1mf/mL<br><br>     - Body weight = 40 kg in women and = 45 kg in men; and less than 85 kg<br><br>     - In good health condition, as determined by the medical questionnaire and the general<br>       clinical examination: absence of acute or chronic infection<br><br>    Exclusion Criteria:<br><br>     - Participation in any study other than purely observational, in the 4 weeks preceding<br>       this study (determined by the theoretical date of administration of LEV or placebo).<br><br>     - Any vaccination in the 4 weeks preceding this study.<br><br>     - Acute infection requiring a treatment in the 10 days preceding this study, determined<br>       by the anamnesis during the medical interview (example: pulmonary infection, ENT,<br>       digestive, cutaneous, with implementation of an antibiotic treatment or not)<br><br>     - Warfarin treatment<br><br>     - Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic<br>       antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term<br>       treatment, or a treatment given in a single dose 10 days before the start of treatment<br>       for the clinical trial (precaution of use compared to the risk of agranulocytosis of<br>       immuno-allergic or toxic origin)<br><br>     - Known immunosuppressive pathology<br><br>     - Past or current history of neurological (including epilepsy) or neuropsychiatric<br>       disease<br><br>     - History of agranulocytosis<br><br>     - Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours<br>       preceding the administration of the treatment of the test determined by the anamnesis<br>       during the medical interview<br><br>     - Any condition, in the opinion of the investigator, which exposes the subject to an<br>       undue risk<br><br>     - Known intolerance to levamisole<br><br>     - Subjects who gave blood in the 8 weeks before entry into the study, with a standard<br>       volume (> 500 mL)<br><br>     - During the clinical examination: symptoms, physical signs or biological constants<br>       suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary,<br>       cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to<br>       interfere with the interpretation results of the test. The doctor may then give a<br>       favorable or unfavorable opinion for the inclusion of the participant<br><br>     - Taking IVM and / or LEV during the last six months; and / or mebendazole or<br>       albendazole in the last month<br><br>     - Pregnant and lactating women (based on self-declaration)<br>   ",,"Onchocerciasis, Ocular;Loiasis","Drug: LEV 1 mg/kg;Drug: LEV 1,5 mg/kg;Drug: LEV 2,5 mg/kg;Drug: Placebo",Safety and tolerability of levamisole;Incidence of adverse events with levamisole,Efficacy of levamisole;Proportion of individuals without microfilariae of Loa loa,EOLoa/LEV,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2019,18.0,No,Yes
NCT03238131,16 December 2017,IVM Alone vs ALB + IVM Against Onchocerciasis,Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis,,University Hospitals Cleveland Medical Center,2017-07-25,20170725,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03238131,Not recruiting,No,18 Years,60 Years,All,01/04/2012,272.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 3,Ghana;Ghana;Ghana;Ghana;Ghana,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Men and women 18-60 years residing in Ashanti and Central Region of Ghana<br><br>     - =1 accessible nodules<br><br>     - any Mf/mg based on skin snips<br><br>     - Willingness to give informed consent to participation in the study<br><br>    Exclusion Criteria:<br><br>     - Last IVM treatment < 7 months<br><br>     - Pregnant (do pregnancy test) + breastfeeding<br><br>     - Permanent disability, serious medical illnesses such as a stroke, advanced heart<br>       disease, uncontrolled diabetes, emphysema, etc that prevents or impedes study<br>       participation and/or comprehension<br><br>     - Weight of <40kg suggesting malnourishment<br><br>     - AST/ALT, ?-GT > 1.5 upper limit of normal<br><br>     - Significant glycosuria or proteinuria (2+ or 3+ protein or glucose)<br><br>     - Any one or more of the previous criteria is sufficient to exclude study participation<br><br>     - Not willing or able to give informed consent to participate in the study.<br>   ;<br>    Inclusion Criteria:<br><br>     - Men and women 18-60 years residing in Ashanti and Central Region of Ghana<br><br>     - =1 accessible nodules<br><br>     - any Mf/mg based on skin snips<br><br>     - Willingness to give informed consent to participation in the study<br><br>    Exclusion Criteria:<br><br>     - Last IVM treatment < 7 months<br><br>     - Pregnant (do pregnancy test) + breastfeeding<br><br>     - Permanent disability, serious medical illnesses such as a stroke, advanced heart<br>       disease, uncontrolled diabetes, emphysema, etc that prevents or impedes study<br>       participation and/or comprehension<br><br>     - Weight of <40kg suggesting malnourishment<br><br>     - AST/ALT, ?-GT > 1.5 upper limit of normal<br><br>     - Significant glycosuria or proteinuria (2+ or 3+ protein or glucose)<br><br>     - Any one or more of the previous criteria is sufficient to exclude study participation<br><br>     - Not willing or able to give informed consent to participate in the study.<br>   ;<br>    Inclusion Criteria:<br><br>     - Men and women 18-60 years residing in Ashanti and Central Region of Ghana<br><br>     - =1 accessible nodules<br><br>     - any Mf/mg based on skin snips<br><br>     - Willingness to give informed consent to participation in the study<br><br>    Exclusion Criteria:<br><br>     - Last IVM treatment < 7 months<br><br>     - Pregnant (do pregnancy test) + breastfeeding<br><br>     - Permanent disability, serious medical illnesses such as a stroke, advanced heart<br>       disease, uncontrolled diabetes, emphysema, etc that prevents or impedes study<br>       participation and/or comprehension<br><br>     - Weight of <40kg suggesting malnourishment<br><br>     - AST/ALT, ?-GT > 1.5 upper limit of normal<br><br>     - Significant glycosuria or proteinuria (2+ or 3+ protein or glucose)<br><br>     - Any one or more of the previous criteria is sufficient to exclude study participation<br><br>     - Not willing or able to give informed consent to participate in the study.<br>   ;<br>    Inclusion Criteria:<br><br>     - Men and women 18-60 years residing in Ashanti and Central Region of Ghana<br><br>     - =1 accessible nodules<br><br>     - any Mf/mg based on skin snips<br><br>     - Willingness to give informed consent to participation in the study<br><br>    Exclusion Criteria:<br><br>     - Last IVM treatment < 7 months<br><br>     - Pregnant (do pregnancy test) + breastfeeding<br><br>     - Permanent disability, serious medical illnesses such as a stroke, advanced heart<br>       disease, uncontrolled diabetes, emphysema, etc that prevents or impedes study<br>       participation and/or comprehension<br><br>     - Weight of <40kg suggesting malnourishment<br><br>     - AST/ALT, ?-GT > 1.5 upper limit of normal<br><br>     - Significant glycosuria or proteinuria (2+ or 3+ protein or glucose)<br><br>     - Any one or more of the previous criteria is sufficient to exclude study participation<br><br>     - Not willing or able to give informed consent to participate in the study.<br>   ",,Onchocerciasis;Onchocerciasis;Onchocerciasis;Onchocerciasis,Drug: Ivermectin;Drug: Albendazole;Drug: Ivermectin;Drug: Albendazole;Drug: Ivermectin;Drug: Albendazole;Drug: Ivermectin;Drug: Albendazole,The percent fertile female O.volvulus worms in nodules;The percent fertile female O.volvulus worms in nodules;The percent fertile female O.volvulus worms in nodules,Percent reduction in skin Mf/mg;Percent reduction in skin Mf/mg;Percent reduction in skin Mf/mg;Percent reduction in skin Mf/mg;Number of nodules with intact Mf;Soil Transmitted Helminth (STH) infections,11-11-36,Please refer to primary and secondary sponsors,Washington University School of Medicine,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2017,18.0,No,Yes
NCT02078024,12 December 2020,"Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana","Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana.",,University Hospitals Cleveland Medical Center,2014-02-28,20140228,10/13/2025 16:01:06,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02078024,Not recruiting,No,18 Years,60 Years,All,01/06/2014,375.0,Interventional,Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ,Phase 3,Ghana, ; ; ,"Christopher L King, MD, PhD;James W Kazura, MD;Nicholas O Opoku, MBChB, MSc",,;;,;;,"Case Western Reserve University;Case Western Reserve University;Municipal Hospital, Hohoe, Ghana","<br>    Inclusion Criteria:<br><br>     1. Men and women 18-60 years residing along the Kpassa in the Nkwanta North District of<br>       the Volta Region in Ghana<br><br>     2. Two or more assessable onchocercal nodules<br><br>     3. Skin microfilaria density =5mf/mg.<br><br>    Exclusion Criteria:<br><br>     1. Prior treatment with the antifilarial and/or anti-nematodal drugs diethylcarbamazine,<br>       suramin, ivermectin, albendazole, levamisole or >1week of treatment with doxycycline,<br>       within 12 months before planned test article administration.<br><br>     2. Pregnant or breastfeeding women.<br><br>     3. Low probability of residency in the area (based on subject's assessment) over the next<br>       36 months.<br><br>     4. Permanent disability, serious medical illnesses such as a stroke, advanced heart<br>       disease, uncontrolled diabetes, emphysema, etc. that prevents or impedes study<br>       participation and/or comprehension<br><br>     5. Weight of <40kg suggesting malnourishment<br><br>     6. Hemoglobin levels <7 gm/dL<br><br>     7. aspartate aminotransferase, alanine aminotransferase, creatinine > 1.5 upper limit of<br>       normal.<br><br>     8. Significant glycosuria or proteinuria (2+ or 3+ protein or glucose).<br><br>     9. Known or suspected allergy to albendazole or ivermectin or other compounds related to<br>       these classes of medication.<br>   ",,Onchocerciasis,Drug: IVM plus ALB;Drug: IVM,parasitologic efficacy,additional measures of parasitologic efficacy;compare the percentage living versus dead female worms;compare the number of nodules with intact microfilaria;assess different treatment regimens on Soil Transmitted Helminth infections;determine if IVM plus ALB enhances immunological reactions;determine if the host immune response facilitates killing or sterilizing adult worms and microfilariae,CWRU-OCR-1;WU-10-205,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2014,18.0,No,Yes
ISRCTN45231833,18 March 2019,"Clinical trials of drugs for onchocerciasis: a randomised, single-ascending-dose, ivermectin-controlled, double-blind, safety, tolerability, pharmacokinetic, and efficacy study of orally administered moxidectin in subjects with Onchocerca volvulus infection (Ghana)","Clinical trials of drugs for onchocerciasis: a randomised, single-ascending-dose, ivermectin-controlled, double-blind, safety, tolerability, pharmacokinetic, and efficacy study of orally administered moxidectin in subjects with Onchocerca volvulus infection (Ghana)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",,UNICEF/UNDP/World Bank/WHO - Special Programme for Research and Training in Tropical Diseases (TDR),2005-06-07,20050607,10/13/2025 16:01:06,ISRCTN,http://isrctn.com/ISRCTN45231833,Not Recruiting,No,,,Both,01/09/2006,192.0,Interventional,"Randomised, single ascending dose, active-control, double-blind trial (Treatment)",Not Applicable,Ghana,,,,,,,"Inclusion criteria: <br>        1. Ivermectin-naïve men and women otherwise healthy, with O. volvulus infection<br>        2. Informed consent<br>        3. Aged 18 to 60 years<br>        4. Body weight more than or equal to 40 kg for women, or more than or equal to 45 kg for men<br>        5. Non-pregnant, non-lactating, willing to use contraception during the first 150 days after treatment<br>        6. Normal medical history, physical examination, Electrocardiogram (ECG) and lab results<br>        7. Adequate hematologic, renal and hepatic functions<br>        8. Skin microfilarial density within the required range for the cohort<br>      ","Exclusion criteria: <br>        1. Participation in any studies other than purely observational ones within four weeks before test article administration<br>        2. Any vaccination within four weeks before test article administration<br>        3. Acute infection requiring therapy within the last ten days before test article administration<br>        4. Any medication (with the exception of medication required to treat any reactions during the screening fluorescein angiography (chlorpheniramine) or paracetamol) or herbal preparation within ten days prior to test article administration or any condition currently requiring regular medication<br>        5. History of drug or alcohol abuse or regular use of more than three cigarettes/day, use of alcohol or other drugs of abuse within 72 hours before test article administration<br>        6. Blood donation within eight weeks before study entry<br>        7. Clinically significant ECG abnormalities, or history of cardiac abnormalities, or past or current history of neurological or neuropsychiatric disease or epilepsy<br>        8. Ocular onchocerciasis<br>        9. Hyperactive onchodermatitis<br>        10. Antifilaria therapy within previous five years<br>        11. Coincidental infection with Loa Loa<br>        12. Orthostatic hypotension<br>        13. Female patient with contraindication to DepoMedroxyProgesterone Acetate (DMPA) if not on Norplant<br>      ",Onchocerciasis <br>Infections and Infestations <br>Onchocerciasis,"Single dose of moxidectin of 2 mg, 4 mg or 8 mg, or ivermectin at the approved dose.","Data on safety and tolerability of a single oral dose of moxidectin (2, 4, or 8 mg)",Skin microfilaria levels up to 18 months post treatment,NCT00300768;980819 (B),United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR),,,01/01/1990,,"          1. Ghana Health Service Ethical Review Committee, 24/08/2006          2. World Health Organization (WHO) Ethics Review Committee, 28/06/2006        ",,,Yes,,,,29/11/2009,,2014 results in: https://www.ncbi.nlm.nih.gov/pubmed/24968000 [added 20/02/2019],,,,Not provided at time of registration,Not provided at time of registration,Yes,False,parent    ,2005,,Unknown,Yes
NCT05999825,30 October 2023,Sm-p80 Schistosomiasis Challenge Study,"Safety and Preliminary Efficacy of Sm-p80 + GLA-SE (SchistoShield®) Vaccine Against Controlled Human Schistosome Infection in Healthy, Schistosoma-naïve Adults",,Leiden University Medical Center,2023-08-11,20230811,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05999825,Not recruiting,No,18 Years,45 Years,All,01/09/2024,48.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor). ",Phase 2,Unknown, ; ,"Meta Roestenberg, Prof;Meta Roestenberg, Prof",,;M.Roestenberg@lumc.nl,;+31715269111,LUMC;,"<br>    Inclusion Criteria:<br><br>     1. Subject is aged = 18 and = 45 years and in good health.<br><br>     2. Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     3. Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     4. Subject will not travel to Schistosoma-endemic countries up until treatment at week<br>       24.<br><br>     5. Subject agrees to refrain from blood and plasma donation to Sanquin or for other<br>       purposes throughout the study period.<br><br>     6. For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     7. Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     1. Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, (severe) psychiatric and<br>       other disorders, which could compromise the health of the participant during the study<br>       or interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >35.0 kg/m2 at screening;<br><br>        - positive HIV, HBV or HCV screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>     2. The chronic use of any drug known to interact with praziquantel, artesunate or<br>       lumefantrine metabolism (e.g. phenytoïn, carbamazepine, phenobarbital, primidon,<br>       dexamethason, rifampicine, cimetidine, flecaïnide, metoprolol, imipramine,<br>       amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics,<br>       antidepressants, macrolides, fluorchinolones, imidazole- and triazole antimycotics,<br>       antihistamines). Because lumefantrine may cause extension of QT-time, chronic use of<br>       drugs with effect on QT interval will result in exclusion from study participation.<br><br>     3. Any planned vaccination within 28 days before the start of the trial until the end of<br>       the immunisation phase (week 12), with the exception of SARS-CoV-2 vaccines or<br>       influenza vaccines.<br><br>     4. For female subjects: positive serum pregnancy test on the day before first<br>       immunisation.<br><br>     5. Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     6. Positive serology for schistosomiasis or elevated serum CAA at screening.<br><br>     7. Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel, artesunate or lumefantrine.<br><br>     8. Being an employee or student of the department of Parasitology or Infectious diseases<br>       of the LUMC.<br>   ",,Schistosoma Mansoni;Schistosomiasis,Biological: Sm-p80 + GLA-SE Vaccine;Other: Placebo;Biological: Schistosoma mansoni infection,Vaccine efficacy,Safety of (repeated) immunisation;Immunogenicity,Sm-p80,Please refer to primary and secondary sponsors,Texas Tech University Health Sciences Center;MRC/UVRI and LSHTM Uganda Research Unit,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2023,18.0,No,Yes
PACTR202307901658960,24 June 2025,"A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar.","A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",,International Vaccine Institute,2023-07-27,20230727,10/13/2025 16:02:07,PACTR,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=24338,Not Recruiting,No,19 Year(s),44 Year(s),Both,01/08/2023,120.0,Interventional,"Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Central randomisation by phone/fax",Phase-1,Burkina Faso;Madagascar,Birkneh,Tadesse,"SNU Research Park, 1 Gwanak-ro, Gwanak-gu",Birkneh.Tadesse@ivi.int,+8228811231,Research Scientist,"Inclusion criteria: 1. Healthy male or female participants aged 20 to 59 years at the time of consent.<br>2. Participant who has completed the deworming using praziquantel (PZQ) and albendazole (ABZ) according to local guidelines, with the last dose of PZQ/ABZ administered at least 5 weeks prior to first dose of study product.<br>3. Participant who, after the nature of the study has been explained, has voluntarily given informed consent, according to the local regulatory requirements, prior to study entry.<br>4. Participant who can comply with the study procedures and available for the entire duration of the study (32 weeks).<br>5. Individuals in good health as determined by the outcome of medical history, physical examination, hematology and biochemistry tests at the time of screening and the clinical judgment of the investigator.<br>6. Women of childbearing potential* with negative urinary test result on a human chorionic gonadotropin pregnancy test on the day of randomization, before receiving any study product.<br>7. Males or females of childbearing potential who are using an effective birth control method recommended by the national health system for at least four (4) weeks before the first vaccination (for female participants only) and up to four (4) weeks after the third vaccination (i.e., for at least 4 months).","Exclusion criteria: 1. Participant with major congenital abnormalities which in the opinion of investigator may affect the subject’s participation in the study.<br>2. Participant concomitantly enrolled or scheduled to be enrolled in another trial.<br>3. Positive rapid test for HIV 1-2 confirmed by a positive blood test for human immunodeficiency virus (positive antibodies to HIV 1/2).<br>4. Participant seropositive for hepatitis B virus surface antigen (HBsAg).<br>5. Participant seropositive for hepatitis C virus (Antibodies to HCV).<br>6. Participant with active or chronic Schistosomiasis infection defined by a positive result for microscopy (Urine filtration, Kato-Katz (KK)) and point-of-care – circulating cathodic antigen (POC –CCA) and/or real-time PCR.<br>7. Participant with soiled transmitted helminths infections (STH) as diagnosed by microscopy (KK) and/or real-time PCR.<br>8. Participant with malaria infection/malaria as diagnosed by the blood smear.<br>9. Any other confirmed or suspected immunosuppressive or immunodeficient state such as asplenia, recurrent severe infections.<br>10. Body mass index (BMI) = 35 kg/m2<br>11. Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisolone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs.<br>12. Receipt of blood or blood-derived products in the past 3 months.<br>13. Participant who has received other vaccines 4 weeks prior to test vaccination or plans to receive any vaccine within 4 weeks of last dose of study vaccine, exception made for COVID-19 vaccines.<br>14. Known history of allergy to study vaccine components and/or excipients or other medications, or any other allergies deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial.<br>15. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time resulting in contraindication for IM injections/blood extractions.", <br>Schistosomiasis;Schistosomiasis,;drug;Placebo,1. Proportion of participants with of any Serious Adverse Events (SAEs)/ adverse events of special interest (AESI) from the time of the first study vaccination through the final study visit.<br>[Time Frame: Day 1 through Day 224]<br>2. Proportion of participants with immediate adverse events (reactogenicity events) within 60 min from the time of each study vaccination<br>[Time Frame: Day 1 through Day 56]<br>3. Proportion of participants with solicited local and solicited systemic AEs as measured for 7 days (inclusive) following immunization with the three different dose formulations.<br>[Time Frame: Day 1 through Day 63]<br>4. Proportion of participants with unsolicited AEs from the time of vaccination until 28 days post immunization with the three different dose formulations.<br>[Time Frame: Day 1 through Day 84]<br>5. Proportion of participants with clinical safety laboratory adverse events measured at 7 days and 28 days after each study vaccination.<br>[Time Frame: Day 1 through Day 84],"6. For Sm-p80 IgG antibodies, seroconversion rate at approximately 4 weeks (28 days) after each dose of study vaccination as compared to baseline<br>[Time Frame: Day 1 through Day 84]<br>7. For Sm-p80 IgG antibodies, seroconversion rate at approximately 24 weeks after third dose of study vaccination as compared to baseline<br>[Time Frame: Day 1 through Day 224]<br>8. Geometric Mean Titers (GMTs) of serum Sm-p80 IgG antibodies at approximately 4 weeks after each dose of study vaccination.<br>[Time Frame: Day 1 through Day 84]<br>9. Geometric Mean Titers (GMTs) of serum Sm-p80 IgG antibodies at approximately 24 weeks after third dose of study vaccination.<br>[Time Frame: Day 1 through Day 224]",,European Commission Horizon 2020,,Approved;Approved,20/03/2023;05/06/2023,Comite dEthique Pour la researche en sante;Comite d Ethique de la Recherche Biomedicale,"03 BP 7009;Agence de Medicament de Madagascar, BP8145 - 101, Antananarivo, Madagascar",+26625488937;+261202236522,kouetafla@yahoo.com;jean.rubis.andriantsoa@gmail.com,Unknown,,,,,,,,,,Yes,"Two years after the study databases are sealed, the database will be made available to external investigators upon request reviewed by VASA consortium and made available without individual identifiers in the VASA repository. The consortium makes combined decisions on the sharing of isolates and biological specimens to external research groups after consideration of reasonable requests.",Yes,False,          ,2023,19.0,No,Yes
NCT05762393,7 April 2025,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar","A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar",,International Vaccine Institute,2023-02-28,20230228,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05762393,Not recruiting,No,20 Years,59 Years,All,17/11/2023,120.0,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor). ",Phase 1,Burkina Faso;Madagascar;Burkina Faso;Madagascar, ,Florian Marks,,,,International Vaccine Institute,"Inclusion Criteria:<br><br> 1. Healthy male or female participants aged 20 to 59 years at the time of consent.<br><br> 2. Participant who has completed the deworming using praziquantel (PZQ) and albendazole<br>   (ABZ) according to local guidelines, with the last dose of PZQ/ABZ administered at<br>   least 5 weeks prior to first dose of study product.<br><br> 3. Participant who, after the nature of the study has been explained, has voluntarily<br>   given informed consent, according to the local regulatory requirements, prior to<br>   study entry.<br><br> 4. Participant who can comply with the study procedures and available for the entire<br>   duration of the study (32 weeks).<br><br> 5. Individuals in good health as determined by the outcome of medical history, physical<br>   examination, hematology and biochemistry tests at the time of screening and the<br>   clinical judgment of the investigator.<br><br> 6. Women of childbearing potential* with negative urinary test result on a human<br>   chorionic gonadotropin pregnancy test on the day of randomization, before receiving<br>   any study product.<br><br> 7. Males or females of childbearing potential who are using an effective birth control<br>   method recommended by the national health system for at least four (4) weeks before<br>   the first vaccination (for female participants only) and up to four (4) weeks after<br>   the third vaccination (i.e., for at least 4 months).<br><br>Exclusion Criteria:<br><br> 1. Participant with major congenital abnormalities which in the opinion of investigator<br>   may affect the subject's participation in the study.<br><br> 2. Participant concomitantly enrolled or scheduled to be enrolled in another trial.<br><br> 3. Positive rapid test for HIV 1-2 confirmed by a positive blood test for human<br>   immunodeficiency virus (positive antibodies to HIV 1/2).<br><br> 4. Participant seropositive for hepatitis B virus surface antigen (HBsAg).<br><br> 5. Participant seropositive for hepatitis C virus (Antibodies to HCV).<br><br> 6. Participant with active or chronic Schistosomiasis infection defined by a positive<br>   result for microscopy (Urine filtration, Kato-Katz (KK)) and point-of-care -<br>   circulating cathodic antigen (POC -CCA) and/or real-time PCR.<br><br> 7. Participant with soiled transmitted helminths infections (STH) as diagnosed by<br>   microscopy (KK) and/or real-time PCR.<br><br> 8. Participant with malaria infection/malaria as diagnosed by the blood smear.<br><br> 9. Any other confirmed or suspected immunosuppressive or immunodeficient state such as<br>   asplenia, recurrent severe infections.<br><br> 10. Body mass index (BMI) = 35 kg/m2<br><br> 11. Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisolone equivalent<br>   for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs.<br><br> 12. Receipt of blood or blood-derived products in the past 3 months.<br><br> 13. Participant who has received other vaccines 4 weeks prior to test vaccination or<br>   plans to receive any vaccine within 4 weeks of last dose of study vaccine, exception<br>   made for COVID-19 vaccines.<br><br> 14. Known history of allergy to study vaccine components and/or excipients or other<br>   medications, or any other allergies deemed by the investigator to increase the risk<br>   of an adverse event if they were to participate in the trial.<br><br> 15. Individuals with a known bleeding diathesis, or any condition that may be associated<br>   with a prolonged bleeding time resulting in contraindication for IM injections/blood<br>   extractions.<br><br> 16. Any abnormality or chronic disease which in the opinion of the investigator might be<br>   detrimental for the safety of the participant and interfere with the assessment of<br>   the study objectives and compromise the health of the volunteers.<br><br> 17. Any female participant who is lactating*, pregnant or planning for pregnancy**<br>   during the course of study period.<br><br> 18. Individuals with behavioral or cognitive impairment or psychiatric disease or neural<br>   disorders that, in the opinion of the investigator, could interfere with the<br>   individual's ability to participate in the trial.<br><br> 19. Any clinically significant abnormal finding on serum chemistry or hematology or<br>   urinalysis at the screening visit as per US FDA toxicity grading scale for healthy<br>   adult and adolescent volunteers enrolled in preventive vaccine clinical trials (any<br>   biological finding grade 4 constitutes an exclusion criteria).<br><br> 20. Individuals who were research staff involved with the clinical study or<br>   family/household members of research staff.<br><br> 21. As per Investigator's medical judgement individual could be excluded from the study<br>   despite meeting all inclusion/exclusion criteria mentioned above.",,Schistosomiasis,Biological: Sm-p80 + GLA-SE,Proportion of participants with of any Serious Adverse Events (SAEs)/ adverse events of special interest (AESI) from the time of the first study vaccination through the final study visit.;Proportion of participants with immediate adverse events (reactogenicity events) within 60 min from the time of each study vaccination;Proportion of participants with solicited local and solicited systemic AEs as measured for 7 days (inclusive) following immunization with the three different dose formulations.;Proportion of participants with unsolicited AEs from the time of vaccination until 28 days post immunization with the three different dose formulations.;Proportion of participants with clinical safety laboratory adverse events measured at 7 days and 28 days after each study vaccination.,"For Sm-p80 IgG antibodies, seroconversion rate at approximately 4 weeks (28 days) after each dose of study vaccination as compared to baseline;For Sm-p80 IgG antibodies, seroconversion rate at approximately 24 weeks after third dose of study vaccination as compared to baseline;Geometric Mean Titers (GMTs) of serum Sm-p80 IgG antibodies at approximately 4 weeks after each dose of study vaccination.;Geometric Mean Titers (GMTs) of serum Sm-p80 IgG antibodies at approximately 24 weeks after third dose of study vaccination.",IVI VASA 001,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2023,20.0,No,Yes
NCT05292391,8 September 2025,"Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults","A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults",,National Institute of Allergy and Infectious Diseases (NIAID),2022-03-03,20220303,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05292391,Not recruiting,No,18 Years,55 Years,All,23/05/2022,45.0,Interventional,Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 1,United States,,,,,,,"Inclusion Criteria:<br><br> 1. Male or non-pregnant female 18 through 55 years of age, inclusive, at the time of<br>   consent.<br><br> 2. Able and willing to participate for the duration of the study and able to understand<br>   and comply with planned study procedures.<br><br> 3. Able and willing to provide written (not proxy) informed consent.<br><br> 4. Is in good health, as judged by the investigator, and determined by medical history<br>   and physical examination*.<br><br>   *Existing medical diagnoses or conditions (except those in the Subject Exclusion<br>   Criteria) must be deemed as stable. A stable medical condition is defined as no<br>   change in prescription medication, dose, or frequency of medication in the last<br>   three months (90 days) and health outcomes of the specific disease are considered to<br>   be within acceptable limits in the last six months (180 days). Any change due to<br>   change of health care provider, insurance company, or that is done for financial<br>   reasons, as long as in the same class of medication, will not be considered a<br>   violation of this inclusion criterion. Any change in prescription medication due to<br>   improvement of a disease outcome, as determined by the site PI or appropriate<br>   sub-investigator, will not be considered a violation of this inclusion criterion.<br>   Subjects may be on chronic or as needed (prn) medications if, in the opinion of the<br>   site PI or appropriate sub-investigator, they pose no additional risk to subject<br>   safety or assessment of solicited events and immunogenicity. Topical, nasal, and<br>   inhaled medications (with the exception of some uses of corticosteroids as outlined<br>   in the Subject Exclusion Criteria), vitamins, and contraceptives are permitted.<br><br> 5. Women of childbearing potential* must have a negative serum pregnancy test at<br>   screening and a negative urine pregnancy test within 24 hours prior to each study<br>   product injection.<br><br>   *Not sterilized via bilateral tubal ligation, bilateral oophorectomy, or<br>   hysterectomy, or, if menopausal, still menstruating or < 1 year of the last menses<br><br> 6. Women of childbearing potential must have used an acceptable form of contraception*<br>   in the 30 days prior to their first study product injection.<br><br>   *Acceptable single forms of contraception include abstinence from sexual activity<br>   that could lead to pregnancy, monogamous relationship with vasectomized partner who<br>   has been vasectomized for six months or more prior to enrollment, successful Essure<br>   placement (permanent, non-surgical, non-hormonal sterilization), intrauterine<br>   devices, and hormonal methods, including the birth control patch, shot<br>   (Depo-Provera), pills, the vaginal ring (NuvaRing), and the contraceptive implant<br>   (Nexplanon). Acceptable barrier methods include diaphragm or cervical cap with<br>   spermicide and the contraceptive sponge.<br><br> 7. Women of childbearing potential must agree to continue use of an acceptable form of<br>   contraception through 30 days after their last study product injection.<br><br> 8. Weight >/= 50 kg and body mass index (BMI) < 35.0 kg/m2<br><br> 9. Vital signs (oral temperature, pulse, and blood pressure) are all within normal<br>   protocol-defined ranges.*<br><br>   *The normal protocol-defined ranges for vital signs include (a) oral temperature<br>   less than 38 degrees C (100.4 degrees F), (b) pulse no greater than 100 bpm, (c)<br>   systolic blood pressure 85 to 150 mmHg, inclusive, and (d) diastolic BP </= 100<br>   mmHg.<br><br> 10. Screening clinical lab values are all within normal protocol-defined reference<br>   ranges.<br><br>    - The normal protocol-defined ranges for laboratory tests include (a) ALT of < 47<br>     IU/L, (b) creatinine less than or equal to the laboratory upper limit of<br>     normal, (c) WBC >/=3.80 x10^3/UL and </=13.00 x10^3/UL, (d) hemoglobin 11.5<br>     g/dL or greater for females or 12.6 g/dL or greater for males, (e) platelets<br>     between 131 x10^3/UL and 415 x10^3/UL, inclusive.<br><br>Exclusion Criteria:<br><br> 1. Has had known schistosomiasis infection or has traveled to an endemic area for<br>   schistosomiasis infection and, during that travel, was potentially exposed to a<br>   Schistosoma species.<br><br> 2. Has been treated for schistosomiasis.<br><br> 3. Has previous exposure to schistosome vaccines or experimental products containing<br>   GLA-SE.<br><br> 4. Female subjects who are breastfeeding a child ,or who plan to breastfeed a child<br>   from the first study product injection through 30 days after the last study product<br>   injection.<br><br> 5. Asthma, other than mild, well-controlled asthma*<br><br>   *Cold or exercise-induced asthma controlled with inhaled medications other than<br>   inhaled corticosteroids is permissible. Subjects should be excluded if they require<br>   daily bronchodilator use, or have had an asthma exacerbation requiring<br>   oral/parenteral steroid use or have used theophylline or inhaled corticosteroids in<br>   the past year<br><br> 6. Known atherosclerotic cardiovascular disease or history of myocardial infarction,<br>   pericarditis, or myocarditis.<br><br> 7. Diabetes mellitus<br><br> 8. History of a psychiatric condition that may make study compliance difficult, such as<br>   schizophrenia, or poorly controlled bipolar disorder**<br><br>   **Includes persons with psychoses or history of suicide attempt or gesture in the 3<br>   years before study entry or an ongoing risk for suicide.<br><br> 9. Chronic or active neurologic condition (including seizures*** and migraine<br>   headaches****).<br><br>   ***Seizure within the past 5 years<br><br>   ****Four or more migraine headaches in the past 12 months that interfered with<br>   normal daily activity or any migraine headache in the past 5 years that required<br>   emergency or inpatient medical care.<br><br> 10. Autoimmune disease******<br><br>   ******autoimmune hypothyroidism with or without replacement therapy, and vitiligo or<br>   mild eczema or psoriasis not requiring chronic therapy, are permissible<br><br> 11. Known or suspected congenital or acquired immunodeficiency including anatomic or<br>   functional asplenia******* or immunosuppression as a result of underlying illness or<br>   treatment.<br><br>   *******Any splenectomy is exclusionary.<br><br> 12. Use of alcohol or drugs that, in the opinion of the investigator, may interfere with<br>   ability to comply with the protocol or increase risk to subject's health during the<br>   study period.<br><br> 13. Active neoplastic disease********<br><br>   ********Subjects with a history of malignancy may be included if treated by surgical<br>   excision, or by chemotherapy or radiation therapy and has been observed for a period<br>   that in the investigator's estimation provides a reasonable assurance of sustained<br>   cure (not less than 36 months). Cervical neoplasia under surveillance and<br>   non-melanoma skin cancer are not exclusionary.<br><br> 14. Chronic topical or systemic corticosteroid use*********<br><br>   *********Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons<br>   using a topical corticosteroid for a limited duration for mild uncomplicated<br>   dermatitis such as poison ivy or contact dermatitis prior to enrollment may be<br>   enrolled the day after their therapy is completed. Oral or parenteral (intravenous,<br>   IM, subcutaneous) corticosteroids given for non-chronic conditions not expected to<br>   recur are permissible if, within the year prior",,Schistosomiasis,Biological: Sm-p80;Biological: Sm-p80 + GLA-SE,"Number of Participants Reporting Serious Adverse Events (SAEs) Throughout the Study;Number of Participants Reporting Solicited Reactogenicity Events Within 7 Days Post Each Dose;Number of Participants Reporting Chemistry Laboratory Adverse Events (AEs) Within 28 Days Post Each Dose;Number of Participants Reporting Hematology Laboratory Adverse Events (AEs) Within 28 Days Post Each Dose;Number of Participants Reporting Unsolicited Adverse Events (AEs) Within 28 Days Post Each Dose;Number of Participants Reporting Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs), New Onset Chronic Medical Condition (NOCMCs), and Potentially Immune-mediated Medical Conditions (PIMMCs)",Number of Participants Achieving Seroconversion in Sm-p80 IgG Antibodies 28 Days Post Each Dose;Geometric Mean Titers (GMTs) of Serum Sm-p80 IgG Antibodies 7 Days and 28 Days Post Each Dose and 124 Days Post Dose 3,5UM1AI148373-03;18-0018,Please refer to primary and secondary sponsors,,,,,,,,Yes,11/04/2025,https://clinicaltrials.gov/ct2/show/results/NCT05292391,,,,,,,,,,Yes,False,          ,2022,18.0,No,Yes
NCT05085470,6 February 2023,Repeated Controlled Human Schistosoma Mansoni Infection,Safety and Protective Efficacy of Repeated Controlled Human Schistosoma Mansoni Infection,,Leiden University Medical Center,2021-08-06,20210806,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT05085470,Not recruiting,No,18 Years,45 Years,All,29/10/2021,24.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Triple (Participant, Care Provider, Investigator). ",Unknown,Netherlands,,,,,,,"<br>    Inclusion Criteria:<br><br>     1. Subject is aged = 18 and = 45 years and in good health.<br><br>     2. Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     3. Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     4. Subject will remain within Europe (excluding Corsica) during the study period.<br><br>     5. Subject agrees to refrain from blood and plasma donation to Sanquin or for other<br>       purposes throughout the study period.<br><br>     6. For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     7. Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     1. Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, (severe) psychiatric and<br>       other disorders, which could compromise the health of the volunteer during the study<br>       or interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >35.0 kg/m2 at screening;<br><br>        - positive HIV, hepatitis B virus or hepatitis C virus screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>     2. The chronic use of any drug known to interact with praziquantel, artesunate or<br>       lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidone,<br>       dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,<br>       amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics,<br>       antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics,<br>       antihistamines). Because lumefantrine may cause extension of QT-time, chronic use of<br>       drugs with effect on QT interval will result in exclusion from study participation.<br><br>     3. For female subjects: positive urine pregnancy test at screening.<br><br>     4. Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     5. Positive serology for schistosomiasis or elevated serum CAA at screening.<br><br>     6. Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel, artesunate or lumefantrine.<br><br>     7. Being an employee or student of the department of Parasitology or Infectious diseases<br>       of the LUMC.<br>   ",,Schistosomiasis;Schistosoma Mansoni,Biological: Schistosoma mansoni infection;Biological: Placebo mock infection,Protective efficacy;Safety of (repeated) exposure to male Sm cercariae based on self-reported adverse events,Time to CAA positivity;Peak serum CAA levels;Eosinophils;Antibody responses;Cellular responses;Attack rate,ReCoHSI,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2021,18.0,No,Yes
ISRCTN17656730,19 August 2024,"Surveys for assessment of urogenital schistosomiasis in pre-school, school-aged children, adolescents and adults in Zanzibar (Unguja and Pemba Islands)","Repeated cross-sectional surveys for monitoring urogenital schistosomiasis in pre-school, school-aged children, adolescents and adults in Zanzibar (Unguja and Pemba Islands)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",,Swiss Tropical and Public Health Institute,2020-07-27,20200727,10/13/2025 16:02:07,ISRCTN,https://www.isrctn.com/ISRCTN17656730,Not Recruiting,No,,,Both,15/02/2018,26970.0,Observational,Repeated cross-sectional surveys in communities and schools to monitor the Schistosoma haematobium prevalence and infection intensity in the study population. (Screening),Not Applicable,Tanzania,,,,,,,"Inclusion criteria: 1. Children attending the selected nurseries and schools<br>2. Adolescents or adults aged =13 years from the selected shehias, including pregnant women, only one adolescent and/or adult per household eligible<br>3. Submitted informed consent form (ICF) signed by a parent or legal guardian in case of participating children and adolescents, or signed by the participant in case of participating adults<br>4. Able to provide one urine sample with sufficient volume to perform diagnostic tests",Exclusion criteria: Does not meet inclusion criteria,"Schistosoma haematobium infections (urogenital schistosomiasis) <br>Infections and Infestations <br>Schistosoma haematobium, urogenital schistosomiasis, bilharziasis","The S. haematobium prevalence will be determined annually (2018, 2019, 2020, 2021) in cross-sectional surveys conducted in schools and communities of the study area.<br><br>Mass drug administration with praziquantel (40 mg/kg) is carried out as part of the routine interventions of the Neglected Tropical Diseases Programme (NTD) of the Zanzibar Ministry of Health at least once per year. In community-based treatment, trained drug distributors use a door-to-door approach to provide praziquantel to all community members aged >3 years that did not receive praziquantel in the same treatment round via school-based treatment, and are not severely sick. In school-based treatment, trained teachers provide directly-observed praziquantel treatment to the children attending school on the day of treatment. Community drug distributors and teachers are supervised by the staff of the NTD Programme.","Current primary outcome measure as of 27/07/2020:<br>Number of S. haematobium infected individuals detected by the urine filtration method (detecting S. haematobium eggs in 10 ml urine) and reagent strip method (Hemastix; detecting microhaematuria in urine) applied on a single urine sample per participant in each annual cross-sectional survey in 2018, 2019, 2020, and 2021<br><br>Previous primary outcome measure:<br>Number of S. haematobium infected individuals detected by the urine filtration method (detecting S. haematobium eggs in 10 ml urine) and reagent strip method (Hemastix; detecting microhaematuria in urine) applied on a single urine sample per participant in each cross-sectional survey at 0, 1, 2, and 3 years","Current secondary outcome measures as of 27/07/2020:<br>1. Impact of mass drug administration (MDA) with praziquantel (40 mg/kg) over time measured in 2018, 2019, 2020, and 2021 during the annual cross-sectional school-based and community-based surveys using:<br>1.1. S. haematobium prevalence measured by urine filtration (S. haematobium egg absence/presence in 10 ml urine) and measured by reagent strips to assess microhaematuria absence/presence<br>1.2. S. haematobium infection intensity measured by urine filtration (S. haematobium egg counts in 10 ml urine)<br>2. Age-prevalence distribution by age and stratified by sex, measured by urine filtration and reagent strips, sex and age will be recorded on enrolment and in 2018, 2019, 2020, and 2021 during the annual cross-sectional school-based and community-based surveys <br>3. Treatment coverage and compliance of MDA with praziquantel (40 mg/kg) preceding the cross-sectional survey, determined with questionnaires in annual cross-sectional surveys (coverage is defined as the percentage of those queried receiving praziquantel tablets during MDA, and compliance is defined as the percentage of those queried swallowing praziquantel tablets in the dose supplied during MDA) in 2018, 2019, 2020, and 2021<br>4. Risk factors for S. haematobium infection determined with questionnaires (query the use of natural open freshwater bodies for washing, bathing and household chores, travel, location of residence and demographic factors) during annual cross-sectional surveys in 2018, 2019, 2020, and 2021<br><br>Previous secondary outcome measures:<br>1. Impact of mass drug administration (MDA) with praziquantel (40 mg/kg) over time measured at 0, 1, 2 and 3 years during the annual cross-sectional school-based and community-based surveys using:<br>1.1. S. haematobium prevalence measured by urine filtration (S. haematobium egg absence/presence in 10 ml urine) and measured by reagent strips to assess microhaematuria absence/presence<br>1.2. S. haematobium infection intensity measured by urine filtration (S. haematobium egg counts in 10 ml urine)<br>2. Age-prevalence distribution by age and stratified by sex, measured by urine filtration and reagent strips, sex and age will be recorded on enrolment and at 0, 1, 2 and 3 years during the annual cross-sectional school-based and community-based surveys <br>3. Treatment coverage and compliance of MDA with praziquantel (40 mg/kg) preceding the cross-sectional survey, determined with questionnaires in annual cross-sectional surveys (coverage is defined as the percentage of those queried receiving praziquantel tablets during MDA, and compliance is defined as the percentage of those queried swallowing praziquantel tablets in the dose supplied during MDA) at 0, 1, 2 and 3 years <br>4. Risk factors for S. haematobium infection determined with questionnaires (query the use of natural open freshwater bodies for washing, bathing and household chores, travel, location of residence and demographic factors) during annual cross-sectional surveys at 0, 1, 2 and 3 years",Nil known;Nil known;Version 1.0 (03.06.2019),Bill and Melinda Gates Foundation,,,01/01/1900,"Old ethics approval format; 1. Approved 01/02/2017, Zanzibar Medical Research and Ethics Committee (ZAMREC) (Ministry of Health Zanzibar, PO Box 236, Vuga, Zanzibar, United Republic of Tanzania), Ref: ZAMREC 0003/SEPTEMBER/0112. Approved April 20/04/2018, Zanzibar Medical Research and Ethics Committee (ZAMREC) (Ministry of Health Zanzibar, PO Box 236, Vuga, Zanzibar, United Republic of Tanzania), Ref: NO.ZAMREC/0001/FEBRUARY/183. Approved 12/06/2019, Zanzibar Health Research Ethics Institute (",,,,Yes,,,,31/12/2022,,2021 Interim results article in https://pubmed.ncbi.nlm.nih.gov/33577601/ (added 31/08/2021),,,,Data sharing statement to be made available at a later date,We intend to publish our study results in the peer-reviewed (whenever possible open-access) literature and international conferences by the end of 2022.,No,False,          ,2020,,Unknown,Yes
NCT04269915,29 April 2024,Single-sex Female Controlled Human Schistosomiasis Mansoni Infection,Establishing a Female-only Controlled Human Schistosoma Mansoni Infection Model: a Safety and Dose Finding Study (CoHSI2),,Leiden University Medical Center,2020-02-10,20200210,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT04269915,Not recruiting,Yes,18 Years,45 Years,All,12/08/2020,13.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ,Unknown,Netherlands,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Subject is aged = 18 and = 45 years and in good health.<br><br>     - Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     - Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     - Subject will remain within Europe (excluding Corsica) during the study period and is<br>       reachable by mobile telephone from week 3 to week 8 of the study period.<br><br>     - Subject agrees to refrain from blood donation to """"Sanquin"""" (blood bank) or for other<br>       purposes throughout the study period.<br><br>     - For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     - Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     - Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, psychiatric and other<br>       disorders, which could compromise the health of the volunteer during the study or<br>       interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;<br><br>        - positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis<br>         C virus (HCV) screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>        - The chronic use of any drug known to interact with praziquantel, artesunate or<br>         lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon,<br>         dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,<br>         amitriptyline, clomipramine, class I-A and III anti-arrythmics, antipsychotics,<br>         antidepressants, macrolides, fluoroquinolones, imidazole- and triazole<br>         antimycotics, antihistamines) Because lumefantrine may cause extension of<br>         QT-time, chronic use of drugs with effect on QT interval are excluded from the<br>         study.<br><br>     - For female subjects: positive urine pregnancy test at screening.<br><br>     - Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     - Positive serology for schistosomiasis or elevated serum CAA at screening.<br><br>     - Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel, artesunate or lumefantrine.<br><br>     - Being an employee or student of the department of parasitology or infectious diseases<br>       of the Leiden University Medical Center.<br>   ",,Schistosomiasis;Schistosomiasis Mansoni,Biological: female Schistosoma mansoni cercariae,"Number and severity of adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with female cercariae.;Number of female cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen.",Average number of weeks until positive serum circulating anodic antigen (CAA) test;Comparison of peak serum circulating anodic antigen (CAA) concentration in different dose groups;Humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals;Ex vivo lymphocyte profiles using flow cytometry between infected and uninfected individuals;Changes over time in commensal gut bacteria by looking at the relative abundance of microbiota using 16S rRNA gene amplicon sequencing after controlled human Schistosoma mansoni infection with female cercariae,CoHSI2,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,True ,parent    ,2020,18.0,No,Yes
NCT04264130,12 December 2020,Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection,Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection,SACT,Centre de Recherche Médicale de Lambaréné,2020-02-06,20200206,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04264130,Not recruiting,No,,,All,31/07/2018,54.0,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Gabon, ,Rella Zoleko Manego,,,,"Centre de Recherches Medicales de Lambarene, Lambarene, Gabon",<br>    Inclusion Criteria:<br><br>     - Malaria infection diagnosed by Rapid Diagnostic Tests (RDTs) or thick blood smear<br><br>     - Urinary schistosomiasis diagnosed by presence of Schistosoma haematobium eggs in the<br>       urine before malaria treatment<br><br>     - Written informed consent<br><br>    Exclusion Criteria:<br><br>     - Patients treated with PZQ during the previous 6 weeks<br><br>     - Known intolerance /allergy to any study drug<br><br>     - Pregnancy<br>   ,,Schistosomiasis Haematobia,Drug: Artesunate-Pyronaridine;Drug: Artemether-Lumefantrine;Drug: Artefenomel-Ferroquine,Egg Reduction Rate (ERR);Egg Reduction Rate (ERR),Cure Rate (CR);Cure Rate (CR),CEI-006/2018,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,No,,No,False,          ,2020,,Unknown,Yes
ISRCTN60517191,4 November 2024,The effect of intensive treatment for schistosomiasis on response to vaccines among island adolescents in Uganda,"Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic infections in the tropics (POPVAC). Trial Protocol A: the effect of intensive treatment for schistosomiasis on response to vaccines among island adolescents in Uganda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",,London School of Hygiene and Tropical Medicine,2019-05-01,20190501,10/13/2025 16:02:07,ISRCTN,https://www.isrctn.com/ISRCTN60517191,Not Recruiting,No,,,Both,08/07/2019,480.0,Interventional,Single-centre open individually randomised two parallel group trial (Other),Not Applicable,Uganda,Emily,Webb,"LSHTM,Keppel St",emily.webb@lshtm.ac.uk,+44 (0)207 9272012,,"Inclusion criteria: 1. Attending the selected school and planning to continue to attend the school for the duration of the study<br>2. Aged 9 to 17 year and enrolled in primary 4, 5 or 6<br>3. Written informed consent by parent or guardian<br>4. Written informed assent by participant<br>5. Agree to avoid pregnancy for the duration of the trial (female only)<br>6. Willing to provide locator information and to be contacted during the course of the trial<br>7. Able and willing (in the investigator's opinion) to comply with all the study requirements","Exclusion criteria: 1. Clinically significant history of immunodeficiency (including HIV), cancer, cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness<br>2. History of serious psychiatric condition or disorder<br>3. Concurrent oral or systemic steroid medication or the concurrent use of other<br>immunosuppressive agents within 2 months prior to enrolment<br>4. History of allergic reaction to immunisation or any allergy likely to be exacerbated by any component of the study vaccines including egg or chicken proteins<br>5. History of previous immunisation with YF, oral typhoid or HPV vaccine; previous immunisation with BCG or Td at age >5 years<br>6. Tendency to develop keloid scars<br>7. Haemoglobin less than 82g/L<br>8. Positive HIV serology<br>9. Positive pregnancy test<br>10. Female currently lactating, confirmed pregnancy or intention to become pregnant during the trial period<br>11. Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccines for 30 days prior to dosing with the study vaccine, or planned use during the study period<br>12. Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial immunisation date",Vaccine responses <br>Infections and Infestations,"A randomisation code will be generated by the trial statistician using a randomly permuted block size. Participants will be allocated in a 1:1 ratio to receive either intensive or standard praziquantel treatment. Participants in the intensive arm will receive three doses of praziquantel (PZQ) (40mg/kg, assessed by height pole) each two weeks apart (the last of these 2-4 weeks before immunisation), followed by quarterly PZQ (approximately; timings adjusted to accommodate school terms) during follow up. Participants in the standard arm will receive annual PZQ (Uganda Ministry of Health (MoH) policy) given after immunisation and after primary endpoint sampling.",1. BCG: BCG-specific IFN-gamma ELIspot response 8 weeks post BCG immunisation<br>2. YF-17D: neutralising antibody titres (plaque-reduction neutralisation test) at 4 weeks post YF immunisation<br>3. Ty21a: Salmonella typhi lipopolysaccharide (LPS)-specific immunoglobulin(Ig)G concentration at 4 weeks post Ty21a immunisation<br>4. HPV: IgG specific for L1-proteins of HPV-16/18 at 4 weeks post HPV priming immunisation<br>5. Td: tetanus and diphtheria toxoid-specific IgG concentration at 4 weeks post Td immunisation,"Current secondary outcome measures as of 24/07/2019:<br>1. Protective immunity. Proportions with protective neutralising antibody (YF); protective IgG levels (TT); seroconversion rates (Ty21a) at 4 weeks post the corresponding immunisation<br>2. Response waning. Primary outcome measures (all vaccines) repeated at week 52, and area-under-the curve (AUC) analyses<br>3. Priming versus boosting. Effects on priming versus boosting will be examined for HPV only, comparing outcomes 4 weeks after the first, and 4 weeks after the second vaccine dose<br>4. Current S. mansoni infection status and intensity. This will be determined by serum/plasma levels of circulating anodic antigen (CAA). The method is quantitative, highly specific for Schistosoma infection, and much more sensitive than the conventional Kato Katz method. CAA will be assessed retrospectively on stored samples collected at baseline, on immunisation days, and on primary and secondary endpoint days. <br><br>Previous secondary outcome measures:<br>1. Protective immunity. Proportions with protective neutralising antibody (YF); protective IgG levels (TT); seroconversion rates (Ty21a) at 4 weeks post the corresponding immunisation<br>2. Response waning. Primary outcome measures (all vaccines) repeated at week 52, and area-under-the curve (AUC) analyses<br>3. Priming versus boosting. Effects on priming versus boosting will be examined for HPV only, comparing outcomes 4 weeks after the first, and 4 weeks after the second vaccine dose",Nil known;Nil known,Medical Research Council,,,01/01/1900,"Old ethics approval format; 1. Approved 05/09/2018, MRC/UVRI and LSHTM Uganda Research Unit Research Ethics Committee (Plot 51-59, Nakiwogo Road, Entebbe, P.O. Box 49, Entebbe-Uganda; +256 414 320 385/6; directoruvri@uvri.go.ug), ref: GC/127/18/09/6802. Approved 07/05/2019, Uganda National Council for Science and Technology (Plot 6, Kimera Road, Ntinda, P.O. Box 6884, Kampala-Uganda; +256 414 705500; infor@uncst.go.ug), ref: HS 24863. Approved 28/05/2019, National Drug Authority (Plot 19 Lumum",,,,Yes,,,,30/11/2020,,2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33593768/ (added 05/05/2022)2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33593767/ scientific rationale and cross-cutting analyses (added 26/10/2022)2024 Results article in https://pubmed.ncbi.nlm.nih.gov/39424571/ (added 21/10/2024),,,,No,"Stored in repository. The de-identified individual participant data that underlie the results reported in journal articles will be stored in a non-publically available repository (LSHTM Data Compass), together with a data dictionary. This will be done at the time of publication. Each dataset will be allocated a unique digital object identifier (DOI). Researchers who would like to access the data may submit a request through LSHTM Data Compass, detailing the data requested, the intended use for the data, and evidence of relevant experience and other information to support the request. The request will be reviewed by the Principal Investigator in consultation with the POPVAC Steering Committee, with oversight from the UVRI and LSHTM ethics committees. In line with the MRC policy on Data Sharing, there will have to be a good reason for turning down a request. Patient Information Sheets and consent forms specifically referenced making anonymised data available and this has been approved by the relevant ethics committees. Researchers given access to the data will sign data sharing agreements which will restrict the use to answering pre-specified research questions.",Yes,False,          ,2019,,Unknown,Yes
NCT03910972,8 September 2025,Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults,"A Phase I/II Study of the Safety, Immunogenicity, and Efficacy of Sm-TSP-2/Alhydrogel® With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Ugandan Adults",,Baylor College of Medicine,2019-04-09,20190409,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03910972,Not recruiting,No,18 Years,45 Years,All,07/10/2019,290.0,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 1/Phase 2,Uganda, ,"Hannah Kibuuka, MD",,,,Makerere University Walter Reed Project,"Inclusion Criteria:<br><br> 1. Provide written informed consent prior to any study procedures.<br><br> 2. Able to understand and comply with planned study procedures and be available for all<br>   study visits.<br><br> 3. Male or non-pregnant female aged 18 to 45, inclusive at the time of enrollment.<br><br> 4. Are in good health, as determined by vital signs (oral temperature, pulse, and blood<br>   pressure), medical history, and brief physical examination at screening.<br><br> 5. Vital signs (oral temperature, pulse, and blood pressure) are all within normal<br>   protocol-defined ranges.<br><br> 6. Laboratory tests (alanine aminotransferase [ALT], creatinine, white blood cell count<br>   (WBC), hemoglobin, and platelets) are all within protocol-defined reference ranges.<br><br> 7. Urinalysis with no greater than trace protein and negative for glucose.<br><br> 8. Female subjects of childbearing potential must agree to practice highly effective<br>   contraception for a minimum of 30 days prior to first vaccination and for 30 days<br>   after last vaccination.<br><br> 9. Female subjects of childbearing potential must have a negative urine pregnancy test<br>   within 24 hours prior to study vaccination.<br><br> 10. Able to correctly answer all questions on the informed consent comprehension<br>   questionnaire.<br><br>Exclusion Criteria:<br><br> 1. Has the intention to become pregnant within 5 months after enrollment in this study.<br><br> 2. Female subjects who are breastfeeding or plan to breastfeed at any given time from<br>   the first study vaccination until 30 days after their last study vaccination.<br><br> 3. Has an acute illness, including a documented oral temperature of 38.0°C or greater,<br>   within 72 hours prior to vaccination.<br><br> 4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,<br>   rheumatologic, autoimmune, diabetes, or renal disease by history, physical<br>   examination, and/or laboratory studies.<br><br> 5. Is immunosuppressed as a result of an underlying illness or treatment.<br><br> 6. Using or intends to continue using oral or parenteral steroids, high-dose inhaled<br>   steroids (>800 µg/day of beclomethasone dipropionate or equivalent) or other<br>   immunosuppressive or cytotoxic drugs.<br><br> 7. Positive test for HIV infection.<br><br> 8. Volunteer has had a history of alcohol or illicit drug abuse during the past 23<br>   months.<br><br> 9. Received immunoglobulin or other blood products (with exception of Rho D<br>   immunoglobulin) within 90 days prior to study vaccination.<br><br> 10. History of a severe allergic reaction or anaphylaxis to known components of the<br>   study vaccines.<br><br> 11. Has an acute or chronic medical condition that, in the opinion of the investigator,<br>   would render participation in this study unsafe or would interfere with the<br>   evaluation of responses.<br><br> 12. History of splenectomy.<br><br> 13. Is participating or plans to participate in another clinical trial with an<br>   interventional agent during the duration of the study.<br><br> 14. Received any licensed live vaccine within 30 days or any licensed inactivated<br>   vaccine within 14 days prior to the first study vaccination.<br><br> 15. Planned receipt of any vaccine from the first study vaccination through 28 days<br>   after the last study vaccination.<br><br> 16. Has any diagnosis, current or past, of schizophrenia, bipolar disease, or other<br>   psychiatric diagnosis that may interfere with subject compliance or safety<br>   evaluations.<br><br> 17. Has any condition that would, in the opinion of the site investigator, place the<br>   subject at an unacceptable risk of injury or render the subject unable to meet the<br>   requirements of the protocol.<br><br> 18. Anti-Sm-TSP-2 IgE antibody level above ELISA reactivity threshold.<br><br>   Part A Only:<br><br> 19. Positive hepatitis B surface antigen (HBsAg).<br><br> 20. Positive confirmatory test for hepatitis C virus (HCV) infection.<br><br>   Part B Only:<br><br> 21. Negative for Schistosoma mansoni eggs, as assessed by the Kato Katz fecal thick<br>   smear during screening.",,Schistosomiasis;Schistosoma Mansoni,Biological: Sm-TSP-2/Alhydrogel® vaccine;Biological: Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701;Biological: ENGERIX-B Hepatitis B Vaccine,Safety and Tolerability: frequency of local and systemic reactogenicity events;Safety and Tolerability: frequency of unsolicited adverse events;Safety and Tolerability: frequency of vaccine-related Serious Adverse Events;Safety and Tolerability: frequency of clinical safety laboratory adverse events;Safety and Tolerability: frequency of new-onset chronic medical conditions;Efficacy: proportion of subjects with detectable S. mansoni eggs;Efficacy: mean S. mansoni eggs per gram of feces;Efficacy: Proportion of subjects with a positive CAA test,Immunogenicity: peak anti-Sm-TSP-2 IgG level;Immunogenicity: anti-Sm-TSP-2 IgG levels over time,TSP-18-03;H-45791,Please refer to primary and secondary sponsors,George Washington University;Makerere University Walter Reed Project,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2019,18.0,No,Yes
NCT03779347,10 August 2021,Schistosomiasis Diagnosis Using a CAA Antigen Test,"Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon",FreebiLyGAB,Centre de Recherche Médicale de Lambaréné,2018-12-08,20181208,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03779347,Recruiting,No,,,Female,01/05/2019,100.0,Interventional,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Diagnostic. Masking: Double (Investigator, Outcomes Assessor). ",Phase 3,Gabon, ; ; ,"Ayola A ADEGNIKA, MD, PhD;Andrea Kreidenweiss, PhD;Ayola A ADEGNIKA, MD, PhD",,;;aadegnika@cermel.org,;;+24106244472,Centre de Recherches Médicales de Lambaréné (CERMEL);University Hospital Tuebingen;,<br>    Inclusion Criteria:<br><br>     - Pregnant women with a gestational age comprised between 16 and 30 weeks (based on last<br>       date of menses)<br><br>     - Willing to deliver in one of the four maternities: three in Lambaréné and one in<br>       Fougamou<br><br>     - Provide a written informed consent for both themselves and for newborn follow-up or<br>       the written informed consent by the legal guardian if pregnant woman is a minor<br><br>    Exclusion Criteria:<br><br>     - - Willing to move out of the study area within the coming 24 months<br><br>     - Known having a medically confirmed complicated pregnancy a complicated pregnancy.<br>   ,,Schistosomiasis Hematobium;Diagnostic;Drug Reaction;Pregnancy,Drug: Praziquantel;Diagnostic Test: UCP-LF CAA;Diagnostic Test: composite diagnostic,UPC-LF CAA performance;Egg reduction rate;CAA reduction rate;Prevalence of S. hematobium in children using UCP-LF CAA;Prevalence of S. hematobium in children using microscopy,Clinical safety assessment upon PZQ intake;Efficacy rate using microscopy;Efficacy rate using UCP-LF CAA test,FreebiLyGAB,Please refer to primary and secondary sponsors,Universität Tübingen,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2018,,Unknown,Yes
NCT03458338,12 December 2020,Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa,CKD Prevalence and the Role of Cardiovascular Risk Factors and Infectious Diseases in a Region of Sub-Saharan Africa,RenalOne,"University Hospital, Basel, Switzerland",2018-03-01,20180301,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03458338,Not recruiting,No,18 Years,100 Years,All,08/12/2010,1006.0,Observational,,Unknown,Switzerland, ,"Michael Mayr, MD",,,,"University Hospital Basel, Basel",<br>    Inclusion Criteria:<br><br>     - =18 years<br><br>    Exclusion Criteria:<br><br>     - pregnant<br><br>     - not able or willing to provide an informed signed consent<br>   ,,Chronic Kidney Diseases;Diabetes Mellitus;Hypertension;Tuberculosis;Schistosomiasis;HIV Infections,Diagnostic Test: estimated glomerular filtration rate and albuminuria,Point prevalence of chronic kidney disease measured by lab values,Risk factors for chronic kidney disease measured by lab values and questionnaire,RenalOne,Please refer to primary and secondary sponsors,Swiss Tropical & Public Health Institute;Ifakara Health Institute,,,,,,,Unknown,,,,,,,,,,No,,No,False,          ,2018,18.0,No,Yes
NCT03158298,25 April 2022,Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas,Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas,Bilharzia,Jena University Hospital,2017-05-16,20170516,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03158298,Not recruiting,No,18 Years,,Female,01/06/2017,82.0,Observational,,Unknown,Germany, ,"Benjamin Schleenvoigt, M.D.",,,,"Center for Infectious Diseases and Infection Control, Jena University Hospital",<br>    Inclusion Criteria:<br><br>     - Pregnancy<br><br>     - Immigration from a country/geographic area with declared endemic schistosomiasis<br>       according to World Health Organization criteria<br><br>     - Signed informed consent<br><br>    Exclusion Criteria:<br><br>     - Placenta pathology of any cause<br><br>     - Any medical condition affecting fetal growth<br>   ,,Schistosomiasis,Other: Specimen collection,Schistosoma Serology,Birth Weight;Preterm Birth;Intrauterine Growth Restriction;Stillbirth,ZKS0094,Please refer to primary and secondary sponsors,"Technische Universität München;Charite University, Berlin, Germany;University Hospital in Halle",,,,,,,Yes,14/04/2022,https://clinicaltrials.gov/ct2/show/results/NCT03158298,,,,,,,,,,Yes,False,          ,2017,18.0,No,Yes
NCT03110757,8 February 2021,"A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults","A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults",,National Institute of Allergy and Infectious Diseases (NIAID),2017-03-21,20170321,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03110757,Not recruiting,No,18 Years,50 Years,All,20/05/2018,60.0,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). ",Phase 1,Brazil,,,,,,,"<br>    Inclusion Criteria:<br><br>     1. Provide written informed consent prior to any study procedures.<br><br>     2. Able to understand and comply with planned study procedures and be available for all<br>       study visits.<br><br>     3. Male or non-pregnant female aged 18 to 50, inclusive at the time of enrollment.<br><br>     4. Are in good health, as determined by vital signs (oral temperature, pulse, and blood<br>       pressure), medical history, and brief physical examination at screening.<br><br>       -Existing medical diagnoses or conditions (except those in the Subject Exclusion<br>       Criteria) must be deemed as stable chronic medical conditions. A stable chronic<br>       medical condition is defined as no change in prescription medication, dose, or<br>       frequency of medication in the last 3 months (90 days) and health outcomes of the<br>       specific disease are considered to be within acceptable limits in the last 6 months<br>       (180 days). Any change due to change of health care provider, or that is done for<br>       financial reasons, as long as in the same class of medication, will not be considered<br>       a violation of this inclusion criterion. Any change in prescription medication due to<br>       improvement of a disease outcome, as determined by the site principal investigator or<br>       appropriate sub-investigator, will not be considered a violation of this inclusion<br>       criterion. Subjects may be on chronic or as needed medications if, in the opinion of<br>       the site principal investigator or appropriate sub-investigator, they pose no<br>       additional risk to subject safety or assessment of reactogenicity and immunogenicity.<br>       Topical, nasal, and inhaled medications (with the exception of corticosteroids as<br>       outlined in the Subjects Exclusion Criteria), vitamins, and contraceptives are<br>       permitted.<br><br>     5. Vital signs (oral temperature, pulse, and blood pressure) are all within normal<br>       protocol-defined ranges.<br><br>       -The normal protocol-defined ranges for vital signs include (a) oral temperature less<br>       than 38.0 degrees celsius, (b) pulse 50 to 100 bpm, inclusive, (c) systolic blood<br>       pressure 85 to 150 mmHg, inclusive, and (d) diastolic blood pressure 55 to 90 mmHg,<br>       inclusive. Pulse rate <50 is acceptable for 2nd and 3rd vaccinations if the subject is<br>       otherwise healthy with documented sinus bradycardia at baseline.<br><br>     6. Laboratory tests (alanine aminotransferase, creatinine, white blood cell count,<br>       hemoglobin, and platelets) are all within protocol-defined reference ranges.<br><br>       -The protocol-defined ranges for laboratory tests include (a) alanine aminotransferase<br>       (ALT) of less than 1.25-times the upper reference limit, (b) creatinine less than 1.25<br>       times the upper reference limit (c) white blood cells (WBC) between 3.3 x10^3/uL and<br>       10.4 x10^3/uL, inclusive, (d) hemoglobin 11.4 g/dL or greater for females or 12.1 g/dL<br>       or greater for males, (e) platelets greater than 130 x10^3/uL. Laboratory test results<br>       for 2nd and 3rd vaccinations may be at Grade 1 if considered unrelated to study<br>       product.<br><br>     7. Urinalysis with no greater than trace protein and negative for glucose.<br><br>     8. Female subjects of childbearing potential must agree to practice highly effective<br>       contraception for a minimum of 30 days prior to study product exposure and for 30 days<br>       after last vaccination.<br><br>        - Female subjects who are surgically sterile via tubal sterilization, bilateral<br>         oophorectomy or hysterectomy or who have been postmenopausal for greater than 1<br>         year are not considered to be of childbearing potential.<br><br>        - Highly effective methods of contraception are defined as having low failure rates<br>         (i.e. less than 1% per year) when used consistently and correctly and may<br>         include, but are not limited to, abstinence from intercourse with a male partner,<br>         monogamous relationship with a vasectomized partner, male condoms or diaphragm<br>         with spermicide, intrauterine devices, and licensed hormonal methods.<br><br>     9. Female subjects of childbearing potential must have a negative urine or serum<br>       pregnancy test within 24 hours prior to study vaccination.<br><br>     10. Able to correctly answer all questions on the informed consent comprehension<br>       questionnaire.<br><br>    Exclusion Criteria:<br><br>     1. Has the intention to become pregnant within 5 months after enrollment in this study.<br><br>     2. Female subjects who are breastfeeding or plan to breastfeed at any given time from the<br>       first study vaccination until 30 days after their last study vaccination.<br><br>     3. Has an acute illness, including a documented oral temperature of 38.0 degrees celsius<br>       or greater, within 72 hours prior to vaccination.<br><br>     4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,<br>       rheumatologic, autoimmune, diabetes, or renal disease by history, physical<br>       examination, and/or laboratory studies.<br><br>     5. Is immunosuppressed as a result of an underlying illness or treatment.<br><br>       -Causes for immunosuppression may include, but are not limited to, poorly-controlled<br>       diabetes mellitus, cirrhosis, renal insufficiency, active neoplastic disease or a<br>       history of any hematologic malignancy, connective tissue disease, organ transplant.<br><br>     6. Using or intends to continue using oral or parenteral steroids, high-dose inhaled<br>       steroids (>800 µg/day of beclomethasone dipropionate or equivalent) or other<br>       immunosuppressive or cytotoxic drugs.<br><br>     7. Positive hepatitis B surface antigen (HBsAg)<br><br>     8. Positive confirmatory test for HIV infection<br><br>     9. Positive confirmatory test for hepatitis C virus (HCV) infection<br><br>     10. Volunteer has had a history of alcohol or illicit drug abuse during the past 24<br>       months.<br><br>     11. Received immunoglobulin or other blood products (with exception of Rho D<br>       immunoglobulin) within 90 days prior to study vaccination.<br><br>     12. History of a severe allergic reaction or anaphylaxis to known components of the study<br>       vaccines.<br><br>     13. Has an acute or chronic medical condition that, in the opinion of the investigator,<br>       would render participation in this study unsafe or would interfere with the evaluation<br>       of responses.<br><br>       -This includes, but is not limited to: known liver disease, renal disease,<br>       neurological disorders, visual field defects, cardiac disorders, pulmonary disorders,<br>       diabetes mellitus, and transplant recipients.<br><br>     14. History of splenectomy<br><br>     15. Is participating or plans to participate in another clinical trial with an<br>       interventional agent during the duration of the study.<br><br>       -This may include other licensed or unlicensed vaccines, drugs, biologics, devices,<br>       blood products, or medications.<br><br>     16. Received any licensed live vacc",,Schistosomiasis,Biological: GLA-AF;Biological: Hepatitis B Virus Vaccine (Recombinant);Biological: Sm-TSP-2/Alhydrogel,The occurrence of new-onset chronic medical conditions (including AESI);The occurrence of solicited injection site reactogenicity;The occurrence of solicited injection site reactogenicity;The occurrence of solicited injection site reactogenicity;The occurrence of solicited systemic reactogenicity;The occurrence of solicited systemic reactogenicity;The occurrence of solicited systemic reactogenicity;The occurrence of study vaccine-related SAEs;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of vaccine-related clinical safety laboratory adverse events,The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG antibody response using an indirect ELISA;The anti-Sm-TSP-2 IgG level using an indirect ELISA,HHSN272201300015I;14-0100,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2017,18.0,No,Yes
NCT02878564,7 November 2016,Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology,Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology,,University of Toronto,2016-08-15,20160815,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02878564,Not recruiting,No,18 Years,45 Years,Female,01/03/2016,34.0,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science",Phase 4,Uganda, ,"Rupert Kaul, MD/PhD",,,,University of Toronto,"<br>    Inclusion Criteria:<br><br>     - Positive (score above """"trace"""") on a urine CCA rapid test<br><br>     - Willing to be treated with praziquantel<br><br>     - Willing to give informed consent, and answer short questionnaires on economic status,<br>       and sexual risk behavior.<br><br>     - Willing to comply with the requirements of the protocol<br><br>     - HIV and classical STI (see below) negative<br><br>    Exclusion Criteria:<br><br>     - HIV infected<br><br>     - Malaria infected<br><br>     - Pregnant.<br><br>     - Irregular menstrual cycle, or actively menstruating at the time of genital sampling.<br><br>     - Tested positive for classical STIs (syphilis, gonorrhea, chlamydia, Trichomonas<br>       vaginalis) or having genital ulcers<br><br>     - Prior hysterectomy<br><br>     - Deemed by physician to be unlikely to complete study protocol.<br>   ",,Schistosomiasis Mansoni;HIV,Drug: Praziquantel,Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.;Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.,Change in the percentage of blood CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.;Change in the phenotype of endocervical and blood CD4+ T cells after treatment of schistosomiasis.;Change in genital proinflammatory cytokine levels after treatment of schistosomiasis.;Change in the cervico-vaginal microbiome after treatment of schistosomiasis.;Change in the cervico-vaginal proteome after treatment of schistosomiasis.;Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.;Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.,UT-Schisto,Please refer to primary and secondary sponsors,"UVRI-IAVI HIV Vaccine Program, Uganda",,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2016,18.0,No,Yes
NCT02755324,12 December 2020,Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding,Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding,,Leiden University,2016-04-25,20160425,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02755324,Not recruiting,No,18 Years,45 Years,All,27/10/2016,17.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ,Unknown,Netherlands, ,Meta Roestenberg,,,,LUMC,"<br>    Inclusion Criteria:<br><br>     1. Subject is aged = 18 and = 45 years and in good health.<br><br>     2. Subject has adequate understanding of the procedures of the study and agrees to abide<br>       strictly thereby.<br><br>     3. Subject is able to communicate well with the investigator, is available to attend all<br>       study visits.<br><br>     4. Subject will remain within Europe (excluding Corsica) during the study period and is<br>       reachable by mobile telephone from week 3 to week 12 of the study period.<br><br>     5. Subject agrees to refrain from blood donation throughout the study period.<br><br>     6. For female subjects: subject agrees to use adequate contraception and not to<br>       breastfeed for the duration of study.<br><br>     7. Subject has signed informed consent.<br><br>    Exclusion Criteria:<br><br>     1. Any history, or evidence at screening, of clinically significant symptoms, physical<br>       signs or abnormal laboratory values suggestive of systemic conditions, such as<br>       cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,<br>       malignant, haematological, infectious, immune-deficient, psychiatric and other<br>       disorders, which could compromise the health of the volunteer during the study or<br>       interfere with the interpretation of the study results. These include, but are not<br>       limited to, any of the following:<br><br>        - body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;<br><br>        - positive HIV, hepatitis B or hepatitis C screening tests;<br><br>        - the use of immune modifying drugs within three months prior to study onset<br>         (inhaled and topical corticosteroids and oral anti-histamines exempted) or<br>         expected use of such during the study period;<br><br>        - history of malignancy of any organ system (other than localized basal cell<br>         carcinoma of the skin), treated or untreated, within the past 5 years;<br><br>        - any history of treatment for severe psychiatric disease by a psychiatrist in the<br>         past year;<br><br>        - history of drug or alcohol abuse interfering with normal social function in the<br>         period of one year prior to study onset.<br><br>        - Any clinically significant abnormalities (including extended QT interval) on<br>         electrocardiogram<br><br>     2. The chronic use of any drug known to interact with praziquantel, or artesunate or<br>       lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon,<br>       dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,<br>       amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics,<br>       antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics,<br>       antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of<br>       drugs with effect on QT interval are excluded from the study.<br><br>     3. For female subjects: positive urine pregnancy test at screening.<br><br>     4. Any history of schistosomiasis or treatment for schistosomiasis.<br><br>     5. Positive serology for schistosomiasis or elevated serum or urine circulating anodic<br>       antigen or positive Schistosoma serology at baseline.<br><br>     6. Known hypersensitivity to or contra-indications (including co-medication) for use of<br>       praziquantel or, artesunate or lumefantrine.<br><br>     7. Being an employee or student of the department of parasitology or infectious diseases<br>       of the Leiden University Medical Center.<br>   ",,Schistosomiasis;Schistosoma Mansoni,Biological: male Schistosoma mansoni cercariae,"Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae.;The number of male cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen (CAA).",Average number of weeks until positive serum circulating anodic antigen test;Comparison of the height of the peak serum circulating anodic antigen concentration in low dose compared with high dose group;Comparison of the humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals;Differences in in ex vivo lymphocyte profiles between infected and uninfected individuals,CoHSI1,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,Undecided,,Yes,False,parent    ,2016,18.0,No,Yes
NCT02337855,16 December 2017,"A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults","A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults",,National Institute of Allergy and Infectious Diseases (NIAID),2015-01-08,20150108,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02337855,Not recruiting,No,18 Years,50 Years,All,04/02/2015,72.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). ",Phase 1,United States;United States;United States;United States;United States,,,,,,,"<br>    Inclusion Criteria:<br><br>    Subjects must meet all of the following inclusion criteria in order to be eligible for<br>    participation in this study. 1. Provide written informed consent prior to any study<br>    procedures. 2. Able to understand and comply with planned study procedures and be available<br>    for all study visits. 3. Male or non-pregnant female aged 18 to 50, inclusive. 4. Are in<br>    good health, as determined by vital signs (oral temperature, pulse, and blood pressure),<br>    medical history, and targeted physical examination based on medical history.1 Existing<br>    medical diagnoses or conditions (except those in the Subject Exclusion Criteria) must be<br>    deemed as stable chronic medical conditions. A stable chronic medical condition is defined<br>    as no change in prescription medication, dose, or frequency of medication in the last 3<br>    months (90 days) and health outcomes of the specific disease are considered to be within<br>    acceptable limits in the last 6 months (180 days). Any change due to change of health care<br>    provider, insurance company, or that is done for financial reasons, as long as in the same<br>    class of medication, will not be considered a violation of this inclusion criterion. Any<br>    change in prescription medication due to improvement of a disease outcome, as determined by<br>    the site principal investigator or appropriate sub-investigator, will not be considered a<br>    violation of this inclusion criterion. Subjects may be on chronic or as needed (prn)<br>    medications if, in the opinion of the site principal investigator or appropriate<br>    sub-investigator, they pose no additional risk to subject safety or assessment of<br>    reactogenicity and immunogenicity. Topical, nasal, and inhaled medications (with the<br>    exception of steroids as outlined in the Subjects Exclusion Criteria), vitamins, and<br>    contraceptives are permitted. 5. Vital signs (oral temperature, pulse, and blood pressure)<br>    are all within normal protocol-defined ranges. Note: The normal protocol-defined ranges for<br>    vital signs include (a) oral temperature less than 100.0°F, (b) pulse 50 to 100 bpm,<br>    inclusive, (c) systolic blood pressure 85 to 150 mmHg, inclusive, and (d) diastolic blood<br>    pressure 55 to 90 mmHg, inclusive. 6. Laboratory tests (alanine aminotransferase,<br>    creatinine, white blood cells, hemoglobin, and platelets) are all within normal<br>    protocol-defined reference ranges.33 The normal protocol-defined ranges for laboratory<br>    tests include (a) alanine aminotransferase (ALT) of 32 IU/L or less for females or 44 IU/L<br>    or less for males, (b) creatinine 1.0 mg/dL or less for females or 1.27 mg/dL or less for<br>    males, (c) white blood cells (WBC) between 3.4 x10^3/uL and 10.8 x10^3/uL, inclusive, (d)<br>    hemoglobin 11.1 g/dL or greater for females or 12.6 g/dL or greater for males, (e)<br>    platelets between 150 x10^3/uL and 379 x10^3/uL, inclusive. Laboratory test results for 2nd<br>    and 3rd vaccinations may be at Grade 1 if considered unrelated to study product. 7.<br>    Urinalysis with no greater than trace protein and negative for glucose. 8. Female subjects<br>    of childbearing potential4 must agree to practice highly effective contraception5 for a<br>    minimum of 30 days prior to study product exposure and through 30 days after last<br>    vaccination.4 Female subjects who are surgically sterile via tubal sterilization, bilateral<br>    oophorectomy or hysterectomy or who have been postmenopausal for greater than 1 year are<br>    not considered to be of childbearing potential.5 Note: Highly effective methods of<br>    contraception are defined as having low failure rates (i.e. less than 1% per year) when<br>    used consistently and correctly and may include, but are not limited to, abstinence from<br>    intercourse with a male partner, monogamous relationship with a vasectomized partner, mal e<br>    condoms or diaphragm with spermicide, intrauterine devices, and licensed hormonal methods.<br>    9. Female subjects of childbearing potential must have a negative urine pregnancy test<br>    within 24 hours prior to study vaccination.<br><br>    Exclusion Criteria:<br><br>    All subjects who meet any of the following exclusion criteria at baseline will be excluded<br>    from participation in the study. 1. Has had known infection due to S. mansoni or has<br>    traveled to an endemic area for S. mansoni infection and, during that travel, was<br>    potentially exposed to S. mansoni. 2. Has a positive urine pregnancy test prior to<br>    vaccination (if female of childbearing potential), or has the intention to become pregnant<br>    within 5 months after enrollment in this study. 3. Female subjects who are breastfeeding or<br>    plan to breastfeed at any given time from the first study vaccination until 30 days after<br>    their last study vaccination. 4. Has an acute illness, including an oral temperature of<br>    100.0 degree F or greater, within 72 hours prior to vaccination. 5. Evidence of clinically<br>    significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes,<br>    or renal disease by history, physical examination, and/or laboratory studies. 6.6 Includes<br>    the conditions and diagnoses defined as AESI in Section 9.3.3. 6. Is immunosuppressed as a<br>    result of an underlying illness or treatment.7.7 Causes for immunosuppression may include,<br>    but are not limited to, poorly-controlled diabetes mellitus, cirrhosis, renal<br>    insufficiency, active neoplastic disease or a history of any hematologic malignancy,<br>    connective tissue disease, organ transplant. 7. Using or intends to continue using oral or<br>    parenteral steroids, high-dose inhaled steroids(> 800 microg/day of beclomethasone<br>    dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs. 8. Positive<br>    hepatitis B surface antigen (HBsAg) 9. Positive confirmatory test for HIV infection 10.<br>    Positive confirmatory test for hepatitis C virus (HCV) infection 11. Volunteer has had a<br>    history of alcohol or illicit drug abuse during the past 24 months. 12. Received<br>    immunoglobulin or other blood products (with exception of Rho D immunoglobulin) within 90<br>    days prior to study vaccination. 13. History of a severe allergic reaction or anaphylaxis<br>    to known components of the vaccine 14. Has an acute or chronic medical condition that, in<br>    the opinion of the investigator, would render participation in this study unsafe or would<br>    interfere with the evaluation of responses. Note: This includes, but is not limited to:<br>    known liver disease, renal disease, neurological disorders, visual field defects, cardiac<br>    disorders, pulmonary disorders, diabetes mellitus, and transplant recipients. 15. History<br>    of splenectomy 16. Plans to undergo surgery (elective or otherwise) from the time of<br>    enrollment through 1 month post dose 3 vaccination. 17. Is participating or plans to<br>    participate in another clinical trial with an interventional agent9 during the duration of<br>    the study. Note: This may include other licensed or unlicensed vaccines, drugs, biologics,<br>    devices, blood products, or medications. 18.Received any licensed live vaccine within 30<br>    days or any licensed inactivated vaccine within 14 days prior to the first study<br>    vaccination. Note: During influenza season, subjects will be of;<br>    Inclusion Criteria:<br><br>    Subjects must meet all of the following inclusion criteria in order to be eligible for<br>    participation in this study. 1. Provide written informed consent prior to any study<br>    procedures. 2. Able to understand and comply with planned study procedures and be available<br>    for all study visits. 3. Male or non-pregnant female aged 18 to 50, inclusive. 4. Are in<br>    good health, as determined by vital signs (oral temperature, pulse, and blood pressure),<br>    medical history, and targeted physical examination based on medical history.1 Existing<br>    medical diagnoses or conditions (except those in the Subject Exclusion Criteria) must be<br>    deemed as stable chronic medical conditions. A stable chronic medical condition is defined<br>    as no change in prescription medication, dose, or frequency of medication in the last 3<br>    months (90 days) and health outcomes of the specific disease are considered to be within<br>    acceptable limits in the last 6 months (180 days). Any change due to change of health care<br>    provider, insurance company, or that is done for financial reasons, as long as in the same<br>    class of medication, will not be considered a violation of this inclusion criterion. Any<br>    change in prescription medication due to improvement of a disease outcome, as determined by<br>    the site principal investigator or appropriate sub-investigator, will not be considered a<br>    violation of this inclusion criterion. Subjects may be on chronic or as needed (prn)<br>    medications if, in the opinion of the site principal investigator or appropriate<br>    sub-investigator, they pose no additional risk to subject safety or assessment of<br>    reactogenicity and immunogenicity. Topical, nasal, and inhaled medications (with the<br>    exception of steroids as outlined in the Subjects Exclusion Criteria), vitamins, and<br>    contraceptives are permitted. 5. Vital signs (oral temperature, pulse, and blood pressure)<br>    are all within normal protocol-defined ranges. Note: The normal protocol-defined ranges for<br>    vital signs include (a) oral temperature less than 100.0°F, (b) pulse 50 to 100 bpm,<br>    inclusive, (c) systolic blood pressure 85 to 150 mmHg, inclusive, and (d) diastolic blood<br>    pressure 55 to 90 mmHg, inclusive. 6. Laboratory tests (alanine aminotransferase,<br>    creatinine, white blood cells, hemoglobin, and platelets) are all within normal<br>    protocol-defined reference ranges.33 The normal protocol-defined ranges for laboratory<br>    tests include (a) alanine aminotransferase (ALT) of 32 IU/L or less for females or 44 IU/L<br>    or less for males, (b) creatinine 1.0 mg/dL or less for females or 1.27 mg/dL or less for<br>    males, (c) white blood cells (WBC) between 3.4 x10^3/uL and 10.8 x10^3/uL, inclusive, (d)<br>    hemoglobin 11.1 g/dL or greater for females or 12.6 g/dL or greater for males, (e)<br>    platelets between 150 x10^3/uL and 379 x10^3/uL, inclusive. Laboratory test results for 2nd<br>    and 3rd vaccinations may be at Grade 1 if considered unrelated to study product. 7.<br>    Urinalysis with no greater than trace protein and negative for glucose. 8. Female subjects<br>    of childbearing potential4 must agree to practice highly effective contraception5 for a<br>    minimum of 30 days prior to study product exposure and through 30 days after last<br>    vaccination.4 Female subjects who are surgically sterile via tubal sterilization, bilateral<br>    oophorectomy or hysterectomy or who have been postmenopausal for greater than 1 year are<br>    not considered to be of childbearing potential.5 Note: Highly effective methods of<br>    contraception are defined as having low failure rates (i.e. less than 1% per year) when<br>    used consistently and correctly and may include, but are not limited to, abstinence from<br>    intercourse with a male partner, monogamous relationship with a vasectomized partner, mal e<br>    condoms or diaphragm with spermicide, intrauterine devices, and licensed hormonal methods.<br>    9. Female subjects of childbearing potential must have a negative urine pregnancy test<br>    within 24 hours prior to study vaccination.<br><br>    Exclusion Criteria:<br><br>    All subjects who meet any of the following exclusion criteria at baseline will be excluded<br>    from participation in the study. 1. Has had known infection due to S. mansoni or has<br>    traveled to an endemic area for S. mansoni infection and, during that travel, was<br>    potentially exposed to S. mansoni. 2. Has a positive urine pregnancy test prior to<br>    vaccination (if female of childbearing potential), or has the intention to become pregnant<br>    within 5 months after enrollment in this study. 3. Female subjects who are breastfeeding or<br>    plan to breastfeed at any given time from the first study vaccination until 30 days after<br>    their last study vaccination. 4. Has an acute illness, including an oral temperature of<br>    100.0 degree F or greater, within 72 hours prior to vaccination. 5. Evidence of clinically<br>    significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes,<br>    or renal disease by history, physical examination, and/or laboratory studies. 6.6 Includes<br>    the conditions and diagnoses defined as AESI in Section 9.3.3. 6. Is immunosuppressed as a<br>    result of an underlying illness or treatment.7.7 Causes for immunosuppression may include,<br>    but are not limited to, poorly-controlled diabetes mellitus, cirrhosis, renal<br>    insufficiency, active neoplastic disease or a history of any hematologic malignancy,<br>    connective tissue disease, organ transplant. 7. Using or intends to continue using oral or<br>    parenteral steroids, high-dose inhaled steroids(> 800 microg/day of beclomethasone<br>    dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs. 8. Positive<br>    hepatitis B surface antigen (HBsAg) 9. Positive confirmatory test for HIV infection 10.<br>    Positive confirmatory test for hepatitis C virus (HCV) infection 11. Volunteer has had a<br>    history of alcohol or illicit drug abuse during the past 24 months. 12. Received<br>    immunoglobulin or other blood products (with exception of Rho D immunoglobulin) within 90<br>    days prior to study vaccination. 13. History of a severe allergic reaction or anaphylaxis<br>    to known components of the vaccine 14. Has an acute or chronic medical condition that, in<br>    the opinion of the investigator, would render participation in this study unsafe or would<br>    interfere with the evaluation of responses. Note: This includes, but is not limited to:<br>    known liver disease, renal disease, neurological disorders, visual field defects, cardiac<br>    disorders, pulmonary disorders, diabetes mellitus, and transplant recipients. 15. History<br>    of splenectomy 16. Plans to undergo surgery (elective or otherwise) from the time of<br>    enrollment through 1 month post dose 3 vaccination. 17. Is participating or plans to<br>    participate in another clinical trial with an interventional agent9 during the duration of<br>    the study. Note: This may include other licensed or unlicensed vaccines, drugs, biologics,<br>    devices, blood products, or medications. 18.Received any licensed live vaccine within 30<br>    days or any licensed inactivated vaccine within 14 days prior to the first study<br>    vaccination. Note: During influenza season, subjects will be of;<br>    Inclusion Criteria:<br><br>    Subjects must meet all of the following inclusion criteria in order to be eligible for<br>    participation in this study. 1. Provide written informed consent prior to any study<br>    procedures. 2. Able to understand and comply with planned study procedures and be available<br>    for all study visits. 3. Male or non-pregnant female aged 18 to 50, inclusive. 4. Are in<br>    good health, as determined by vital signs (oral temperature, pulse, and blood pressure),<br>    medical history, and targeted physical examination based on medical history.1 Existing<br>    medical diagnoses or conditions (except those in the Subject Exclusion Criteria) must be<br>    deemed as stable chronic medical conditions. A stable chronic medical condition is defined<br>    as no change in prescription medication, dose, or frequency of medication in the last 3<br>    months (90 days) and health outcomes of the specific disease are considered to be within<br>    acceptable limits in the last 6 months (180 days). Any change due to change of health care<br>    provider, insurance company, or that is done for financial reasons, as long as in the same<br>    class of medication, will not be considered a violation of this inclusion criterion. Any<br>    change in prescription medication due to improvement of a disease outcome, as determined by<br>    the site principal investigator or appropriate sub-investigator, will not be considered a<br>    violation of this inclusion criterion. Subjects may be on chronic or as needed (prn)<br>    medications if, in the opinion of the site principal investigator or appropriate<br>    sub-investigator, they pose no additional risk to subject safety or assessment of<br>    reactogenicity and immunogenicity. Topical, nasal, and inhaled medications (with the<br>    exception of steroids as outlined in the Subjects Exclusion Criteria), vitamins, and<br>    contraceptives are permitted. 5. Vital signs (oral temperature, pulse, and blood pressure)<br>    are all within normal protocol-defined ranges. Note: The normal protocol-defined ranges for<br>    vital signs include (a) oral temperature less than 100.0°F, (b) pulse 50 to 100 bpm,<br>    inclusive, (c) systolic blood pressure 85 to 150 mmHg, inclusive, and (d) diastolic blood<br>    pressure 55 to 90 mmHg, inclusive. 6. Laboratory tests (alanine aminotransferase,<br>    creatinine, white blood cells, hemoglobin, and platelets) are all within normal<br>    protocol-defined reference ranges.33 The normal protocol-defined ranges for laboratory<br>    tests include (a) alanine aminotransferase (ALT) of 32 IU/L or less for females or 44 IU/L<br>    or less for males, (b) creatinine 1.0 mg/dL or less for females or 1.27 mg/dL or less for<br>    males, (c) white blood cells (WBC) between 3.4 x10^3/uL and 10.8 x10^3/uL, inclusive, (d)<br>    hemoglobin 11.1 g/dL or greater for females or 12.6 g/dL or greater for males, (e)<br>    platelets between 150 x10^3/uL and 379 x10^3/uL, inclusive. Laboratory test results for 2nd<br>    and 3rd vaccinations may be at Grade 1 if considered unrelated to study product. 7.<br>    Urinalysis with no greater than trace protein and negative for glucose. 8. Female subjects<br>    of childbearing potential4 must agree to practice highly effective contraception5 for a<br>    minimum of 30 days prior to study product exposure and through 30 days after last<br>    vaccination.4 Female subjects who are surgically sterile via tubal sterilization, bilateral<br>    oophorectomy or hysterectomy or who have been postmenopausal for greater than 1 year are<br>    not considered to be of childbearing potential.5 Note: Highly effective methods of<br>    contraception are defined as having low failure rates (i.e. less than 1% per year) when<br>    used consistently and correctly and may include, but are not limited to, abstinence from<br>    intercourse with a male partner, monogamous relationship with a vasectomized partner, mal e<br>    condoms or diaphragm with spermicide, intrauterine devices, and licensed hormonal methods.<br>    9. Female subjects of childbearing potential must have a negative urine pregnancy test<br>    within 24 hours prior to study vaccination.<br><br>    Exclusion Criteria:<br><br>    All subjects who meet any of the following exclusion criteria at baseline will be excluded<br>    from participation in the study. 1. Has had known infection due to S. mansoni or has<br>    traveled to an endemic area for S. mansoni infection and, during that travel, was<br>    potentially exposed to S. mansoni. 2. Has a positive urine pregnancy test prior to<br>    vaccination (if female of childbearing potential), or has the intention to become pregnant<br>    within 5 months after enrollment in this study. 3. Female subjects who are breastfeeding or<br>    plan to breastfeed at any given time from the first study vaccination until 30 days after<br>    their last study vaccination. 4. Has an acute illness, including an oral temperature of<br>    100.0 degree F or greater, within 72 hours prior to vaccination. 5. Evidence of clinically<br>    significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes,<br>    or renal disease by history, physical examination, and/or laboratory studies. 6.6 Includes<br>    the conditions and diagnoses defined as AESI in Section 9.3.3. 6. Is immunosuppressed as a<br>    result of an underlying illness or treatment.7.7 Causes for immunosuppression may include,<br>    but are not limited to, poorly-controlled diabetes mellitus, cirrhosis, renal<br>    insufficiency, active neoplastic disease or a history of any hematologic malignancy,<br>    connective tissue disease, organ transplant. 7. Using or intends to continue using oral or<br>    parenteral steroids, high-dose inhaled steroids(> 800 microg/day of beclomethasone<br>    dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs. 8. Positive<br>    hepatitis B surface antigen (HBsAg) 9. Positive confirmatory test for HIV infection 10.<br>    Positive confirmatory test for hepatitis C virus (HCV) infection 11. Volunteer has had a<br>    history of alcohol or illicit drug abuse during the past 24 months. 12. Received<br>    immunoglobulin or other blood products (with exception of Rho D immunoglobulin) within 90<br>    days prior to study vaccination. 13. History of a severe allergic reaction or anaphylaxis<br>    to known components of the vaccine 14. Has an acute or chronic medical condition that, in<br>    the opinion of the investigator, would render participation in this study unsafe or would<br>    interfere with the evaluation of responses. Note: This includes, but is not limited to:<br>    known liver disease, renal disease, neurological disorders, visual field defects, cardiac<br>    disorders, pulmonary disorders, diabetes mellitus, and transplant recipients. 15. History<br>    of splenectomy 16. Plans to undergo surgery (elective or otherwise) from the time of<br>    enrollment through 1 month post dose 3 vaccination. 17. Is participating or plans to<br>    participate in another clinical trial with an interventional agent9 during the duration of<br>    the study. Note: This may include other licensed or unlicensed vaccines, drugs, biologics,<br>    devices, blood products, or medications. 18.Received any licensed live vaccine within 30<br>    days or any licensed inactivated vaccine within 14 days prior to the first study<br>    vaccination. Note: During influenza season, subjects will be of;<br>    Inclusion Criteria:<br><br>    Subjects must meet all of the following inclusion criteria in order to be eligible for<br>    participation in this study. 1. Provide written informed consent prior to any study<br>    procedures. 2. Able to understand and comply with planned study procedures and be available<br>    for all study visits. 3. Male or non-pregnant female aged 18 to 50, inclusive. 4. Are in<br>    good health, as determined by vital signs (oral temperature, pulse, and blood pressure),<br>    medical history, and targeted physical examination based on medical history.1 Existing<br>    medical diagnoses or conditions (except those in the Subject Exclusion Criteria) must be<br>    deemed as stable chronic medical conditions. A stable chronic medical condition is defined<br>    as no change in prescription medication, dose, or frequency of medication in the last 3<br>    months (90 days) and health outcomes of the specific disease are considered to be within<br>    acceptable limits in the last 6 months (180 days). Any change due to change of health care<br>    provider, insurance company, or that is done for financial reasons, as long as in the same<br>    class of medication, will not be considered a violation of this inclusion criterion. Any<br>    change in prescription medication due to improvement of a disease outcome, as determined by<br>    the site principal investigator or appropriate sub-investigator, will not be considered a<br>    violation of this inclusion criterion. Subjects may be on chronic or as needed (prn)<br>    medications if, in the opinion of the site principal investigator or appropriate<br>    sub-investigator, they pose no additional risk to subject safety or assessment of<br>    reactogenicity and immunogenicity. Topical, nasal, and inhaled medications (with the<br>    exception of steroids as outlined in the Subjects Exclusion Criteria), vitamins, and<br>    contraceptives are permitted. 5. Vital signs (oral temperature, pulse, and blood pressure)<br>    are all within normal protocol-defined ranges. Note: The normal protocol-defined ranges for<br>    vital signs include (a) oral temperature less than 100.0°F, (b) pulse 50 to 100 bpm,<br>    inclusive, (c) systolic blood pressure 85 to 150 mmHg, inclusive, and (d) diastolic blood<br>    pressure 55 to 90 mmHg, inclusive. 6. Laboratory tests (alanine aminotransferase,<br>    creatinine, white blood cells, hemoglobin, and platelets) are all within normal<br>    protocol-defined reference ranges.33 The normal protocol-defined ranges for laboratory<br>    tests include (a) alanine aminotransferase (ALT) of 32 IU/L or less for females or 44 IU/L<br>    or less for males, (b) creatinine 1.0 mg/dL or less for females or 1.27 mg/dL or less for<br>    males, (c) white blood cells (WBC) between 3.4 x10^3/uL and 10.8 x10^3/uL, inclusive, (d)<br>    hemoglobin 11.1 g/dL or greater for females or 12.6 g/dL or greater for males, (e)<br>    platelets between 150 x10^3/uL and 379 x10^3/uL, inclusive. Laboratory test results for 2nd<br>    and 3rd vaccinations may be at Grade 1 if considered unrelated to study product. 7.<br>    Urinalysis with no greater than trace protein and negative for glucose. 8. Female subjects<br>    of childbearing potential4 must agree to practice highly effective contraception5 for a<br>    minimum of 30 days prior to study product exposure and through 30 days after last<br>    vaccination.4 Female subjects who are surgically sterile via tubal sterilization, bilateral<br>    oophorectomy or hysterectomy or who have been postmenopausal for greater than 1 year are<br>    not considered to be of childbearing potential.5 Note: Highly effective methods of<br>    contraception are defined as having low failure rates (i.e. less than 1% per year) when<br>    used consistently and correctly and may include, but are not limited to, abstinence from<br>    intercourse with a male partner, monogamous relationship with a vasectomized partner, mal e<br>    condoms or diaphragm with spermicide, intrauterine devices, and licensed hormonal methods.<br>    9. Female subjects of childbearing potential must have a negative urine pregnancy test<br>    within 24 hours prior to study vaccination.<br><br>    Exclusion Criteria:<br><br>    All subjects who meet any of the following exclusion criteria at baseline will be excluded<br>    from participation in the study. 1. Has had known infection due to S. mansoni or has<br>    traveled to an endemic area for S. mansoni infection and, during that travel, was<br>    potentially exposed to S. mansoni. 2. Has a positive urine pregnancy test prior to<br>    vaccination (if female of childbearing potential), or has the intention to become pregnant<br>    within 5 months after enrollment in this study. 3. Female subjects who are breastfeeding or<br>    plan to breastfeed at any given time from the first study vaccination until 30 days after<br>    their last study vaccination. 4. Has an acute illness, including an oral temperature of<br>    100.0 degree F or greater, within 72 hours prior to vaccination. 5. Evidence of clinically<br>    significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes,<br>    or renal disease by history, physical examination, and/or laboratory studies. 6.6 Includes<br>    the conditions and diagnoses defined as AESI in Section 9.3.3. 6. Is immunosuppressed as a<br>    result of an underlying illness or treatment.7.7 Causes for immunosuppression may include,<br>    but are not limited to, poorly-controlled diabetes mellitus, cirrhosis, renal<br>    insufficiency, active neoplastic disease or a history of any hematologic malignancy,<br>    connective tissue disease, organ transplant. 7. Using or intends to continue using oral or<br>    parenteral steroids, high-dose inhaled steroids(> 800 microg/day of beclomethasone<br>    dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs. 8. Positive<br>    hepatitis B surface antigen (HBsAg) 9. Positive confirmatory test for HIV infection 10.<br>    Positive confirmatory test for hepatitis C virus (HCV) infection 11. Volunteer has had a<br>    history of alcohol or illicit drug abuse during the past 24 months. 12. Received<br>    immunoglobulin or other blood products (with exception of Rho D immunoglobulin) within 90<br>    days prior to study vaccination. 13. History of a severe allergic reaction or anaphylaxis<br>    to known components of the vaccine 14. Has an acute or chronic medical condition that, in<br>    the opinion of the investigator, would render participation in this study unsafe or would<br>    interfere with the evaluation of responses. Note: This includes, but is not limited to:<br>    known liver disease, renal disease, neurological disorders, visual field defects, cardiac<br>    disorders, pulmonary disorders, diabetes mellitus, and transplant recipients. 15. History<br>    of splenectomy 16. Plans to undergo surgery (elective or otherwise) from the time of<br>    enrollment through 1 month post dose 3 vaccination. 17. Is participating or plans to<br>    participate in another clinical trial with an interventional agent9 during the duration of<br>    the study. Note: This may include other licensed or unlicensed vaccines, drugs, biologics,<br>    devices, blood products, or medications. 18.Received any licensed live vaccine within 30<br>    days or any licensed inactivated vaccine within 14 days prior to the first study<br>    vaccination. Note: During influenza season, subjects will be of",,Schistosomiasis;Schistosomiasis;Schistosomiasis;Schistosomiasis,Other: Placebo;Biological: Sm-TSP-2/Alhydrogel;Biological: Sm-TSP-2/Alhydrogel/GLA-AF;Other: Placebo;Biological: Sm-TSP-2/Alhydrogel;Biological: Sm-TSP-2/Alhydrogel/GLA-AF;Other: Placebo;Biological: Sm-TSP-2/Alhydrogel;Biological: Sm-TSP-2/Alhydrogel/GLA-AF;Other: Placebo;Biological: Sm-TSP-2/Alhydrogel;Biological: Sm-TSP-2/Alhydrogel/GLA-AF,The occurrence of new-onset chronic medical conditions (including AESI) through 12 months after the third study vaccination.;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of study vaccine-related SAEs from the time of the first study vaccination through approximately 12 months after the last study vaccination;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of new-onset chronic medical conditions (including AESI) through 12 months after the third study vaccination.;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of study vaccine-related SAEs from the time of the first study vaccination through approximately 12 months after the last study vaccination;The occurrence of vaccine-related clinical safety laboratory adverse events;The occurrence of new-onset chronic medical conditions (including AESI) through 12 months after the third study vaccination.;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited injection site reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination;The occurrence of solicited systemic reactogenicity on the day of each study vaccination through 7 days after each study vaccination.;The occurrence of study vaccine-related SAEs from the time of the first study vaccination through approximately 12 months after the last study vaccination;The occurrence of vaccine-related clinical safety laboratory adverse events,"The IgG antibody response using an indirect enzyme-linked immunosorbent assay (ELISA) on the day of each dose, 14 days after each dose, and 3 and 6 months after the third dose of Sm-TSP-2/Alhydrogel (10ug, 30ug, or 100ug) with or without GLA-AF;The IgG level using an indirect enzyme-linked immunosorbent assay (ELISA) at Day 127",HHSN272200800002C;13-0009,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2015,18.0,No,Yes
ISRCTN48837681,24 October 2022,Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands),Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ,,Natural History Museum (UK),2012-09-05,20120905,10/13/2025 16:02:07,ISRCTN,https://www.isrctn.com/ISRCTN48837681,Not Recruiting,No,,,Both,01/11/2011,72000.0,Interventional,Randomised intervention trial with three study arms (Treatment),Not Applicable,Switzerland;Tanzania;United Kingdom;England,,,,,,,"Inclusion criteria: <br>        1. Schoolchildren, either male or female, aged 9-12 years, attending the selected schools (in each study year)<br>        2. First-year students, either male or female, attending the selected schools (in years 1 and 5)<br>        3. Adults aged 20-55 years from the selected communities (shehias), only one adult per household, pregnant women are eligible (in years 1 and 5)<br>        4. Submitted written informed consent sheet signed by parent or legal guardian in case of participating children or signed by the participant in case of participating adults<br>        5. Oral assent from participant given<br>        6. One urine sample provided (from 9-12-year old children in each study year; from first-year students and adults in years 1 and 5)<br>        7. One blood sample obtained (from first-year students in years 1 and 5)<br>      ","Exclusion criteria: <br>        1. Children not attending the selected schools<br>        2. Children not aged 9-12 years (in years 2, 3, and 4)<br>        3. Children not aged 9-12 years or being first-year students (in years 1 and 5)<br>        4. Adults not resident in the selected shehias<br>        5. Adults aged <20 or >55 years (in years 1 and 5)<br>        6. Written informed consent not submitted or not signed by parent or legal guardian in case of participating children or not signed by the participant in case of participating adults<br>        7. No oral assent given<br>        8. No urine sample provided (for 9-12-year old children in each study year; for first-year students and adults in years 1 and 5)<br>        9. No blood sample obtained (from first-year students in years 1 and 5)<br>      ",Schistosoma haematobium infections <br>Infections and Infestations <br>Schistosomiasis due to Schistosoma haematobium [urinary schistosomiasis],"<br>        The study will be implemented in 45 shehias in both Unguja and Pemba. Among the 45 shehias on each island 15 were randomly assigned to one of the following three intervention arms:<br>        1. Treatment per the National Plan of the Zanzibar Ministry of Health (twice yearly preventive chemotherapy with praziquantel, including social mobilization and education)<br>        2. Treatment per the National Plan plus snail control<br>        3. Treatment per the National Plan plus intensive behaviour change interventions<br>",<br>        Current primary outcome measure as of 25/03/2019:<br>        S. haematobium infection prevalence and intensity based on urine filtration results in 9- to 12-year-old children after five years of follow-up (i.e. at the 5-year endline survey in 2017)<br><br>        Previous primary outcome measure:<br>        Elimination of urogenital schistosomiasis in Unguja and reduction of the S. haematobium prevalence <10% in Pemba after 5 years of interventions<br>      ,"<br>        1. Prevalence and intensity of S. haematobium infections in 9-12-year-old schoolchildren and antibody levels against S. haematobium in first-year students, hence judging current infection status and history of exposure, and prevalence and intensity of S. haematobium infections in adults and first-year students<br>        2. Impact of niclosamide on snail populations, schistosome transmission and reinfection of the Zanzibari population<br>        3. Changes in the behaviour of the human population associated with parasite transmission<br>        4. Sensitivity and specificity of novel diagnostic methods<br>      ",Nil known;Nil known;N/A,"University of Georgia Research Foundation Inc. (USA), World Health Organization (Switzerland), The Schistosomiasis Control Initiative (UK), Bayer S.A.S. (France)",,,01/01/1900,"          1. Ethikkommission beider Basel, Switzerland, 08/08/2011, ref: 236/11          2. Zanzibar Medical Research Ethical Committee of the Zanzibar Ministry of Health (ZAMREC, United Republic of Tanzania, 29/09/2011, ref: ZAMREC/0003/Sept/011          3. Institutional Review Board of the University of Georgia, USA, 27/10/2011, ref: 2012-10138-0        ",,,,Yes,,,,31/12/2017,,        2012 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/23110494 protocol        2013 Results article in https://www.ncbi.nlm.nih.gov/pubmed/24147165 results        2015 Results article in https://www.ncbi.nlm.nih.gov/pubmed/25973845 results        2015 Results article in https://www.ncbi.nlm.nih.gov/pubmed/26329827 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/26727915 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27399310 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27428066 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27498244 results        2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27986092 results        2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30352631 results        2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31255591 results (added 02/07/2019)        2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31059495 results (added 03/01/2020)        2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32887642/ qPCR results (added 07/09/2020)        Results article in https://pubmed.ncbi.nlm.nih.gov/36215334/ Population genetic analysis of Schistosoma haematobium (added 11/10/2022)      ,,,,Available on request,    The trialists intend to publish our study results in the peer-reviewed (whenever possible open-access) literature before the end of 2018.    Updated 26/03/2019: The investigators intend to publish the study results in the peer-reviewed open access literature before the end of 2019.,No,False,          ,2012,,Unknown,Yes
NCT01288872,12 December 2020,Praziquantel-Pharmacokinetic Study,Praziquantel Pharmacokinetics in Pregnancy and During Lactation,,National Institute of Allergy and Infectious Diseases (NIAID),2011-01-28,20110128,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01288872,Not recruiting,No,18 Years,99 Years,Female,01/01/2012,47.0,Interventional,Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 1,Philippines,,,,,,,"<br>    Inclusion Criteria:<br><br>    Screening:<br><br>     - Woman must be age 18 or over.<br><br>     - Present to a study midwife or health center.<br><br>     - Live in a study village.<br><br>    Inclusion criteria for the study are as follows:<br><br>     - Infected with Schistosomiasis (S.) japonicum.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       (if pregnant) and laboratory assessment, with the exception of laboratory values cited<br>       in Exclusion Criteria.<br><br>     - Early pregnancy cohort: pregnant, between 12-16 weeks gestation.<br><br>     - Late pregnancy cohort: pregnant, between 30-36 weeks gestation<br><br>     - Lactating nonpregnant: 5-7 months postpartum inclusive (up to 7 months and 31 days)<br>       with negative pregnancy test.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound (if pregnant) and laboratory<br>       assessment. In particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g., active hepatitis, renal<br>         disease, tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dL will be excluded.<br><br>        3. If pregnant, with myoma on ultrasound that are sub-mucosal OR women with myoma<br>         that are in any location and greater than 5 cm in size.<br><br>        4. If pregnant, with congenital anomalies of the reproductive tract that would be<br>         expected to cause decreased fetal weight or greatly increase the risk of<br>         pre-maturity such as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, we will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions, such as urinary tract<br>         infection, pneumonia, or febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the<br>         illness).<br><br>     - For lactating postpartum subjects: milk supply suspected to be marginal so that 24<br>       hour interruption of nursing likely to lead to inability to restart breast feeding,<br>       evidence of breast infection, or history of breast surgery.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - If pregnant, fetus has congenital anomaly determined by ultrasound or is determined to<br>       be nonviable e.g., blighted ovum.<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study or its companion study (""""S. japonicum and<br>       pregnancy outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT). DMID<br>       Protocol Number: 06-0039"""") for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other reason, or refuses to provide informed consent.<br><br>     - Subjects receiving during the previous month any of the following drugs which may<br>       interact with praziquantel (PZQ) bioavailability, metabolism and/or elimination:<br>       carbamazepine, chloroquine, cimetidine, dexamethasone, erythromycin, fosphenytoin,<br>       itraconazole, ketoconazole, phenobarbital, phenytoin, rifampin, or any protease<br>       inhibitor or non-nucleoside reverse transcriptase inhibitor.<br><br>     - Subjects ingesting grapefruit juice during the previous week.<br>   ",,Schistosomiasis,Drug: Praziquantel,"Comparison of PZQ and 4-hydroxy PZQ PK parameters in pregnant and nonpregnant lactating subjects, central tendency and distribution (Cmax, Tmax, t ½, AUC, CL/F and Vd/F).;Early Pregnancy Cohort only: Assessed for the presence of pre-eclampsia.;Pregnant women only: newborn congenital anomalies. The number of infants with congenital anomalies;Early Pregnancy Cohort only: number of subjects experiencing a spontaneous abortion and number of stillbirths reported after drug administration; and live birth rate among pregnant subjects.;Toxicity to maternal bone marrow, kidney, and liver will be assessed by measurement of complete blood count, blood urea nitrogen (BUN) and creatinine, and liver function tests (AST, ALT, and bilirubin).;Subjects will be observed in hospital for adverse events/serious adverse events (AE/SAEs).",,5U01AI066050-07;08-0049,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2011,18.0,No,Yes
NCT01154049,22 August 2016,Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis,Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis,,Oswaldo Cruz Foundation,2010-06-29,20100629,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01154049,Not recruiting,No,18 Years,49 Years,Both,01/03/2011,20.0,Interventional,"Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention",Phase 1,Brazil, ,"Marilia S Oliveira, MD, MsC",,,,Instituto de Pesquisa Clínica Evandro Chagas (IPEC),"<br>    Inclusion Criteria:<br><br>     - Aged between 18 and 49 years.<br><br>     - Available for follow-up throughout the study period (approximately 120 days).<br><br>     - Ability to understand and sign the informed consent form (IC).<br><br>     - HIV serology negative<br><br>     - Absence of helminth infections in general (nematodes, cestodes and trematodes, among<br>       which Schistosoma mansoni) at the inclusion in the study.<br><br>     - Patients who has not chronic use or have not used in the past 45 days any medication,<br>       except trifling as nasal saline and vitamins.<br><br>     - Be in good health without significant medical history.<br><br>     - Screening physical examination without clinical significant abnormalities.<br><br>     - Screening laboratory tests without significant abnormalities according to normal<br>       standards and the evaluation of investigators.<br><br>     - Additional criteria for females of childbearing potential: Negative pregnancy test at<br>       screening; consistent use of contraceptive methods (male or female condom, diaphragm,<br>       IUD and oral contraceptives or """"patches"""").<br><br>    Exclusion Criteria:<br><br>     - Women who are pregnant or breastfeeding.<br><br>     - Use of cytotoxic or immunosuppressive drugs in the last six months, except for spray<br>       nasal corticosteroids for allergic rhinitis or topical corticosteroids for<br>       uncomplicated dermatitis.<br><br>     - Immunoglobulin use 60 days prior to vaccination.<br><br>     - Use of any type of vaccine 30 days prior to vaccination.<br><br>     - Plan to receive any other vaccine during the period of participation in the study<br>       (four months)<br><br>     - Use any type of investigational medication in a period of 30 days prior to<br>       vaccination<br><br>     - Use of allergy shots with antigens within 14 days prior to vaccination.<br><br>     - Psychiatric illness that hinders adherence to the protocol, such as psychosis,<br>       obsessive-compulsive neurosis, bipolar disorder treatment, diseases that require<br>       treatment with lithium, and suicide thoughts in the last 5 years prior to inclusion.<br><br>     - Presence of neurological disease, liver disease or kidney disease (diseases which<br>       have led to hospitalization or prolonged treatment).<br><br>     - History of sickle cell anemia.<br><br>     - Asplenia (no spleen or its removal).<br><br>     - History of alcohol use/abuse (CAGE criterion) or illicit drugs.<br><br>     - Blood pressure above 140/90 mmHg at screening or hypertension requiring drug<br>       treatment.<br><br>     - Coagulopathy diagnosed by a doctor or report of capillary fragility (eg, bruising,<br>       bleeding, etc.) after injections or blood sampling.<br><br>     - Active malignancy (eg, any type of cancer) or treated so it may relapse during the<br>       study.<br><br>     - History of allergy to vaccines containing adjuvants composed of lipids (GLA or MPL)<br>   ",,Schistosomiasis,Biological: sm14 antigen plus adjuvant GLA,Safety of the vaccine,Proportion of seroconversion;Cellular immune response to sm-14 vaccination in health adults,sm14-CT001P1,Please refer to primary and secondary sponsors,Financiadora de Estudos e Projetos,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2010,18.0,No,Yes
NCT01132248,19 February 2015,Activity of Mefloquine Against Urinary Schistosomiasis,Activity of Mefloquine Against Urinary Schistosomiasis,,Albert Schweitzer Hospital,2010-05-27,20100527,10/13/2025 16:02:07,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01132248,Not recruiting,No,,,Female,01/05/2010,65.0,Interventional,"Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 2,Gabon,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Pregnant women after first trimester and before 28th week of pregnancy<br><br>     - HIV negative<br><br>     - Egg excretion of Schistosoma haematobium (mean >10 eggs per mL urine)<br><br>     - Asymptomatic (no signs of complicated Schistosomiasis, no severe anemia)<br><br>     - Ability to comply with study protocol<br><br>    Exclusion Criteria:<br><br>     - Intake of anthelminthic or antimalarial drug within 2 months prior to inclusion<br><br>     - Allergy to study drugs<br>   ",,Urinary Schistosomiasis,Drug: Mefloquine;Drug: S/P,Reduction of egg excretion,Cure rate,IDC-2010-1,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2010,,Unknown,Yes
ISRCTN00393859,17 October 2016,"Praziquantel, praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of schistosomiasis","Praziquantel, praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of infections with Schistosoma spp. in Cote d'Ivoire                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",,Swiss Tropical and Public Health Institute (Switzerland),2010-05-27,20100527,10/13/2025 16:02:07,ISRCTN,http://isrctn.com/ISRCTN00393859,Not Recruiting,No,,,Both,01/07/2011,150.0,Interventional,Randomised exploratory open-label active-controlled parallel-group phase II trial (Treatment),Phase II,Cote d'Ivoire,,,,,,,"Inclusion criteria: 1. Patients (male and female school children older than 8 years) infected with Schistosoma mansoni and S. haematobium, as assessed by the presence of eggs in the urine or stool<br>2. Weight of patient greater than 25 kg<br>3. Able and willing to be examined by a study physician at the beginning of the study and at the end of study (3 weeks post-treatment and 2 - 3 months post-treatment)<br>4. Able and willing to provide multiple stool and urine samples at the beginning and end of study<br>5. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment<br>6. Absence of psychiatric and neurological disorders<br>7. No known or reported hypersensitivity to mefloquine, praziquantel and/or artesunate<br>8. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease<br>9. Signed written informed consent sheet<br>10. For females aged 12 years and above, not pregnant in the first trimester, as assessed by a pregnancy test, upon initial clinical assessment","Exclusion criteria: 1. Pregnancy first trimester<br>2. Presence of any abnormal medical condition, judged by the study physician<br>3. History of acute or severe chronic disease<br>4. Known or reported psychiatric or neurological disorders<br>5. Use of antimalarial or anthelminthic drug within the past month<br>6. Attending other clinical trials during the study",Infection with Schistosoma spp. <br>Infections and Infestations <br>Schistosomiasis [bilharziasis] ,"Drug administration, namely:<br>1. Praziquantel (1 x 40 mg/kg)<br>2. Mefloquine (1 x 25 mg/kg) plus praziquantel (1 x 40 mg/kg) on the next day<br>3. Mefloquine-artesunate combination (300/750 mg in three divided doses within 3 days) plus praziquantel (1 x 40 mg/kg) on day 4<br><br>The duration of treatment is dependant on the drug regimen (i.e., 1 - 4 days). The total duration of follow-up is 3 - 5 days.","Cure rate and egg reduction rate, measured at 21 - 28 days and 2 - 3 months post-treatment by multiple stool and urine sampling (Kato Katz method, urine filtration and ether concentration technique)","Adverse events. Patients will be monitored for 3 hours post-treatment and once daily during treatment and for 3 days after the last dose. Details of adverse events will recorded by the study physician during the trial, including variables describing their incidence, onset, cessaton, duration, intensity, frequency, seriousnes and causality.",N/A ,Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland),,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2010,,Unknown,Yes
ISRCTN06498763,13 January 2015,Mefloquine and artesunate against schistosomiasis,"Mefloquine, artesunate and mefloquine-artesunate in the treatment of Schistosoma mansoni and Schistosoma haematobium infections in Côte d?Ivoire                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",,Swiss Tropical Institute (Switzerland),2008-10-17,20081017,10/13/2025 16:02:07,ISRCTN,http://isrctn.com/ISRCTN06498763,Not Recruiting,No,,,Both,30/10/2008,120.0,Interventional,Open-label randomised trial (Treatment),Unknown,Cote d'Ivoire,,,,,,,"Inclusion criteria: 1. Schoolchild (aged 8 - 16 years, either sex) infected with S. mansoni (study 1) or S. haematobium (study 2), as assessed by the presence of egg(s) in the stool (S. mansoni) or urine (S. haematobium)<br>2. Weight of schoolchild greater than 25 kg<br>3. Able and willing to be examined by a physician at the beginning of the study and at the end of study (3 weeks post-treatment) <br>4. Able and willing to provide multiple stool or urine samples at the beginning and end of study<br>5. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment<br>6. Absence of psychiatric disorders and epilepsy<br>7. No known or reported hypersensitivity to mefloquine and/or artesunate<br>8. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease<br>9. Signed written informed consent sheet by parents/legual guardians and child<br>10. For females aged 12 years and above, not pregnant in the first trimester, as assessed by a female nurse (interview and pregnancy test if need be), upon initial clinical assessment","Exclusion criteria: 1. Schoolchild who has clinical malaria (i.e. axillary temperature greater than or equal to 37.5°C and parasitaemia, as assessed by thick and thin blood film examination)<br>2. Pregnancy first trimester<br>3. Presence of any abnormal medical condition, judged by the study physician<br>4. History of acute or severe chronic disease, including hepato-splenic schistosomiasis, macrohaematuria and bloody stools<br>5. Psychiatric disorders and epilepsy<br>6. Use of artesunate, artemether, any artemisinin-based combination therapy, mefloquine or praziquantel within the past 7 days<br>7. Attending other clinical trials during the study",Schistosomiasis (Schistosoma mansoni; Schistosoma haematobium) <br>Infections and Infestations <br>Schistosomiasis [bilharziasis] ,"1. Mefloquine (1 x 25 mg/kg)<br>2. Artesunate (10 mg/kg in three divided doses within 1 day)<br>3. Mefloquine-artesunate combination (300/750 mg in three divided doses within 3 days)<br>4. Praziquantel (1 x 40 mg/kg)<br><br>The duration of treatment is, depending on the drug, 1 - 3 days; duration of follow-up is 3 - 5 days.","Cure rate and egg reduction rate, measured 21 - 28 days post-treatment by multiple stool sampling using the Kato-Katz method (study 1) and multiple urine sampling using standard urine filtration method (study 2).","Patients will be monitored for three hours post-treatment and once daily for 5 days. Details of adverse events will be recorded by the study physician during the trial including variables describing their incidence, onset, cessation, duration, intensity, frequency, seriousness and causality.",,Mepha Pharma AG (Switzerland),,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2008,,Unknown,Yes
NCT00486863,19 October 2017,S. Japonicum and Pregnancy Outcomes,"S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)",,National Institute of Allergy and Infectious Diseases (NIAID),2007-06-14,20070614,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00486863,Not recruiting,No,18 Years,99 Years,Female,01/08/2007,370.0,Interventional,,Phase 2,Philippines;United States;Philippines;United States;Philippines;United States;Philippines;United States,,,,,,,"<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ;<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ;<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ;<br>    Inclusion Criteria:<br><br>    For screening:<br><br>     - Female, age 18 or over.<br><br>     - Present to a study midwife with suspected pregnancy.<br><br>     - Live in a study village.<br><br>    For the main study:<br><br>     - Infected with S. japonicum.<br><br>     - Pregnancy as determined by urine pregnancy test.<br><br>     - Age 18 or older.<br><br>     - Participant is otherwise healthy as determined by history, physical exam, ultrasound<br>       and laboratory assessment.<br><br>     - Pregnancy between 12-16 weeks gestation.<br><br>     - Ability to provide informed consent to participate.<br><br>    Exclusion Criteria:<br><br>     - Presence of significant disease/illness that is either acute or chronic. This will be<br>       defined by history, physical examination, ultrasound and laboratory assessment. In<br>       particular:<br><br>        1. History of seizures or other neurologic disorder, chronic medical problem<br>         determined by history or physical examination, e.g. active hepatitis,<br>         tuberculosis, heart disease.<br><br>        2. Grade 3 or higher laboratory abnormality of blood urea nitrogen (BUN),<br>         Creatinine, bilirubin, white blood cell count, or platelet count will warrant<br>         exclusion. Grade 2 or higher abnormality of alanine aminotransferase (ALT) or<br>         aspartate aminotransferase (AST) will warrant exclusion. For hemoglobin, women<br>         with severe anemia defined as hemoglobin less than 7.0 g/dl will be excluded.<br><br>        3. Women with myoma on ultrasound that are sub-mucosal or women with myoma that is<br>         in any location and greater than 5 cm in size.<br><br>        4. Women with congenital anomalies of the reproductive tract that would be expected<br>         to cause decreased fetal weight or greatly increase the risk of prematurity such<br>         as duplicate uterus, uterine septum.<br><br>        5. For less clear cases, the researchers will define significant illness as one that<br>         significantly alters a woman's ability to perform activities of daily living,<br>         causes symptoms at least two days per week, or necessitates regular use of<br>         medication. In the case of acute medical conditions such as urinary tract<br>         infection, pneumonia, febrile illness, enrollment may be postponed until the<br>         illness is successfully treated (not currently on any medication for the illness)<br>         or the illness self resolves if this occurs before 16 weeks gestation.<br><br>     - Presence of cysts in the eye suggestive of neurocysticercosis.<br><br>     - Regular use of a medication for a chronic medical condition.<br><br>     - History of severe allergic reaction (anaphylaxis, facial swelling, or difficulty<br>       breathing) or seizure with praziquantel administration.<br><br>     - Fetus has congenital anomaly determined by 12-16 week ultrasound or is determined to<br>       be nonviable (e.g. blighted ovum).<br><br>     - Twin or higher order pregnancy.<br><br>     - Woman has been enrolled into this study for a previous pregnancy.<br><br>     - Inability to comprehend study procedures and provide informed consent due to limited<br>       cognitive abilities or other, or refuses to provide informed consent.<br>   ",,Schistosomiasis;Schistosomiasis;Schistosomiasis;Schistosomiasis,Drug: Praziquantel;Other: Placebo;Drug: Praziquantel;Other: Placebo;Drug: Praziquantel;Other: Placebo;Drug: Praziquantel;Other: Placebo,Mean Newborn Birth Weight;Mean Newborn Birth Weight,"Number of Participants Whose Pregnancy Resulted in a Live Birth;Mean Change in Maternal Hemoglobin From 14 to 32 Weeks Gestation;Median Change in Maternal Transferrin Receptor:Ferritin Ratio From 14 to 32 Weeks Gestation;Median Maternal Hepcidin at 32 Weeks Gestation;Mean Change in Maternal Weight From 14 to 32 Weeks Gestation;Mean Change in Maternal Thigh Skinfold Thickness From 14 to 32 Weeks Gestation;Newborn Median Serum Transferrin Receptor:Ferritin Ratio;Number of Subjects With Reduction in S. Japonicum Egg Counts From Screening to 22 Weeks Gestation of Greater Than 90 Percent;Number of Participants Reporting Serious Adverse Events Within 24 Hours of Dosing;Number of Participants Experiencing Fetal Loss by Abortion;Number of Participants Reporting Abnormalities in Hematology Assessments Within 24 Hours of Dosing;Number of Participants Reporting Abnormalities in Clinical Chemistry Assessments Within 24 Hours of Dosing;Number of Participants Whose Infant Was Born With Congenital Anomalies;Number of Participants With Pre-eclampsia;Maternal Serum Cytokine Levels of TNF-alpha, TNF-alpha Receptors I and II, IL-1, and IL-6;Placental Blood Cytokine Levels;Cytokeratin 18 Neo-epitope Staining as a Measure of Apoptosis;Praziquantel Pharmacokinetic Concentrations;4-hydroxy Praziquantel Pharmacokinetic Concentrations",06-0039,Please refer to primary and secondary sponsors,,,,,,,,Yes,07/02/2014,https://clinicaltrials.gov/ct2/show/results/NCT00486863,,,,,,,,,,Yes,False,          ,2007,18.0,No,Yes
NCT00138450,12 December 2020,Urinary Schistosomiasis Infection,Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease,,National Institute of Allergy and Infectious Diseases (NIAID),2005-08-26,20050826,10/13/2025 16:02:07,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00138450,Not recruiting,No,,99 Years,All,25/10/2005,4400.0,Observational,,Unknown,Kenya;United States,,,,,,,"<br>    Inclusion Criteria:<br><br>     1. Kenyan residents, newborn to adult, either male or female.<br><br>     2. Residence in areas of Kwale District endemic for Schistosoma haematobium<br><br>    Exclusion Criteria:<br><br>    Pregnancy (this is a partial exclusion). Pregnant women will participate in the<br>    parasitological screening phase of the study. However, because of pregnancy-related effects<br>    on the urinary system, their ultrasound examinations will be excluded from the analysis of<br>    hydronephrosis. Further, because of potential toxicity of praziquantel (Category B) and its<br>    alternative, metrifonate (an anticholinesterase), post-protocol anti-parasitic therapy will<br>    be delayed until the mother delivers and has stopped breastfeeding her infant.<br>   ",,Diseases of the Urinary System;Schistosomiasis Haematobia,,,,01-588,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2005,,Unknown,Yes
ISRCTN63456799,10 December 2019,Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?,Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ,,University of Antwerp (Belgium),2004-12-01,20041201,10/13/2025 16:02:07,ISRCTN,http://isrctn.com/ISRCTN63456799,Not Recruiting,No,,,Both,01/01/2006,20.0,Interventional,Randomised controlled trial (Treatment),Not Specified,Belgium,,,,,,,"Inclusion criteria: <br>        Schistosoma mansoni infected adolescent patients with variceal bleeding in the last 24 hours.<br><br>        The inclusion criteria will be established fibrosis due to schistosomiasis of clinical history, physical examination and laboratory findings (and an examination compatible with the presence of portal hypertension due to fibrosis). Clinically active upper gastrointestinal bleeding (haematemesis of fresh or semi fresh blood and/or melena and/or haematochezia) with or without haemodynamic instability (systolic blood pressure < 80 mm Hg and heart rate > 120 bpm) will be selected. Subjects must be male or non-pregnant, non-lactating female subjects. Females of childbearing potential will have to utilize contraception for the duration of the study. Written or verbal documented informed consent will be needed from all subjects.<br>      ","Exclusion criteria: Exclusion criteria will include participation by subjects in another investigational study within the last 14 days. Subjects may not undergo treatment with endotherapy, i.e. band ligation, sclerotherapy or other (balloon tamponade). Treatment with somatostatin, vasopressin or their analogues will also be a exclusion criteria. Subjects with end stage liver disease with hepatorenal syndrome, diffuse hepatocellular carcinoma, patent porto-systemic shunts, known diagnosis of non-fibrotic portal hypertension, severe cardiovascular diseases, i.e. acute myocardial infarction and heart failure will be excluded. Concurrent use of metoclopramide is also not advised.",Schistosomiasis <br>Infections and Infestations <br>Schistosomiasis,"<br>        Intervention: Intravenous (IV) infusion with somatostatin consisting of one bolus and infusion for 24 hours.<br>        Control: Standard care, which is a beta blocker propanolol.<br>        To study end results, questionnaires and sonography will be used.<br>","<br>        The primary efficacy variable is the number of patients meeting the failure of therapy definition during the infusion period. Failure criteria are defined as death during infusion, persistence of active bleeding (The haemodynamic instability criteria points to the inability to achieve and maintain a systolic blood pressure of 80 mmHg OR presence of a 20 mmHg drop in systolic blood pressure from the highest post resuscitation value AND achieving a heart rate of 120 bpm OR a 20 bpm increase from highest post resuscitation value OR inability to achieve and maintain a Hct of ? 27% of Hb of ? 9 g/dl despite blood transfusion of 2 units or more.<br><br>        The clinical criteria of active bleeding include hematemesis (fresh or semi fresh blood), hematochezia, melena.<br>      ",Not provided at time of registration,Nil known;Nil known;Nil known,"External funding for this protocol comes from UCB-Pharma, Brussels, Belgium who have gifted the somatostatin (Belgium)",,,01/01/1990,,Not provided at time of registration,,,Yes,,,,31/12/2006,,Study protocol: http://www.ncbi.nlm.nih.gov/pubmed/15596012,,,,Not provided at time of registration,Not provided at time of registration,Yes,False,          ,2004,,Unknown,Yes
ISRCTN01779485,13 January 2015,"Epidemiology and treatment of soil-transmitted helminthiasis, with particular consideration to strongyloidiasis, in Yunnan province, China",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ,,Swiss National Science Foundation (SNSF) (Switzerland),2008-08-21,20080821,10/13/2025 16:02:45,ISRCTN,http://isrctn.com/ISRCTN01779485,Not Recruiting,No,,,Both,01/05/2007,300.0,Interventional,"Open-label, randomised controlled trial (Not Specified)",Unknown,China,,,,,,,"Inclusion criteria: 1. Both males and females, age >=5 years<br>2. Submission of >=1 stool sample for the baseline parasitological survey<br>3. For females, not pregnant, as verbally assessed by medical personnel on the day of treatment<br>4. Absence of major systemic illnesses, as assessed by medical personnel on the day of treatment<br>5. Written informed consent by the head of the household on behalf of the whole family","Exclusion criteria: 1. Presence of any abnormal medical condition, as judged by the medical personnel<br>2. No stool sample submitted for baseline parasitological survey<br>3. Enrolled in any other clinical investigation during the study<br>4. For females: pregnancy",Helminth infections <br>Infections and Infestations,"The participants who were diagnosed with helminthiases at the baseline parasitological survey were randomly allocated to the following arms: <br><br>Arm 1: Single-dose albendazole (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years<br>Arm 2: Single-dose tribendimidine (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged >=15 years","1. Reduction of infection prevalence of intestinal helminths, assessed by examination of stool samples 2-4 weeks after drug administration <br>2. Frequency and severity of adverse events were recorded within 24 hours after drug administration","Kato-Katz-derived egg count reduction of common soil-transmitted helminths, assessed 2-4 weeks after drug administration. ",,"Main funder:, Commission for Research Partnership with Developing Countries (KFPE) through the Swiss Agency for Development and Cooperation (SDC) (Switzerland), Other funders:, Voluntary Academic Society (Freiwillige Akademische Gesellschaft) (Switzerland), Janggen-Pöhn Foundation (Janggen-Pöhn-Stiftung) (Switzerland), Chinese Ministry of Science and Technology, through their support to the Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health (China) (grant ref: 2005DKA21104), Swiss National Science Foundation (Switzerland) (project numbers PPOOB-102883 and PPOOB-119129)",,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2008,,Unknown,Yes
NCT03926728,16 May 2022,Safety and Immunogenicity of a Chlamydia Vaccine CTH522,"A Phase I, Double-blind, Parallel, Randomised and Placebo-controlled Trial Investigating the Safety and Immunogenicity of a Chlamydia Vaccine, CTH522, in Healthy Adults",CHLM-02,Statens Serum Institut,2019-04-15,20190415,10/13/2025 16:04:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03926728,Not recruiting,No,18 Years,45 Years,All,17/02/2020,65.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 1,United Kingdom, ; ; ; ; ,"Alvaro Borges, MD;Katrina Pollock, MD;Lina S Stoey, MPH;Pernille N Tingskov, BS;Rebecca B Dohn, Pharm",,;;;;,;;;;,Statens Serum Institut;Imperial Clinical Tesearch Facility Hammersmith Hospital;Statens Serum Institut;Statens Serum Institut;Statens Serum Institut,"<br>    Inclusion Criteria:<br><br>    IC1: Healthy males and females between 18-45 years old on the day of the first vaccination<br>    IC2: Has been properly informed about the trial and signed the consent form IC3: Is willing<br>    and likely to comply with trial procedures IC4: Is prepared to grant authorised persons<br>    access to his/her trial-related medical record IC5: Is willing to use acceptable<br>    contraceptive measures during the trial (two weeks before and two weeks after the trial).<br>    Heterosexually active female capable of becoming pregnant must agree to use hormonal<br>    contraception, intrauterine device, intrauterine hormonereleasing system, or to complete<br>    abstinence from at least two weeks before the first vaccination until at least two weeks<br>    after the last. Complete abstinence (defined as refraining from heterosexual intercourse)<br>    must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence<br>    (e.g. calendar, ovulation, symptothermal, post-ovulation methods), withdrawal and<br>    progestogen-only oral hormonal contraception where inhibition of ovulation is not the<br>    primary mode of action are not acceptable methods of contraception<br><br>    Exclusion criteria:<br><br>    EX1: Is positive for C. trachomatis via urine PCR or has a known history of C. trachomatis<br>    EX2: Is positive for gonorrhoea via urine PCR test, or HIV, hepatitis B/C, syphilis via<br>    blood tests EX3: Has a significant active disease such as cardiac, liver, immunological,<br>    neurological, psychiatric or clinically significant abnormality of haematological or<br>    biochemical parameters EX4: Has BMI = 35 kg/m2 EX5: Is currently participating in another<br>    clinical trial with an investigational or noninvestigational drug or device, or was treated<br>    with an investigational drug within 28 days before the first vaccination EX6: Has received,<br>    or plans to receive, any immunisation within 14 days of the start of the trial or during<br>    the trial immunisations EX7: Is currently receiving treatment with systemic<br>    immunosuppressive agents. Topical steroids are allowed unless applied to the IM or ID<br>    injection site EX8: Has a condition which in the opinion of the investigator is not<br>    suitable for participation in the trial EX9: Is known or confirmed to have an allergy to<br>    any of the vaccine constituents EX10: Is unable to refrain from the use of contact lenses.<br>    Contact lenses should be avoided two days before TO administration and for seven days later<br>    (longer if any ongoing local eye AE) EX11: Has any evident ocular disease upon<br>    ophthalmoscopic exam at screening or any medical history of ocular disease that, in the<br>    opinion of the investigator, may impact the subject's participation in the trial EX12: Is<br>    pregnant (positive pregnancy test) or breastfeeding or not willing to use contraception<br>    during the trial EX13: Has confirmed a history of pelvic inflammatory disease or<br>    significant gynaecological diseases<br>   ",,Trachoma,Biological: CTH522-CAF01 IM;Biological: CTH522-CAF09b IM;Biological: CTH522 ID;Biological: CTH522 TO;Biological: Placebo (Saline),Local injection reactions;Local ocular reactions;Systemic reactions,Secondary - immunogenicity,CHLM-02,Please refer to primary and secondary sponsors,Imperial College London,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2019,18.0,No,Yes
NCT03676140,12 December 2020,Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ),"A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases",,Lihir Medical Centre,2018-09-16,20180916,10/13/2025 16:04:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03676140,Not recruiting,No,,,All,01/10/2018,20000.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 3,Papua New Guinea, ,"Lucy John, MD",,,,National Department of Health of Papua New Guinea,"<br>    Inclusion Criteria:<br><br>     - Able to give consent<br><br>    Exclusion Criteria:<br><br>     - Unable to give consent.<br><br>     - Less than 5 years of age (not eligible for ivermectin)**<br><br>     - Pregnant women (azithromycin only, not eligible for albendazole and ivermectin)<br><br>     - Lactating women (Only administered azithromycin and albendazole, not eligible for<br>       ivermectin)**<br><br>     - History of allergies to the drugs being studied<br><br>     - Residents who cannot swallow tablets<br><br>    Note that patients that are not eligible for a specific drug will receive all other<br>    treatments and will be followed up through the same procedure as the other participants<br>    drug therapy to try to track any AEs attributed to specific drug combinations<br>   ",,Trachoma;Yaws;Lymphatic Filariases;Scabies;Strongyloidiasis,Drug: Albendazole on Day 1;Drug: Ivermectin on Day 1;Drug: Diethylcarbamazine on day 1;Drug: Azithromycin on Day 1;Drug: Azithromycin on Day 8,Self Reported Adverse Event,,ComboNTDs - CRT,Please refer to primary and secondary sponsors,London School of Hygiene and Tropical Medicine,,,,,,,Unknown,,,,,,,,,,No,,Yes,False,          ,2018,,Unknown,Yes
NCT01949454,2 May 2016,Fluorometholone as Ancillary Therapy for TT Surgery,"Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study",,University of Pennsylvania,2013-09-19,20130919,10/13/2025 16:04:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01949454,Not recruiting,No,18 Years,,Both,01/11/2013,154.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Unknown,Ethiopia, ; ,"John H Kempen, MD MPH PhD;Wondu Alemayehu, MD, MPH",,;,;,University of Pennsylvania;Berhan Public Health & Eye Care Consultancy PLC,"<br>    Inclusion Criteria:<br><br>     1. Age 18 years or more<br><br>     2. Diagnosis with trachomatous trichiasis<br><br>     3. Plan for lid rotation surgery (Bilamellar Tarsal Rotation) on at least one upper<br>       eyelid<br><br>     4. LOCS 3 cataract grading is level 3 or less for the nuclear cataract scale, and level<br>       2 or less for the cortical cataract and posterior subcapsular cataract scales.<br><br>     5. Intraocular pressure between 8-20 mm Hg in the study eye.<br><br>    Exclusion Criteria:<br><br>     1. Contraindications to the use of the test articles<br><br>     2. Known allergy or sensitivity to any medication used in this study, including the<br>       study medication or its components (e.g., fluorometholone)<br><br>     3. Currently taking more than two ocular anti-hypertensive medications in the study eye<br>       (prior IOP-lowering surgery is acceptable; combinations of two agents such as Cosopt<br>       and Combigan are considered two medications)<br><br>     4. Glaucoma sufficiently advanced that an intraocular pressure spike potentially would<br>       put the patient at substantial risk of vision loss, per study ophthalmologist's<br>       judgment.<br><br>     5. Non-phakic (i.e., pseudophakic or aphakic) study eye (contralateral non-phakic eye is<br>       permitted).<br><br>     6. Other than trachoma, any active ocular infections (bacterial, viral, or fungal), or<br>       any active ocular inflammation (e.g., scleritis, iritis).<br><br>     7. History or diagnosis of ocular herpes or presence of a corneal lesion of suspected<br>       herpetic origin; or a diagnosis or suspected diagnosis of ophthalmic mycobacterial<br>       infection in either eye.<br><br>     8. Corneal or scleral thinning in either eye.<br><br>     9. A severe / serious ocular pathology or medical condition which may preclude study<br>       completion.<br><br>     10. Any condition for which it is anticipated ocular or systemic corticosteroid therapy<br>       would be required.<br><br>     11. Unwilling to discontinue use of contact lenses for the duration of the study (should<br>       the unusual circumstance of a trachomatous trichiasis patient who uses contact lenses<br>       be encountered)<br><br>     12. Any significant illness or condition that could, in the investigator's or<br>       sub-investigator's opinion, be expected to interfere with the study parameters or<br>       study conduct; or put the subject at significant risk<br><br>     13. For women of childbearing age, currently pregnant and/or breastfeeding, as obtained<br>       by self-report (because of concerns about the (programmatic) use of azithromycin in<br>       this setting).<br><br>     14. Cataract in the study eye, defined as LOCS-3 cataract grading is level 3.1 or more<br>       for the nuclear cataract scale, or level 2.1 or more for the cortical cataract or<br>       posterior subcapsular cataract scales.<br>   ",,Trichiasis;Trachoma;Bilamellar Tarsal Rotation,Drug: Fluorometholone 0.1% ophthalmic solution;Other: Artificial tears (Placebo),Safety assessments,Recurrence of trichiasis in the study eye,SF1707/UND,Please refer to primary and secondary sponsors,Lions Clubs International Foundation (funding);Berhan Public Health and Eye Care Consultancy PLC;Grarbet Tehadiso Mahber,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2013,18.0,No,Yes
NCT01202331,16 December 2017,Tripartite International Research for the Elimination of Trachoma,Tripartite International Research for the Elimination of Trachoma,TIRET,"University of California, San Francisco",2010-09-13,20100913,10/13/2025 16:04:53,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01202331,Not recruiting,No,,,All,01/11/2010,29000.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ,Phase 4,Ethiopia;Ethiopia;Ethiopia;Ethiopia;Ethiopia, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ,"Tom Lietman, MD;Kieran S O'Brien, MPH;Paul Emerson, PhD;Tom Lietman, MD;Kieran S O'Brien, MPH;Paul Emerson, PhD;Tom Lietman, MD;Kieran S O'Brien, MPH;Paul Emerson, PhD;Tom Lietman, MD;Kieran S O'Brien, MPH;Paul Emerson, PhD;Tom Lietman, MD;Kieran S O'Brien, MPH;Paul Emerson, PhD",,;;;;;;;;;;;;;;,;;;;;;;;;;;;;;,"F.I. Proctor Foundation, UCSF;F.I. Proctor Foundation, UCSF;Emory University;F.I. Proctor Foundation, UCSF;F.I. Proctor Foundation, UCSF;Emory University;F.I. Proctor Foundation, UCSF;F.I. Proctor Foundation, UCSF;Emory University;F.I. Proctor Foundation, UCSF;F.I. Proctor Foundation, UCSF;Emory University;F.I. Proctor Foundation, UCSF;F.I. Proctor Foundation, UCSF;Emory University","<br>    Inclusion Criteria:<br><br>     - All residents residing in the state-teams which are randomly selected for this study.<br><br>    Exclusion Criteria:<br><br>     - Pregnant women<br><br>     - Children under 6 months of age<br><br>     - All those who are allergic to macrolides or azalides<br><br>     - Refusal of village chief (for village inclusion), or refusal of parent or guardian<br>       (for individual inclusion)<br><br>    Individuals in these three exclusion criteria will not be given the study antibiotic<br>    azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin<br>    for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day,<br>    topically to both eyes, for six weeks. Note that the exclusion criteria refer to the<br>    exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and<br>    examinations.<br>   ;<br>    Inclusion Criteria:<br><br>     - All residents residing in the state-teams which are randomly selected for this study.<br><br>    Exclusion Criteria:<br><br>     - Pregnant women<br><br>     - Children under 6 months of age<br><br>     - All those who are allergic to macrolides or azalides<br><br>     - Refusal of village chief (for village inclusion), or refusal of parent or guardian<br>       (for individual inclusion)<br><br>    Individuals in these three exclusion criteria will not be given the study antibiotic<br>    azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin<br>    for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day,<br>    topically to both eyes, for six weeks. Note that the exclusion criteria refer to the<br>    exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and<br>    examinations.<br>   ;<br>    Inclusion Criteria:<br><br>     - All residents residing in the state-teams which are randomly selected for this study.<br><br>    Exclusion Criteria:<br><br>     - Pregnant women<br><br>     - Children under 6 months of age<br><br>     - All those who are allergic to macrolides or azalides<br><br>     - Refusal of village chief (for village inclusion), or refusal of parent or guardian<br>       (for individual inclusion)<br><br>    Individuals in these three exclusion criteria will not be given the study antibiotic<br>    azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin<br>    for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day,<br>    topically to both eyes, for six weeks. Note that the exclusion criteria refer to the<br>    exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and<br>    examinations.<br>   ;<br>    Inclusion Criteria:<br><br>     - All residents residing in the state-teams which are randomly selected for this study.<br><br>    Exclusion Criteria:<br><br>     - Pregnant women<br><br>     - Children under 6 months of age<br><br>     - All those who are allergic to macrolides or azalides<br><br>     - Refusal of village chief (for village inclusion), or refusal of parent or guardian<br>       (for individual inclusion)<br><br>    Individuals in these three exclusion criteria will not be given the study antibiotic<br>    azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin<br>    for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day,<br>    topically to both eyes, for six weeks. Note that the exclusion criteria refer to the<br>    exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and<br>    examinations.<br>   ",,Trachoma;Chlamydia;Trachoma;Chlamydia;Trachoma;Chlamydia;Trachoma;Chlamydia,Drug: mass treatment with oral azithromycin;Drug: mass treatment with oral azithromycin;Drug: mass treatment with oral azithromycin;Drug: mass treatment with oral azithromycin,"The average prevalence of ocular chlamydia infection in communities in an arm as determined by pooled NAAT (Nucleic Acid Amplification Test)(at 36 months versus 0 months for Aim 1, at 36 months for Aim 2 and Aim 3);The average prevalence of ocular chlamydia infection in communities in an arm as determined by pooled NAAT (Nucleic Acid Amplification Test)(at 36 months versus 0 months for Aim 1, at 36 months for Aim 2 and Aim 3);The average prevalence of ocular chlamydia infection in communities in an arm as determined by pooled NAAT (Nucleic Acid Amplification Test)(at 36 months versus 0 months for Aim 1, at 36 months for Aim 2 and Aim 3)","Clinical active trachoma in community, as determined by the WHO simplified grading system;Childhood mortality (6 months -5 years of age), 6-10 years of age, and >10 years;Macrolide resistance in pneumococcus, Haemophilus influenzae, and Staphylococcus aureus (% resistance over time, clustered by randomization unit);Anthropometric measurements (weight and height), as outlined by WHO child growth standards (0-5 years of age);Health clinic visits (due to all causes and due to infectious causes) in children aged 6 months-5 years, 6-10 years, and >10 years;Prevalence of anemia (hemoglobin levels in 0-9 year olds) and the prevalence of malaria;Clinically active trachoma in a school (all children under age 10), as determined by the WHO simplified grading system;Cost-effectiveness of mass azithromycin administration, per infection year prevented and cost per eliminated village;Estimate of chlamydial load from real-time, qPCR",10-02169,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2010,,Unknown,Yes
NCT05957978,8 September 2025,"LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study","A Randomized, Open-label, Phase II, Single-centre Study to Evaluate the Efficacy, Safety and Pharmacokinetics of LXE408 in Patients With Primary Visceral Leishmaniasis in Ethiopia",,Drugs for Neglected Diseases,2023-06-14,20230614,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05957978,Not recruiting,No,18 Years,44 Years,All,29/03/2024,52.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 2,Ethiopia, ,"Mezgebu Silamsaw, Dr",,,,"University of Gondar, Ethiopia","Inclusion Criteria:<br><br> - Male and female patients =18 and <45 years (at the time of the screening visit) who<br>   are able to comply with the study protocol<br><br> - Written informed consent must be obtained before any study protocol specific<br>   assessment is performed, other than procedures performed as part of standard of care<br><br> - Primary symptomatic VL (defined as typical parameters including, but not limited to,<br>   fever for >2 weeks, weight loss and splenomegaly)<br><br> - Visualization of Leishmania amastigotes by microscopy in tissue samples (spleen or<br>   bone marrow)<br><br>Exclusion Criteria:<br><br> - Clinical signs of severe VL (including for example jaundice, spontaneous bleeding,<br>   oedema, ascites, coma, organ failure)<br><br> - Laboratory abnormalities including ALT/SGPT >3 times ULN, total bilirubin >1.5 times<br>   ULN, creatinine >1.5 times ULN, serum amylase or lipase >1.5 times ULN, haemoglobin<br>   <6 g/dL or other clinically significant abnormal laboratory parameters which, in the<br>   opinion of the investigator, may indicate severe VL<br><br> - Patients with history of visceral leishmaniasis and confirmed relapse<br><br> - Patients with para-kala-azar dermal leishmaniasis<br><br> - Patients with severe malnutrition (Mid-Upper Arm Circumference (MUAC) <170 mm)<br><br> - History of congenital or acquired immunodeficiency, including positive HIV (test at<br>   screening), as these patients present lower efficacy rates, higher toxicity and<br>   higher lethality compared to non-HIV patients, requiring different case management<br>   and care<br><br> - ECG abnormalities, either historic (no longer present) or current which, in the view<br>   of the investigator, indicate a significant risk to study participation. These<br>   include, but are not limited to, the following:<br><br>    1. Clinically significant cardiac arrhythmias (e.g., sustained ventricular<br>     tachycardia and clinically significant second- or third-degree AV block without<br>     a pacemaker)<br><br>    2. QTcF = 450 ms<br><br>    3. History of familial long QT syndrome or known family history of Torsades de<br>     Pointes<br><br>    4. Resting heart rate (physical exam or 12 lead ECG) <60 bpm<br><br> - Concomitant known infections, including tuberculosis, severe malaria and any other<br>   serious underlying disease that may interfere with disease assessment (e.g.,<br>   cardiac, renal, hepatic, haematologic and pancreatic)<br><br> - Infection with hepatitis B (HBV) or hepatitis C virus (HCV). Patients with a<br>   positive HBV surface antigen (HBsAg) test, or if standard local practice, a positive<br>   HBV core antigen test, and patients with a positive HCV antibody test must be<br>   excluded and will be followed up as per local practice.<br><br> - Known history of hearing impairment and/or clinical signs and symptoms of hearing<br>   impairment identified during routine physical examination<br><br> - Patients with previous history of hypersensitivity reaction or known drug class<br>   allergy to any of the study treatments or excipients<br><br> - Pregnant or nursing (lactating) women<br><br> - Women of childbearing potential who do not agree to have a pregnancy test done at<br>   screening and who do not agree to use highly effective contraception while taking<br>   the investigational drug and for 5 days after stopping the investigational drug<br><br> - Sexually active males unwilling to use a condom during intercourse while taking the<br>   investigational drug and for 5 days after stopping the investigational drug<br><br> - Patients who cannot comply with the planned scheduled visits and procedures of the<br>   study protocol",,Primary Visceral Leishmaniasis,Drug: LXE408;Drug: sodium stibogluconate;Drug: Paromomycin,Proportion of patients treated with LXE408 with initial cure at Day 28,Mortality;Cmax for LXE408;CLss/F for LXE408;AUCtau for LXE408;Tmax for LXE408;Proportion of LXE408 and SSG/PM patients with definitive cure at Day 180;Proportion of patients treated with SSG/PM with initial cure at Day 28;Proportion of patients with positive/negative qPCR;Tissue parasite loads in LXE408 and SSG/PM patients,CLXE408A12202R;DNDi-LXE408-02-VL,Please refer to primary and secondary sponsors,Novartis Pharmaceuticals,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2023,18.0,No,Yes
NCT05593666,8 September 2025,"A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis","A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis",,Drugs for Neglected Diseases,2022-10-20,20221020,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05593666,Not recruiting,No,18 Years,,All,27/12/2022,101.0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). ",Phase 2,India,,,,,,,"Inclusion Criteria:<br><br> - Male and female patients = 18 years (at the time of the screening visit) who are<br>   able to comply with the study protocol. Following a favourable interim analysis<br>   result, patients =12 <18 years will also be enrolled in the trial<br><br> - Patients for whom written informed consent has been obtained (if aged 18 years and<br>   over) or signed by parent(s) or legal guardian for patients under 18 years of age.<br>   In the case of minors, assent from the child also needs to be obtained<br><br> - Primary symptomatic VL (defined as typical parameters including, but not limited to,<br>   fever for > 2 weeks, weight loss, and splenomegaly)<br><br> - Visualization of Leishmania amastigotes by microscopy in tissue samples (spleen or<br>   bone marrow)<br><br>Exclusion Criteria:<br><br> - Clinical signs of severe VL (jaundice, spontaneous bleeding, edema, ascites, coma,<br>   organ failure)<br><br> - Laboratory abnormalities including ALT/SGPT > 3 times ULN, total bilirubin > 1.5<br>   times ULN, creatinine >1.5 times ULN, amylase or lipase > 1.5 times ULN, haemoglobin<br>   < 6 g/dL or other clinically significant abnormal laboratory parameters which, in<br>   the opinion of the investigator, may indicate severe VL<br><br> - Patients with history of previous leishmaniasis and confirmed relapse<br><br> - Patients with para-kala-azar dermal leishmaniasis<br><br> - Patients with severe malnutrition (for children =12-<18 years: BMI-for-age WHO<br>   reference curves by sex, z score < -3; for adults =18 years: BMI < 16)<br><br> - History of congenital or acquired immunodeficiency, including positive HIV (test at<br>   screening)<br><br> - Known hypersensitivity to amphotericin B deoxycholate or any other constituents of<br>   AmBisome®<br><br> - Concomitant infections such as tuberculosis, severe malaria, or any other serious<br>   underlying disease that may interfere with the disease assessment (e.g., cardiac,<br>   renal, hepatic, haematologic, and pancreatic)<br><br> - Infection with hepatitis B (HBV) or hepatitis C virus (HCV). A positive HBV surface<br>   antigen (HBsAg) test, or if standard local practice, a positive HBV core antigen<br>   test, excludes a subject. Patients with a positive HCV antibody test should have HCV<br>   RNA levels measured. Patients with positive (detectable) HCV RNA should be excluded.<br><br> - Pregnant or nursing (lactating) women<br><br> - Women of childbearing potential who do not accept to have a pregnancy test done at<br>   screening and/or who do not agree to use highly effective contraception while taking<br>   the investigational drug and for 5 half-lives or 5 days, whichever is longer, after<br>   stopping the investigational drug.<br><br> - Sexually active males unwilling to use a condom during intercourse while taking the<br>   investigational drug and for 5 half-lives or 5 days, whichever is longer, after<br>   stopping the investigational drug.",,Primary Visceral Leishmaniasis,Drug: LXE408;Other: Placebo;Drug: AmBisome®,Proportion of patients with initial cure at Day 28 for LXE408,Mortality;Cmax for LXE408;Tmax for LXE408;AUCtau for LXE408;CLss/F for LXE408;Cmax for Amphotericin B;AUC0-24h for Amphotericin B;AUC0-infinity for Amphotericin B;Blood parasite clearance;Proportion of patients with a positive loop-mediated isothermal amplification (LAMP) from blood samples;Tissue parasite loads;Proportion of patients with a positive loop-mediated isothermal amplification (LAMP) from tissue samples;Proportion of patients with initial cure at Day 28 for AmBisome®;Proportion of patients with definitive cure at Day 180 for LXE408 and AmBisome®,CLXE408A12201R;DNDi-LXE408-01-VL,Please refer to primary and secondary sponsors,Novartis Pharmaceuticals,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2022,18.0,No,Yes
ChiCTR2000039891,22 February 2021,Bioequivalence Study of (amphotericin B) liposome for injection in fed condition,"Open-Label, Randomized, Two treatment, Parallel, Single period, Bioequivalence study of Amphotericin B Liposome for Injection of Beijing Tide Pharmaceutical CO.,LTD. and AmBisome (Amphotericin B) Liposome for Injection of Astellas Pharma US, inc. in healthy volunteers under fed condition.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",,Shulan (Hangzhou) Hospital,2020-11-13,20201113,10/13/2025 16:05:22,ChiCTR,http://www.chictr.org.cn/showproj.aspx?proj=64218,Recruiting,No,18,55,Both,11/12/2020,200.0,Interventional study,Parallel,1,China,Vincent Li,,"8 Rongjing Street East, Beijing Economic Technological Development Area, Beijing, China",lijt@tidepharm.com,+86 13910333054,"Beijing Tide Pharmaceutical Co., Ltd.","Inclusion criteria: 1.Healthy volunteers must be give written informed consent and fully understand the study.<br>2.Ability to comply with all study requirements.<br>3.healthy volunteers must agree to take effective contraceptive methods to prevent pregnancy from the start of screening until 6 months of last dose administration.<br>4.Male and female healthy volunteers aged between 18 to 55 years (both inclusive).<br>5.Body mass index (BMI) ranges from 18.0 to 28.0 kg/m2, body weight >= 50 kg for male and 45 kg for female.<br>6.Medically healthy subjects with clinically normal laboratory profiles and ECGs.<br>7.No history of heart, liver, kidney, gastrointestinal tract diseases, nervous system, neural abnormities or metabolic abnormalities; No preparation allergies, serious infection or injury, etc.","Exclusion criteria: 1.Smoking >= 5 cigarettes per day during the period from 3 months to 1 month before the study,or using any type of tobacco products within 1 month before the trial;<br>2.Known allergy or hypersensitivity reactions to any components of conventional or liposomal Amphotericin B formulations. Known allergy or hypersensitivity reactions to two or more drugs and foods;<br>3.AST, ALT, total bilirubin, direct bilirubin ,alkaline phosphatase, Serum creatinine concentration greater than the upper limit of normal (ULN). Clinically significant screening laboratory parameters and accessory examination in the opinion of the investigator;<br>4.Average weekly drinking of more than 14 units of alcohol in the 180 days before the trial, 1 unit =360 mL beer or 45 mL 40% spirits or 150 mL wine;<br>5.Subjects who have donated blood or lost blood equal to or more than 400 mL within 90 days before the test, or intend to donate blood or blood components during or within 3 months after the test;<br>6.Subjects enroll in other clinical trials and take corresponding experimental drugs within 90 days before the trial, or participate in other clinical trials;<br>7.Pregnant or lactating women;<br>8.A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test;<br>9.Subjects with acute disease prior to the study;<br>10.Subjects had taken Chocolate, any food or beverage contain caffeine or xanthine within 24 hours before the test;<br>11.Subjects had taken any alcoholic product within 24 hours before the test;<br>12.Positive results for alcohol or drugs.History of drug abuse in the past 5 years or had used drugs in the 3 months prior to the test;<br>13.Subjects who have the difficulty in venous blood, or can not tolerate venipuncture, or have a history of dizziness;<br>14.Other situations that the researchers considered unsuitable to enroll the subject.","fungal infection; presumed fungal infection in febrile,neutropenic patients; visceral leishmaniasis",investigational products group:investigational products;control group:reference listed drug;,Cmax;AUC0-t;,,,"Beijing Tide Pharmaceutical Co.,LTD.",,Approved,30/10/2020,Guan Wenhua,"848 Dongxin Road, Xiacheng District, Hangzhou, Zhejiang",+86 571-56131318,yljdll@shulan.com,Unknown,,,,,,,,,,,,Yes,False,          ,2020,18.0,No,Yes
ISRCTN54981564,10 July 2023,Study of first dosing of a new compound DNDi-6148 in healthy volunteers to assess safety and drug levels in blood and urine after escalating single dose,"A Phase I, blinded, randomized, single-centre, parallel-group, single-dose, dose-escalation, placebo-controlled study of the safety, tolerability, and pharmacokinetics of DNDI-6148 after oral dosing in healthy male subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",,Drugs for Neglected Diseases Initiative,2020-07-03,20200703,10/13/2025 16:05:22,ISRCTN,https://www.isrctn.com/ISRCTN54981564,Not Recruiting,No,,,Male,04/02/2020,64.0,Interventional,Single-center interventional blinded randomized parallel-group single-dose dose-escalation placebo-controlled study (Treatment),Phase I,France,,,,,,,"Inclusion criteria: 1. Healthy Caucasian male volunteer aged 18 to 50 years inclusive<br>2. Non-smoker or light smoker of not more than 5 cigarettes a day. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study<br>3. Body Mass Index (BMI) between 18 and 30.1 kg/m2 inclusive at screening<br>4. Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical and neurological examination)<br>5. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position:<br>5.1. 95 mmHg = Systolic Blood Pressure (SBP) = 140 mmHg<br>5.2. 50 mmHg = Diastolic Blood Pressure (DBP) = 90 mmHg<br>5.3. 45 bpm = HR = 90 bpm<br>5.4. Or considered NCS by investigators<br>6. Normal ECG recording on a 12-lead ECG at the screening visit:<br>6.1. 120 ms < PR < 210 ms<br>6.2. QRS < 120 ms<br>6.3. QTcf = 430 ms for male<br>6.4. No sign of any relevant trouble of sinusal automatism <br>6.5. Or considered as non-clinically significant by investigators<br>7. Laboratory parameters within the normal range of the laboratory (hematological, hormonology, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged non-clinically significant by the Investigator; for example, isolated elevated bilirubin is acceptable if judged by the physician without clinical relevance (i.e. Gilbert's syndrome)<br>8. ALAT, ASAT and Creatinine values strictly within the normal range<br>9. A negative result for diagnostic test of SARS-CoV-2 at D-1<br>10. Normal dietary habits<br>11. Provision of written informed consent to participate as shown by a signature on the volunteer consent form, after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate<br>12. Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study<br>13. Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research<br>14. Must agree to adhere to the contraception requirements defined in Section 4.3: use of condom by the male volunteer plus an effective method of contraception for the volunteer or their partner of childbearing potential from study drug administration until 90 days post-dosing OR use of a condom for 10 days post-dosing if the partner is known to be pregnant","Exclusion criteria: 1. Having previously received DNDI-6148, or who participated in another clinical trial within 3 months prior and during the study, or 5-times the half-life of the drug tested in the previous clinical trial, whichever is longer (time calculated relative to the last dose in the previous clinical trial)<br>2. Any history (direct questioning) or presence (physical examination) of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious acute or chronic disease; including known or suspected HIV, HBV or HCV infection<br>3. With any clinically significant abnormality following review of pre-study laboratory tests, vital signs, full physical examination and ECG<br>4. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position<br>5. Who have a history of allergy, intolerance or photosensitivity to any drug<br>6. Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug<br>7. Who have a history of additional risk factors for “Torsades de Pointe” (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)<br>8. Current suicide risk or history of suicide risk (CSSRS baseline: “yes” answer to items 4 and/or 5); participants with a “yes” answer for current suicide risk should be referred for psychiatric evaluation<br>9. Participants with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency<br>10. Who used a prescription medicine during the 28 days before the first dose of trial medication or use of an over-the-counter medicine (including antacid drug, with the exception of acetaminophen (paracetamol)), during the 7 days before the first dose of trial medication<br>11. History or presence of drug or alcohol abuse (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol)<br>12. Excessive consumption of beverages with xanthine bases (more than one liter/day)<br>13. Who drink more than 8 cups daily of beverage containing caffeine<br>14. Who has regular daily consumption of more than 5 cigarettes daily, or use more than 3 grams (1/8 ounce) of tobacco<br>15. Who use dietary supplements or herbal remedies (such as St John’s Wort) known to interfere with the CYP3A4 and/or P-gp metabolic pathways during the 28 days before the first dose of trial medication<br>16. Grapefruit should also be avoided during the 7 days before the first dose of trial medication<br>17. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV 1 or 2) tests<br>18. Positive results of screening for drugs of abuse (opiates, cocaine, amphetamine, cannabis, benzodiazepines)<br>19. Blood donation (including in the frame of a clinical trial) within 12 weeks before administration<br>20. General anaesthesia within 3 months before trial medication administration<br>21. Inability to abstain from intensive muscular effort<br>22. Who have any clinical condition or prior therapy which, in the opinion, of the Investigator, made the participant unsuitable for the study<br>23. Who had surgery (e.g. stomach bypass) or medical condition that might affect absorption of study drug taken orally<br>24. Who had febrile illness within 1 week before the start of the study<br>25. Participant who, in t",Treatment of visceral and/or cutaneous leishmaniasis <br>Infections and Infestations <br>Leishmaniasis,"Sixty-four (64) healthy male volunteers, aged 18 to 50 will be included in the study. Randomization is performed by block of 2 (1:1 for placebo:active) for the sentinel group, followed by block of 6 (1:5) for the main group of each dose cohort. A coding list was issued at the start of the trial, only available to unblinded personnel. Each cohort will include 8 participants (randomized in 6 active/2 placebo). A single dose of treatment will be administered as an oral suspension with increasing doses for each cohort of 8, such as 10 mg, 20 mg, 40 mg, 80 mg, 160 mg, 260 mg, 380 mg and 500 mg. The treatment will be administered as a single dose on Day 1. Last follow up visit is 72 h post-dosing.","Safety and tolerability of DNDI-6148 measured by:<br>1. Frequency of adverse events (AEs), based on the clinical judgement of the investigator, occurring from dosing up to 72 h post-dose<br>2. Frequency of participants reporting AEs, based on the clinical judgement of the investigator, from dosing up to 72 h post-dose<br>3. Causality of AEs based on the clinical judgement of the investigator, occurring from dosing up to 72 h post-dose, The possible relationship between the AE and the study drug will be quoted as following:<br>Not related: There is no reasonable possibility of causal relationship.<br>Related: There is at least a reasonable possibility of a causal relationship between an adverse event and an investigational medicinal product. This means that there are facts (evidence) or arguments to suggest a causal relationship.<br>4. Severity of AEs assessed based on the clinical judgement of the investigator, occurring from dosing up to 4 days post-dose, The severity of the AEs will be determined in the following manner:<br>Mild: The participant is aware of the event or symptom, but the event or symptom is easily tolerated (e.g. no reduction in daily activities is required).<br>Moderate: The participant experiences sufficient discomfort to interfere with or reduces his or her usual level of activity.<br>Severe: Significant impairment of functioning: the participant is unable to carry out usual activities and/or the participant's life is at risk from the event.<br>Life-threatening: The participant is at significant risk of life; it does not refer to an event which hypothetically might have caused death if it were more severe (life-threatening consequences, urgent intervention required).<br>Death: Death related to an event.",1. AUC0-8 (area under the plasma concentration-time curve from administration up to infinity with extrapolation of the terminal phase) calculated following quantification of DNDI-6148 by LC/MS-MS in plasma from dosing up to 72 hours post dose<br>2. Cmax (observed maximum plasma concentration) calculated following quantification of DNDI-6148 by LC/MS-MS in plasma from dosing up to 72 hours post dose<br>3. Other PK descriptive parameters derived from quantification of DNDI-6148 in plasma and urine by LC/MS-MS from dosing up to 72 hours post dose<br>4. Cardiologic pharmacodynamics parameters of DNDI-6148 measured from electrocardiograms (ECG) recordings from baseline up to 72 hours post dose,2018-004023-37;Nil known;DNDi-6148-01 / OP105718.DND,Wellcome Trust,,,01/01/1900,"Old ethics approval format; Approved 07/12/2018, Committee of people protection South-East and Overseas II (Comité de Protection des Personnes, Agence regionale de santé Occitanie, Bureau 1048, 10 chemin du raisin, 31050 Toulouse Cedex9, France; +33 (0)5 34 30 27 55; cppsoom2@ars.sante.fr), ref: 2-18-90 / SI 1823",,,,Yes,,,,08/03/2022,,,,,,Other,Planned publication in a high-impact peer-reviewed journal. The protocol will be available.,No,False,          ,2020,,Unknown,Yes
CTRI/2019/04/018673,24 November 2021,"To compare the blood levels and side effects between liposomal Amphotericin B Injection of Sun Pharmaceutical Industries Limited and AmBisomeÂ® of Astellas Pharma US, Inc.","A Randomized, Open Label, Multicenter, Two Treatment, Multiple Dose, Steady State, Parallel Group, Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg / vial of Sun Pharmaceutical Industries Limited and AmBisomeÂ® (Amphotericin B) Liposome for Injection 50 mg / vial of Astellas Pharma US, Inc. under Fed Condition.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",,Sun Pharmaceutical Industries Ltd India,2019-04-22,20190422,10/13/2025 16:05:22,CTRI,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27597,Not Recruiting,No,,,,15/05/2019,140.0,BA/BE,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label",Unknown,India,Sharad P Kholambe,,"Sun house, CTS NO B1, Western Highway, Goregaon East, Mumbai ",ARSHAD.KHUROO@sunpharma.com,01244768005,Sun Pharmaceutical Industries Ltd,"Inclusion criteria: Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified. <br/ ><br>1.Male and non-pregnant, non-lactating female subjects with 18 to 75 years (both inclusive) of age. <br/ ><br> <br/ ><br>2.Immunocompetent subjects who need Amphotericin B treatment for no less than 5 days as part of his/her therapy for following disease condition: <br/ ><br>a. Presence of amastigotes of leishmania on smears of bone marrow aspirate, or smears of splenic aspirate, or histology of liver, marrow, or spleen or presence of amastigotes (Leishmania Donovani bodies) detected by rK39 dipstick test, and <br/ ><br>b. Clinical Symptoms of visceral Leishmaniasis (fever of over 2 weeks duration, weight loss and splenomegaly) <br/ ><br> <br/ ><br>3. Subjects with life expectancy greater than or equal to 4 weeks. <br/ ><br> <br/ ><br>4. Subject having sufficient venous access to permit administration of study drug. <br/ ><br> <br/ ><br>5. Subjects must have clinically acceptable results from all the screening and check-in laboratory investigations. <br/ ><br> <br/ ><br>6. Subject and/or LAR who can able to understand and provide written informed consent. <br/ ><br> <br/ ><br>7. Able to comply with study requirements and assessments. <br/ ><br> <br/ ><br>8. Subjects of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as birth control pills (if taken for at least 3 months prior to receiving the study medication), progestin injection or implants, condom plus spermicide, diaphragm plus spermicide, IUD, or vaginal spermicidal suppository or abstinence from sexual activity. <br/ ><br>OR <br/ ><br>Postmenopausal with spontaneous amenorrhea for at least past 12 months (in case of Postmenopausal with spontaneous amenorrhea for at least 6 months then serum FSH level > 40 mIU/ml. <br/ ><br>OR <br/ ><br>Surgically sterile (subjects with bilateral tubal ligation / bilateral oophorectomy / hysterectomy) <br/ ><br>","Exclusion criteria: Subjects must not be enrolled in the study if they meet any one of the following criteria: <br/ ><br>1. Subjects with allergy or significant history of hypersensitivity or idiosyncratic reactions to any drug or excipients. <br/ ><br>2. Subject had moderate or severe liver disease which is defined as: <br/ ><br>(a) Transaminase (SGOT/AST or SGPT/ALT) > 10 times upper limit of normal (ULN) <br/ ><br>(b) Total bilirubin > 5 times ULN <br/ ><br>(c) Alkaline phosphatase > 5 times ULN <br/ ><br>3. Subjects with Serum Creatinine > 2 x upper limit of normal. <br/ ><br>4. Subjects with potassium levels <= 3.0 mmol/L or mEq/L. <br/ ><br>5. Subjects who require concomitant therapy with intravenous fat emulsions, such as total parental nutrition (TPN). <br/ ><br>6. Subjects with Hemoglobin level < 6 gm%, neutrophils <750/ mm3 and platelets <50,000 / mm3 <br/ ><br>7. Subjects with splenectomy <br/ ><br>8. Subjects with Post-kala-azar dermal leishmaniasis. <br/ ><br>9. Subjects who are receiving corticosteroids and corticotropin (ACTH), digitalis glycosides, azoles, other nephrotoxic medications, skeletal muscle relaxants (e.g. tubocurarine) within 30 days prior to enrollment in the study. <br/ ><br>10. Subjects who are currently receiving or received antineoplastic agents prior to enrollment in the study. <br/ ><br>11. Subjects who require leukocyte transfusions while receiving Amphotericin B. <br/ ><br>12. Subjects who have shown positive result in breath alcohol test and/or urine drug screening test prior to check in <br/ ><br>13. Subjects with history of drug or substance abuse or dependence, history of alcoholism in the past 1 year prior to screening. <br/ ><br>14. Subjects who have donated blood or loss of blood or plasma of one unit (about 450 mL whole blood or 220 mL plasma) in the previous 60 days. <br/ ><br>15. Subjects with history of difficulty with donating blood or difficulty in accessibility of veins or intolerance to venipuncture. <br/ ><br>16. Subjects with history of allergic response to heparin. <br/ ><br>17. Subjects with positive hepatitis screen (includes subtypes B & C). <br/ ><br>18. Subjects with positive test result for HIV antibody. <br/ ><br>19. Subjects with positive test result for syphilis (RPR/VDRL). <br/ ><br>20. Subjects with any clinically significant ECG findings. <br/ ><br>21. Participation in any investigational drug study within 30 days prior to first dose of study drug <br/ ><br>22. Subjects with history of or current clinically significant medical illness including (but not limited to) cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological, or psychiatric disease or any other illness that, that the investigator considers should exclude the subject. <br/ ><br>23. Subjects with any other medical condition or comorbid complication that, in the investigatorâ??s judgment, might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study. <br/ ><br>",Health Condition 1: B550- Visceral leishmaniasis,"Intervention1: Amphotericin B Liposome for Injection 50 mg / vial (Test) of Sun Pharmaceutical Industries Limited: Subjects requiring Amphotericin B as part of their therapy will be administered either test or reference product (as per randomization) of Amphotericin B Liposome for Injection using a controlled infusion device by intravenous route, over a period of 120 (Â± 02) minutes, 2.5 hours after start of standard (non-high fat) breakfast (500-600 Kcal) in the morning as per randomization schedule for five consecutive days [Day 01 to 05].<br>Control Intervention1: AmBisomeÂ® [Amphotericin B] Liposome for Injection 50 mg / vial (Reference) of Astellas Pharma US, Inc: Subjects requiring Amphotericin B as part of their therapy will be administered either test or reference product (as per randomization) of Amphotericin B Liposome for Injection using a controlled infusion device by intravenous route, over a period of 120 (Â± 02) minutes, 2.5 hours after start of standard (non-high fat) breakfast (500-600 Kcal) in the morning as per randomization schedule for five consecutive days [Day 01 to 05].<br>","To assess the steady state bioequivalence between Test Product (Amphotericin B Liposome for Injection 50 mg / vial of Sun Pharmaceutical Industries Limited) and Reference Product (AmBisomeÂ® (Amphotericin B) Liposome for Injection 50 mg / vial of Astellas Pharma US, Inc.) under Fed Conditions.Timepoint: At the end of the study when all 140 patients have <br/ ><br>completed the study",To evaluate the safety of Test Product and Reference Product.Timepoint: At the end of the study when all 140 patients have <br/ ><br>completed the study,CRL121842. Protocol Version 1.0 dated 18 Dec 2018,"Sun Pharmaceutical Industries limited, Tandalja, Vadodara 390012",,Approved;Approved,18/03/2019;20/06/2019,"Ethics Committee, Kala Azar Medical Research Centre Rambagh Road, Muzaffarpur-842001 Bhiar India;Institutional Ethics Committee, Rajendra Memorial Research Institute of Medical Sciences RMRIMS Indian Council of medical Research Agamkuan Patna-800007 Bihar india",;,;,;,Unknown,,,,,,,,,,,,Yes,False,          ,2019,,Unknown,Yes
NCT03929016,9 January 2023,Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects,"A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Subjects",,Drugs for Neglected Diseases,2019-04-09,20190409,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03929016,Not recruiting,No,18 Years,60 Years,All,04/04/2019,64.0,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ",Phase 1,United Kingdom, ,"Sharan Sidhu, MD",,,,Quotient Sciences,"<br>    Inclusion Criteria:<br><br>     - Healthy males (Cohorts 1 to 7) or healthy WONCBP (Cohort 8)<br><br>     - 18 to 55 years (Cohorts 1 to 7) or 18 to 60 years (Cohort 8)of age at the time of<br>       signing informed consent<br><br>     - Body mass index (BMI) of 18.0 to 30.1 kg/m2 as measured at screening<br><br>     - General good physical health determined by medical and surgical history, physical<br>       examination, 12-lead ECG, vital signs and clinical laboratory tests<br><br>     - Normal blood pressure: Systolic blood pressure between =90 and =140 mmHg, Diastolic<br>       blood pressure =90 mmHg, measured after 10 min rest in supine position at screening,<br>       admission and pre-dose<br><br>     - A resting Heart Rate (HR) between =40 and =90 bpm measured after 10 min rest in supine<br>       position at screening, admission and pre-dose<br><br>     - ECG recording without clinically significant abnormality, including QTcF measure of<br>       =450 msec (male) or =470 msec (female) at screening, admission and pre-dose<br><br>     - Having had no febrile seizures or infectious illness for at least 7 days prior to<br>       administration of the Investigational Medicinal Product (IMP)<br><br>     - Must be willing and able to communicate and participate in the whole study<br><br>     - Must provide written informed consent<br><br>     - Must agree to adhere to the contraception requirements and life-style restrictions<br>       defined in the protocol<br><br>    Exclusion Criteria:<br><br>     - Subjects who have received any IMP in a clinical research study within the 3 months or<br>       90 days prior to Day 1<br><br>     - Subjects who are study site employees, or immediate family members of a study site or<br>       sponsor employee<br><br>     - Subjects who have previously been enrolled in this study and/or have received<br>       DNDI-0690 previously<br><br>     - History of any drug or alcohol abuse in the past 2 years<br><br>     - Demonstrating excess in caffeine/xanthine consumption (more than 6 cups of coffee or<br>       equivalent a day)<br><br>     - Regular alcohol consumption in males >21 units per week and females >14 units per week<br>       (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of<br>       wine, depending on type). As confirmed by a positive alcohol breath test at screening<br>       or admission<br><br>     - Current smokers and those who have smoked within the last 12 months. As confirmed by a<br>       breath carbon monoxide reading of greater than 10 ppm at screening or admission<br><br>     - Current users of e-cigarettes and nicotine replacement products and those who have<br>       used these products within the last 12 months<br><br>     - Females of childbearing potential including those who are pregnant or lactating (all<br>       female subjects must have a negative serum pregnancy test at screening and admission).<br>       A woman is considered of childbearing potential unless she is permanently sterile<br>       (hysterectomy, bilateral salpingectomy, bilateral tubal ligation, bilateral tubal<br>       occlusion and bilateral oophorectomy) or is postmenopausal (had no menses for 12<br>       months without an alternative medical cause and a serum follicle stimulating hormone<br>       [FSH] concentration =40 IU/L)<br><br>     - Subjects who do not have suitable veins for multiple venepunctures/cannulation as<br>       assessed by the investigator or delegate at screening<br><br>     - Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis<br>       (especially aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma<br>       glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), creatinine, and blood urea<br>       nitrogen (BUN)) as judged by the investigator (laboratory parameters are listed in<br>       Appendix 1). Subjects with Gilbert's syndrome are allowed<br><br>     - Confirmed positive drugs of abuse test result<br><br>     - Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or<br>       human immunodeficiency virus (HIV) results<br><br>     - Evidence of renal impairment at screening or admission, as indicated by an estimated<br>       creatinine clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation<br><br>     - History of clinically significant cardiovascular, renal, hepatic, neurological<br>       (especially seizures), immunological, psychiatric, myopathies, bleeding tendency,<br>       respiratory and particularly gastrointestinal (GI) disease, especially peptic<br>       ulceration and chronic gastritis, GI bleeding, ulcerative colitis, Crohn's Disease or<br>       Irritable Bowel Syndrome, as judged by the investigator<br><br>     - History of additional risk factors for Torsades des Pointe (eg heart failure,<br>       hypokalaemia, family history of long QT syndrome)<br><br>     - Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or<br>       sucrose-isomaltase insufficiency<br><br>     - Any relevant GI complaints within 7 days of dosing<br><br>     - Subjects with a history of cholecystectomy or gall stones (Cohort 7 only)<br><br>     - Serious adverse reaction or clinically relevant hypersensitivity to any drug or the<br>       formulation excipients (Hypromellose [HPMC], sodium lauryl sulphate [SLS], sucrose,<br>       croscarmellose sodium and magnesium stearate)<br><br>     - Presence or history of clinically significant allergy requiring treatment (including<br>       asthma, urticaria, clinically significant allergic rash or other severe allergic<br>       diathesis), as judged by the investigator. Hay fever is allowed unless it is active<br><br>     - Donation or loss of greater than 500 mL of blood within the previous 3 months or more<br>       than 100 mL within 30 days before signing Informed Consent Form (ICF) to this trial<br><br>     - Subjects who are taking, or have taken, any prescribed or over-the-counter drug<br>       (including anti-acid drugs) or vitamins/herbal remedies (eg St. John's Wort and others<br>       which are known to interfere with the Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein<br>       (P-gp) metabolic pathways) or HRT in the 21 days before IMP administration.<br>       Administration of up to 4 g of paracetamol per day within 7 days of IMP administration<br>       is allowed<br><br>     - Surgery within 12 weeks prior to screening, with the exception of appendectomy<br><br>     - Any surgery (eg gastric bypass) or medical condition that may affect absorption of<br>       orally administered drugs<br><br>     - Failure to satisfy the investigator of fitness to participate for any other reason<br>   ",,Visceral Leishmaniasis;Cutaneous Leishmaniases,Drug: DNDI-0690;Drug: Placebo of DNDI-0690,Safety and Tolerability of DNDI-0690 by Assessing the Occurrence of Treatment-emergent adverse events (TEAEs);Safety and Tolerability of DNDI-0690 by Assessing the Changes in 12-lead electrocardiogram (ECG) parameters;Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to liver function;Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to liver function;Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to renal function;Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to renal function;Safety and Tolerability of DNDI-0690 by Assessing the Changes of Troponin I as a cardiac safety marker,Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity (AUC0-inf);Observed Maximum Concentration (Cmax);Time to Maximum Observed Plasma Concentration (Tmax);Apparent elimination half-life (T1/2),2018-002021-35;QSC200932;DNDi-0690-01,Please refer to primary and secondary sponsors,Wellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable Elimination of Leishmaniasis,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2019,18.0,No,Yes
CTRI/2018/04/013350,24 November 2021,Clinical Study of Amphotericin B Liposome in patients with Visceral Leishmaniasis under fed (non-high fat breakfast) condition,"A Multi-Center Open-Label Randomized Two treatment Parallel Single period Multiple-Dose Steady state Global Bioequivalence study of Amphotericin B Liposomefor Injection 50mg vial (Test) of Auromedics Pharma LLC USA and AmBisome (Amphotericin B) Liposomefor Injection 50mg/vial (Reference) of Astellas Pharma US, inc in patients with Visceral Leishmaniasisunder fed (non-high fat breakfast) condition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",,APL Research Center Aurobindo Pharma Limited,2018-04-18,20180418,10/13/2025 16:05:22,CTRI,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=25496,Not Recruiting,Yes,,,,26/04/2018,140.0,BA/BE,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label",Unknown,Bangladesh;India,DrSubhraLahiri,,AXIS Clinicals Ltd1-121/1 Miyapur Hyderabad 500049Telangana INDIA ,subhra.l@axisclinicals.com,,AXIS Clinicals Ltd,"Inclusion criteria: <br/ ><br>Inclusion criteria <br/ ><br> <br/ ><br>1.Male and female patients aged between 18 to 65 years (both inclusive). <br/ ><br>2.Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration, weight loss and splenomegaly). <br/ ><br>3.Presence of amastigotes (Leishmania Donovani bodies) at prescreening detected by rK39 dipstick test. <br/ ><br>4.Female subjects of childbearing potential must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of birth control, i.e. barrier method, intrauterine device, or tubal ligation. <br/ ><br>5.Ability to comply with all study requirements. <br/ ><br>6.Patients with Hb >= 6.0 g/dl  <br/ ><br>7.Patients with platelets count >= 50000/mm3 <br/ ><br>8.Patients and/ or LAR must be give written informed consent <br/ ><br>Patients with clinically acceptable results from all the screening laboratory parameters and investigations. <br/ ><br>","Exclusion criteria: Exclusion Criteria: <br/ ><br> <br/ ><br>1.Known allergy or hypersensitivity reactions to any components of conventional or liposomal Amphotericin B formulations. <br/ ><br>2.Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up. <br/ ><br>3.Pregnant or lactating women <br/ ><br>4.Patients requiring dose adjustment during the study. <br/ ><br>5.Serum creatinine concentration greater than twice the upper limit of normal (ULN), AST or ALT value greater than 10 times the ULN <br/ ><br>6.Patients who are required to be on concomitant therapy with IV fat emulsions, such as total parental nutrition (TPN). <br/ ><br>7.Patients with total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl). <br/ ><br>8.Patient with clinically significant Hematopoietic, renal, hepatic and electrolyte disorders (Low level of Magnesium and potassium) will be excluded as per the discretion of Investigator <br/ ><br>9.Patients with Clinically significant screening laboratory parameters in the opinion of the investigator. <br/ ><br>10.Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. <br/ ><br>11.History of uncontrolled diseases, such as thyroidal dysfunction, angina pectoralis, serious cardiac arrhythmias, serious heart failure, neuropsychiatric infection or disease. <br/ ><br>12.Patients with controlled and uncontrolled diabetes mellitus <br/ ><br>13.Patients with Uncontrolled hypertension will be excluded. <br/ ><br>14.Patients with known positivity for human immunodeficiency virus (HIV), HBsAg and HCV. <br/ ><br>15.Positive results for drugs of abuse (benzodiazepines, opioids, amphetamines, cannabinoids, cocaine and barbiturates) in urine. <br/ ><br>16.Positive results for alcohol as detected by alcohol breath analyzer. <br/ ><br>17.History of difficulty with donating blood or difficulty in accessibility of veins. <br/ ><br>18.An unusual or abnormal diet, for whatever reason e.g. religious fasting. <br/ ><br>19.History of donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product in the study <br/ ><br>",Health Condition 1: null- Visceral Leishmaniasis in adult patients,"Intervention1: Liposomal Amphotericin B<br>3mg/kg/day for 5days <br>: The study will consist of single period. Each eligible patient will receive either test or reference drug for five consecutive days under non high fat breakfast condition everyday<br>Control Intervention1: AmBisomeÂ® Liposome for Injeciton<br>50mg/vial <br>Marketed by:<br>Astellas Pharma<br>US,Inc.USA<br>: The study will consist of single period. Each eligible patient will receive either test or reference drug for five consecutive days under non high fat breakfast condition everyday<br>","AUC0 Area under the plasma concentration time curve over the steady state dosing intervalCmax-ss: Maximum concentration over the steady state dosing intervalTimepoint: Day 5, venous blood samples (3 mL) will be collected at 0.083, 0.25, 0.50, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 18.00 and 24.00 (Day 6)",Cminss Minimum concentration over the steady state dosing interval Cavgss Average concentration over the steady state dosing interval Percentage fluctuation maxss Cminss Cavgss 100 Tmax ss Time of maximum measured plasma concentration over the steady state dosing interval Swing Cmax ss Cmin ss Cmin ss <br/ ><br>Cpd pre-dose concentration Pre dose concentrations determined before a dose at steady stateTimepoint: Venous blood samples 3 mL will be withdrawn within 5 minutes prior to dosing on Day 3 4 5 to confirm steady-state condition <br/ ><br>On Day 5 venous blood samples 3 mL will be collected at 0083 025 050 100 133 167 200 during drug infusion 233 267 300 350 400 500 600 800 1000 1200 1800 and 2400 Day 6 hours after the start of the infusion Post dose samples will be collected with allowed window period of 3 minutes <br/ ><br>,"CR179-17, Version 1.0, Dated 22.09.2017",Aurobindo Pharma Limited Hyderabad,AXIS Clinicals Ltd,Approved;Approved;Approved,29/12/2017;22/12/2017;21/12/2017,"EC-Kala-Azar Medical Research Centre, Rambagh road, Muzaffarpur(Bihar)-842001,India;Ethics Committee, Rajendra Memorial Research Institute of Medical Sciences,Agam Kuan Flyover, Sadikpur, Patna-800007,Bihar,India;Institutional Ethics Committee, Calcutta School of Tropical Medicine,108,Chittaranjan Avenue, Kolkata 700073,India",;;,;;,;;,Unknown,,,,05/04/2019,,,,,,,,Yes,True ,parent    ,2018,,Unknown,Yes
NCT03303898,28 March 2022,"ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -","ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - POSTULATE PRIOR TO HUMAN VACCINAL TRIALS Immune Response of Asymptomatic Carriers to L. Infantum",Asymptoleish,Centre Hospitalier Universitaire de Nice,2017-10-03,20171003,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03303898,Not recruiting,No,19 Years,,All,10/11/2017,30.0,Interventional,Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). ,Unknown,France,,,,,,,<br>    Inclusion Criteria for asymptomatic careers<br><br>     - Male and Female<br><br>     - Age between 18 and 80 years<br><br>     - PCR and western blot positive to L. Infantum (these exams will be redone as part of<br>       the study).<br><br>     - Signature of informed consent<br><br>     - Affiliation to a social security scheme<br><br>    Exclusion Criteria:<br><br>     - Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people<br>       will be excluded because of the immunosuppressive action of HIV on the immune system.<br>       HIV status will be determined by interrogation.<br><br>     - Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion<br>       proposal) will be performed for women of child-bearing age. The results will be<br>       communicated to the patient by a doctor of her choice.<br><br>     - Persons under guardianship<br><br>    Inclusion Criteria for healthy patient<br><br>     - Male or Female<br><br>     - Age between 18 and 80 years<br><br>     - PCR and western blot negative Leishmania (these exams will be redone as part of the<br>       study).<br><br>     - Signature of informed consent<br><br>     - Affiliation to a social security scheme<br><br>    Exclusion Criteria:<br><br>     - Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people<br>       will be excluded because of the immunosuppressive action of HIV on the immune system.<br>       HIV status will be determined by interrogation.<br><br>     - Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion<br>       proposal) will be performed for women of child-bearing age. The results will be<br>       communicated to the patient by a doctor of her choice.<br>   ,,"Leishmaniasis, Cutaneous",Procedure: Blood sampling,immune response of lymphocytes from asymptomatic carriers,,17-AOI-04,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2017,19.0,No,Yes
NCT02071758,14 March 2016,Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers,"A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects",,IDRI,2014-02-24,20140224,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02071758,Not recruiting,No,18 Years,49 Years,Both,01/04/2014,39.0,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention",Phase 1,United States, ,"Anna Marie Beckmann, PhD",,,,IDRI,"<br>    Inclusion Criteria:<br><br>     - Males and females 18 to 49 years of age.<br><br>     - Must be in good general health as confirmed by a medical history and physical exam.<br><br>     - Female subjects must have a negative serum pregnancy test at screening and a negative<br>       urine pregnancy test on the day of each study vaccination, must not be<br>       breast-feeding, and are required to use one of the following methods of contraception<br>       during the first 3 months of the study: hormonal (e.g., oral, transdermal,<br>       intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm with<br>       spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6<br>       months minimum); abstinence; or bilateral tubal ligation (if no conception<br>       post-procedure). These precautions are necessary due to unknown effects that LEISH-F3<br>       + SLA-SE or LEISH-F3 + GLA-SE might cause in a fetus or newborn infant.<br><br>     - The following screening laboratory values must be within the normal ranges or not<br>       clinically significant as determined by the PI and Medical Monitor (MM): sodium,<br>       potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting<br>       glucose, total WBC count, hemoglobin, and platelet count.<br><br>     - The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface<br>       antigen (HBsAg), and hepatitis C virus (HCV) antibody.<br><br>     - Negative urine test for recreational drugs and alcohol per Clinical Research Unit<br>       standards.<br><br>     - Urinalysis not clinically significant as determined by the study clinician.<br><br>     - Must be capable of completing a study memory aid in English.<br><br>     - Must give informed consent, be able and willing to make all evaluation visits, be<br>       reachable by telephone or personal contact by the study site personnel, and have a<br>       permanent address.<br><br>    Exclusion Criteria:<br><br>     - History of possible infection with Leishmania or previous exposure to Leishmania<br>       vaccines or experimental products containing SLA or GLA.<br><br>     - Veterans who served in the military in the Middle East (Iran, Iraq), Afghanistan, or<br>       any other areas endemic to Leishmania.<br><br>     - Travelers to, or immigrants from, areas endemic to Leishmania.<br><br>     - Participation in another experimental protocol or receipt of any investigational<br>       products within the past 3 months.<br><br>     - Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as<br>       prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy<br>       drugs or radiation) within the past 6 months.<br><br>     - Received a blood transfusion within the past 3 months.<br><br>     - Donated blood products (platelets, whole blood, plasma, etc.) within past one month.<br><br>     - Received any vaccine within past 1 month and no planned immunizations while on study<br>       with the exception of seasonal influenza vaccine which should not be given between<br>       Day 0-84 or Day 138-168 due to 30-day washout period prior to immunology blood draws.<br><br>     - History of autoimmune disease or other causes of immunosuppressive states.<br><br>     - History or evidence of any acute or chronic illness (including cardiovascular,<br>       pulmonary, neurological, hepatic, rheumatic, hematological, metabolic, or renal<br>       disorders, controlled hypertension), or use of medication that, in the opinion of the<br>       Principal Investigator, may interfere with the evaluation of the safety or<br>       immunogenicity of the vaccine.<br><br>     - Rash, tattoos, or any other dermatological condition that could adversely affect the<br>       vaccine injection site or interfere with its evaluation.<br><br>     - BMI, that in the opinion of the Investigator, poses a health risk.<br><br>     - Hypertension (systolic >150 or diastolic >95).<br><br>     - History of significant psychiatric illness with current use of medication.<br><br>     - Known or suspected alcohol or drug abuse within the past 6 months.<br><br>     - Chronic smoker (> 20 pack years).<br><br>     - Subjects with a history of previous anaphylaxis or severe allergic reaction to<br>       vaccines, eggs, or unknown allergens.<br><br>     - Subjects who are unlikely to cooperate with the requirements of the study protocol.<br>   ",,Visceral Leishmaniasis,Biological: LEISH-F3 + SLA-SE;Biological: LEISH-F3 + GLA-SE,Number of Adverse Events,Immunogenicity,IDRI-LVVPX-117,Please refer to primary and secondary sponsors,Bill and Melinda Gates Foundation,,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2014,18.0,No,Yes
NCT02011958,12 December 2020,Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.,A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.,,Drugs for Neglected Diseases,2013-11-18,20131118,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02011958,Not recruiting,No,18 Years,60 Years,All,01/07/2014,59.0,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ,Phase 3,Ethiopia, ,"Ermias Diro, Dr. MD",,,,University of Gondar,"<br>    Inclusion Criteria:<br><br>     - Confirmed HIV positive test (2 rapid diagnostics tests (RDTs) followed by a<br>       confirmatory ELISA test).<br><br>     - Diagnosis of VL (first episode or relapse) confirmed by bone marrow or spleen<br>       aspirate.<br><br>     - Male and female age: 18-60 years.<br><br>     - Written informed consent from the patient.<br><br>    Exclusion Criteria:<br><br>     - Women of child-bearing potential (defined as women who have achieved menarche) who are<br>       not using an assured method of contraception or are unwilling to use an assured method<br>       of contraception for the duration of treatment and four months after.<br><br>     - Pregnant women or breast-feeding mothers.<br><br>     - Patients with grade 2 or 3 post kala-azar dermal leishmaniasis (PKDL) lesions.<br><br>     - Clinical or biological evidence of severe cardiac, renal or hepatic impairment.<br><br>     - Known hypersensitivity to AmBisome® and/or miltefosine.<br><br>     - Patients receiving allopurinol treatment<br>   ",,Visceral Leishmaniasis,Drug: Liposomal Amphotericin B;Drug: Miltefosine,Initial parasitological cure at day 29,Relapse-free survival at day 390,HIV/VL 0511,Please refer to primary and secondary sponsors,"Medecins Sans Frontieres, Netherlands;London School of Hygiene and Tropical Medicine;Addis Ababa University;Institute of Tropical Medicine, Belgium;Slotervaart Hospital;University of Gondar",,,,,,,Unknown,,,,,,,,,,,,Yes,False,          ,2013,18.0,No,Yes
NCT01975051,19 February 2015,"A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)","A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)",,"International Centre for Diarrhoeal Disease Research, Bangladesh",2013-10-23,20131023,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01975051,Not recruiting,No,18 Years,60 Years,Both,01/01/2013,36.0,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 4,Bangladesh, ,"Dinesh Mondal, MB; MD; PhD",,,,"International Centre for Diarrhoeal Disease Research, Bangladesh",<br>    Inclusion Criteria:<br><br>     - History of Visceral Leishmaniasis<br><br>     - Presence of hypopigmented rash<br><br>     - Rk39 strip test positive<br><br>     - Written informed consent from the participant<br><br>    Exclusion Criteria:<br><br>     - Any medical condition that may affect the safety of the patient during study<br>       procedure<br><br>     - Any condition which comprises the ability to comply the study procedure<br><br>     - Presence of splenomegaly<br><br>     - Posotive skin smear for mycobacterium leprae<br><br>     - Positive skin smear for fungus<br><br>     - Pregnancy test positive<br>   ,,Post-kala-azar Dermal Leishmaniasis,Drug: Mitefosine,"Explore the association of treatment regimens for visceral leishmaniasis, host immunological, genetical and nutrition factors with Post-kala-azar Dermal Leishmaniasis (PKDL)",,PR-12057,Please refer to primary and secondary sponsors,University of Nagasaki.,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2013,18.0,No,Yes
NCT01437020,19 February 2015,SCH708980 With and Without AmBisome for Visceral Leishmaniasis,"A Phase I/II Clinical Trial To Assess the Safety and Biologic Activity of the Anti-IL-10 Monoclonal Antibody, SCH708980, in Combination With AmBisome(Registered Trademark), Versus That of Placebo in Combination With Ambisome(Registered Trademark), in Subjects With Visceral Leishmaniasis (VL)",,National Institute of Allergy and Infectious Diseases (NIAID),2011-09-16,20110916,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT01437020,Not recruiting,No,18 Years,60 Years,Both,01/08/2011,0.0,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 1/Phase 2,India, ; ,"Shyam Sundar, MD;David Sacks, PhD",,;,;,"Institute of Medical Sciences, Banaras Hindu Universtiy, Varanasi, India;Laboratory of Parasitic Diseases, NIAID, NIH","<br>    - INCLUSION CRITERIA:<br><br>    Subjects (18 to 60 years of age) who meet the following criteria are eligible to enter the<br>    study:<br><br>     - Newly diagnosed VL (within 4 to 5 days of screening) and confirmed by spleen or bone<br>       marrow aspirate.<br><br>     - Clinical signs and symptoms compatible with VL: fever (> 99 degrees F) over a 2-week<br>       duration, splenomegaly (palpable spleen below the costal margin), and weight loss.<br><br>     - Biochemical and hematological test values:<br><br>    Hemoglobin > 6.0g/100mL.<br><br>    WBC count > 1.0 times 10(9)/L.<br><br>    Platelet count > 40 times 10(9)/L.<br><br>    Aspartate aminotransferase (AST),alanine transaminase (ALT), and alkaline phosphatase < 3<br>    times the upper limit of normal.<br><br>    Prothrombin time (PT) < 4 seconds above the control values.<br><br>    Serum creatinine levels within normal limits (males, 0.7 mg/dL - 1.1 mg/dL; females, 0.6<br>    mg/dL - 0.9 mg/dL).<br><br>     - Human immunodeficiency virus (HIV)-negative status.<br><br>     - Willingness to be hospitalized for 30 days.<br><br>     - Willingness to have samples stored.<br><br>     - Negative serum pregnancy test result for women of childbearing potential.<br><br>    EXCLUSION CRITERIA:<br><br>     - A history of intercurrent or concurrent diseases (e.g., chronic alcohol consumption<br>       or drug addiction; renal, hepatic, cardiovascular, or central nervous system disease;<br>       diabetes; tuberculosis or other infectious or major psychiatric diseases) that may<br>       introduce variables affecting the outcome of the study.<br><br>     - Any condition which, in the investigator's opinion, may prevent the subject from<br>       completing the study and the subsequent follow-up.<br><br>     - Previous treatment for VL within 45 days of study enrollment.<br><br>     - A history of allergy or hypersensitivity to amphotericin B.<br><br>     - Prior treatment failures with amphotericin B.<br><br>     - Current use of other drugs with known anti-leishmanial activity (e.g., antimonials,<br>       pentamidine, paromomycin, miltefosine), azoles (e.g., fluconazole, ketoconazole or<br>       itraconazole), nephrotoxic drugs, immunosuppressive drugs, other investigational<br>       agents, immunomodulatory drugs.<br><br>     - Breastfeeding women<br><br>     - Vaccinations within 30 days prior to enrollment in the study.<br><br>    Exclusion of children:<br><br>    Subjects younger than 18 years of age will be excluded from the study because insufficient<br>    data are available supporting dosing with SCH708980 in adults to judge the potential risk<br>    in children.<br><br>    Exclusion of women:<br><br>    Pregnant and lactating women are excluded from the study because insufficient data are<br>    available supporting dosing with SCH708980 in these populations to judge the potential<br>    risk.<br>   ",,Leishmaniasis;Effects of Immunotherapy,Drug: SCH708980 Anti-IL-10 monoclonal;Drug: AmBisome,"Evaluate the safety and tolerability of a single IV infusion of SCH708980 (0.3 mg/kg, 1.0 mg/kg, 3 mg/kg, or 10 mg/kg) over the initial 7 days and in combination with a single IV infusion of AmBisome® (10 mg/kg) on the 8th day in part 1 of the study","The anti-IL-10 parasitic effect, as measured by real-time polymerase chain reaction (RT-PCR);Serum concentrations of SCH708980;Clinical response;Outcomes at 6 months post-treatment",11-I-N222;11-I-N222,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2011,18.0,No,Yes
NCT01360762,12 December 2020,Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study,Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study,,"Institute of Tropical Medicine, Belgium",2011-05-24,20110524,10/13/2025 16:05:22,ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01360762,Not recruiting,No,18 Years,,All,01/11/2011,74.0,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). ,Phase 3,Ethiopia, ; ,"Ermias Diro, MD;Johan Van Griensven, MD, PhD",,;,;,"University of Gondar, Ethiopia;ITM","<br>    Inclusion Criteria:<br><br>     - Patients diagnosed with Visceral Leishmaniosis (VL) during the recruitment period that<br>       are EITHER treated for VL relapse and have a documented negative test of cure (TOC),<br>       OR are treated for primary VL and have a documented CD4 <200 or WHO stage 4 disease<br>       during the recruitment period and have a documented negative TOC<br><br>     - Patients treated for VL in the past with documented CD4 <200 or WHO stage 4 disease<br>       during the recruitment period AND documented negative TOC after the latest VL<br>       treatment and currently asymptomatic OR currently negative diagnostic test<br>       (microscopy)<br><br>     - Patients agreeing to start or continue antiretroviral treatment (first or second line)<br><br>     - Patients willing to provide written informed consent<br><br>    Exclusion Criteria:<br><br>     - Patients with known hypersensitivity to pentamidine<br><br>     - Patients with known renal failure<br><br>     - Patients with diabetes mellitus (type I or II)<br><br>     - Patients unlikely to attend follow-up visits/comply with study requirements<br><br>     - Pregnant and lactating women<br><br>     - Any other condition that could increase the risk of toxicity of pentamidine to such an<br>       extent outweighing the expected benefit (eg severe cardiac dysfunction).<br>   ",,Visceral Leishmaniosis;HIV-infection/Aids,Drug: Pentamidine,Probability of Relapse-free Survival;Number of Participants With Serious Adverse Events (SAEs),Number of Participants With Adverse Events;Number of Treatment Discontinuations and Interruptions;Number of Required Additional Interventions,ITMC0109,Please refer to primary and secondary sponsors,"Addis Ababa University;University of Gondar;Tigray Regional Health Bureau, Tigray Region;Amhara Regional Health Bureau, Amhara Region;Medecins Sans Frontieres, Netherlands;Leishmania East Africa Platform (LEAP);Drugs for Neglected Diseases",,,,,,,Yes,15/02/2019,https://clinicaltrials.gov/ct2/show/results/NCT01360762,,,,,,,,,,Yes,False,          ,2011,18.0,No,Yes
CTRI/2009/091/000058,24 November 2021,Comparing the treatments of Two Different Lipid preparations of Amphotericin B for the treatment of Kala Azar,"A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of AmphomulÂ® (Amphotericin B Emulsion) As Compared To AmBisome In Patients Of Visceral Leishmaniasis (Kala Azar)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",,Bharat Serums and Vaccines Ltd,2009-03-13,20090313,10/13/2025 16:05:22,CTRI,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=334,Not Recruiting,No,,,,03/08/2009,500.0,Interventional,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Permuted block randomization, fixed  Method of allocation concealment:Centralized  Blinding and masking:Open Label",Phase 3,India,Taref Kanthawala,,"Bharat Serums and Vaccines Ltd,17th floor, Hoechst House, Nariman Point ",gautam.daftary@bharatserums.com,02266560925,Bharat Serums and Vaccines Ltd.,"Inclusion criteria: 1.Male or female patients aged between 5 to 65 years (both inclusive).<br>2.Patient/patient&#039;s legally acceptable representative (LAR) is willing and able to give written informed consent to participate in the study.<br>3.Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration and splenomegaly)<br>4.Presence of amastigotes (Leishmania-Donovani bodies) at prescreening detected by recombinant K39 protein (rK39) dipstick test with confirmation of Kala-azar by splenic or bone marrow aspirate smear examination.<br>5.No previous treatment for Visceral Leishmaniasis within 30 days from screening.<br>6.Non-pregnant, non-lactating females of age equal to or greater than 5 years, and woman of childbearing potential (any woman who has reached menarche) who are willing to use acceptable methods of contraception like long term acting injections ex. Depo-Provera. <br>7.Negative Urine pregnancy test (UPT) in all women physiologically capable of becoming pregnant (any woman who has reached menarche)<br>8.Hemoglobin equal to or greater than 5 g/dL<br>9.White blood cells (WBC) count equal to or greater than 1000/cmm<br>10.Platelet count equal to or greater than 50000/cmm<br>11.Alanine amino transferase (ALT), aspartate amino transferase (AST) and alkaline phosphatase equal to or less than 2.5 times the upper limit of normal (ULN)<br>12.Prothrombin time equal to or less than 4 seconds above the control.<br>13.Normal serum creatinine and serum potassium levels<br>14.Negative tests for Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) and Hepatitis B surface antigen (HBsAg).","Exclusion criteria: 1.Patients with past history of treatment with Amphotericin B or any other drug for Visceral Leishmaniasis within 30 days prior to screening.<br>2.Patients positive for HIV, HCV and HBsAg infection, immunocompromised patients (through history).<br>3.A history or evidence of any concurrent disease that may be serious or life threatening, significant hematological, cardiac, hepatic, renal, respiratory, neurological or metabolic disease or any condition which, in the opinion of the investigator, may constitute a safety concern or interfere with the evaluation of the study objectives or may prevent the patient from the completing study therapy or subsequent follow-up<br>4.Concurrent diabetes, tuberculosis or bacterial pneumonia (on chest X-ray, erythrocyte sedimentation rate (ESR) at screening, past history) or any other infectious or major psychiatric disease.<br>5.Patients with concurrent Malaria will not be included in the trial. Parascreen antigen test for detection of malarial parasites will be performed at screening visit. Patients diagnosed with malaria could be rescreened for enrollment in the trial after adequate treatment of Malaria; and if the parascreen antigen test for detection of malarial parasites is found negative then the patient could be enrolled in the trial.<br>6.History of major surgery within 2 weeks prior to screening<br>7.Blood urea nitrogen (BUN) and serum creatinine &gt;1.5 times ULN, and serum bilirubin &gt;1.5 times ULN<br>8.Proteinurea equal to or greater than 2+<br>9.Pregnant or nursing women<br>10.History of alcoholism or illicit drug use/ abuse, or any condition associated with poor compliance<br>11.Known hypersensitivity to Amphotericin B, inactive ingredients of Amphomul&reg; formulation, inactive ingredients of AmBisome formulation.<br>12.Patients receiving any of the medications prohibited by the study protocol.<br>13.Simultaneous participation in another trial or received any IP less than 30 days prior to enrolment.<br>14.Any condition which in the investigator&#039;s opinion may prevent the patient from completing the study therapy or follow-up",Health Condition 1: B550- Visceral leishmaniasis,Intervention1: Amphotericin B Emulsion (Amphomul): 15mg/kg single bolus dose<br>Control Intervention1: Liposomal Amphotericin B (AmBisome): 15mg/kg single bolus dose<br>,"1. Initial cure (splenic aspirate score 0)<br>2. Clinical improvement after study drug administration<br>oAbsence of fever; and &gt;1 out of following:<br>?Increase in hemoglobin concentration by &gt;10% compared to baseline<br>?Any weight gain compared to the baseline visit<br>?Decrease in spleen size by &gt;33% from baseline <br>Timepoint: 1. Day 30 or Day 45<br>2. Day 30;1. Initial cure (splenic aspirate score on Day 30 and 45)<br>2. Clinical improvement on Day 30 after first dose of study drug<br>oAbsence of fever; and &gt;1 out of following:<br>    &amp;#61607;Increase in hemoglobin concentration by &amp;#8805;10% compared to baseline<br>    &amp;#61607;Weight gain compared to baseline visit<br>    &amp;#61607;Decrease in spleen size by &gt;33% compared to baseline <br>Timepoint: 1. Day 30 or Day 45 2. Day 30;oDefinitive cure <br>1.Initial cure at Day 30 or Day 45<br>2.No signs and symptoms of relapse of Kala-azar for 6 months after study drug administration. If signs and symptoms of relapse of the disease are suspected at any time during the 6 months follow up, splenic aspirate shall be performed at 6 months or earlier after study drug administration.<br>Proportion of patients achieving all three-efficacy endpoints will be compared across the two groups.<br>Timepoint: 6 months",1.Incidence of DLTs.<br>2.Incidence of IRTs<br>3.Incidence of nephrotoxicity and hepatotoxicity<br>4.Number of AEs and SAEs<br>5.Laboratory values for different parameters <br>Timepoint: 6 months;?Incidence of DLTs.<br>?Incidence of IRTs<br>?Incidence of nephrotoxicity and hepatotoxicity<br>?Number of AEs and SAEs<br>?Laboratory values for different parameters <br>Timepoint: 6 months,BSV-AMBE-III-KA-0908;NCT00876824,Bharat Serums & Vaccines Limited,,Approved;Approved;Approved;Approved,26/06/2009;03/07/2009;17/08/2009;03/07/2009,"Ethics Committee, Patna - 800007;Ethics Committee,Muzaffarpur-842 001;Ethics Committee,Muzaffarpur-842 003;Ethics Committee,Patna-800 001",;;;,;;;,;;;,Unknown,,,,14/01/2011,,,,,,,,Yes,False,parent    ,2009,,Unknown,Yes
NCT00696969,19 February 2015,Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis,"Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL).",,Drugs for Neglected Diseases,2008-06-11,20080611,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00696969,Not recruiting,No,18 Years,60 Years,Both,01/06/2008,634.0,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 3,India, ,Farrokh Modabber,,,,Drugs for Neglected Diseases,"<br>    Inclusion Criteria:<br><br>     - Adults ( male or female) 18-60 years of age<br><br>     - Acute, symptomatic, non-severe (minimum Hb.5 gm/dL) VL proven by parasitological<br>       examination of splenic or bone marrow aspirate.<br><br>     - History of fever.<br><br>     - Living within reachable distance of the trial site to enable attendance for follow-up<br>       visits<br><br>     - Written informed consent to participate<br><br>     - Proven HIV negative status<br><br>     - Women of child-bearing potential who are using an assured method of contraception<br><br>    Exclusion Criteria:<br><br>     - Signs/symptoms indicative of severe VL ( Hb.< 5gm/dl, evidence of cardiac failure,<br>       etc)<br><br>     - Patients who have received anti-leishmanial or anti-fungal treatment within the last<br>       45 days<br><br>     - Patients who have received any investigational (unlicensed) drugs within the last 6<br>       months<br><br>     - Severe malnutrition BMI<15 in adults, weight for height less than 60% in children.<br><br>     - Chronic underlying disease such as severe cardiac, renal, or hepatic impairment.<br><br>     - Renal function tests (serum creatinine) outside the normal range<br><br>     - Liver function tests (transaminases) more than three times the upper limit of the<br>       normal range at study entry<br><br>     - Jaundice (bilirubin >2.0mg/dL)<br><br>     - Known hepatitis B or C positive<br><br>     - Platelet count less than 40,000/mm3<br><br>     - Prothrombin time 5 seconds or greater than normal range<br><br>     - TotalWBC < 1,000/mm3<br><br>     - Known alcohol or other drug abuse<br><br>     - HIV positive status<br><br>     - Pregnancy and/or lactation<br><br>     - Females having unprotected sexual intercourse, or using a non-assured method of<br>       contraception (e.g. condom)<br><br>     - Concomitant chronic drug treatment eg for diabetes, hypertension, TB, HIV etc<br><br>     - Concomitant drug usage for acute infection, eg malaria, pneumonia etc within the last<br>       7 days<br><br>     - Any other condition which may invalidate the trial<br><br>     - Known hypersensitivity to AmBisome, Paromomycin, amphotericin B and/or Miltefosine<br>   ",,Visceral Leishmaniasis,Drug: Amphotericin B Deoxycholate;Drug: Ambisome + Miltefosine;Drug: Ambisome and Paromomycin;Drug: Miltefosine and Paromomycin,"Definitive cure based on parasitological clearance at Day 15 after start of combination therapy (Day 31 for standard therapy), no evidence of parasites at day 45 and no clinical signs or symptoms of VL at 6 months post treatment.",,VL Combo 07,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2008,18.0,No,Yes
NCT00497601,19 February 2015,A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar,"A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar).",,Banaras Hindu University,2007-07-05,20070705,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00497601,Not recruiting,No,18 Years,65 Years,Both,01/02/2007,60.0,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 2,India, ,Shyam Sundar,,,,Banaras Hindu University,"<br>    Inclusion Criteria:<br><br>     1. Male or female subjects between 18 years and 65 years of age (both inclusive).<br><br>     2. Subject/subject's legally acceptable representative is willing and able to give<br>       written informed consent to participate in the study.<br><br>     3. Treatment naive subjects having symptoms and/or signs of visceral leishmaniasis with<br>       parasitological confirmation of Kala-azar (by splenic or bone marrow aspirate smear<br>       examination).<br><br>    If subjects are previously treated with other antileishmanial drugs except amphotericin B<br>    containing preparations, they will be enrolled in the study only after clinical and<br>    parasitological evidence that the disease is unresponsive to adequate treatment with other<br>    drugs, and after an appropriate wash out period<br><br>    Exclusion Criteria:<br><br>     1. Subjects with past history of treatment with Amphotericin B for Kala-azar.<br><br>     2. Subjects positive for HIV infection.<br><br>     3. Concomitant life threatening or serious disease.<br><br>     4. Concurrent malaria (malarial parasite test to be negative prior to study treatment<br>       administration), tuberculosis or bacterial pneumonia.<br><br>     5. Haemoglobin < 6 gm/dl, total leukocyte count < 1,500/cmm, platelet count < 50,000/cmm<br><br>     6. Abnormal liver and renal functions (BUN and serum creatinine > 1.5 times upper limit<br>       of normal (ULN), AST/ALT > 2.5 times ULN, and bilirubin > 1.5 times ULN).<br><br>     7. Pregnant or nursing women.<br><br>     8. Known hypersensitivity to Amphotericin B or inactive ingredients of study drug<br>       formulation.<br><br>     9. Subjects receiving any of the medications prohibited by the study protocol.<br><br>     10. Evidence of significant haematological, cardiac, hepatic, renal, respiratory,<br>       neurological or metabolic disease or any condition which, in the opinion of the<br>       investigator, might interfere with the evaluation of the study objectives.<br><br>     11. Simultaneous participation in another trial or received any investigational product <<br>       30 days prior to enrolment.<br>   ",,Visceral Leishmaniasis,Drug: Amphotericin B fat emulsion in visceral leishmaniasis;Drug: Amphotericin B fat emulsion;Drug: Amphotericin B in fat emulsion,"Clinical and parasitological cure at end of treatment and final cure (no relapse) at six months, no hematological, hepatic or renal toxicity",,BSV-AMBE II-KA-706,Please refer to primary and secondary sponsors,,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2007,18.0,No,Yes
NCT00486382,13 April 2015,Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India,"A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India",,IDRI,2007-06-12,20070612,10/13/2025 16:05:22,ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00486382,Not recruiting,No,18 Years,54 Years,Both,01/04/2007,36.0,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",Phase 1,India, ; ,"Shyam Sundar, MD;Franco M Piazza, MD, MPh",,;,;,Banaras Hindu University;IDRI,"<br>    Inclusion Criteria:<br><br>     - Males and females = 18 years and < 55 years of age.<br><br>     - Must be in good general health as confirmed by a medical history and physical exam.<br><br>     - DAT titer must be <1:400 and rK39 serology negative (for inclusion in the<br>       DAT-negative group) or DAT titer =1:1600 (for inclusion in the DAT-positive group).<br><br>     - The following laboratory blood tests must have values within the normal ranges at<br>       screening (Appendix 4): sodium, potassium, urea, ALT, AST, total bilirubin,<br>       creatinine, alkaline phosphatase, glucose, hemoglobin, total WBC count and platelet<br>       count.<br><br>     - The following serology tests must be negative at screening: HIV 1/2, hepatitis B<br>       surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All subjects will<br>       receive HIV related counseling prior to testing. Subjects with positive HIV test<br>       results will receive counseling at the University and will be referred to the<br>       national AIDS control program for treatment if appropriate.<br><br>     - Subjects must give written informed consent, be willing and able to attend all<br>       required visits, have a permanent address, and be reachable by study site personnel.<br><br>     - Female subjects of childbearing potential must have a negative urine pregnancy test<br>       at screening, a negative urine pregnancy test within 24 hours before study injection,<br>       must not be breast-feeding, and are required to use adequate contraception through<br>       Day 84 of the study. These precautions are necessary due to unknown effects that<br>       Leish-111f + MPL-SE might have in a fetus or newborn infant.<br><br>    Exclusion Criteria:<br><br>     - Previous exposure to Leishmania vaccines or experimental products containing MPL-SE.<br><br>     - Participation in another experimental protocol or receipt of any investigational<br>       products within 30 days prior to the first administration of study injection.<br><br>     - Known use of injected or oral corticosteroids within 6 weeks prior to the first<br>       administration of study injection.<br><br>     - History of autoimmune disease or other causes of immunosuppressive states.<br><br>     - History or evidence of any acute or chronic illness that, in the opinion of the<br>       Principal Investigator, may interfere with the evaluation of the safety or the<br>       immunogenicity of the vaccine. (Potential subjects presenting with concomitant<br>       illness will be referred for clinical care.)<br><br>     - History of use of any medication that, in the opinion of the Principal Investigator,<br>       may interfere with the evaluation of the safety or the immunogenicity of the vaccine.<br><br>     - History of significant psychiatric illness.<br><br>     - Known to be a current drug or alcohol abuser.<br><br>     - Subjects with a history of previous anaphylaxis, severe allergic reaction to vaccines<br>       or unknown allergens, or allergic reaction to eggs.<br><br>     - History of chronic headaches or migraine.<br><br>     - Subjects who are unlikely to cooperate with the requirements of the study protocol.<br><br>     - Subjects who are not permanent residents or who are planning to move to another<br>       town/city.<br>   ",,Visceral Leishmaniasis;Post-kala-azar Dermal Leishmaniasis,Biological: Leish-111f + MPL-SE Adjuvant,Injection site reactions,,IDRI-LVVPX-104,Please refer to primary and secondary sponsors,Bill and Melinda Gates Foundation,,,,,,,Unknown,,,,,,,,,,,,No,False,          ,2007,18.0,No,Yes
